



**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES**

**OCTOBER 2020 MEETING  
EDUCATIONAL AFFAIRS - RESOLUTION ROSTER  
WITH ACTION**

**HOUSE OF DELEGATES' REFERENCE COMMITTEE DESCRIPTION:**

- Committee on Educational Affairs (200 series)  
This reference committee reviews and considers matters relating to osteopathic education, osteopathic colleges, and postdoctoral training.

Res. No.	Resolution Title	Submitted By	Action
H200	Graduate Medical Education – Training of US Medical School Graduates (H213-A/15)	BOE	ADOPTED
H201	Rural Sites – Osteopathic Education in (H214-A/15)	BOE	ADOPTED
H202	Directors of Medical Education Overseeing Osteopathic Postdoctoral Training Programs (H216-A/15)	BOE	ADOPTED as AMENDED
H203	Autopsies (H217-A/15)	BOE	ADOPTED
H204	Clarity Regarding Matching Service Listing of AOA Residencies with ACGME Pre-Accreditation Status (H219-A/15)	BOE	ADOPTED <i>(for sunset)</i>
H205	Blue Ribbon Commission Report (H223-A/15)	BOE	ADOPTED
H206	AOA to Support Education and Advocate for Policies Relating to Climate Change	MOA	NOT ADOPTED
H207	Adoption of Specific Informed Consent Guideline for Sensitive Exams Under Anesthesia for Education Purposes	SOMA	REFERRED
H208	Incorporating Continuing Medical Education Opportunities on Human Trafficking	SOMA	REFERRED
H209	Incorporating Continued Medical Education Regarding Intellectual and Developmental Disabilities	SOMA	ADOPTED as AMENDED
H210	Recommendation of Buprenorphine Waiver Training in Osteopathic Medical Schools	BSAPH	NOT ADOPTED
H211	Referred Res. No H-224 – A/2019 AOA Board Certification Terminology	BOS	NOT ADOPTED
H212	Residency Redistribution of Center for Medicare/Medicaid Services Funding Following Single Accreditation Systems (SAS)	OPSC	NOT ADOPTED
H213	Training High Quality Physicians in a Healthy and Safe Environment	MAOP	NOT ADOPTED
H214	Audition Rotations for Osteopathic Medical Students	IOMA	ADOPTED as AMENDED

SUBJECT: H213-A/15 GRADUATE MEDICAL EDUCATION – TRAINING OF  
US MEDICAL SCHOOL GRADUATES

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Committee on Educational Affairs

---

1 RESOLVED, that the Bureau of Osteopathic Education recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H213-A/15 GRADUATE MEDICAL EDUCATION – TRAINING OF US**  
5 **MEDICAL SCHOOL GRADUATES**

6 The American Osteopathic Association advocates for the elimination of limitations on the  
7 number of funded graduate medical education positions to accommodate increases in US  
8 medical school enrollment; places great emphasis on establishing graduate medical education  
9 opportunities for osteopathic medical school graduates in geographic areas that lack adequate  
10 training capacity and as needed to meet future workforce needs. 2009; referred 2014; approved  
11 as amended 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H214-A/15 RURAL SITES – OSTEOPATHIC EDUCATION IN

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Committee on Educational Affairs

---

1 RESOLVED, that the Bureau of Osteopathic Education recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H214-A/15 RURAL SITES – OSTEOPATHIC EDUCATION IN**

5 The American Osteopathic Association encourages clinical rotations in rural settings by  
6 osteopathic medical students and graduates during their respective predoctoral and postdoctoral  
7 education programs. 1990; revised 1995, 2000, 2005, 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H216-A/15 DIRECTORS OF MEDICAL EDUCATION OVERSEEING  
OSTEOPATHIC POSTDOCTORAL TRAINING PROGRAMS

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Committee on Educational Affairs

---

1 RESOLVED, that the Bureau of Osteopathic Education recommends ~~that~~ the following policy  
2 be ~~SUNSET REAFFIRMED~~ as **AMENDED**.

3 (Old language is crossed out and new language is in CAPS)

4 **H216-A/15 ~~DIRECTORS OF MEDICAL EDUCATION OVERSEEING~~**  
5 **~~OSTEOPATHIC POSTDOCTORAL TRAINING PROGRAMS~~**

6 The American Osteopathic Association will ~~continue the present requirement that the Director~~  
7 ~~of Medical Education overseeing osteopathic postdoctoral training programs must be an~~  
8 ~~osteopathic physician~~ **ENCOURAGENSURE** THE CONTINUED TEACHING OF  
9 **OSTEOPATHIC PRINCIPLES AND PRACTICES THROUGH BUT NOT LIMITED**  
10 **TO OSTEOPATHIC RECOGNITION** IN GRADUATE MEDICAL EDUCATION  
11 PROGRAMS AND ENCOURAGES OSTEOPATHIC PHYSICIANS TO SEEK FACULTY  
12 AND ADMINISTRATIVE POSITIONS IN GRADUATE MEDICAL EDUCATION  
13 PROGRAMS. 2010, reaffirmed 2015.

Explanatory Statement: Submitted by Author

The BOE recommends this policy be sunset because Directors of Medical Education are not required by the ACGME.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H217-A/15 AUTOPSIES

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Committee on Educational Affairs

---

1 RESOLVED, that the Bureau of Osteopathic Education recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H217-A/15 AUTOPSIES**

5 The American Osteopathic Association encourages medical schools, private hospital systems  
6 and public medical facilities to allow the viewing of autopsies by medical students and residents  
7 for teaching purposes. 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H219-A/15 CLARITY REGARDING MATCHING SERVICE LISTING  
OF AOA RESIDENCIES WITH ACGME PRE-  
ACCREDITATION STATUS

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Committee on Educational Affairs

---

1 RESOLVED, that the Bureau of Osteopathic Education recommends that the following policy  
2 be SUNSET.

3 (Old language is crossed out and new language is in CAPS)

4 **H219-A/15 CLARITY REGARDING MATCHING SERVICE LISTING OF AOA**  
5 **RESIDENCIES WITH ACGME PRE-ACCREDITATION STATUS**

6 The American Osteopathic Association (AOA) will provide guidance to the osteopathic student  
7 body regarding the timelines of residency program transition between the NRMP and NMS  
8 matching services. The AOA will openly distribute information regarding the match transition  
9 and its implications to osteopathic medical students applying to those residency programs,  
10 starting in the period leading up to the pre-accreditation eligibility of AOA residency programs.  
11 2015

Explanatory Statement: Submitted by Author

The BOE recommends this policy be sunset because the AOA no longer offers a separate AOA Match.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED (for sunset)**

DATE: **October 14, 2020**

SUBJECT: H223-A/15 BLUE RIBBON COMMISSION REPORT

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Committee on Educational Affairs

---

1 RESOLVED, that the Bureau of Osteopathic Education recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H223-A/15 BLUE RIBBON COMMISSION REPORT**

5 The American Osteopathic Association (AOA) encourages colleges of osteopathic medicine to  
6 collaborate with appropriate regulatory authorities, licensing boards, certifying boards, the  
7 National Board of Osteopathic Medical Examiners, and other stakeholders in their pursuit of  
8 innovative pilot studies to produce primary care, competency-based physician team leaders and  
9 the AOA will monitor the outcomes of these pilot programs and the route to board  
10 certification. 2015

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: HOD Reference Committee

The Committee heard singular testimony advocating sunset due to perceived lack of action, while others felt there remains ongoing value in the collaboration embodied in the resolution. The resolution directs the AOA to monitor the Blue Ribbon Commission pilot studies and the Committee respectfully recommends a summary report be provided by the AOA as an informational item for the 2021 House of Delegates.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

---

DATE: **October 14, 2020**

---

SUBJECT: AOA TO SUPPORT EDUCATION AND ADVOCATE FOR POLICIES  
RELATING TO CLIMATE CHANGE

SUBMITTED BY: Maine Osteopathic Association

REFERRED TO: Committee on Educational Affairs

---

1 WHEREAS, there is agreement within the scientific community that the Earth is undergoing  
2 adverse global climate change and that anthropogenic contributions are significant; and

3 WHEREAS, these climate changes will create conditions that affect public health, with  
4 disproportionate impacts on vulnerable populations, including children, the elderly, and  
5 the economically disadvantaged; and

6 WHEREAS, the American Osteopathic Association (AOA) has encouraged efforts to promote  
7 standards which will prevent human suffering and death from environmental threats  
8 and hazards; and supported efforts to eradicate environmentally related health risks  
9 since 1970; now, therefore be it

10 RESOLVED, that the American Osteopathic Association (AOA) supports educating the  
11 medical community on the potential adverse public health effects of global climate  
12 change; and, be it further

13 RESOLVED, that AOA encourages American Association of Colleges of Osteopathic  
14 Medicine (AACOM) to advocate for their member osteopathic medical schools to  
15 incorporate the health implications of climate change into their curricula, including  
16 topics such as population displacement, heat waves and drought, flooding, infectious  
17 and vector-borne diseases, and potable water supplies and, be it further

18 RESOLVED, that AOA advocates for and support epidemiological, translational, clinical and  
19 basic science research, in order that global climate change policy decisions related to  
20 health care and treatment have an appropriate evidence base and, be it further

21 RESOLVED, that AOA encourages physicians to assist in educating patients and the public on  
22 environmentally sustainable practices, and to serve as role models for promoting  
23 environmental sustainability.

Explanatory Statement: Submitted by Author

Resolved 3 refers to H402-A/18 ENVIRONMENTAL HEALTH. Passed in 1970; revised 1978; reaffirmed 1983; revised 1988; reaffirmed 1993; revised 1998, 2003; reaffirmed 2008; reaffirmed 2013; 2018.

Explanatory Statement: Reference Committee

The Committee heard testimony mostly against the resolution. Advocates commented that environmental health is a public health issue. The Committee believes that the current policy, H402-A/18 demonstrates the AOA's commitment to Environmental Health. In H402-A/18, the AOA strongly encourages the federal government to increase its efforts to promote standards which will



prevent human suffering and death from environmental threats and hazards; and reaffirms its commitment to support governmental agencies' efforts in eradicating environmentally related health risks. Regarding this resolution's call for incorporating health implications of climate change into osteopathic medical school curricula, the Committee believes that osteopathic medical schools should have the autonomy to choose their curricula based on the COCA requirements, their curriculum committee, and their mission statement, and that this was beyond the scope and authority of the AOA.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H402-A/18 ENVIRONMENTAL HEALTH

**Prior HOD action on similar or same topic:** Policy reaffirmed in 2018.

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: ADOPTION OF SPECIFIC INFORMED CONSENT GUIDELINE FOR SENSITIVE EXAMS UNDER ANESTHESIA FOR EDUCATION PURPOSES

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Educational Affairs

---

1 WHEREAS, patient consent is critical to patient care; and  
2 WHEREAS, physicians, residents, and medical students have a duty to respect the autonomy of  
3 patients; and  
4 WHEREAS, sensitive exams are defined as pelvic exams, rectal exam, clinical breast exam,  
5 urogenital exams<sup>1</sup>; and  
6 WHEREAS, the performance of sensitive exams under general anesthesia without specific  
7 informed consent can lead to severe psychological stress for the patient, damage to the  
8 patient provider relationship, and a distressing experience for the medical student or  
9 resident<sup>2</sup>; and  
10 WHEREAS, thirty-nine states have no law explicitly banning the practice of performing pelvic  
11 exams on general anesthetized patients without their specific consent<sup>3</sup>; and  
12 WHEREAS, in a study conducted in 2003, 90% of students surveyed had completed a pelvic  
13 exam on general anesthetized patient who had not given informed consent<sup>4</sup>; and  
14 WHEREAS, If asked for specific consent prior to surgery, 62% of women claimed they would  
15 consent to a medical student performing a pelvic exam while under general anesthesia  
16 for educational purposes, showing that asking does not significantly impact learning  
17 opportunities<sup>5</sup>; now, therefore be it  
18 RESOLVED, that the American Osteopathic Association (AOA) adopt guidelines that require  
19 the practicing physician or resident to obtain specific informed consent before the  
20 resident or medical student performs a sensitive exam for education purposes on a  
21 patient who is under general anesthesia.

Explanatory Statement: Submitted by Author

Performing sensitive exams on unconscious patients for educational purposes is not a new practice<sup>5</sup>. Public awareness in the 1990's saw the introduction of limited state legislation against the practice<sup>2</sup>. Today there are 11 states that have banned the performance of sensitive exams under anesthesia without specific consent<sup>3</sup>; Wisconsin and Florida have proposed bills under consideration<sup>6,7</sup>. It is difficult to predict the number of educational pelvic exams under anesthesia without specific consent being performed today but recent lawsuits as well as reports from patients and medical students indicate the practice is still occurring nationally<sup>2,3,6,7</sup>.

## References

1. University Health Service. (n.d.). *University of Michigan*. Retrieved February 21, 2020, from <https://www.uhs.umich.edu/sensitive-exams>
2. Friesen, P. Educational pelvic exams on anesthetized women: Why consent matters. *Bioethics*. 2018; 32: 298– 307. <https://doi.org/10.1111/bioe.12441>
3. Goldberg, E. (2020, February 17). She Didn't Want a Pelvic Exam. She Received One Anyway. *New York Times*. Retrieved February 21, 2020, from <https://www.nytimes.com/2020/02/17/health/pelvic-medical-exam-unconscious.html>
4. Ubel, Peter A, et al. (February 2003). Don't ask, don't tell: A change in medical student attitudes after obstetrics/gynecology clerkships toward seeking consent for pelvic examinations on an anesthetized patient. *American Journal of Obstetrics & Gynecology*, Volume 188, Issue 2, 575 – 579
5. Cundall, H., MacPhedran, S., & Arora, K. (2019, December). Consent for Pelvic Examinations Under Anesthesia by Medical...: *Obstetrics & Gynecology*. Retrieved February 21, 2020, from [https://journals.lww.com/greenjournal/Fulltext/2019/12000/Consent\\_for\\_Pelvic\\_Examinations\\_Under\\_Anesthesia.23.aspx?casa\\_token=oPri3J4ogx8AAAAA:k-v1Z0A8izkAtAX3vcyWc\\_0MTL7uUDLFIPKzbSVUxGIVULCED7SQcmEtOi4bM48xh-nbgFr312d8Yk6VhtT9z5X](https://journals.lww.com/greenjournal/Fulltext/2019/12000/Consent_for_Pelvic_Examinations_Under_Anesthesia.23.aspx?casa_token=oPri3J4ogx8AAAAA:k-v1Z0A8izkAtAX3vcyWc_0MTL7uUDLFIPKzbSVUxGIVULCED7SQcmEtOi4bM48xh-nbgFr312d8Yk6VhtT9z5X)
6. Wahlberg, D., & Wisconsin State Journal. (2020, January 7). Bill seeks informed consent for pelvic exams under anesthesia by medical students. Retrieved February 20, 2020, from [https://madison.com/wsj/news/local/health-med-fit/bill-seeks-informed-consent-for-pelvic-exams-under-anesthesia-by/article\\_ab30b282-0507-5c0f-93c5-83143f74ae86.html](https://madison.com/wsj/news/local/health-med-fit/bill-seeks-informed-consent-for-pelvic-exams-under-anesthesia-by/article_ab30b282-0507-5c0f-93c5-83143f74ae86.html)
7. Press, T. A. (2020, February 19). Florida bill would require consent to perform pelvic exams. Retrieved February 21, 2020, from <https://www.wfla.com/news/florida/florida-bill-would-require-consent-to-perform-pelvic-es/>

### Explanatory Statement: Reference Committee

The Committee respectfully recommends this resolution be referred back to its authors, the Student Osteopathic Medical Association (SOMA). The Committee was supportive of the resolution's intent but felt that current policy, H223-A/19, is broad enough to include the encounters such as that referred to in the resolution. The Committee recommends that the SOMA study current AOA policy H223-A/19 and consider resubmitting a resolution for a future HOD that amends H223-A/19, should the SOMA believe there is a need to include specific informed consent for sensitive exams under anesthesia in the current AOA policy. In addition, the Committee also recommends the authors consider defining sensitive exams in a Resolved statement so that its definition will be included in the AOA policy compendium.

### Background Information: Provided by AOA Staff

**Current AOA Policy:** H223-A/19 EDUCATION OF STUDENTS AND FACULTY ON OBTAINING PERMISSION BEFORE ALL STUDENT AND PATIENT ENCOUNTERS

**Prior HOD action on similar or same topic:** Policy approved in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Student Osteopathic Medical Association)*

DATE: **October 14, 2020**

SUBJECT: **INCORPORATING ENCOURAGING** CONTINUING MEDICAL  
EDUCATION OPPORTUNITIES ON HUMAN TRAFFICKING

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Educational Affairs

---

1 WHEREAS, human trafficking is defined as ~~the use of force, fraud, or coercion to obtain~~  
2 ~~some type of labor or commercial sex act~~ **COMPLEX CRIME INVOLVING**  
3 **THE EXPLOITATION OF SOMEONE FOR THE PURPOSES OF**  
4 **COMPELLED LABOR OR A COMMERCIAL SEX ACT, THROUGH THE**  
5 **USE OF FORCE, FRAUD, OR COERCION. WHEN A PERSON UNDER 18**  
6 **IS USED TO PERFORM A COMMERCIAL SEX ACT, IT IS HUMAN**  
7 **TRAFFICKING WHETHER OR NOT THERE IS ANY FORCE, FRAUD,**  
8 **OR COERCION<sup>1</sup>; and**

9 WHEREAS, an estimated 40.3 million people are victims of human trafficking globally, 4.8  
10 million of which are in forced sexual exploitation for profits of an estimated \$99 Billion  
11 US dollars per year<sup>2</sup>; and

12 WHEREAS, 1 million children are victims of sex trafficking globally<sup>3</sup>; and

13 ~~WHEREAS, 14,500 to 17,500 people are trafficked into the United States each year<sup>4</sup>; and~~

14 WHEREAS, 1 in 6 reported runaways in the United States are presumed to be victims of child  
15 sex trafficking<sup>5</sup>; and

16 WHEREAS, trafficking victims experience higher rates of the following healthcare concerns:  
17 STP's, pregnancy, unsafe abortion, malnourishment, illness from unsanitary conditions,  
18 and physical and mental abuse manifestations such as PTSD and depression<sup>6</sup>; and

19 WHEREAS, studies have shown that 28-88% of trafficking victims have come into contact  
20 with the healthcare system while being trafficked <sup>6,7</sup>; and

21 WHEREAS, the American College of Osteopathic Emergency Physicians reports that only  
22 10% of physicians recognize human trafficking victims and 3% of emergency physicians  
23 receive training on human trafficking<sup>8</sup>; and

24 WHEREAS, only three medical schools in the United States have formal case based simulation  
25 training in identifying victims of human trafficking during the first three years of  
26 medical education, none of which are osteopathic medical schools<sup>9,10</sup>; and

27 WHEREAS, "Educating healthcare professionals on the topic cannot be limited to one  
28 subspecialty as trafficking victims have a wide variety of physical symptoms... To reach  
29 the widest range of subspecialties, education must occur during undergraduate medical  
30 education and focus on practical aspects of providing care for trafficked persons as well  
31 as identifying elements of trafficking"<sup>10</sup>; and

1 WHEREAS, a multitude of organizations, including the World Health Organization, have  
2 released statements regarding the need for awareness of the signs of human trafficking  
3 in healthcare professionals<sup>8,11,12,13</sup>; and

4 WHEREAS, it is recommended that medical school and emergency medicine residency  
5 curricula should include training in recognizing and intervening for patients surviving  
6 human trafficking<sup>8</sup>; and

7 WHEREAS, American Osteopathic Association policy H401-A/14 Human Trafficking—  
8 Awareness as a Global Health Problem acknowledges human trafficking as a global  
9 public health problem and encourages awareness among osteopathic physicians<sup>14</sup>; now,  
10 therefore be it

11 RESOLVED, that the American Osteopathic Association (AOA) **incorporate**  
12 **ENCOURAGE** continuing medical education opportunities on recognizing the signs  
13 and risk factors of human trafficking.

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. Human trafficking definition: Department of Homeland Security. (2019, June 28). What Is Human Trafficking? Retrieved from <http://www.dhs.gov/blue-campaign/what-human-trafficking>
2. Worldwide Human trafficking prevalence: International Labor Organization. (2017, September 19). Forced labour, modern slavery and human trafficking. Retrieved from <https://www.ilo.org/global/topics/forced-labour/lang--en/index.h>
3. Global Estimates of Modern Slavery: Forced Labour and Forced Marriage. (2017, September 19). Retrieved February 25, 2020, from [https://www.ilo.org/global/publications/books/WCMS\\_575479/lang--en/index.htm](https://www.ilo.org/global/publications/books/WCMS_575479/lang--en/index.htm)
4. Clawson, H. J., Dutch, N., Solomon, A., & Goldblatt Grace, L. Human trafficking into and within the United States: a review of the literature 1–54 (n.d.). Office of the Assistant Secretary for Planning and Evaluation. <https://aspe.hhs.gov/report/human-trafficking-and-within-united-states-review-literature#Trafficking>
5. National Center for Missing and Exploited Children. (n.d.). About NCMEC. Retrieved February 10, 2020, from <http://www.missingkids.org/footer/media/keyfacts>
6. Sy, E., Pusey, J. O., Cho, N., Marin, L., Dagdagan, M., Whiteman, R., ... Marigold, J. A. (2005). Turning pain into power: Trafficking survivors' perspectives on early intervention strategies. [Booklet]. San Francisco, CA: Family Violence Prevention Fund.
7. Lederer, L. J., & Wetzal, C. A. (2014). The Health Consequences of Sex Trafficking and Their Implications for Identifying Victims in Healthcare Facilities.
8. Reyes, J. (2019, July 24). Confronting Human Trafficking. Retrieved from American College of Osteopathic Emergency Physicians: <https://acoep.org/main/publications/patientswithautism-4/>
9. University of Louisville. UofL, Harvard and USF provide model for medical schools to teach the signs of human trafficking. Retrieved February 17, 2020, from <https://louisville.edu/medicine/departments/pediatrics/news/uofl-harvard-and-usf-provide-model-for-medical-schools-to-teach-the-signs-of-human-trafficking>

10. Hanni Stoklosa, Michelle Lyman, Carrie Bohnert & Olivia Mittel (2017) Medical education and human trafficking: using simulation, Medical Education Online, 22:1, 1412746, DOI: 10.1080/10872981.2017.1412746
11. Human Trafficking. (2016, October 4). Retrieved February 25, 2020, from <https://www.aafp.org/about/policies/all/human-trafficking.html>
12. Human Trafficking. (n.d.). Retrieved February 25, 2020, from <https://www.acep.org/patient-care/policy-statements/human-trafficking/>
13. Human trafficking. (2014, November 28). Retrieved February 25, 2020, from [https://www.who.int/reproductivehealth/publications/violence/rhr12\\_42/en/](https://www.who.int/reproductivehealth/publications/violence/rhr12_42/en/)
14. HUMAN TRAFFICKING – AWARENESS AS A GLOBAL HEALTH PROBLEM. (2019). Retrieved February 17, 2020, from <https://osteopathic.org/about/leadership/policy-search/?aoatextsearchinline=trafficking>
15. INCLUSION OF HUMAN TRAFFICKING TRAINING IN OSTEOPATHIC MEDICAL SCHOOL CURRICULA. (2017, March 4). Retrieved February 17, 2020, from <https://studentdo.org/soma-policy-database/?aoatextsearchinline=traffickin>

Explanatory Statement: Reference Committee

The Committee recommends amendments to correct terminology and statistics and to reduce the perceived fiscal impact on the AOA as well as encourage all CME sponsors to consider providing educational offerings on this topic. Further, the Committee was informed that a number of State licensing boards already include this topic among those required.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H401-A/19 HUMAN TRAFFICKING – AWARENESS AS A GLOBAL HEALTH PROBLEM

**Prior HOD action on similar or same topic:** Policy reaffirmed in 2019.

FISCAL IMPACT: Up to approximately \$130,000 in additional expense.

The amount of additional expense will depend upon the type of activity and number of CME hours involved. For example, a conservative estimate based upon a one CME hour journal article would be \$13,000, whereas, a high-end estimate based upon a 10 credit CME in-person workshop could be \$130,000.

ACTION TAKEN: **REFERRED** (*to Bureau of Osteopathic Education with proposed amendments*)

DATE: **October 14, 2020**





1 WHEREAS, medical students, residents, and practicing physicians have demonstrated  
2 deficiencies in the most basic patient care towards common forms of disability, such as  
3 cerebral palsy and learning disabilities<sup>5</sup>; and

4 WHEREAS, given the range in exposure to clinical populations, there is no guarantee that  
5 medical students will interact with patients with disabilities in medical school<sup>6</sup>; and

6 WHEREAS, providers have reported feeling inadequate in addressing this population's  
7 healthcare needs due to lack of education received in prior years of schooling,<sup>4</sup> and  
8 illnesses that are readily apparent in persons without disabilities may remain  
9 undiagnosed in individuals with I/DD<sup>3</sup>; and

10 WHEREAS, 40% of internal medicine physicians do not feel comfortable caring for patients  
11 with chronic disease of childhood-onset secondary to lack of familiarity with the  
12 literature, lack of training with this population, and lack of coordination among  
13 specialists<sup>8</sup>; and

14 WHEREAS, Section 5307 of the Patient Protection and Affordable Care Act states that a  
15 model disability curriculum should be developed that addresses “cultural competency,  
16 prevention, public health proficiency, reducing health disparities, and aptitude for  
17 working with individuals with disabilities”;<sup>2</sup> however, only a few healthcare programs  
18 have included disability topics within their curriculum<sup>2</sup>; and

19 WHEREAS, a multitude of medical schools have incorporated education tools within their  
20 curriculum to improve medical students' preparedness for communicating with persons  
21 with disabilities that led students to report feeling more prepared and knowledgeable  
22 about properly caring for this community<sup>6</sup>; and

23 WHEREAS, a study of pre-clinical medical school curriculum focused on healthcare disparities  
24 of and biases towards disabled communities in an effort to change the current attitudes  
25 of healthcare providers towards persons with disabilities led to the majority of medical  
26 students involved in this curriculum development course responding positively and  
27 believing community involvement with patients would be helpful for future clinical  
28 work<sup>2</sup>; and

29 WHEREAS, results from physician education seminars for a clinical improvement program in  
30 the treatment of the intellectual and developmental disabilities population reveal  
31 statistically significant improvements in self-assessed competence and clinician  
32 knowledge<sup>9</sup>; and

33 WHEREAS, in order to improve the quality of healthcare for people with I/DD, individual  
34 providers must expand their knowledge base and skill set via professional education to  
35 be integrated with didactic and clinical training that include: direct interactions with  
36 these patients, history taking, cultural practices, diagnostic treatment, as well as  
37 counseling and supporting individuals<sup>7</sup>; and

38 WHEREAS, AOA sponsored conferences since January 1, 2019 did not discuss specific topics  
39 regarding the care and treatment of the adult intellectual and developmental disabilities  
40 population<sup>9</sup>; and

1 WHEREAS, AOA Resolution H211-A/18 “encourages osteopathic medical schools to develop  
2 and implement curricula on the care of people with developmental disabilities<sup>10</sup>”; and

3 WHEREAS, by instilling earlier education into the medical curriculum, along with continuing  
4 education for all levels of practice, improvements may be seen in the degree of comfort  
5 and quality of care that is delivered<sup>10</sup>; now, therefore be it

6 RESOLVED, that the American Osteopathic Association (AOA) **incorporates**  
7 **ENCOURAGES CONTINUING MEDICAL EDUCATION**  
8 **OPPORTUNITIES** ~~content~~ regarding intellectual and developmental disability care  
9 for adults ~~during AOA-sponsored conferences.~~

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. Davis, L.J. (2015). Enabling acts: the hidden story of how the Americans with Disabilities Act gave the largest U.S. minority its rights. Boston: Beacon Press.
2. Rogers J.M., Morris M.A., Hook C.C., Havyer R.D. Introduction to disability and health for preclinical medical students: didactic and disability panel discussion. MedEdPORTAL. 2016;12:10429. [https://doi.org/10.15766/mep\\_2374-8265.10429](https://doi.org/10.15766/mep_2374-8265.10429)
3. Curriculum-NCIDM. (n.d.). Retrieved February 2, 2020, from <https://aadmd.org/page/ncidmpreamble>
4. Who.int. (2020). Disability and health. Retrieved February 1, 2020, from <https://www.who.int/newsroom/factsheets/detail/disability-and-health>
4. Symons, A. B., McGuigan, D., & Akl, E. A. (2009). A curriculum to teach medical students to care for people with disabilities: development and initial implementation. BMC medical education, 9, 78. <https://doi.org/10.1186/1472-6920-9-787>
5. Minihan, P. M., Bradshaw, Y. S., Long, L. M., Altman, W., et al. (2004). Teaching about disability: involving patients with disabilities as medical educators. Disability Studies Quarterly, 24(4). doi: 10.18061/dsq.v24i4.883
6. Office of the Surgeon General (US); National Institute of Child Health and Human Development (US); Centers for Disease Control and Prevention (US). (2002). Closing the gap: a national blueprint to improve the health of persons with mental retardation: report of the surgeon general's conference on health disparities and mental retardation. Washington (DC): US Department of Health and Human Services. Goals and Action Steps. Retrieved January 10, 2020, from <https://www.ncbi.nlm.nih.gov/books/NBK44354/>
7. Douthitt Stief, H., & Clark, M. (2013, December 29). A survey of patients, families and providers about care of patients with intellectual disabilities. Retrieved February 2, 2020, from <http://aadmd.org/articles/survey-patients-families-and-providers-about-care-patients-intellectualdisabilities>
8. Social model of disability. (2017, April 12). Retrieved February 14, 2020, from <https://www.mentalhealth.org.uk/learning-disabilities/a-to-z/s/social-model-disability>
9. American Osteopathic Association Events. (2019). <https://osteopathic.org/about/aoa-events/>
10. American Osteopathic Association 98th Annual House of Delegates Meeting. (2018). <http://policysearch.wpengine.com/wp-content/uploads/H211-A2018->

[DEVELOPMENTAL-DISABILITIES-CURRICULUM-ON-THE-CARE-OF-PEOPLE.pdf](#)

Explanatory Statement: Reference Committee

The Committee heard mixed testimony on this resolution. Advocates wished to highlight the topic of disability through inclusion during AOA conferences. Those in opposition cited the potential fiscal note. The Committee believes the AOA House of Delegates should not mandate specific CME content at AOA-sponsored conferences. Decisions on CME content should be based on the CME sponsor's practice gap analysis of its intended audience, which may include sessions regarding the care of disabled patients.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: Up to approximately \$130,000 in additional expense.

The amount of additional expense will depend upon the type of activity and number of CME hours involved. For example, a conservative estimate based upon a one CME hour journal article would be \$13,000, whereas, a high-end estimate based upon a 10 credit CME in-person workshop could be \$130,000.

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: RECOMMENDATION OF BUPRENORPHINE WAIVER TRAINING IN  
OSTEOPATHIC MEDICAL SCHOOLS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Educational Affairs

---

- 1 WHEREAS, opioid overdose has become a leading cause of death in the United States<sup>1</sup>; and
- 2 WHEREAS medication-assisted treatment (MAT), including buprenorphine formulations and  
3 other opioid receptor agonists and antagonists, is an effective, evidence-based treatment  
4 for opioid use disorder (OUD) and is an integral part of guidelines promoted by the  
5 National Institute on Drug Abuse and the American Society of Addiction Medicine<sup>2</sup>;  
6 and
- 7 WHEREAS the Drug Addiction Treatment Act of 2000 (DATA 2000) requires prescribers to  
8 undergo a training regimen designed by the US Drug Enforcement Agency (DEA)  
9 before receiving authorization to prescribe MAT<sup>3</sup>; and
- 10 WHEREAS the American Osteopathic Association and its member institutions are committed  
11 to fully equipping osteopathic medical students with the evidence-based tools needed to  
12 meet the most pressing needs of 21<sup>st</sup> century medicine<sup>4</sup>; now, therefore be it
- 13 RESOLVED, the American Osteopathic Association recommends that osteopathic medical  
14 schools will adopt and incorporate an approved DATA 2000 waiver training program  
15 into their core curricula, with implementation no later than the matriculating class of  
16 2022.

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. Lawrence Scholl et al., “Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017,” *MMWR. Morbidity and Mortality Weekly Report* 67, no. 5152 (January 4, 2018): 1419–27, <https://doi.org/10.15585/mmwr.mm675152e1>.
2. National Institute on Drug Abuse, “Principles of Effective Treatment,” accessed May 28, 2020, <https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/principles-effective-treatment>; Sandra Comer et al., “National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use,” 2015, 66; Roger D. Weiss et al., “Long-Term Outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study,” *Drug and Alcohol Dependence* 150 (May 1, 2015): 112–19, <https://doi.org/10.1016/j.drugalcdep.2015.02.030>.
3. Substance Abuse and Mental Health Services Administration, “MAT Statutes, Regulations, and Guidelines,” accessed May 28, 2020, <https://www.samhsa.gov/>.

4. Stephen C. Shannon, “Reevaluating Osteopathic Medical Education for the 21st Century and Beyond,” *The Journal of the American Osteopathic Association* 114, no. 4 (April 1, 2014): 228–30, <https://doi.org/10.7556/jaoa.2014.046>.

Explanatory Statement: Reference Committee

The Committee believes the policy as written is inappropriate because the AOA lacks sufficient authority over educational curricula, as that rests with the COCA. Curricular initiatives addressing the treatment of pain and opioid use disorder already currently exist at many osteopathic medical schools. In addition, the Committee believes that waiver training in osteopathic medical school may be too early since osteopathic medical students do not have DEA certificates and would be more appropriate training during residency, temporally closer to the time when they would prescribe medications for opioid use disorder.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: REFERRED RES. NO H-224 – A/2019 AOA BOARD CERTIFICATION  
TERMINOLOGY

SUBMITTED BY: Bureau of Osteopathic Specialists

REFERRED TO: Committee on Educational Affairs

---

1 RESOLVED, THAT THE TERMINOLOGY FOR AMERICAN OSTEOPATHIC  
2 ASSOCIATION ISSUED BOARD CERTIFICATIONS SHOULD STATE THAT A  
3 CERTIFICATE HOLDER IS “BOARD CERTIFIED IN THE PRINCIPLES AND  
4 PRACTICE OF OSTEOPATHIC “SPECIALTY”

Explanatory Statement: Submitted by Author:

The BOS believes that adding Osteopathic in front of the specialty name is redundant and unnecessary. The certification is an osteopathic certification because it comes from the American Osteopathic Association, and therefore, the inclusion of Osteopathic Principles and Practices is strongly implied. There is no doubt that the certification is osteopathic as the word osteopathic appears on each certificate a minimum of five (5) times.

Explanatory Statement: Reference Committee

At the 2019 House of Delegates, the House referred Resolution H224-A/19 to the Bureau of Osteopathic Specialists (BOS) for review and recommendation. Resolution H211, submitted by BOS, does not respond to the 2019 House of Delegates request, and therefore, Resolution H224-A/19 still requires final action by the House of Delegates. The Committee presents Substitution Resolution H211, which is the resolved statement from H224-A/19. The testimony heard by the Committee was in opposition to this language, and generally supportive of the current terminology included on AOA board certificates. The Committee supports the BOS and its member certifying boards, believing that the BOS and its member certifying boards must have the authority to determine the terminology used on AOA board certificates. Current AOA board certificates state the word, “Osteopathic” a minimum of five (5) times and the Committee believes this to be sufficient.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: AOA BOARD CERTIFICATION TERMINOLOGY

SUBMITTED BY: Massachusetts Osteopathic Society

REFERRED TO: Committee on Educational Affairs

---

1 WHEREAS, the mission statement of the American Osteopathic Association (AOA) is to  
2 “advance the distinctive philosophy and practice of osteopathic medicine”; and

3 WHEREAS, the mission statement of the Bureau of Osteopathic Specialties (BOS) states that  
4 “the BOS is the certifying body for the approved specialty boards of the AOA and is  
5 dedicated to establishing the high standards for certification of osteopathic physicians”;  
6 and

7 WHEREAS, the AOA advertises the DO difference on [www.doctorsthatdo.org](http://www.doctorsthatdo.org), by stating that  
8 “There are more than 100,000 DOs in the US, practicing their distinct philosophy in  
9 every medical specialty. We have additional training in OMT and use this tool to help  
10 diagnose, treat and prevent illness and injury”; and

11 WHEREAS, [www.doctorsthatdo.org](http://www.doctorsthatdo.org) also claims that “by combining the latest advances in  
12 medical technology with OMT, Doctors of Osteopathic Medicine offer their patients  
13 the most comprehensive care available in medicine today”; and

14 WHEREAS, osteopathic medical schools provide 4 years of distinct training in Osteopathic  
15 Principles and Practice (OPP) and OMT via minimal standards established by ECOP,  
16 including over 200 hours of training in OMT, with practical exams, OSCE, and  
17 COMLEX exams”; and

18 WHEREAS, the results of a survey of 214 people, 96% of whom were practicing DOs across  
19 the USA, shows that 88% of respondents agree that osteopathic certification  
20 terminology should clearly state a holder is certified in osteopathic principles and  
21 practice; and

22 WHEREAS, Appendix A of the July 2018 BOS Handbook has approved terminology for  
23 certification already approved that states, “General certification represents a distinct and  
24 well defined field of osteopathic medical practice; now, therefore be it

25 RESOLVED, that the terminology for American Osteopathic Association issued board  
26 certifications should state that a certificate holder is “Board certified in the Principles  
27 and Practice of Osteopathic “Specialty”.

Reference Committee Explanatory Statement:

Specific terminology on certificates is determined by the BOS and the individual certifying boards. The Committee requests the BOS report back to the 2020 House of Delegates on this issue.

ACTION TAKEN **REFERRED** *(to Bureau of Specialists)*

DATE **July 27, 2019** \_\_\_\_\_

ACTION TAKEN: **NOT ADOPTED by action of substitute resolution H211 – Oct. 13 2020**

DATE: **October 14, 2020** \_\_\_\_\_



SUBJECT: RESIDENCY REDISTRIBUTION OF CENTER FOR  
MEDICARE/MEDICAID SERVICES FUNDING FOLLOWING  
SINGLE ACCREDITATION SYSTEMS (SAS)

SUBMITTED BY: Osteopathic Physicians & Surgeons of California

REFERRED TO: Committee on Educational Affairs

---

1 WHEREAS, the Accreditation Council of Graduate Medical Education (ACGME) ratified the  
2 Memorandum of Understanding (MOU) for the Single Accreditation Systems (SAS)  
3 with the American Osteopathic Association (AOA) and American Association of  
4 Colleges of Osteopathic Medicine (AACOM) in 2014 for the transition of AOA  
5 accredited residencies into ACGME accredited programs starting in 2015; and

6 WHEREAS, the majority of Graduate Medical Education (GME) residency funding is by  
7 Centers of Medicare Medicaid Services (CMS) through direct graduate medical  
8 education (DGME) funding and indirect funding (IME); and

9 WHEREAS, the vast majority of those AOA accredited residencies that applied under SAS  
10 successfully achieved ACGME accreditation but without an increase in the total CMS  
11 funded GME residency positions; and

12 WHEREAS, a percentage of AOA accredited programs did not apply for ACGME  
13 accreditation and will close after the July 2020 date with a loss of CMS funded GME  
14 positions during a time when more funded ACGME positions are needed; and

15 WHEREAS, the consequence of many the AOA accredited programs not applying for  
16 transition from AOA accreditation to ACGME accreditation will be the loss of CMS  
17 funded positions and will significantly affect those communities that had GME  
18 positions prior to July 1, 2020 and are in need for medical care; and

19 WHEREAS, CMS may redistribute some or all the GME funded but closed residency training  
20 positions to other ACGME residencies; now therefore be it

21 RESOLVED, that the American Osteopathic Association (AOA) advocate and work in  
22 conjunction with the Accreditation Council of Graduate Medical Education (ACGME)  
23 to advocate for the continued development and Centers of Medicare Medicaid Services  
24 (CMS) funding of ACGME accredited residency training programs in rural and  
25 underserved areas affected by Graduate Medical Education (GME) residency position  
26 losses; and, be it further

27 RESOLVED, that the AOA advocates that CMS prioritizes funding new residency positions,  
28 and that these funds are not used to offset non-CMS funded residency positions.

Explanatory Statement: Submitted by Author  
None provided.

Explanatory Statement: Reference Committee

The Committee received testimony that was mostly against the adoption of this resolution, including a desire by the authors to withdraw the resolution. The Committee believes that the current policies, H213-A/15, H329-A/16, and H201-A/19 satisfactorily address the concepts proposed within this resolution.

Background Information: Provided by AOA Staff

**Current AOA Policy:**

H329-A/16 GRADUATE MEDICAL EDUCATION FUNDING AND INCENTIVES

H201-A/19 GRADUATE MEDICAL EDUCATION – INCREASING OPPORTUNITIES

**Prior HOD action on similar or same topic:** H320-A/16 policy approved in 2016; H201-A/19 reaffirmed in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: TRAINING HIGH QUALITY PHYSICIANS IN A HEALTHY AND SAFE ENVIRONMENT

SUBMITTED BY: Maryland Association of Osteopathic Physicians

REFERRED TO: Committee on Educational Affairs

---

1 WHEREAS, the goal of osteopathic medical schools is to train competent, caring physicians  
2 who will be comfortable caring for people in all clinical care settings, and

3 WHEREAS, all osteopathic medical schools have developed their own method of assessment  
4 designed to assure that students acquire and demonstrate core clinical skills, and

5 WHEREAS, the COVID-19 pandemic has created challenges and risks to students who have to  
6 travel to national standardized examinations administered by the National Board of  
7 Osteopathic Medical Examiners (NBOME) to one of two standardized testing centers  
8 run by the NBOME, and

9 WHEREAS, the COVID-19 pandemic has created challenges and risks to students by exposing  
10 students to standardized patients, and

11 WHEREAS, the NBOME is still striving to schedule and administer a standardized clinical  
12 skills/performance evaluation examination to all current osteopathic medical students in  
13 a safe manner, and

14 WHEREAS, the NBOME has provided conflicting information on scheduling dates for this  
15 examination to osteopathic medical students which has necessitated multiple  
16 rescheduled examinations, and

17 WHEREAS, communication from the NBOME on plans to make the performance  
18 evaluation/clinical skills exam safe for students and with key stakeholders needs to be  
19 done in a timely manner, and

20 WHEREAS, the time and resources required of students to take the clinical skills/performance  
21 evaluation removes students from the learning environment with required travel for  
22 longer than other alternatives, and

23 WHEREAS, all osteopathic medical schools have clinical skills training sites at each college of  
24 osteopathic medicine, and

25 WHEREAS, technology has provided us with new efficient and safe ways to assess the same  
26 skills; now therefore be it,

27 RESOLVED, that the American Osteopathic Association (AOA) work with key stakeholders  
28 to provide safe and remote clinical skills testing without granting a monopoly to any one  
29 business entity; and be it further

- 1           RESOLVED, that clinical skills testing in a standardized, safe and effective format be provided  
2                    in the safest manner possible even if that means that the tests be provided through the  
3                    Colleges of Osteopathic Medicine or other entities such as state or specialty societies,  
4                    and be it further
- 5           RESOLVED, that American Association of Colleges of Osteopathic Medicine (AACOM) and  
6                    the AOA work to create a feedback system for the National Board of Osteopathic  
7                    Medical Examiners' (NBOME) performance regarding communication with students  
8                    and key stakeholders, and attention to safety and industry standards in scheduling test  
9                    administration to see how the NBOME performs and where an increased focus might  
10                  be necessary to meet the standards expected.

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

The Committee heard mixed testimony, but mostly against the adoption of this resolution. The Committee believes that the resolution is not within the AOA's authority. The AOA does not mandate the work of AACOM, NBOME, or Colleges of Osteopathic Medicine. The intent of the resolution is wholly supported, and the Committee is hopeful that the clinical skills testing will be given in a standardized, safe and effective format.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H206-A/16 COMPLEX-USA LEVEL 2-PE

**Prior HOD action on similar or same topic:** Policy reaffirmed in 2016.

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: AUDITION ROTATIONS FOR OSTEOPATHIC MEDICAL STUDENTS

SUBMITTED BY: Iowa Osteopathic Medical Association

REFERRED TO: Committee on Educational Affairs

---

1        **WHEREAS**, the Single Accreditation System (SAS) was fully implemented on July 1, 2020; and  
2        WHEREAS, most FOURTH-YEAR medical students ~~must~~ CHOOSE TO schedule  
3        VISITING STUDENT OR “audition” rotations at ~~hospitals~~ INSTITUTIONS,  
4        OTHER THAN THOSE AFFILIATED WITH THEIR OWN MEDICAL SCHOOL  
5        ~~which~~ THAT sponsor residencies into which the student desires to match; and  
6        WHEREAS, some ~~hospitals~~ INSTITUTIONS charge FOURTH-YEAR medical students a fee  
7        for ~~participating in audition~~ VISITING STUDENT rotations; and  
8        WHEREAS, in some ~~hospitals~~ INSTITUTIONS, FOURTH-YEAR osteopathic medical  
9        students are required to pay substantially higher fees than allopathic students ~~are~~  
10       ~~required to pay~~ or are being refused the opportunity to participate in ~~audition~~  
11       VISITING STUDENT rotations solely because they are enrolled in an osteopathic  
12       medical college<sup>1</sup>; ~~and~~  
13       ~~WHEREAS, this places osteopathic medical students at a significant disadvantage in matching~~  
14       ~~into their desired residency program and causes them to incur significantly higher~~  
15       ~~expenses compared to allopathic medical students; now therefore be it,~~  
16       RESOLVED, that the American Osteopathic Association (AOA), ~~through its representatives to~~  
17       ~~the Accreditation Council in Graduate Medical Education (ACGME)~~ PARTNER  
18       WITH INTERESTED STAKEHOLDERS INCLUDING, BUT NOT LIMITED TO,  
19       THE ASSOCIATION OF AMERICAN MEDICAL COLLEGES(AAMC) AND  
20       AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE  
21       (AACOM) TO ADDRESS ~~seek changes to the institutional accreditation standards to~~  
22       ~~prohibit~~ the discriminatory practice of **PROHIBITING MEDICAL STUDENTS**  
23       **FROM VISITING STUDENT ROTATIONS OR CHARGING DIFFERENT**  
24       **FEES TO MEDICAL STUDENTS BASED SOLELY ON THEIR**  
25       **OSTEOPATHIC TRAINING** ~~charging osteopathic medical students a fee different~~  
26       ~~than~~ FROM THAT is charged to allopathic students for ~~audition~~ VISITING  
27       STUDENT rotations (E.G. AUDITION ROTATIONS); and, be it further  
28       RESOLVED, that the AOA WORK WITH ANY AND ALL RELEVANT  
29       ORGANIZATIONS TO ~~also seek any other~~ necessary changes in institutional or  
30       residency standards **POLICIES AND/OR PRACTICES THAT PROHIBIT**  
31       **VISITING STUDENT ROTATIONS OR CHARGE INEQUITABLE FEES**  
32       **TO MEDICAL STUDENTS BASED SOLELY ON THEIR OSTEOPATHIC**  
33       **TRAINING** ~~to prevent any ACGME accredited institution or program from~~  
34       ~~discriminating~~ THAT MAY ALLOW FOR BIAS against osteopathic medical students  
35       or residents ~~in any way~~; and, be it further

1 RESOLVED, that ~~when~~ the AOA WILL CONTINUE TO ADVOCATE FOR  
2 OSTEOPATHIC MEDICAL STUDENTS AND RESIDENTS WITH  
3 INSTITUTIONS, PROGRAMS, AND OTHER RELEVANT STAKEHOLDERS  
4 WHEN THE AOA becomes aware of any instance of discrimination ~~against~~  
5 ~~osteopathic medical students, it shall advocate on behalf of the students with the~~  
6 ~~institution.~~

Explanatory Statement: Submitted by Author

1. See the following example:

**“The University of Iowa Carver College of Medicine annually accepts applications from visiting fourth year medical students from LCME accredited schools. (We cannot accept applications from D.O. students in Osteopathic programs)”**

“Visiting Student Information and Application”, *University of Iowa, Carver School of Medicine*, <https://medicine.uiowa.edu/md/student-support/visiting-student-information-and-application>, accessed June 10, 2020

“A nonrefundable application fee of \$150 for MD students is due on receipt of an offer for externship. DO and International medical students are required to pay a nonrefundable fee of \$4,150 on receipt of an offer for externship.”

“Visiting Students for Academic Year 2020-2021”, *University of Colorado School of Medicine*, <http://www.ucdenver.edu/academics/colleges/medicalschoo/education/studentaffairs/extern/Pages/default.aspx>, accessed June 10, 2020

**“2. APPLICATION FEE – NOT REQUIRED FOR LCME-APPROVED OR DOMESTIC MEDICAL SCHOOLS.**

Osteopathic Students: \$50 payable to “UIC” in the form of a money order, traveler’s check or cashier’s check.

Fee waived (LCME/domestic)”

“Checklist for non-UIC medical students applying for electives and sub-internships at the university of Illinois college of medicine”, *University of Illinois, College of Medicine*, [http://chicago.medicine.uic.edu/wp-content/uploads/sites/6/2017/08/Medical-students-Visiting-Complete-packet\\_032917-1.pdf](http://chicago.medicine.uic.edu/wp-content/uploads/sites/6/2017/08/Medical-students-Visiting-Complete-packet_032917-1.pdf), accessed June 10, 2020

Explanatory Statement: Reference Committee

The committee heard mixed testimony but general support for the premise of the initial resolution. It was noted that the ACGME does not have purview over medical students or any fees charged to them for visiting, or "audition", rotations. The committee believes that the proposed amended resolution captures the spirit of the initial resolution and addresses the responsible stakeholder organizations.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**



**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES  
OCTOBER 2020 MEETING  
PROFESSIONAL AFFAIRS - RESOLUTION ROSTER  
WITH ACTION**

**HOUSE OF DELEGATES' REFERENCE COMMITTEE DESCRIPTION:**

- Committee on Professional Affairs (300 series)  
This reference committee reviews and considers matters relating to osteopathic health care facilities, advocacy, legislation, membership and conventions.

Res. No.	Resolution Title	Submitted By	Action
H300	Intractable and/or Chronic Pain (Not Associated with End of Life Care) (H327-A/15)	BSGA	REFERRED
H301	Retail-Based Health Clinics and Urgent Care Centers (H303-A/15)	BSAPH	ADOPTED as AMENDED
H302	Protecting American Students from Profit-Driven Foreign Medical Schools (H304-A/15)	BFHP	ADOPTED
H303	Remove FDA Ban on Anonymous Sperm Donation from Men Who Have Sex with Men (H305-A/15)	BFHP / BSAPH	ADOPTED
H304	Improving Competitive Edge for Membership in the AOA (H308-A/15)	BOM	ADOPTED
H305	Tax Credit for Precepting (H312-A/15)	BSGA	ADOPTED as AMENDED
H306	Site Neutral Reimbursement (H396-A/15)	BFHP	ADOPTED as AMENDED
H307	Supporting the Use of OMM in the VA (H311-A/15)	BHFP	ADOPTED
H308	Practice Rights of Osteopathic Physicians (H313-A/15)	BSGA	ADOPTED as AMENDED
H309	Retail Medical Clinics in Facilities Selling Tobacco, Nicotine or Vaping Products (H314-A/15)	BSAPH	ADOPTED as AMENDED
H310	Osteopath and Osteopathy - Use of the Term (H315-A/15)	BIOM	ADOPTED
H311	Patient Access in Rural Areas (H317-A/15)	BSGA	ADOPTED <i>(for sunset)</i>
H312	Physician Office Laboratories (H318-A/15)	BFHP	ADOPTED
H313	Postgraduate Compensation (H319A/15)	BOE	ADOPTED as AMENDED
H314	Second Opinion, Surgical Cases (H320-A/15)	BSA	ADOPTED
H315	Uniformed Services: Endorsement of Physicians Serving in the Uniformed Services (H322-A/15)	BFHP	ADOPTED as AMENDED
H316	Emergency Medical Services for Children, Support of (H323-A/15)	BFHP	ADOPTED as AMENDED





**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES  
OCTOBER 2020 MEETING  
PROFESSIONAL AFFAIRS - RESOLUTION ROSTER  
WITH ACTION**

Res. No.	Resolution Title	Submitted By	Action
H317	Physician Incentives to Underserved Areas (H324-A/15)	BSGA	ADOPTED
H318	Vaccines Shortages (H326-A/15)	BFHP	ADOPTED as AMENDED
H319	Medicare Balance Billing (H329-A/15)	BFHP	ADOPTED as AMENDED
H320	Electronic Prescribing of Controlled Substances (H332-A/15)	BSA	ADOPTED ( <i>for sunset</i> )
H321	Professional Organization -- Physicians Choosing to Which They Belong (H334-A/15)	BOM	NOT ADOPTED
H322	Prescription Drug Diversion and Abuse – Education, Research, and Advocacy (H335-A/15)	BSGA	ADOPTED
H323	Buprenorphine Maintenance Treatment Insurance Coverage (H336-A/15)	BSA	ADOPTED
H324	Violence Against Healthcare Staff (H337-A/15)	BSGA	ADOPTED as AMENDED
H325	Low Back Pain Clinical Practice Guidelines, Revision of (H338-A/15)	BOCER	ADOPTED as AMENDED
H326	Addressing the Effects of Climate on National Health	SOMA	REFERRED
H327	Adverse Childhood Experiences Screening	SOMA	ADOPTED as AMENDED
H328	Inclusion of Patient Education on Organ Donation as a Component of a Primary Care Visit	SOMA	NOT ADOPTED
H329	Inequalities in Medicaid Funding Affecting U.S. Territories	SOMA	ADOPTED as AMENDED
H330	Improving Insulin Affordability	SOMA	REFERRED
H331	Medication for Opioid Use Disorder Insurance Coverage	AOAAM	NOT ADOPTED
H332	Recruitment and Retention of Native Americans in Medicine	SOMA	NOT ADOPTED
H333	WITHDRAWN	SOMA	WITHDRAWN
H334	Sustainability at AOA Events	MOA	NOT ADOPTED
H335	H357-A/19 Nutrition and Leading By Example	OPSC	NOT ADOPTED
H336	REFERRED RESOLUTION: H324-A/14 Use of the Term “Physician” “Doctor” and “Provider”	BSGA	ADOPTED



---

**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES  
OCTOBER 2020 MEETING  
PROFESSIONAL AFFAIRS - RESOLUTION ROSTER  
WITH ACTION**

<b>Res. No.</b>	<b>Resolution Title</b>	<b>Submitted By</b>	<b>Action</b>
H337	CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016	IOMA	ADOPTED as AMENDED

SUBJECT: H327-A/15 INTRACTABLE AND / OR CHRONIC PAIN (NOT ASSOCIATED WITH END OF LIFE CARE)

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H327-A/15 INTRACTABLE AND/OR CHRONIC PAIN (NOT ASSOCIATED**  
5 **WITH END OF LIFE CARE)**

6 The American Osteopathic Association supports the enactment of legislation concerning the  
7 administration of controlled substances to persons experiencing intractable and/or chronic  
8 non-malignant pain substantially conforming to the attached definitions and requirements; and  
9 will advocate and promote to students, residents, fellows and practicing physicians educational  
10 resources regarding addictive disorders, diversion awareness and monitoring and appropriate  
11 referral resources, as well as the prevention and treatment of pain disorders.

12 **Definitions:**

13 A. Intractable ~~and/or chronic~~ pain means a pain state in which the cause of the pain  
14 cannot be removed or otherwise definitively treated and which in the generally accepted  
15 course of medical practice, no relief or cure of the cause of the pain is possible or none  
16 has been found after reasonable efforts including, but not limited to, a face to face  
17 evaluation by the attending physician and one or more physicians specializing in the  
18 treatment of the area, system, or organ of the body perceived as the source of the pain.  
19 Chronic non-malignant pain may be associated with a long-term incurable or intractable  
20 medical condition or disease.

21 THE CENTERS FOR DISEASE CONTROL AND PREVENTION DEFINES  
22 CHRONIC PAIN AS “PAIN THAT TYPICALLY LASTS >3 MONTHS OR PAST  
23 THE TIME OF NORMAL TISSUE HEALING. CHRONIC PAIN CAN BE THE  
24 RESULT OF AN UNDERLYING MEDICAL DISEASE OR CONDITION,  
25 INJURY, MEDICAL TREATMENT, INFLAMMATION, OR AN UNKNOWN  
26 CAUSE.”<sup>1</sup>

27 ~~Requirement~~ GUIDELINES:

28 A. Notwithstanding any other provision of law, a physician may prescribe or administer  
29 controlled substances to a person in the course of the physician's treatment of the  
30 person for a diagnosed condition causing intractable and/or chronic pain. This includes  
31 patients with chemical dependency and/or substance abuse history if chronic pain exists

---

<sup>1</sup> Dowell, Deborah; Haegerich, Tamara; Chou, Roger. “CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016.” *Recommendations and Reports*, March 18, 2016 / 65(1);1–49. See [https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6501e1er.htm](https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6501e1er.htm).

1 and controlled substance management is indicated. Physician hypervigilance in  
2 screening for drugs of abuse, as well as the presence of the treatment medication in  
3 these patients is necessary.

4 B. No physician shall be subject to ~~disciplinary~~-ADVERSE action (by the state medical  
5 board, EMPLOYERS, INSURERS, ETC.) for appropriately prescribing or  
6 administering controlled substances in the course of treatment of a person for  
7 intractable pain and/or chronic pain.

8 C. No physician shall be subject to criminal prosecution (by state or federal agencies) for  
9 appropriately prescribing or administering medically necessary controlled substances in  
10 the course of treatment of a person for intractable pain and/or chronic pain.

11 D. This section shall not authorize a physician to prescribe or administer controlled  
12 substances to a person the physician knows to be using drugs or substances for non-  
13 therapeutic purposes.

14 E. This section ~~does not affect~~ IS NOT INTENDED TO INTERFERE WITH the  
15 power (of the state medical board) to deny, revoke, or suspend the license of any  
16 physician who fails to keep accurate records of purchases and disposal of controlled  
17 substances, writes false or fictitious prescriptions for controlled substances, or  
18 prescribes, administers, or dispenses in violation of state controlled substances actS.

19 ~~Recent court decisions in multiple states have criminalized civil malpractice litigation. This has~~  
20 ~~resulted in subsequent incarceration and/or other imposed criminal sentencing. Therefore, the~~  
21 ~~previously adopted AOA language supporting appropriate, medically necessary pain~~  
22 ~~management needs to be revisited. Furthermore, the term intractable pain is ambiguous as to~~  
23 ~~the source. A policy on hospice related pain exists and is supportive of palliative care, including~~  
24 ~~opiate and/or controlled substance management for terminally ill patients. This defines~~  
25 ~~intractable pain in the terminally ill, but further clarification is necessary for chronic pain.~~  
26 ~~Chronic pain might also necessitate opiate and/or controlled substance management for~~  
27 ~~patients when other interventions have been inadequate. Opiate and/or controlled substance~~  
28 ~~management in treating chronic pain patients in those with substance abuse disease issues is~~  
29 ~~now supported as a standard of care by the medical literature. Such patients require physician~~  
30 ~~hypervigilance as part of this standard of care. (2005, revised 2010)~~

Explanatory Statement: Submitted by Author

The final paragraph was deleted because according to Suffolk University's *Journal of Health & Biomedical Law*, "only about 15 appellate cases of criminal medical malpractice" occurred between 1809 and 1981, and there have only been a handful of criminal cases since. This data does not support the statements that "[r]ecent court decisions in multiple states have criminalized civil malpractice litigation. This has resulted in subsequent incarceration and/or other imposed criminal sentencing. Therefore, the previously adopted AOA language supporting appropriate, medical necessary pain management needs to be revisited."

H438-A/17 END OF LIFE CARE – POLICY STATEMENT ON is the current AOA policy referenced in lines 28-29 on page 2. This policy is supportive of palliative care and physicians' ability to prescribe appropriate analgesics for pain without fear of repercussions, but it does not define "intractable pain" or specifically mention opioids; therefore, those lines have been deleted.

Explanatory Statement: Reference Committee

It is unclear if this is to be a guideline as suggested by the change from “Requirement” to “Guidelines” in page 1, line 27, or if it is to be model legislation as suggested by the language in section B or C of the “Guidelines”. Recommend language be clarified to be consistent with model legislation since there is a lack of evidence-based literature referenced. Also recommend title of resolution be updated to match language change proposed on page 1, line 13.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** (*to Council on State Health Affairs*)

DATE: **October 14, 2020**

SUBJECT: H303-A/15 RETAIL-BASED HEALTH CLINICS AND URGENT CARE CENTERS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommend that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H303-A/15 RETAIL-BASED HEALTH CLINICS AND URGENT CARE**  
5 **CENTERS**

6 The American Osteopathic Association recommends that retail-based health clinics and urgent  
7 care centers adhere to the following principles and standards to guide their establishment and  
8 operation (2006; reaffirmed as amended 2011; revised 2015)

- 9 1. Retail-based health clinics and urgent care centers must establish arrangements by  
10 which their health care practitioners have direct access to and supervision by physicians  
11 at levels that meet or exceed respective state laws.
- 12 2. Retail-based health clinics and urgent care centers must encourage patients to establish  
13 care with a primary care physician to ensure continuity of care. If a patient's conditions  
14 or symptoms are beyond the scope of services provided by the clinic, that patient must  
15 immediately be referred to an appropriate physician or emergency facility. Also, retail-  
16 based health clinics urgent care centers should be encouraged to use electronic health  
17 records as a means of communicating information with the patient's primary physician  
18 and facilitating continuity of care.
- 19 3. Whether by electronic communication, or some other acceptable means, retail-based  
20 health clinics urgent care centers must send detailed information on services provided  
21 to the patient's primary care physician in a timely manner to ensure continuity of care.
- 22 4. The clinic must have a well-defined and limited scope of clinical services. These  
23 services must not exceed the on-site health provider's scope of practice, as determined  
24 by state law.
- 25 5. Retail-based health clinics AND urgent care centers ~~urgent care centers~~ must use  
26 standardized medical protocols developed from evidence-based practice guidelines for  
27 non-physician practitioners.
- 28 6. Retail-based healthcare clinics AND urgent care centers must comply with all  
29 applicable standards of state and federal regulations expected of physician offices.
- 30 7. Retail-based healthcare clinics and urgent care centers must not expand into programs  
31 offering patient care for the management of chronic and complex conditions.

32 Retail-based healthcare clinics located in or affiliated with a pharmacy must inform patients that  
33 any medication prescribed or recommended may be purchased at the patient's pharmacy of  
34 choice.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H304-A/15 PROTECTING AMERICAN STUDENTS FROM PROFIT-DRIVEN FOREIGN MEDICAL SCHOOLS

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H304-A/15 PROTECTING AMERICAN STUDENTS FROM PROFIT-DRIVEN**  
5 **FOREIGN MEDICAL SCHOOLS**

6 The American Osteopathic Association will officially adopt and advocate for the position that  
7 federal student loans shall be restricted from medical schools not subject to the accreditation  
8 standards of the Commission on Osteopathic College Accreditation or the Liaison Committee  
9 on Medical Education. 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**



SUBJECT: H305-A/15 REMOVE FDA BAN ON ANONYMOUS SPERM DONATION FROM MEN WHO HAVE SEX WITH MEN

SUBMITTED BY: Bureau on Federal Health Programs / Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs and the Bureau on Scientific Affairs  
2 and Public Health recommend that the following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H305-A/15 REMOVE FDA BAN ON ANONYMOUS SPERM DONATION FROM**  
5 **MEN WHO HAVE SEX WITH MEN**

6 The American Osteopathic Association (AOA) will call for an end to the five-year deferment  
7 period for anonymous sperm donation for men who have sex with men, and modify the  
8 exclusion criteria for men who have sex with men to be consistent with deferrals for those to be  
9 judged at an increased risk of infection. The AOA supports lobbying measures with the  
10 intention of amending this policy. 2015

Explanatory Statement: Submitted by Author  
None provided.

Explanatory Statement: Reference Committee  
The FDA five-year deferment period for anonymous sperm donation for men who have sex with men has been in place since 2005.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

---

DATE: **October 14, 2020**

---

SUBJECT: H308-A/15 IMPROVING COMPETITIVE EDGE FOR MEMBERSHIP  
IN THE AOA

SUBMITTED BY: Bureau of Membership

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of Membership recommend that the following policy be  
2 REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H308-A/15 IMPROVING COMPETITIVE EDGE FOR MEMBERSHIP IN THE**  
5 **AOA**

6 The American Osteopathic Association will review all membership dues, fees, and duration of  
7 certification to become more cost competitive with allopathic organizations to help build and  
8 maintain membership. 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H312-A/15 TAX CREDIT FOR PRECEPTING

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H312-A/15 TAX CREDIT FOR PRECEPTING**

5 The American Osteopathic Association (AOA) will SUPPORT ~~develop a template for model~~  
6 **STATE** legislation ~~and a toolkit with strategies~~ to implement precepting tax credit ~~S~~ legislation.  
7 2015.

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

Tax credits could be either state or federal.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H309-A/15 SITE NEUTRAL REIMBURSEMENT

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H309-A/15 SITE NEUTRAL REIMBURSEMENT PAYMENT**

5 The American Osteopathic Association (AOA) **SUPPORTS** that payments from all payers  
6 should reflect the resources required to provide patient care in each setting, ~~and therefore,~~  
7 ~~may vary to the extent that documented resource differences may vary.~~

8 The AOA ~~believes~~ **SUPPORTS** that payments for all sites of care should account for costs  
9 incurred in that setting, and should take into account the nature of the patient population  
10 served by each type of provider and other factors, such as, but not limited to, the provision of  
11 care coordination, access to after-hours care, emergency care, quality activities, and regulatory  
12 compliance costs.

13 The AOA ~~believes~~ **SUPPORTS** that efforts should be made to collect comprehensive and  
14 reliable data regarding the extent of actual cost differences among sites of service, the impact of  
15 current site of service differentials on patient access; the extent to which recent site of service  
16 shifts are attributable to payment differentials; and the potential impact of the elimination or  
17 reduction of such differentials on providers' ability to cover their reasonable costs.

18 The AOA ~~believes~~ **SUPPORTS** that pending collection of such data, private and public  
19 payers should avoid reductions in payment that create or aggravate existing site of service  
20 differentials for services that are demonstrably similar in terms of nature, scope, and patient  
21 population.

22 The AOA ~~believes~~ **SUPPORTS** that Medicare patients should be provided access to data  
23 regarding differences in copayment requirements among various sites of service. 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H311-A/15 SUPPORTING THE USE OF OMM IN THE VA

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H311-A/15 SUPPORTING THE USE OF OSTEOPATHIC MANIPULATIVE**  
5 **MEDICINE (OMM) IN THE VETERANS ADMINISTRATION (VA)**

6 The American Osteopathic Association (AOA) will work with the Veterans Administration  
7 (VA) to: 1) establish the position of National Osteopathic Manipulative Medicine (OMM)  
8 Director within the Veterans Administration System; 2) create National VA Regulation  
9 promoting the use of Osteopathic Manipulative Medicine; 3) create Manual Medicine Clinics; 4)  
10 to hire physicians trained in Osteopathic Manipulative Medicine, to staff manual medicine  
11 clinics within the department of Physical Medicine and Rehabilitation (PMR); 5) assist the  
12 National OMM Director in coordinating support for manual medicine clinics by encouraging  
13 Osteopathic Schools to sign Memorandum Of Understandings that allow osteopathic students  
14 and residents to rotate through the manual medicine clinics and eventually apply for jobs in  
15 these clinics on an equal opportunity basis; 6) and the AOA will work with Congress to pass  
16 any legislation required to put forth the promotion of OMM in the VA (see policy background  
17 in VHA Directive 2009-059 supporting Chiropractic Care. The AOA will continue to educate  
18 the VA on the benefit of OMM to patient care. 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H313-A/15 PRACTICE RIGHTS OF OSTEOPATHIC PHYSICIANS

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
2 policy be REAFFIRM AS AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H313-A/15 PRACTICE RIGHTS OF OSTEOPATHIC PHYSICIANS**

5 The American Osteopathic Association and its component societies ~~be~~ **ARE** encouraged to  
6 ~~promote~~ **SUPPORT OSTEOPATHIC PHYSICIANS AND THEIR PRACTICES** ~~unity and~~  
7 ~~the practice rights of osteopathic physicians; by establishing a specific Practice Rights agenda~~  
8 ~~and support the development of seminars or other vehicles to carry out the following~~  
9 ~~objectives:~~ (1) **WORKING WITH THE AMERICAN OSTEOPATHIC INFORMATION**  
10 **ASSOCIATION** to educate physicians as to the importance of compliance, risk management,  
11 ~~at~~ **AND** risk agreements with managed care, billing and coding, documentation, and fraud and  
12 abuse issues. (2). Identify**ING** supportive **STATE AND FEDERAL** agencies,  
13 **PROFESSIONAL** liability **INSURANCE** companies, and physicians with expertise ~~in~~ **ON**  
14 these issues. (3) **ENCOURAGING** ~~Encourage~~**ING** government **AGENCIES** and insurance  
15 ~~agencies~~ **COMPANIES** to utilize only expert witnesses **GOVERNMENT AGENCIES AND**  
16 **INSURANCE COMPANIES TO UTILIZE ONLY EXPERT WITNESSES WHO**  
17 **ARE OSTEOPATHIC PHYSICIANS IN PEER REVIEW, FRAUD AND ABUSE,**  
18 **CIVIL AND CRIMINAL CASES INVOLVING OSTEOPATHIC PHYSICIANS AND**  
19 **BOARDS WITH “LIKE OSTEOPATHIC SPECIALTY”.** (4) ~~who are osteopathic~~  
20 ~~physicians in peer review, fraud and abuse, civil and criminal cases involving osteopathic~~  
21 ~~physicians and boards with “like osteopathic specialty”.~~ (4) ~~Develop~~**ING** and ~~a~~**AdvisE****ING**  
22 ~~the AOA AND STATE SOCIETY leadership and state societies of the ANY needs, trends;~~  
23 ~~and~~ **OR** issues of concern **RELATED TO THE ABOVE**, which will ~~encourage~~ ~~unity,~~ and  
24 enhance the **RIGHTS AND practiceS** ~~rights~~ of our fellow **OSTEOPATHIC** physicians. ~~The~~  
25 ~~AOA will take steps to address the above listed issues at the national level. 1999; revised 2004;~~  
26 ~~reaffirmed as amended 2009; reaffirmed 2015~~

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN \_\_\_\_\_

DATE \_\_\_\_\_



SUBJECT: H314-A/15 RETAIL MEDICAL CLINICS IN FACILITIES SELLING TOBACCO, NICOTINE OR VAPING PRODUCTS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommend that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H314-A/15 RETAIL MEDICAL CLINICS IN FACILITIES SELLING TOBACCO,**  
5 **NICOTINE OR VAPING PRODUCTS**

6 The American Osteopathic Association discourages the placement of medical practices AND  
7 LIMITED SERVICE CLINICS in retail settings ~~and limited service health clinics~~ that promote  
8 and sell tobacco because it is contrary to the efforts and standards of the health care community  
9 at large. 2010; revised 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H315-A/15 OSTEOPATH AND OSTEOPATHY - USE OF THE TERM

SUBMITTED BY: Bureau of International Osteopathic Medicine

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of International Osteopathic Medicine recommend that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H315-A/15 OSTEOPATH AND OSTEOPATHY - USE OF THE TERM**

5 The American Osteopathic Association policy both officially in our publications and  
6 individually on a conversational basis, is to preferentially use the term “osteopathic physician”  
7 in place of the word “osteopath” and the term “osteopathic medicine” in place of the word  
8 “osteopathy;” and that the words “osteopath” and “osteopathy” be reserved in the United  
9 States for the following purposes: (1) previously named entities within the osteopathic medical  
10 profession; (2) historical, sentimental and informal discussions; and (3) osteopaths with a  
11 limited scope of practice. 1994; reaffirmed 2000; revised 2005; revised 2010; revised 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H317-A/15 PATIENT ACCESS IN RURAL AREAS

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
2 policy be SUNSET.

3 (Old language is crossed out and new language is in CAPS)

4 **H317-A/15 PATIENT ACCESS IN RURAL AREAS**

5 The American Osteopathic Association supports policy on the state and federal levels that  
6 would require all managed care health plans to have reasonably placed network physicians and  
7 hospital access; if the distance is unreasonable, the plans should pay for out of network  
8 services at no additional cost to the patient. 1995; revised 2000, 2005, 2010; revised 2015

Explanatory Statement: Submitted by Author

Submitted a new resolution for consideration by 2020 HOD that combines this policy with H635-A/16 ACCESS TO CARE – NETWORK ADEQUACY AND COVERAGE.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H635-A/16 ACCESS TO CARE – NETWORK ADEQUACY AND COVERAGE.

**Prior HOD action on similar or same topic:** Policy approved in 2016.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED (for sunset)**

DATE: **October 14, 2020**

SUBJECT: H318-A/15 PHYSICIAN OFFICE LABORATORIES

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H318-A/15 PHYSICIAN OFFICE LABORATORIES**

5 The American Osteopathic Association supports the development and expansion of Waived  
6 Physician Office Laboratory testing and will work to ensure that physician office laboratory  
7 certification be as non-intrusive into the practice of medicine as possible; and will seek  
8 assurances that access to any laboratory tests deemed medically necessary by the physician, not  
9 be limited by unnecessary regulations. 1990; revised 1995, 2000, 2005, 2010; revised 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H319-A/15 POSTGRADUATE COMPENSATION

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of Osteopathic Education recommend that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H319-A/15 POSTGRADUATE COMPENSATION**

5 The American Osteopathic Association affirms its support for ~~maintaining and~~ enhancing the  
6 quality of teaching programs, and urges Congress to provide more equitable graduate medical  
7 education funding so hospitals and other healthcare delivery systems can provide competitive  
8 compensation for postgraduate training. 1990; revised 1995; reaffirmed 2000, revised 2005,  
9 reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

Maintaining and enhancing are two separate actions which are mutually exclusive of one another.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H320-A/15 SECOND OPINION, SURGICAL CASES

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommend that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H320-A/15 SECOND OPINION, SURGICAL CASES**

5 The American Osteopathic Association believes that AOA members who are board certified, or  
6 board eligible and qualified by their training and experience to render a second surgical opinion  
7 in any given case, be recognized and utilized as qualified and reimbursed by entities  
8 underwriting such opinions and that this policy statement in no way advocates the institution of  
9 any mandatory second surgical opinion programs, by any entity. 1980; revised 1985, 1990;  
10 reaffirmed 1995; revised 2000, 2005, revised 2010; revised 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H322-A/15 UNIFORMED SERVICES: ENDORSEMENT OF  
PHYSICIANS SERVING IN THE UNIFORMED SERVICES

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H322-A/15 UNIFORMED SERVICES: ENDORSEMENT OF PHYSICIANS**  
5 **SERVING IN THE UNIFORMED SERVICES**

6 The American Osteopathic Association(AOA) will continue to assist the Surgeons General of  
7 the uniformed services and the American public in maintaining and assuring the highest quality  
8 of healthcare by its representatives in the uniformed services and recognizes the 55<sup>th</sup> **ANNUAL**  
9 anniversary of osteopathic physicians being commissioned in the military. 1985; revised 1990,  
10 1995; 2000, 2005; revised 2010; revised 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H323-A/15 EMERGENCY MEDICAL SERVICES FOR CHILDREN,  
SUPPORT OF

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H323-A/15 EMERGENCY MEDICAL SERVICES FOR CHILDREN, SUPPORT**  
5 **OF**

6 The American Osteopathic Association (AOA) supports the availability of state of the art  
7 emergency medical care for ill and injured children and adolescents; that pediatric services are  
8 well integrated into an emergency medical service system backed by optimal resources; and the  
9 entire spectrum of emergency services, including primary prevention of illness and injury, acute  
10 care, and rehabilitation, are provided to children and adolescents as well as adults, no matter  
11 where they live, attend school or travel. The federal Emergency Medical Services for Children  
12 (EMSC) program achieves these goals and as such, AOA supports full funding and  
13 reauthorization of this program WHEN NEEDED. 2005, reaffirmed 2010; reaffirmed as  
14 revised 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN \_\_\_\_\_

DATE \_\_\_\_\_



SUBJECT: H324-A/15 PHYSICIAN INCENTIVES TO UNDERSERVED AREAS

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H324-A/15 PHYSICIAN INCENTIVES TO UNDERSERVED AREAS**  
5 The American Osteopathic Association will ~~focus attention on potential~~ SUPPORT  
6 FEDERAL AND STATE legislation to increase physician loan repayment programs and tax  
7 deductions/~~or tax credits~~ FOR INDIVIDUALS WHO ~~when initiating a practice in~~  
8 underserved RURAL AND URBAN areas ~~to assist and assure an adequate supply of physicians~~  
9 ~~in the future.~~ 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H326-A/15 VACCINES SHORTAGES

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H326-A/15 ACCESS TO VACCINES SHORTAGES**

5 The American Osteopathic Association (AOA) will COMMUNICATE WITH THE  
6 CENTERS FOR DISEASE CONTROL AND PREVENTION ~~AND AS WELL AS FOOD~~  
7 AND DRUG ADMINISTRATION ON ISSUES RELATING TO SCHEDULE  
8 ADHERENCE AND VACCINE SHORTAGES AND WILL ENGAGE FEDERAL  
9 LAWMAKERS ON POLICY SOLUTIONS AS NEEDED. ~~outreach federal legislators and~~  
10 ~~the Centers for Disease Control & Prevention on the critical issue of vaccine shortage.~~ The  
11 AOA will also communicate ANY ACTIONS BEING TAKEN TO URGE ~~that steps be taken~~  
12 ~~to give manufacturers of vaccine immunity from lawsuits because of complications which are~~  
13 ~~not due to negligence; that additional U.S. companies will be urged~~ to manufacture vaccines for  
14 ~~the~~ U.S. citizens; ~~and that the public be provided information on potential side effects and~~  
15 ~~complications of vaccines so they are fully informed and responsible for their decision to be~~  
16 ~~immunized.~~ 2005; revised 2010; reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H329-A/15 MEDICARE BALANCE BILLING

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H329-A/15 MEDICARE BALANCE BILLING**

5 The American Osteopathic Association (AOA) SUPPORTS ENACTMENT OF FEDERAL  
6 LEGISLATION THAT PROMOTES EQUITABLE BALANCE BILLING PRACTICES  
7 WITHIN MEDICARE THAT FACILITATE CONTINUED PHYSICIAN  
8 PARTICIPATION IN MEDICARE. ~~encourages federal legislation to support Medicare~~  
9 ~~balance billing and take the necessary steps to initiate federal legislation to achieve~~  
10 ~~balance billing for Medicare patients to support continued participation by physicians.~~  
11 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H332-A/15 ELECTRONIC PRESCRIBING OF CONTROLLED  
SUBSTANCES

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommend that the following policy  
2 be SUNSET.

3 (Old language is crossed out and new language is in CAPS)

4 **H332-A/15 ELECTRONIC PRESCRIBING OF CONTROLLED SUBSTANCES**  
5 The American Osteopathic Association will continue to encourage the US Drug Enforcement  
6 Administration to modify rules to reduce any potential administrative barriers to electronic  
7 prescribing of controlled substances. Electronic prescribing systems should be interoperable  
8 with data collection and tracking systems for the prescribing of controlled substances. 2010;  
9 reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author

The content of this resolution is already covered by H318-A/19 which was approved last year. This policy is duplicative and therefore should be sunset.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H318-A/19 ELECTRONIC PRESCRIBING

**Prior HOD action on similar or same topic:** Policy reaffirmed as amended in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED (for sunset)**

DATE: **October 14, 2020**

SUBJECT: H334-A/15 PROFESSIONAL ORGANIZATION -- PHYSICIANS  
CHOOSING TO WHICH THEY BELONG

SUBMITTED BY: Bureau of Membership

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of Membership recommend that the following policy be  
2 REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H334-A/15 PROFESSIONAL ORGANIZATION -- PHYSICIANS CHOOSING TO**  
5 **WHICH THEY BELONG**

6 The American Osteopathic Association supports all physicians having the right to choose  
7 which medical associations they join, even when the employer is paying the membership fees;  
8 and will provide the physician with a letter template stating their desire to have dues paid to an  
9 osteopathic medical association. 2005; reaffirmed 2010; 2015

Explanatory Statement: Submitted by Author

The AOA acknowledges that the number of employed physicians is increasing each year.

The AOA strongly supports and advocates this self-determination of choice of medical association membership.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H335-A/15 PRESCRIPTION DRUG DIVERSION AND ABUSE –  
EDUCATION, RESEARCH, AND ADVOCACY

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H335-A/15 PRESCRIPTION DRUG DIVERSION AND ABUSE – EDUCATION,**  
5 **RESEARCH, AND ADVOCACY**

6 The American Osteopathic Association (AOA) will advance knowledge and understanding of  
7 appropriate use of prescription drugs through the education of the public and osteopathic  
8 medical education at all levels.

9 The AOA will work with other associations representing health care professionals to educate on  
10 the indicators of potential prescription drug abuse, misuse and diversion. The AOA will  
11 encourage the Institute of Medicine and other private and public organizations/agencies to  
12 conduct further research into development of reliable outcome indicators for assessing the  
13 effectiveness of measures proposed to reduce prescription drug abuse, misuse and diversion.

14 The AOA will advocate for evidence-informed use of state prescription monitoring programs,  
15 tamper resistant drug formulas and support efforts to assist state osteopathic medical  
16 associations in developing physician drug abuse, misuse and diversion awareness and  
17 prevention education programs.

18 The AOA supports policies that do not hinder patient access to and coverage of appropriate  
19 pharmacologic and non-pharmacologic treatments. It is a right of all patients to have access to  
20 medically appropriate intervention and/or treatment for conditions, including acute and chronic  
21 pain. It is the right of all physicians, to provide medically appropriate intervention and  
22 treatment modalities that will achieve safe and effective treatment, including pain control, for all  
23 their patients.

24 The AOA will not support any program which limits access to prescription drugs for patients  
25 with legitimate need and will not support any program which reduces the provider's ability to  
26 inform the patient's care. In addition, it is in the best interest of all patients not to confine, or  
27 seek to regulate medications, including opioid/opiate, by limiting their use to a small number of  
28 selected specialties of medicine. This would also extend to modalities now developed, or yet to  
29 be developed, such as long-acting opioid/opiate preparations. These exclusionary strategies will  
30 limit access for patients with medical indications for therapy, complicate delivery of care, and  
31 add to pain and suffering of patients.

32 The AOA will continue to cooperate with the pharmaceutical industry, law enforcement, and  
33 government agencies to stop prescription drug abuse, misuse and diversion as a threat to the  
34 health and well-being of the American public.

1 The AOA opposes the imposition of administrative or financial deterrents that decrease access  
2 to and coverage of prescription drugs with abuse-deterrent properties. 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H336-A/15 BUPRENORPHINE MAINTENANCE TREATMENT  
INSURANCE COVERAGE

SUBMITTED BY: Bureau on Socioeconomic Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Socioeconomic Affairs recommend that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H336-A/15 BUPRENORPHINE MAINTENANCE TREATMENT INSURANCE**  
5 **COVERAGE**

6 The American Osteopathic Association (AOA) recommends that state Medicaid administrators  
7 remove any arbitrary and restrictive limits for buprenorphine coverage and that state Medicaid  
8 administrators and third party payers recognize that chronic disease management includes a  
9 combination of psychotherapeutic and pharmacological interventions that will yield the best  
10 outcomes for patients with opioid use disorder. 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

---

DATE: **October 14, 2020**

---



SUBJECT: H337-A/15 VIOLENCE AGAINST HEALTHCARE STAFF

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
2 policy be REAFFIRM as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H337-A/15 VIOLENCE AGAINST HEALTHCARE STAFF**

5 The American Osteopathic Association supports LEGISLATION TO ~~legislative change~~ hold  
6 patients and their associates (that includes friends, family, and anyone WHO ACCOMPANIES  
7 that affiliates with them) accountable for PHYSICAL ASSAULT AND VERBAL THREATS  
8 TO HEALTH CARE STAFF by upgrading penalties under **FEDERAL AND** relevant state  
9 ~~laws~~ **LAW AND LEGISLATION** from misdemeanors to felonies where applicable. 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H338-A/15 LOW BACK PAIN CLINICAL PRACTICE GUIDELINES,  
REVISION OF

SUBMITTED BY: Bureau on Osteopathic Clinical Education & Research

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau on Osteopathic Clinical Education & Research recommend that  
2 the following policy be REAFFIRMED:

3 (Old language is crossed out and new language is in CAPS)

4 **H338-A/15 LOW BACK PAIN CLINICAL PRACTICE GUIDELINES, REVISION**  
5 **OF**

6 The American Osteopathic Association approves the attached Guidelines for Patients with Low  
7 Back Pain. 2009; referred 2014; reaffirmed as amended 2015.

8 **American Osteopathic Association Guidelines for Osteopathic Manipulative Treatment**  
9 **(OMT) for Patients with Low Back Pain**

10 Executive Summary:

11 The American Osteopathic Association recommends that osteopathic physicians use Osteopathic  
12 manipulative treatment (OMT) in the care of patients with low back pain. Evidence from systematic  
13 reviews and meta-analyses of randomized clinical trials (Evidence Level 1a) supports this  
14 recommendation.

15 1. Overview material: Provide a structured abstract that includes the guideline’s release date, status  
16 (original, revised, updated), and print and electronic sources.

17 ~~Release Date (expected) August 1, 2015. THE CURRENT This G~~ guidelineS ARE is  
18 available through the AOA web site and National Guidelines Clearinghouse, AHRQ. The  
19 guideline is partially based upon the following study:

20 Franke H, Franke J-D, Fryer G. Osteopathic manipulative treatment for nonspecific low back  
21 pain: a systematic review and meta-analysis. BMC Musculoskeletal Disorders 2014, 15:286  
22 doi:10.1186/1471-2474-15-286. (Published: 30 August 2014)

23 The format used for this guideline is in accordance with the 2013 (Revised) Criteria for Inclusion of  
24 Clinical Practice Guidelines in NGC and uses the 2011 definition of clinical practice guideline  
25 developed by the Institute of Medicine (IOM): “Clinical practice guidelines are statements that include  
26 recommendations intended to optimize patient care that are informed by a systematic review of  
27 evidence and an assessment of the benefits and harms of alternative care options”.

28 **ABSTRACT**

29 **Background**

30 Osteopathic manipulative treatment (OMT) is a distinctive modality commonly used by osteopathic  
31 physicians to complement conventional treatment of musculoskeletal disorders, including those that  
32 cause low back pain. OMT is defined in the Glossary of Osteopathic Terminology as: “The therapeutic

1 application of manually guided forces by an osteopathic physician (US Usage) to improve physiologic  
2 function and/or support homeostasis that has been altered by somatic dysfunction. OMT employs a  
3 variety of techniques” (see Appendix 1 for list). Somatic dysfunction is defined as: “Impaired or altered  
4 function of related components of the somatic (body framework) system: skeletal, arthrodiagonal and  
5 myofascial structures, and their related vascular, lymphatic, and neural elements. Somatic dysfunction is  
6 treatable using osteopathic manipulative treatment.”

7 This guideline updates the AOA guideline for osteopathic physicians to utilize OMT for patients with  
8 nonspecific acute or chronic LBP published in 2010 on the National Guideline Clearinghouse.<sup>1</sup>

## 9 **Methods**

10 This guideline update process commenced with literature searches that included electronic databases,  
11 personal contact with key researchers of OMT and low back pain, and internet search engines. Early in  
12 the process, the AOA discovered the systematic literature review conducted by Franke, Franke and  
13 Fryer (2014)<sup>2</sup> which serves as the basis for this updated guideline.

14 Franke et al searched electronic databases, reference lists and personal communications. Their inclusion  
15 criteria consisted of randomized clinical trials of adults (>18 years of age) with nonspecific back pain  
16 treated by osteopathic physicians or osteopaths who used their clinical judgment as opposed to a  
17 standard predetermined protocol. Studies with pregnant and postpartum participants were also  
18 included. Studies excluded from the review were those where co-interventions were not performed on  
19 both comparison groups; the OMT intervention could not be assigned an effect size; participants had  
20 specific back pain from pathology (i.e., fracture, tumor, metastasis, inflammation, infection); or the  
21 intervention consisted of a single manual technique (see Appendix 2 for the list of references in Franke  
22 et al).

23 The primary outcomes for the Franke et al review were pain and functional status. The authors  
24 measured pain using the visual analogue scale (VAS), number rating scale (NRS), or the McGill Pain  
25 Questionnaire. Functional status was measured using the Roland-Morris Disability Questionnaire,  
26 Oswestry- Disability Index, or other valid instrument. The point of measurement for both outcomes  
27 was the first 3 month interval.

28 Studies were independently reviewed using a standardized form. The mean difference (MD) or standard  
29 mean difference (SMD) with 95% confidence intervals (CIs) and overall effect size were calculated at 3  
30 months post treatment. GRADE approach, as recommended by the updated Cochrane Back Review  
31 Group method guidelines, was used to assess quality of evidence.

## 32 **Results**

33 The authors of the systematic review identified 307 studies. Thirty-one were evaluated and 16 excluded.  
34 Of the 15 studies included in the review, 6 were retrieved from the grey literature in Germany, 5 from  
35 the United States, 2 from the United Kingdom, and 2 from Italy. Ten studies investigated effectiveness  
36 of OMT for nonspecific LBP, 3 studies examined the effect of OMT for LBP in pregnant women, and  
37 2 studied the effect of OMT for LBP in postpartum women. All studies reported on the effect of OMT  
38 on pain, and all but one reported on back pain specific functional status. There were a total of 1502  
39 participants included in the qualitative and quantitative analysis.

40 OMT significantly reduces pain and improves functional status in patients, including pregnant and  
41 postpartum women, with nonspecific acute and chronic LBP. Franke et al found that in acute and  
42 chronic non-specific LBP, moderate-quality evidence suggested OMT had a significant effect on pain  
43 relief (MD:-12.91, 95% CI: -20.00 to -5.82) and functional status (SMD:-0.36, 95%CI: -0.58 to -0.14).  
44 More specifically, in chronic nonspecific LBP, evidence suggested a significant difference in favor of  
45 OMT regarding pain (MD:-14.93, 95%CI:-25.18 to -4.68) and functional status (SMD:-0.32, CI:-0.58 to

1 -0.07). When examining nonspecific LBP in pregnancy, low-quality evidence suggested a significant  
 2 difference in favor of OMT for pain (MD, -23.01; 95% CI, -44.13 to -1.88) and functional status (SMD,  
 3 -0.80; 95% CI, -1.36 to -0.23). Conversely for nonspecific LBP postpartum, Franke et al found that  
 4 moderate-quality evidence suggested a significant difference in favor of OMT for pain (MD, -41.85;  
 5 95% CI, -49.43 to -34.27) and functional status (SMD, -1.78; 95% CI, -2.21 to -1.35).<sup>2</sup>

## 6 **Conclusions**

7 Clinically relevant effects of OMT were found for reducing pain and improving functional status in  
 8 patients with acute and chronic nonspecific LBP and for LBP in pregnant and postpartum women at 3  
 9 months post treatment.

10 OMT significantly reduces low back pain. The level of pain reduction is clinically important, greater  
 11 than expected from placebo effects alone, and may persist through the first year of treatment.  
 12 Additional research is warranted to elucidate mechanistically how OMT exerts its effects, to determine  
 13 if OMT benefits extend beyond the first year of treatment, and to assess the cost-effectiveness of OMT  
 14 as a complementary treatment for low back pain.

15 2. Focus: Describe the primary disease/condition and intervention/service/technology that the  
 16 guideline addresses. Indicate any alternative preventive, diagnostic or therapeutic interventions that  
 17 were considered during development.

18 These guidelines are intended to assist osteopathic physicians in appropriate utilization of OMT for  
 19 patients with low back pain. Other alternative preventive, diagnostic and therapeutic interventions  
 20 considered during development of these guidelines were those noted in the following published  
 21 guidelines for physicians caring for patients with low back pain:

22 1) Chou R, Qaseem A, Snow V, Casey D, Cross JT Jr, Shekelle P, Owens DK: Clinical Efficacy  
 23 Assessment Subcommittee of the American College of Physicians, American College of  
 24 Physicians, American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of  
 25 low back pain: a joint clinical practice guideline from the American College of Physicians and  
 26 the American Pain Society. *Ann Intern Med* 2007 Oct 2;147(7):478-91)

## 27 **BACKGROUND**

28 Historically, low back pain has been the most common reason for visits to osteopathic physicians.<sup>3</sup>  
 29 More recent data from the Osteopathic Survey of Health Care in America has confirmed that a majority  
 30 of patients visiting osteopathic physicians continue to seek treatment for musculoskeletal conditions.<sup>4,5</sup>  
 31 A distinctive element of low back care provided by osteopathic physicians is osteopathic manipulative  
 32 treatment (OMT). A comprehensive evaluation of spinal manipulation for low back pain undertaken by  
 33 the Agency for Health Care Policy and Research in the United States concluded that spinal  
 34 manipulation can be helpful for patients with acute low back problems without radiculopathy when  
 35 used within the first month of symptoms.<sup>6</sup> Nevertheless, because most studies of spinal manipulation  
 36 involve chiropractic or physical therapy,<sup>7</sup> it is unclear if such studies adequately reflect the efficacy of  
 37 OMT for low back pain. Although the professional bodies that represent osteopaths, chiropractors, and  
 38 physiotherapists in the United Kingdom developed a spinal manipulation package consisting of three  
 39 common manual elements for the UK Back pain Exercise and Manipulation (UK BEAM) trial,<sup>8</sup> there  
 40 are no data on the comparability of profession specific outcomes.<sup>9,10</sup> It is well known that OMT  
 41 comprises a diversity of techniques.<sup>11</sup> These OMT techniques are not adequately represented by the UK  
 42 BEAM trial package. Professional differences in spinal manipulation are more pronounced in research  
 43 studies, in which chiropractors have focused almost exclusively on high-velocity-low amplitude  
 44 techniques.<sup>12</sup> For example, a major trial of chiropractic manipulation as adjunctive treatment for  
 45 childhood asthma used a high-velocity-low amplitude thrust as the active treatment.<sup>13</sup> The simulated

1 treatment provided in the sham manipulation arm of this chiropractic trial, which ostensibly was used  
2 to provide no therapeutic effect, bore a marked similarity to OMT.<sup>12,14</sup> Because differences in  
3 professional background and training lend themselves to diverse manipulation approaches, clinicians  
4 have been warned about generalizing the findings of systematic reviews to practice.<sup>15</sup> In addition to  
5 professional differences in the manual techniques themselves, osteopathic physicians in the United  
6 States, unlike allopathic physicians or chiropractors, can treat this condition simultaneously using both  
7 conventional primary care approaches and complementary spinal manipulation. This represents a  
8 unique philosophical approach in the treatment of low back pain. Consequently, there is a need for  
9 empirical data that specifically address the efficacy of OMT for conditions such as low back pain.<sup>16</sup>

10 These guidelines are based on a systematic review of the literature on OMT for patients with low back  
11 pain and a meta-analysis of all randomized controlled trials of OMT for patients with low back pain in  
12 ambulatory settings.<sup>2</sup>

13 3. Goal: Describe the goal that following the guideline is expected to achieve, including the rationale for  
14 development of a guideline on this topic.

15 The goal of these guidelines is to enable osteopathic physicians as well as other physicians, other health  
16 professionals, and third party payers, to understand the evidence underlying recommendations for  
17 appropriate utilization of OMT, which is not detailed in the current sets of guidelines developed by  
18 other physicians. The American Osteopathic Association does not believe it is appropriate for other  
19 professionals to create guidelines for utilization of OMT since it is not a procedure or approach used by  
20 those physicians. It is, however, the purview and duty of the American Osteopathic Association to  
21 inform its members and the public about the appropriate utilization of OMT.

22 4. Users/setting: Describe the intended users of the guideline (e.g., provider types, patients) and the  
23 settings in which the guideline is intended to be used.

24 These guidelines are to be used by osteopathic physicians in application of OMT to patients with  
25 nonspecific low back pain, which can be defined as tension, soreness, or stiffness in the lower back  
26 region with an unidentified cause<sup>2</sup>, in the ambulatory setting.

27 5. Target population: Describe the patient population eligible for guideline recommendations and list  
28 any exclusion criteria.

29 Patients with nonspecific low back pain of musculoskeletal origin are eligible for guideline  
30 recommendations. Patients with visceral disease conditions that refer pain to the low back are excluded  
31 from these guidelines. Other conditions of exclusion are when the following are the identified source of  
32 the low back pain: vertebral fracture; vertebral joint dislocation; muscle tears or lacerations; spinal or  
33 vertebral joint ligament rupture; inflammation of intervertebral discs, spinal zygapophyseal facets joints,  
34 muscles or fascia; skin lacerations; sacroiliitis; ankylosing spondylitis; or masses in or from the low back  
35 structures that are the source of the pain. Exclusion from this guideline does not imply that OMT is  
36 contraindicated in these conditions.

37 6. Developer: Identify the organization(s) responsible for guideline development and the  
38 names/credentials/potential conflicts of interest of individuals involved in the guideline's development.

39 American Osteopathic Association, Bureau of Osteopathic Clinical Education and Research, Task  
40 Force on the Low Back Pain Clinical Practice Guidelines: Richard J. Snow, DO, MPH, (chair), Michael  
41 Seffinger, DO, Kendi Hensel, DO, PhD, and Rodney Wiseman, DO.

42 7. Funding source/sponsor: Identify the funding source/sponsor and describe its role in developing  
43 and/or reporting the guideline. Disclose potential conflict of interest.

1 This project was funded by the American Osteopathic Association. The AOA Bureau of Osteopathic  
2 Clinical Education and Research convened a Task Force on the Low Back Pain Clinical Practice  
3 Guidelines to revise the guidelines. Upon approval of these recommendations by the AOA Board of  
4 Trustees and the AOA House of Delegates, the guidelines will be submitted to the National Guidelines  
5 Clearinghouse for public record and access. As the guidelines were developed based on the peer  
6 reviewed scientific literature, no conflict of interest is claimed by the developers. A well rounded,  
7 objective perspective is presented. Any views from an osteopathic perspective that is not supported by  
8 the scientific literature is stated and clearly identified so the reader is able to discern any potential for  
9 bias.

10 8. Evidence collection: Describe the methods used to search the scientific literature, including the range  
11 of dates and databases searched, and criteria applied to filter the retrieved evidence.

12 This guideline update process commenced with literature searches that included electronic databases,  
13 personal contact with key researchers of OMT and low back pain, and internet search engines. Early in  
14 the process, the AOA discovered the systematic literature review conducted by Franke, Franke and  
15 Fryer (2014) which serves as the basis for this updated guideline.

16 Franke et al<sup>2</sup> searched electronic reference databases, Cochrane Central Register of Controlled Trials  
17 (CENTRAL), MEDLINE, Embase, CINAHL, PEDro, OSTMED.DR, and Osteopathic Web  
18 Research using the following search terms: low back pain, back pain, lumbopelvic pain, dorsalgia,  
19 osteopathic manipulative treatment, OMT, and osteopathic medicine. In addition to the listed  
20 databases, the authors conducted searches in an ongoing trial database (metaRegister of Controlled  
21 Trials. To enhance their search, the authors tracked citations of identified trials, and manually searched  
22 reference lists for other relevant papers.

23 The authors reviewed all the studies using a standardized form, and all mean differences (MD) and  
24 standard mean differences (SMD) were calculated with 95% confidence intervals (CIs). Overall effect  
25 size was calculated at the 3month post treatment follow-up. GRADE approach, as recommended by  
26 the updated Cochrane Back Review Group method guidelines, was used to assess quality of evidence.

27 9. Recommendation grading criteria: Describe the criteria used to rate the quality of evidence that  
28 supports the recommendations and the system for describing the strength of the recommendations.  
29 Recommendation strength communicates the importance of adherence to a recommendation and is  
30 based on both the quality of the evidence and the magnitude of anticipated benefits or harms.

31 Franke et al<sup>2</sup> evaluated the methodological quality of the studies using the Risk of Bias tool of the  
32 Cochrane Back Review Group. Studies were scored as 'low risk', 'high risk', or 'unclear', and included  
33 assessments of randomization, blinding, baseline comparability between groups, patient compliance,  
34 and dropping out. Per the Cochrane Back Review Group, studies received a 'low risk' score when a  
35 minimum of 6 criteria were met and it was determined that the study had no serious flaws (e.g., a  
36 drop-out rate over 50%). Disagreements about the quality of the studies were resolved through  
37 discussion and consensus. Franke et al used Review Manager to analyze the data for the meta-analysis.  
38 The authors converted the NRS and VAS scores from the included studies to a 100-point scale for the  
39 pain measurement, and calculated the mean difference (MD) with 95% CIs for the random effects  
40 model.

41 Franke et al conducted other noteworthy analysis. They used the standard mean difference (SMD) was  
42 also used in a random effects model to determine functional status. The authors grouped the 1 study  
43 examining acute LBP and the 3 studies examining patients with both acute and chronic LBP together  
44 for the purpose of their meta-analyses. Overall, they created four groups: (1) acute and chronic LBP;

1 (2) chronic LBP (duration of pain more than 3 months); (3) LBP in pregnant women; and (4) LBP in  
2 postpartum women.

3 Franke et al also assessed the clinical relevance of each study using the Cochrane Back Review Group  
4 recommendations. A small effect was defined as MD less than 10% of the scale and SMD less  
5 than 0.5. A medium effect was defined as MD 10% to 20% of the scale and SMD from 0.5 to 0.8. A  
6 large effect was defined as MD greater than 20% of the scale and SMD greater than 0.8.

7 10. Method for synthesizing evidence: Describe how evidence was used to create recommendations,  
8 e.g., evidence tables, meta-analysis, decision analysis.

9 Due to the applicability of the Franke et al review to this updated guideline and consequently, the  
10 reliance thereon, the AOA will describe how the authors synthesized their evidence.

### 11 **OMT versus other interventions for acute and chronic nonspecific low back pain**

12 Franke et al<sup>2</sup> analyzed the effect of OMT for pain in acute and chronic LBP using ten studies with 12  
13 comparison groups and 1141 participants. Six studies reported a significant effect of OMT on pain, 3  
14 studies showed a non-significant effect, and 3 studies reported a non-significant effect in favor of the  
15 control treatment. Collectively, the studies showed moderate-quality evidence that OMT had a  
16 significant effect on pain relief (MD:-12.91, 95% CI: -20.00 to -5.82).

17 For functional status, the authors based their results on 9 studies with 10 comparisons groups and  
18 1046 participants. The studies revealed moderate-quality evidence that a significant difference in favor  
19 of OMT existed (SMD:-0.36, 95%CI: -0.58 to -0.14). Four studies reported a significant effect of  
20 OMT, 3 studies reported a non- significant effect, and 1 study reported a non-significant effect in  
21 favor of the control group.

### 22 **OMT versus other interventions for chronic nonspecific low back pain**

23 For nonspecific LBP, Franke et al<sup>2</sup> analyzed 6 studies with 7 comparisons and 769 participants. This  
24 analysis revealed moderate-quality evidence that a significant difference in favor of OMT existed  
25 (MD:-14.93, 95%CI:-25.18 to -4.68)

26 For functional status outcomes, the authors reviewed 3 studies which reported a significant  
27 improvement for OMT. One study reported a non-significant effect for OMT, and 1 study reported  
28 an effect for the control group. Collectively, the analysis showed moderate-quality evidence for a  
29 significant difference in favor of OMT (SMD:-0.32, CI:-0.58 to -0.07).

### 30 **OMT versus usual obstetric care, sham ultrasound, and untreated for nonspecific 31 low back pain in pregnant women**

32 For LBP in pregnant women, the authors reviewed three studies with 4 comparisons and 242  
33 participants. Two studies showed a significant improvement following OMT, and 1 study showed a  
34 non-significant improvement. The final analysis of these studies resulted in low- quality evidence for a  
35 significant difference in favor of OMT for LBP in pregnant women (MD, -23.01; 95% CI, -44.13 to  
36 -1.88) and functional status (SMD, -0.80; 95% CI, -1.36 to -0.23).<sup>2</sup>

37 Hensel, et al<sup>17</sup> found that OMT was effective for mitigating pain and functional deterioration  
38 compared with usual care only; however, OMT did not differ significantly from placebo ultrasound  
39 treatment. The authors concluded that OMT is a safe, effective adjunctive modality to improve pain  
40 and functioning during the third trimester.

41

## 1 **OMT versus untreated for nonspecific low back pain in postpartum women**

2 Franke et al reviewed two studies focusing on OMT for LBP in postpartum women. Both studies  
3 reported significant improvement following OMT. The moderate-quality evidence showed a  
4 significant difference in favor of OMT for pain (MD, -41.85; 95% CI, -49.43 to -34.27) and  
5 functional status (SMD, -1.78; 95% CI, -2.21 to -1.35).

## 6 **DISCUSSION**

### 7 Efficacy of OMT

8 The overall results clearly demonstrate a statistically significant reduction in low back pain with OMT.  
9 Subgroup meta-analyses to control for moderator variables demonstrated that OMT significantly  
10 reduced low back pain vs active treatment or placebo control and vs no treatment control. If it is  
11 assumed, as shown in a review<sup>18</sup>, that the effect size is -0.27 for placebo control vs no treatment in  
12 trials involving continuous measures for pain, then the results of our study are highly congruent (i.e.,  
13 effect size for OMT vs no treatment [-0.53] = effect size for OMT vs active treatment or placebo  
14 control [-0.26] + effect size for placebo control vs no treatment [-0.27]). It has been suggested that the  
15 therapeutic benefits of spinal manipulation are largely due to placebo effects.<sup>19</sup> A preponderance of  
16 results from our sensitivity analyses supports the efficacy of OMT vs active treatment or placebo  
17 control and therefore indicates that low back pain reduction with OMT is attributable to the  
18 manipulation techniques, not merely placebo effects. Also, as indicated above, OMT vs no treatment  
19 control demonstrated pain reductions twice as great as previously observed in clinical trials of placebo  
20 vs no treatment control.<sup>18</sup> The clinical significance of our findings is readily evident when compared  
21 with nonsteroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors. A recent meta-  
22 analysis of the efficacy of these drugs included 23 randomized placebo controlled trials for  
23 osteoarthritic knee pain, representing over 10,000 subjects, and measured pain outcomes up to three  
24 months following randomization.<sup>20</sup> This study found an overall effect size of -0.32 (95% CI, -0.24 - -  
25 0.39) and effect size of -0.23 (95% CI, -0.16 - -0.31) when drug non-responders were not excluded  
26 from the analyses. Thus, our effect size of -0.26 (95% CI, -0.48 - -0.05) for OMT in trials vs active  
27 treatment or placebo control suggests that OMT provides an analgesic effect comparable to  
28 nonsteroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors. Unlike the meta-analysis  
29 of nonsteroidal anti-inflammatory drugs,<sup>20</sup> however, Licciardone et al found that OMT also significantly  
30 reduced pain during the three to 12 month period following randomization.<sup>21</sup> Thus, OMT for low back  
31 pain may eliminate or reduce the need for drugs that can have serious adverse effects.<sup>22</sup> Because  
32 osteopathic physicians provide OMT to complement conventional treatment for low back pain, they  
33 tend to avoid substantial additional costs that would otherwise be incurred by referring patients to  
34 chiropractors or other practitioners.<sup>23</sup> With regard to back pain, osteopathic physicians make fewer  
35 referrals to other physicians and admit a lower percentage of patients to hospitals than allopathic  
36 physicians,<sup>3</sup> while also treating back pain episodes with substantially fewer visits than chiropractors.<sup>24</sup>  
37 Although osteopathic family physicians are less likely to order radiographs or prescribe nonsteroidal  
38 anti-inflammatory drugs, aspirin, muscle relaxants, sedatives, and narcotic analgesics for low back pain  
39 than their allopathic counterparts, osteopathic physicians have a substantially higher proportion of  
40 patients returning for follow-up back care than allopathic physicians.<sup>25</sup> In the United Kingdom, where  
41 general practitioners may refer patients with spinal pain to osteopaths for manipulation, it has been  
42 shown that OMT improved physical and psychological outcomes at little extra cost.<sup>26</sup>

43 Licciardone et al<sup>27</sup>, in the OSTEOPATHic Health outcomes In Chronic low back pain  
44 (OSTEOPATHIC) Trial studied OMT and ultrasound therapy for short term relief of nonspecific  
45 chronic low back pain. The authors found that the patients receiving OMT showed moderate to  
46 substantial improvements in low back pain which met or exceeded the Cochrane Back Review Group  
47 criterion for a medium effect size in relieving chronic low back pain.



1 11. Prerelease review: Describe how the guideline developer reviewed and/or tested the guidelines prior  
2 to release.

3 Guidelines were reviewed by the Bureau of Osteopathic Clinical Education and Research, the AOA  
4 Board of Trustees, and the AOA House of Delegates.

5 12. Update plan: State whether or not there is a plan to update the guideline and, if applicable, an  
6 expiration date for this version of the guideline. The guidelines will be updated every 5 years.

7 13. Definitions: Define unfamiliar terms and those critical to correct application of the guideline that  
8 might be subject to misinterpretation.

9 OMT referred specifically to manual treatment provided by osteopathic physicians, or other physicians  
10 who had demonstrated training and proficiency in OMT, such as those practitioners in Europe who  
11 may have undertaken osteopathic conversion programs.

12 14. Recommendations and rationale: State the recommended action precisely and the specific  
13 circumstances under which to perform it. Justify each recommendation by describing the linkage  
14 between the recommendation and its supporting evidence. Indicate the quality of evidence and the  
15 recommendation strength, based on the criteria described in 9.

16 Based on this meta-analysis (evidence level 1a – see Table 1) of RCTs on OMT for patients with low  
17 back pain, it is recommended that OMT be utilized by osteopathic physicians for musculoskeletal  
18 causes of low back pain, i.e., to treat the diagnoses of somatic dysfunctions related to the low back pain.

19 **Table 1. Levels of Evidence**

<b>Strength of evidence</b>	<b>Type of Study</b>	<b>Comment</b>
1a	Systematic review with homogeneity of randomized controlled trials	Individual trials should be free of substantial variations in the directions and magnitudes of results
1b	Individual randomized controlled trial with narrow confidence interval	Confidence interval should indicate a clinically important OMT effect
1c	Differential frequency of adverse outcomes	An adverse outcome was frequently observed in patients who did not receive OMT, but was infrequently observed in patients who did receive OMT (equivalent to a small number needed to treat)
2a	Systematic review with homogeneity of cohort studies	Individual studies should be free of substantial variations in the directions and magnitudes of OMT effects

2b	Individual cohort study or low-quality randomized controlled trial	Low quality may be indicated by such factors as important differences in baseline characteristics between groups, lack of concealment of treatment allocation, and excessive losses to follow-up
3a	Systematic review with homogeneity of case-control studies	Individual studies should be free of substantial variations in the directions and magnitudes of OMT effects
3b	Individual case-control study	These should be free of substantial evidence of selection bias, information bias, or confounding variables
4	Case series and low quality cohort and case-control studies	Low quality of cohort and case control studies may be indicated by such factors as important sources of selection bias, information bias, or confounding variables
5	Expert opinion without explicit critical appraisal, or based on physiology, bench research, or "first principles"	These generally will have limited empirical data relevant to OMT effects in human populations

1 \*Adapted from Straus SE, Richardson WS, Glasziou P, and Haynes RB, Evidence-Based Medicine.  
 2 How to Practice and Teach EBM (3rd ed), 2005

3 15. Potential benefits and harms: Describe anticipated benefits and potential risks associated with  
 4 implementation of guideline recommendations.

5 Potential benefits include but are not limited to improved care for patients seeing osteopathic  
 6 physicians or practitioners for somatic dysfunctions causing low back pain. Harms have not been  
 7 identified in randomized clinical trials on OMT for patients with low back pain. OMT for somatic  
 8 dysfunction has not demonstrated harm in any clinical trials to date.

9 16. Patient preferences: Describe the role of patient preferences when a recommendation involves a  
 10 substantial element of personal choice or values.


11 Patients have a choice of provider and services when they suffer from low back pain. OMT offers  
 12 another option for care for low back pain from somatic dysfunction and can be provided by  
 13 osteopathic physicians. It is utilized as an adjunct or complementary to conventional or alternative  
 14 methods of treatment.

17. Algorithm: Provide (when appropriate) a graphical description of the stages and decisions in clinical care described by the guideline.

Once a patient with low back pain is diagnosed with somatic dysfunction as the cause, or contributing factor, of the low back pain, OMT should be utilized by the osteopathic physician. The diagnosis of somatic dysfunction entails a focal or complete history and physical exam, including an osteopathic structural exam that provides evidence of asymmetrical anatomical landmarks, restriction or altered range of joint motion, and palpatory abnormalities of soft tissues. OMT to treat somatic dysfunction is utilized after other potential causes of low back pain are ruled out or considered improbable by the treating physician; i.e., vertebral fracture; vertebral joint dislocation; muscle tears or lacerations; spinal or vertebral joint ligament rupture; inflammation of intervertebral discs, spinal zygapophyseal facets joints, muscles or fascia; skin lacerations; sacroiliitis; ankylosing spondylitis; masses in or from the low back structures; or organic (visceral) disease referring pain to the back or causing low back muscle spasms.

**Algorithm for OMT LBP decision making.**

Adapted from: Chapter 4. “The manipulative prescription,” In: Somatic Dysfunction in Osteopathic Family Medicine. Nelson, Glonek, eds., Baltimore, MD: Lippincott, Williams & Wilkins; 2007;27-32.



↓

Follow-up, if appropriate, and repeat steps A-F.

18. Implementation considerations: Describe anticipated barriers to application of the recommendations. Provide reference to any auxiliary documents for providers or patients that are intended to facilitate implementation. Suggest review criteria for measuring changes in care when the guideline is implemented.

One of the barriers to application of the recommendations cited by osteopathic physicians has been poor reimbursement for OMT.<sup>28</sup> However, Medicare has reimbursed osteopathic physicians for this procedure (ICD-9 code: 98926-9), for over 30 years. Many osteopathic physicians apparently do not utilize OMT in clinical practice due to a number of barriers, including time constraints, lack of confidence, loss of skill over time from disuse, and inadequate office space.<sup>28</sup> Some specialists, i.e., pathologists and radiologists, do not use OMT as it is not applicable to their duties within their specialty. The AOA believes patients with low back pain should be treated with OMT given the high level of evidence that supports its efficacy. Changes in care when this guideline is implemented will be determined by physician and patient surveys, billing and coding practice patterns amongst osteopathic physicians, data gathered from osteopathic physicians via the AOA's Clinical Assessment Program, and other registry data gathering tools currently being developed by researchers.

## REFERENCES

1. Clinical Guideline Subcommittee on Low Back Pain. American Osteopathic Association Guidelines for Osteopathic Manipulative Treatment (OMT) for Patients With Low Back Pain. JAOA Vol 110, No 11, November 2010.
2. Franke H, Franke J-D, Fryer G. Osteopathic manipulative treatment for nonspecific low back pain: a systematic review and meta-analysis. BMC Musculoskeletal Disorders 2014, 15:286 doi:10.1186/1471-2474-15-286. (Published: 30 August 2014)
3. Cypress BK: Characteristics of physician visits for back symptoms: a national perspective. American Journal of Public Health 1983, 73:389-395.
4. Licciardone JC, Herron KM: Characteristics, satisfaction, and perceptions of patients receiving ambulatory healthcare from osteopathic physicians: a comparative national survey. Journal of the American Osteopathic Association 2001, 101:374-385.
5. Licciardone JC: Awareness and use of osteopathic physicians in the United States: results of the Second Osteopathic Survey of Health Care in America (OSTEOSURV-II). Journal of the American Osteopathic Association 2003, 103:281-289.
6. Bigos S, Bowyer O, Braen G, et al: Acute Low Back Problems in Adults. Clinical Practice Guideline No. 14. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services; 1994.
7. Kuchera ML, DiGiovanna EL, Greenspan PE: Efficacy and complications. In Foundations for Osteopathic Medicine. 2nd edition. Edited by Ward RC. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:1143-1152.
8. Harvey E, Burton AK, Moffett JK, Breen A: Spinal manipulation for low-back pain: a treatment package agreed by the UK chiropractic, osteopathy and physiotherapy professional associations. Manual Therapy 2003, 8:46-51.
9. UK BEAM Trial Team: United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. British Medical Journal 2004, 329:1377- doi:10.1136/bmj.38282.669225.AE.
10. UK BEAM Trial Team: United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. British Medical Journal 2004, 329:1381- doi:10.1136/bmj.38282.607859.AE.
11. Lesho EP: An overview of osteopathic medicine. Archives of Family Medicine 1999, 8:477-484.
12. Mein EA, Greenman PE, McMillin DL, Richards DG, Nelson CD: Manual medicine diversity: research pitfalls and the emerging medical paradigm. Journal of the American Osteopathic Association 2001, 101:441-444.
13. Balon J, Aker PD, Crowther ER, et al: A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma. New England Journal of Medicine 1998, 339:1013-20.

14. Nelson CD, McMillin DL, Richards DG, Mein EA, Redwood D: Manual healing diversity and other challenges to chiropractic integration. *Journal of Manipulative and Physiological Therapeutics* 2000, 23:202-207.
15. Bronfort G, Haas M, Evans RL, Bouter LM: Efficacy of spinal manipulation and mobilization for low back pain and neck pain: a systematic review and best evidence synthesis. *The Spine Journal* 2004, 4:335-356.
16. Howell JD: The paradox of osteopathy. *New England Journal of Medicine* 1999, 341:1465-1468.
17. Hensel KL, Buchanan S, Brown SK, et al. Pregnancy Research on Osteopathic Manipulation Optimizing Treatment Effects: the PROMOTE study. *Am J Obstet Gynecol* 2014;211.
18. Hróbjartsson A, Gøtzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *New England Journal of Medicine* 2001, 344:1594-1602.
19. Ernst E: Does spinal manipulation have specific treatment effects? *Family Practice* 2000, 17:554-556.
20. Bjordal JM, Ljunggren AE, Klovning A, Slørdal L: Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. *British Medical Journal* 2004, 329:1317-doi:10.1136/bmj.38273.626655.63
21. Licciardone JC, Stoll ST, Fulda KG, Russo DP, Siu J, Winn W, Swift J: Osteopathic manipulative treatment for chronic low back pain: a randomized controlled trial. *Spine* 2003, 28:1355-1362.
22. Andersson GBJ, Lucente T, Davis AM, Kappler RE, Lipton JA, Leurgans S: A comparison of osteopathic spinal manipulation with standard care for patients with low back pain. *New England Journal of Medicine* 1999, 341:1426-1431.
23. Reilly BM, Hart A, Evans AT: Part II. Evidence-based medicine: a passing fancy or the future of primary care? *Disease-a-Month* 1998, 44:370-399.
24. Shekelle PG, Markovich M, Louie R: Factors associated with choosing a chiropractor for episodes of back pain care. *Medical Care* 1995, 33:842-850.
25. Hart LG, Deyo RA, Cherkin DC: Physician office visits for low back pain: frequency, clinical evaluation, and treatment patterns from a U.S. national survey. *Spine* 1995, 20:11-19.
26. Williams NH, Wilkinson C, Russell I, Edwards RT, Hibbs R, Linck P, Muntz R: Randomized osteopathic manipulation study (ROMANS): pragmatic trial for spinal pain in primary care. *Family Practice* 2003, 20:662-669.
27. Licciardone, JC, Minotti, DE, Gatchel, RJ, Kearns, CM, Singh, KP. Osteopathic Manual Treatment and Ultrasound Therapy for Chronic Low Back Pain: A Randomized Controlled Trial. *Ann Fam Med* 2013;11:122-129.
28. Johnson SM, Kurtz ME, Kurtz JC: Variables influencing the use of osteopathic manipulative treatment in family practice. *J Am Osteopath Assoc.* 1997 Feb;97(2):80-7. Erratum in: *J Am Osteopath Assoc* 1997 Apr;97(4):202.

## Appendix 1

### DEFINITION OF TERMS USED

Glossary of Osteopathic Terminology, Revised November 2011. Reprinted with permission from the American Association of Colleges of Osteopathic Medicine. All rights reserved.

To download the complete Glossary, please go to <http://www.aacom.org/news-and-events/publications/glossary-of-osteopathic-terminology>

**osteopathic manipulative treatment (OMT):** The therapeutic application of manually guided forces by an osteopathic physician (U.S. usage) to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. OMT employs a variety of techniques including:

**active method,** technique in which the person voluntarily performs an osteopathic practitioner-directed motion.

**articulatory treatment,** (Archaic). See *osteopathic manipulative treatment, articulatory treatment system.*

**articulatory (ART),** a low velocity/ moderate to high amplitude technique where a joint is carried through its full motion with the therapeutic goal of increased range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier.

1 **balanced ligamentous tension (BLT)**, 1. According to Sutherland’s model, all the joints in  
2 the body are balanced ligamentous articular mechanisms. The ligaments provide  
3 proprioceptive information that guides the muscle response for positioning the joint, and the  
4 ligaments themselves guide the motion of the articular components. (*Foundations*) 2. First  
5 described in “Osteopathic Technique of William G. Sutherland,” that was published in the  
6 *1949 Year Book of Academy of Applied Osteopathy*. See also *ligamentous articular strain*.

7 **Chapman reflex**, See *Chapman reflex*.

8 **combined method**, 1. A treatment strategy where the initial movements are indirect; as the  
9 technique is completed the movements change to direct forces. 2. A manipulative sequence  
10 involving two or more different osteopathic manipulative treatment systems (e.g., Spencer  
11 technique combined with muscle energy technique). 3. A concept described by Paul  
12 Kimberly, DO.

13 **combined treatment**, (Archaic). See *osteopathic manipulative treatment, combined method*.

14 **compression of the fourth ventricle (CV-4)**, a cranial technique in which the lateral angles  
15 of the occipital squama are manually approximated slightly exaggerating the posterior  
16 convexity of the occiput and taking the cranium into sustained extension.

17 **counterstrain (CS)**, 1. A system of diagnosis and treatment that considers the dysfunction  
18 to be a continuing, inappropriate strain reflex, which is inhibited by applying a position of  
19 mild strain in the direction exactly opposite to that of the reflex; this is accomplished by  
20 specific directed positioning about the point of tenderness to achieve the desired therapeutic  
21 response. 2. Australian and French use: Jones technique, (correction spontaneous by  
22 position), spontaneous release by position. 3. Developed by Lawrence Jones, DO in 1955  
23 (originally “Spontaneous Release by Positioning,” later termed “strain-counterstrain”).

24 **cranial treatment (CR)**, See *primary respiratory mechanism*. See *osteopathy in the cranial*  
25 *field*.

26 **CV-4**, abbreviation for compression of the fourth ventricle. See *osteopathic manipulative*  
27 *treatment, compression of the fourth ventricle*.

28 **Dalrymple treatment**, See *osteopathic manipulative treatment, pedal pump*.

29 **direct method (D/DIR)**, an osteopathic treatment strategy by which the restrictive barrier is  
30 engaged and a final activating force is applied to correct somatic dysfunction.

31 **exaggeration method**, an osteopathic treatment strategy by which the dysfunctional  
32 component is carried away from the restrictive barrier and beyond the range of voluntary  
33 motion to a point of palpably increased tension.

34 **exaggeration technique**, an indirect procedure that involves carrying the dysfunctional part  
35 away from the restrictive barrier, then applying a high velocity/low amplitude force in the  
36 same direction.

37 **facilitated oscillatory release technique (FOR)**, 1. A technique intended to normalize  
38 neuromuscular function by applying a manual oscillatory force, which may be combined  
39 with any other ligamentous or myofascial technique. 2. A refinement of a long-standing use  
40 of oscillatory force in osteopathic diagnosis and treatment as published in early osteopathic  
41 literature. 3. A technique developed by Zachary Comeaux, DO.

1 **facilitated positional release (FPR)**, a system of indirect myofascial release treatment. The  
2 component region of the body is placed into a neutral position, diminishing tissue and joint  
3 tension in all planes, and an activating force (compression or torsion) is added. 2. A  
4 technique developed by Stanley Schiowitz, DO.

5 **fascial release treatment**, See *osteopathic manipulative treatment, myofascial release*.

6 **fascial unwinding**, a manual technique involving constant feedback to the osteopathic  
7 practitioner who is passively moving a portion of the patient's body in response to the  
8 sensation of movement. Its forces are localized using the sensations of ease and bind over  
9 wider regions.

10 **functional method**, an indirect treatment approach that involves finding the dynamic  
11 balance point and one of the following: applying an indirect guiding force, holding the  
12 position or adding compression to exaggerate position and allow for spontaneous  
13 readjustment. The osteopathic practitioner guides the manipulative procedure while the  
14 dysfunctional area is being palpated in order to obtain a continuous feedback of the  
15 physiologic response to induced motion. The osteopathic practitioner guides the  
16 dysfunctional part so as to create a decreasing sense of tissue resistance (increased  
17 compliance).

18 **Galbreath treatment**, See *osteopathic manipulative treatment, mandibular drainage*.

19 **hepatic pump**, rhythmic compression applied over the liver for purposes of increasing  
20 blood flow through the liver and enhancing bile and lymphatic drainage from the liver.

21 **high velocity/low amplitude technique (HVLA)**, an osteopathic technique employing a  
22 rapid, therapeutic force of brief duration that travels a short distance within the anatomic  
23 range of motion of a joint, and that engages the restrictive barrier in one or more planes of  
24 motion to elicit release of restriction. Also known as thrust technique.

25 **Hoover technique**, 1. A form of functional method. 2. Developed by H.V. Hoover, DO. See  
26 also *osteopathic manipulative treatment, functional technique*.

27 **indirect method (I/IND)**, a manipulative technique where the restrictive barrier is  
28 disengaged and the dysfunctional body part is moved away from the restrictive barrier until  
29 tissue tension is equal in one or all planes and directions.

30 **inhibitory pressure technique**, the application of steady pressure to soft tissues to reduce  
31 reflex activity and produce relaxation.

32 **integrated neuromusculoskeletal release (INR)**, a treatment system in which combined  
33 procedures are designed to stretch and reflexly release patterned soft tissue and joint-related  
34 restrictions. Both direct and indirect methods are used interactively.

35 **Jones technique**, See *osteopathic manipulative treatment, counterstrain*.

36 **ligamentous articular strain technique (LAS)**, 1. A manipulative technique in which the  
37 goal of treatment is to balance the tension in opposing ligaments where there is abnormal  
38 tension present. 2. A set of myofascial release techniques described by Howard Lippincott,  
39 DO, and Rebecca Lippincott, DO. 3. Title of reference work by Conrad Speece, DO, and  
40 William Thomas Crow, DO.

41 **liver pump**, See *hepatic pump*.

1 **lymphatic pump**, 1. A term used to describe the impact of intrathoracic pressure changes on  
2 lymphatic flow. This was the name originally given to the thoracic pump technique before  
3 the more extensive physiologic effects of the technique were recognized. 2. A term coined  
4 by C. Earl Miller, DO.

5 **mandibular drainage technique**, soft tissue manipulative technique using passively  
6 induced jaw motion to effect increased drainage of middle ear structures via the eustachian  
7 tube and lymphatics.

8 **mesenteric release technique (mesenteric lift)**, technique in which tension is taken off the  
9 attachment of the root of the mesentery to the posterior body wall. Simultaneously, the  
10 abdominal contents are compressed to enhance venous and lymphatic drainage from the  
11 bowel.

12 **muscle energy**, a form of osteopathic manipulative diagnosis and treatment in which the  
13 patient's muscles are actively used on request, from a precisely controlled position, in a  
14 specific direction, and against a distinctly executed physician counterforce. First described  
15 in 1948 by Fred Mitchell, Sr, DO.

16 **myofascial release (MFR)**, a system of diagnosis and treatment first described by Andrew  
17 Taylor Still and his early students, which engages continual palpatory feedback to achieve  
18 release of myofascial tissues.

19 **direct MFR**, a myofascial tissue restrictive barrier is engaged for the myofascial  
20 tissues and the tissue is loaded with a constant force until tissue release occurs.

21 **indirect MFR**, the dysfunctional tissues are guided along the path of least resistance  
22 until free movement is achieved.

23 **myofascial technique**, any technique directed at the muscles and fascia. See also  
24 *osteopathic manipulative treatment, myofascial release*. See also *osteopathic manipulative*  
25 *treatment, soft tissue technique*.

26 **myotension**, a system of diagnosis and treatment that uses muscular contractions and  
27 relaxations under resistance of the osteopathic practitioner to relax, strengthen or stretch  
28 muscles, or mobilize joints.

29 **Osteopathy in the Cranial Field (OCF)**, 1. A system of diagnosis and treatment by an  
30 osteopathic practitioner using the primary respiratory mechanism and balanced membranous  
31 tension. See also *primary respiratory mechanism*. 2. Refers to the system of diagnosis and  
32 treatment first described by William G. Sutherland, DO. 3. Title of reference work by  
33 Harold Magoun, Sr, DO.

34 **passive method**, based on techniques in which the patient refrains from voluntary muscle  
35 contraction.

36 **pedal pump**, a venous and lymphatic drainage technique applied through the lower  
37 extremities; also called the pedal fascial pump or Dalrymple treatment.

38 **percussion vibrator technique**, 1. A manipulative technique involving the specific  
39 application of mechanical vibratory force to treat somatic dysfunction. 2. An osteopathic  
40 manipulative technique developed by Robert Fulford, DO.



1 **positional technique**, a direct segmental technique in which a combination of leverage,  
2 patient ventilatory movements and a fulcrum are used to achieve mobilization of the  
3 dysfunctional segment. May be combined with springing or thrust technique.

4 **progressive inhibition of neuromuscular structures (PINS)**, 1. A system of diagnosis and  
5 treatment in which the osteopathic practitioner locates two related points and sequentially  
6 applies inhibitory pressure along a series of related points. 2. Developed by Dennis  
7 Dowling, DO.

8 **range of motion technique**, active or passive movement of a body part to its physiologic or  
9 anatomic limit in any or all planes of motion.

10 **soft tissue (ST)**, A system of diagnosis and treatment directed toward tissues other than  
11 skeletal or arthroal elements.

12 **soft tissue technique**, a direct technique that usually involves lateral stretching, linear  
13 stretching, deep pressure, traction and/or separation of muscle origin and insertion while  
14 monitoring tissue response and motion changes by palpation. Also called myofascial  
15 treatment.

16 **Spencer technique**, a series of direct manipulative procedures to prevent or decrease soft  
17 tissue restrictions about the shoulder. See also *osteopathic manipulative treatment (OMT)*,  
18 *articular treatment (ART)*.

19 **splenic pump technique**, rhythmic compression applied over the spleen for the purpose of  
20 enhancing the patient's immune response. See also *osteopathic manipulative treatment*  
21 *(OMT)*, *lymphatic pump*.

22 **spontaneous release by positioning**, See *osteopathic manipulative treatment*,  
23 *counterstrain*.

24 **springing technique**, a low velocity/ moderate amplitude technique where the restrictive  
25 barrier is engaged repeatedly to produce an increased freedom of motion. See also  
26 *osteopathic manipulative treatment*, *articular treatment system*.

27 **Still Technique**, 1. Characterized as a specific, non-repetitive articular method that is  
28 indirect, then direct. 2. Attributed to A.T. Still. 3. A term coined by Richard Van Buskirk,  
29 DO, PhD.

30 **Strain-Counterstrain,®** 1. An osteopathic system of diagnosis and indirect treatment in  
31 which the patient's somatic dysfunction, diagnosed by (an) associated myofascial  
32 tenderpoint(s), is treated by using a passive position, resulting in spontaneous tissue release  
33 and at least 70 percent decrease in tenderness. 2. Developed by Lawrence H. Jones, DO, in  
34 1955. See *osteopathic treatments*, *counterstrain*.

35 **thoracic pump**, 1. A technique that consists of intermittent compression of the thoracic  
36 cage. 2. Developed by C. Earl Miller, DO.

37 **thrust technique (HVLA)**, See *osteopathic manipulative treatment*, *high velocity/low*  
38 *amplitude technique (HVLA)*.

39 **toggle technique**, short lever technique using compression and shearing forces.

40 **traction technique**, a procedure of high or low amplitude in which the parts are stretched or  
41 separated along a longitudinal axis with continuous or intermittent force.

1 **v-spread**, technique using forces transmitted across the diameter of the skull to accomplish  
2 sutural gapping.

3 **ventral techniques**, See *osteopathic manipulative treatment, visceral manipulation*.

4 **visceral manipulation (VIS)**, a system of diagnosis and treatment directed to the viscera to  
5 improve physiologic function. Typically, the viscera are moved toward their fascial  
6 attachments to a point of fascial balance. Also called ventral techniques.

7 **somatic dysfunction**: Impaired or altered function of related components of the somatic  
8 (body framework) system: skeletal, arthrodiagonal and myofascial structures, and their related  
9 vascular, lymphatic, and neural elements. Somatic dysfunction is treatable using osteopathic  
10 manipulative treatment.

## 11 Appendix 2

### 12 References cited in Franke et al systematic review

- 13 1. van Tulder M, Becker A, Bekkering T, Breen A, del Real MT, Hutchinson A, Koes B, Laerum E, Malmivaara A, Care  
14 CBWGoGftMoALBPiP: Chapter 3. European guidelines for the management of acute nonspecific low back pain in  
15 primary care. *Eur Spine J* 2006, 15(Suppl 2):S169–S191.
- 16 2. Airaksinen O, Brox JI, Cedraschi C, Hildebrandt J, Kluber-Moffett J, Kovacs F, Mannion AF, Reis S, Staal JB, Ursin H,  
17 Zanoli G: Chapter 4. European guidelines for the management of chronic nonspecific low back pain. *Eur Spine J* 2006,  
18 15(Suppl 2):S192– S300.
- 19 3. Deyo RA, Weinstein JN: Low back pain. *N Engl J Med* 2001, 344:363–370.
- 20 4. National Collaborating Centre for Primary Care: Low Back Pain: Early Management of Persistent Non-specific Low  
21 Back Pain. NICE Clinical Guideline 88. London: National Institute for Health and Clinical Excellence; 2009.  
22 <http://www.nice.org.uk/nicemedia/pdf/CG88NICEGuideline.pdf>.
- 23 5. Burton AK, Balague F, Cardon G, Eriksen HR, Henrotin Y, Lahad A, Leclerc A, Muller G, van der Beek AJ: Chapter 2.  
24 European guidelines for prevention in low back pain. *Eur Spine J* 2006, 15(Suppl 2):S136–S168.
- 25 6. Dagenais S, Caro J, Haldeman S: A systematic review of low back pain cost of illness studies in the United States and  
26 internationally. *Spine J* 2008, 8:8–20.
- 27 7. Croft P, Papageorgiou A: Low back pain in the community and in hospitals. A report to the Clinical Standards Advisory  
28 Group of the Department of Health, Arthritis and Rheumatism Council. Manchester: Epidemiology Research Unit  
29 University of Manchester; 1994.
- 30 8. Vermani E, Mittal R, Weeks A: Pelvic girdle pain and low back pain in pregnancy: a review. *Pain Pract* 2010, 10:60–71.
- 31 9. Vleeming A, Albert HB, Ostgaard HC, Sturesson B, Stuge B: European guidelines for the diagnosis and treatment of  
32 pelvic girdle pain. *Eur Spine J* 2008, 17:794–819.
- 33 10. Gutke A, Ostgaard HC, Oberg B: Predicting persistent pregnancy-related low back pain. *Spine* 2008, 33:E386–E393.
- 34 11. Ostgaard HC, Zetherstrom G, Roos-Hansson E, Svanberg B: Reduction of back and posterior pelvic pain in  
35 pregnancy. *Spine* 1994, 19:894–900.
- 36 12. Sabino J, Grauer JN: Pregnancy and low back pain. *Curr Rev Musculoskelet Med* 2008,1:137–141.
- 37 13. Majchrzycki M, Mrozikiewicz PM, Kocur P, Bartkowiak-Wieczorek J, Hoffmann M, Stryla W, Seremak-Mrozikiewicz  
38 A, Grzeskowiak E: Low back pain in pregnant women. *Ginekol Pol* 2010, 81:851–855.
- 39 14. Gutke A, Ostgaard HC, Oberg B: Association between muscle function and low back pain in relation to pregnancy. *J*  
40 *Rehabil Med* 2008, 40:304–311.
- 41 15. Brown S, Lumley J: Maternal health after childbirth: results of an Australian population based survey. *Br J Obstet*  
42 *Gynaecol* 1998, 105:156–161.
- 43 16. MacArthur C, Lewis M, Knox EG: Health after childbirth. *Br J Obstet Gynaecol* 1991,98:1193–1195.
- 44 17. Patel RR, Peters TJ, Murphy DJ: Is operative delivery associated with postnatal back pain at eight weeks and eight  
45 months? a cohort study. *Acta Obstet Gynecol Scand* 2007, 86:1322–1327.
- 46 18. Saurel-Cubizolles MJ, Romito P, Lelong N, Ancel PY: Women's health after childbirth: a longitudinal study in  
47 France and Italy. *BJOG* 2000, 107:1202–1209.
- 48 19. DiGiovanna EL, Schiowitz S, Dowling DJ: *An Osteopathic Approach to Diagnosis & Treatment*. 3rd edition.  
49 Philadelphia: Lippincott William & Wilkins; 2005.
- 50 20. Vaughan B, Morrison T, Buttigieg D, Macfarlane C, Fryer G: *Approach to low back pain - osteopathy*. Aust Fam  
51 *Physician* 2014, 43:197–198.
- 52 21. Greenman PE: *Principles of Manual Medicine*. 3rd edition. Philadelphia: Lippincott William & Wilkins; 2003.

- 1 22. Maniadakis N, Gray A: The economic burden of back pain in the UK. *Pain* 2000, 84:95–103.
- 2 23. Fawkes CA, Leach CM, Mathias S, Moore AP: A profile of osteopathic care in private practices in the United Kingdom:  
3 a national pilot using standardised data collection. *Man Ther.* in press.
- 4 24. General Osteopathic Council: Snapshot Survey. London, UK: General Osteopathic Council; 2001.  
5 [http://www.osteopathy.org.uk/uploads/survey2snapshot\\_survery\\_results\\_2001.pdf](http://www.osteopathy.org.uk/uploads/survey2snapshot_survery_results_2001.pdf).
- 6 25. Walker BF, Muller R, Grant WD: Low back pain in Australian Adults. health provider utilization and care  
7 seeking. *J Manipulative Physiol Ther* 2004, 27:327–335.
- 8 26. Orrock P: Profile of members of the Australian Osteopathic Association: part 2 - the patients. *Int J Osteopath Med*  
9 2009, 12:128–139.
- 10 27. Licciardone JC: The epidemiology and medical management of low back pain during ambulatory medical care visits in  
11 the United States. *Osteopath Med Prim Care* 2008, 2:11.
- 12 28. Licciardone JC, Brimhall AK, King LN: Osteopathic manipulative treatment for low back pain: a systematic review and  
13 meta-analysis of randomized controlled trials. *BMC Musculoskelet Disord* 2005, 6:43.
- 14 29. Franke H: Why reservations remain: a critical reflection about the systematic review and meta-analysis “Osteopathic  
15 manipulative treatment for low back pain” by Licciardone et al. *J Bodyw Mov Ther* 2012, 16:411–415.
- 16 30. Orrock PJ, Myers SP: Osteopathic intervention in chronic non-specific low back pain: a systematic review. *BMC*  
17 *Musculoskelet Disord* 2013, 14:129.
- 18 31. Higgins JPT, Green S: *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0. Cochrane  
19 Collaboration; 2011. [www.cochrane-handbook.org](http://www.cochrane-handbook.org).
- 20 32. Rubinstein SM, Terwee CB, Assendelft WJ, de Boer MR, van Tulder MW: Spinal manipulative therapy for acute low  
21 back pain: an update of the cochrane review. *Spine* 2013, 38:E158–E177.
- 22 33. Rubinstein SM, van Middelkoop M, Assendelft WJ, de Boer MR, van Tulder MW: Spinal manipulative therapy for  
23 chronic low-back pain: an update of a Cochrane review. *Spine* 2011, 36:E825–E846.
- 24 34. Johnson SM, Kurtz ME: Osteopathic manipulative treatment techniques preferred by contemporary osteopathic  
25 physicians. *J Am Osteopath Assoc* 2003, 103:219–224.
- 26 35. Orrock P: Profile of members of the Australian Osteopathic Association: part 1 - the practitioners. *Int J Osteopath*  
27 *Med* 2009, 12:14–24.
- 28 36. Fryer G, Johnson JC, Fossum C: The use of spinal and sacroiliac joint procedures within the British osteopathic  
29 profession. part 2: treatment. *Int J Osteopath Med* 2010, 13:152–159.
- 30 37. Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample.  
31 *BMC Med Res Methodol* 2005, 5:13.
- 32 38. Furlan AD, Pennick V, Bombardier C, van Tulder M: 2009 updated method guidelines for systematic reviews in the  
33 *Cochrane Back Review Group*. *Spine (Phila Pa 1976)* 2009, 34:1929–1941.
- 34 39. Cruser dA, Maurer D, Hensel K, Brown S, White K, Stoll S: A randomized, controlled trial of osteopathic manipulative  
35 treatment for acute low back pain in active duty military personnel. *J Man Manip Ther* 2012, 20:5–15.
- 36 40. Andersson GB, Lucente T, Davis AM, Kappler RE, Lipton JA, Leurgans S: A comparison of osteopathic spinal  
37 manipulation with standard care for patients with low back pain. *N Engl J Med* 1999, 341:1426–1431.
- 38 41. Gibson T, Grahame R, Harkness J, Woo P, Blagrove P, Hills R: Controlled comparison of short-wave diathermy  
39 treatment with osteopathic treatment in non-specific low back pain. *Lancet* 1985, 1:1258–1261.
- 40 42. Heinze G: The Effectiveness of a Holistic Osteopathic Treatment in Subacute Low Back Pain. A Randomized  
41 Controlled Trial, Unpublished D.O. Thesis. Akademie für Osteopathie; 2006. [http://www.osteopathic-](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=13797&lang=en)  
42 [research.com/index.php?option=com\\_jresearch&view=publication&task=show&id=13797&lang=en](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=13797&lang=en). 43. Kunz R,  
43 Djulbegovic B, Schunemann HJ, Stanulla M, Muti P, Guyatt G: Misconceptions, challenges, uncertainty,  
44 and progress in guideline recommendations. *Semin Hematol* 2008, 45:167–175.
- 45 43. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A: GRADE guidelines: a new series of articles  
46 in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol* 2011, 64:380–382.
- 47 44. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher  
48 D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare  
49 interventions: explanation and elaboration. *BMJ* 2009, 339:b2700.
- 50 45. Adorján-Schaumann K, Höhrhan G, Wille H, Wolff A: Osteopathic Treatment of Chronic Low Back Pain. A  
51 Randomized Controlled Trial, Unpublished D.O. Thesis. Akademie für Osteopathie; 1999. [http://www.osteopathic-](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=13311&lang=en)  
52 [research.com/index.php?option=com\\_jresearch&view=publication&task=show&id=13311&lang=en](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=13311&lang=en).
- 53 46. Chown M, Whittamore L, Rush M, Allan S, Scott D, Archer M: A prospective study of patients with chronic back pain  
54 randomised to group exercise, physiotherapy or osteopathy. *Physiother* 2008, 94:21–28.
- 55 47. Gundermann S: Effectiveness of Osteopathic Treatment in Pregnant Women Suffering From Low Back Pain. A  
56 Randomized Controlled Trial, Unpublished D.O. Thesis. Akademie für Osteopathie; 2013. [http://www.osteopathic-](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=15363&lang=en)  
57 [research.com/index.php?option=com\\_jresearch&view=publication&task=show&id=15363&lang=en](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=15363&lang=en).

- 1 48. Licciardone JC, Buchanan S, Hensel KL, King HH, Fulda KG, Stoll ST: Osteopathic manipulative treatment of back  
2 pain and related symptoms during pregnancy: a randomized controlled trial. *Am J Obstet Gynecol* 2009, 202:43–48.
- 3 49. Licciardone JC, Minotti DE, Gatchel RJ, Kearns CM, Singh KP: Osteopathic manual treatment and ultrasound therapy  
4 for chronic low back pain: a randomized controlled trial. *Ann Fam Med* 2013, 11:122–129.
- 5 50. Licciardone JC, Stoll ST, Fulda KG, Russo DP, Siu J, Winn W, Swift J Jr: Osteopathic manipulative treatment for  
6 chronic low back pain: a randomized controlled trial. *Spine (Phila Pa 1976)* 2003, 28:1355–1362.
- 7 51. Mandara A, Fusaro A, Musicco M, Bado F: A randomised controlled trial on the effectiveness of osteopathic  
8 manipulative treatment of chronic low back pain (abstract). *Int J Osteopath Med* 2008, 11:156.
- 9 52. Peters R, Van Der Linde M: Osteopathic Treatment of Women with Low Back Pain during Pregnancy. A Randomized  
10 Controlled Trial, Unpublished D.O. Thesis. : Akademiefür Osteopathie; 2006. [http://www.osteopathic-](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=13801&lang=en)  
11 [research.com/index.php?option=](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=13801&lang=en)  
12 53. Recknagel C, Roá J: Study on the Effectiveness of Osteopathic Treatment for Women with Persistent Post Partum  
13 Back Pain. A Randomized Controlled Trial, Unpublished D.O. Thesis. Akademie für Osteopathie; 2007.  
14 [http://www.osteopathic-](http://www.osteopathic-research.com/index.php?option)  
15 [research.com/index.php?option=](http://www.osteopathic-research.com/index.php?option)  
16 54. Schwerla F, Rother K, Rother D, Ruetz M: Osteopathic treatment of women with persistent low back / pelvic girdle  
17 pain postpartum. In *Vol Proceedings of the 9th International Symposium of Osteopathy 2012*. Nantes, France:  
18 Akademie für Osteopathie; 2012. [http://www.osteopathic-](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=15181&lang=en)  
19 [research.com/index.php?option=com\\_jresearch&view=publication&task=show&id=15181&lang=en](http://www.osteopathic-research.com/index.php?option=com_jresearch&view=publication&task=show&id=15181&lang=en).
- 20 55. Vismara L, Cimolin V, Menegoni F, Zaina F, Galli M, Negrini S, Villa V, Capodaglio P: Osteopathic manipulative  
21 treatment in obese patients with chronic low back pain: a pilot study. *Man Ther* 2012, 17:451–455.
- 22 56. Boesler D, Warner M, Alpers A, Finnerty EP, Kilmore MA: Efficacy of high-velocity low-amplitude manipulative  
23 technique in subjects with low-back pain during menstrual cramping. *J Am Osteopath Assoc* 1993, 93:203–204.
- 24 57. Cleary C, Fox JP: Menopausal symptoms: an osteopathic investigation. *Complement Ther Med* 1994, 2:181–186.
- 25 58. Hoehler FK, Tobis JS, Buerger AA: Spinal manipulation for low back pain. *JAMA* 1981, 245:1835–1838.
- 26 59. Tozzi P, Bongiorno D, Vitturini C: Low back pain and kidney mobility: local osteopathic fascial manipulation decreases  
27 pain perception and improves renal mobility. *J Bodyw Mov Ther* 2012, 16:381–391.
- 28 60. Caragan C, Tang PY, Slack M, Leiber JD, Koskinen J, Züst D, Cragun T: Pilot clinical study of osteopathic  
29 manipulative treatment in pregnant patients with acute low back pain. *Int J Osteopath Med* 2008, 11:155.
- 30 61. Hoffman KS, Hoffman LL: Effects of adding sacral base leveling to osteopathic manipulative treatment of back pain: a  
31 pilot study. *J Am Osteopath Assoc* 1994, 94:216–217.
- 32 62. Parker J, Heinking KP, Kappler RE: Efficacy of osteopathic manipulative treatment for low back pain in euhydrated  
33 and hypohydrated conditions: a randomized crossover trial. *J Am Osteopath Assoc* 2012, 112:276–284.
- 34 63. Williams NH, Wilkinson C, Russell I, Edwards RT, Hibbs R, Linck P, Muntz R: Randomized osteopathic manipulation  
35 study (ROMANS): pragmatic trial for spinal pain in primary care. *Fam Pract* 2003, 20:662–669.
- 36 64. MacDonald RS, Bell CM: An open controlled assessment of osteopathic manipulation in nonspecific low-back pain.  
37 *Spine (Phila Pa 1976)* 1990, 15:364–370.
- 38 65. Williams NH, Edwards RT, Linck P, Muntz R, Hibbs R, Wilkinson C, Russell I, Russell D, Hounsborne B: Cost-utility  
39 analysis of osteopathy in primary care: results from a pragmatic randomized controlled trial. *Fam Pract* 2004, 21:643–  
40 650.
- 41 66. Kirk L, Underwood M, Chappell L, Martins-Mendez M, Thomas P: The effect of osteopathy in the treatment of  
42 chronic low back pain. A feasibility study. *Int J Osteopath Med* 2005, 8:5–11.
- 43 67. Burton AK, Tillotson KM, Cleary J: Single-blind randomised controlled trial of chemonucleolysis and manipulation in  
44 the treatment of symptomatic lumbar disc herniation. *Eur Spine J* 2000, 9:202–207.
- 45 68. Posadzki P, Ernst E: Osteopathy for musculoskeletal pain patients: a systematic review of randomized controlled trials.  
46 *Clin Rheumatol* 2011, 30:285–291.
- 47 69. Walker BF, French SD, Grant W, Green S: A Cochrane review of combined chiropractic interventions for low-back  
48 pain. *Spine* 2011, 36:230–242.

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

**RECOMMEND THAT REFERENCES BE UPDATED PRIOR TO THE NEXT  
PUBLICATION OF THE RESOLUTION**

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: ADDRESSING THE EFFECTS OF CLIMATE ON NATIONAL HEALTH

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Professional Affairs

---

1 WHEREAS, rising average temperatures will lead to increased frequency and longevity of heat  
2 waves<sup>2</sup>; and

3 WHEREAS, these environmental changes will translate to poorer health outcomes in the  
4 United States—projections show, within the next 80 years, additional deaths due to  
5 climate change may reach up to tens of thousands per year<sup>1</sup>; and

6 WHEREAS, these deaths will not be offset by a smaller reduction in cold-related deaths in  
7 winter months<sup>1</sup>; and

8 WHEREAS, exposure to extreme heat can lead to heat stroke and dehydration, as well as  
9 cardiovascular, respiratory, and cerebrovascular disease<sup>4</sup>; and

10 WHEREAS, certain patient populations will be more vulnerable to extreme heat due to  
11 impaired heat regulatory functions, including young children, pregnant women, the  
12 elderly, and persons with inherent medical conditions and/or disabilities<sup>1</sup>; and

13 WHEREAS, climate change is projected to increase the vulnerability of urban populations to  
14 heat-related health impacts in the future<sup>1</sup>; and

15 WHEREAS, metropolitan areas such as St. Louis, Philadelphia, Chicago, and Cincinnati have  
16 already seen notable increases in death rates during heat waves<sup>2</sup>; and

17 WHEREAS, warmer temperatures are associated with periods of stagnant air, leading to  
18 increases in air pollution and associated health effects<sup>2</sup>: asthma attacks and other  
19 respiratory and cardiovascular health effects<sup>1</sup>; and

20 WHEREAS, wildfires, which are expected to continue to increase in number and severity as the  
21 climate changes, create smoke and other air pollutants<sup>1</sup>; and

22 WHEREAS, despite significant improvements in U.S. air quality since the 1970s, as of 2014  
23 about 57 million Americans lived in counties that did not meet national air quality  
24 standards<sup>5</sup>; and

25 WHEREAS, scientists predict warmer temperatures from climate change will increase the  
26 frequency of days with unhealthy levels of ground-level ozone, a harmful air pollutant,  
27 and a component in smog<sup>1</sup>; and

28 WHEREAS, people exposed to higher levels of ground-level ozone are at greater risk of dying  
29 prematurely or being admitted to the hospital for respiratory problems<sup>1</sup>; and

1 WHEREAS, ground-level ozone can damage lung tissue, reduce lung function, and inflame  
2 airways: increasing national incidences of asthma or other lung diseases<sup>1</sup>; and

3 WHEREAS, children, older adults, outdoor workers, and those with asthma and other chronic  
4 lung diseases are particularly at risk<sup>5</sup>; and

5 WHEREAS, warm, stagnant air tends to increase the formation of ozone, therefore, climate  
6 change is likely to increase levels of ground-level ozone in already-polluted areas of the  
7 United States, thereby further decreasing air quality<sup>1</sup>; and

8 WHEREAS, the higher concentrations of ozone due to climate change may result in tens to  
9 thousands of additional ozone-related illnesses and premature deaths per year by 2030  
10 in the United States, assuming no change in projected air quality policies<sup>1</sup>; and

11 WHEREAS, climate-related changes in stagnant air episodes, wind patterns, emissions from  
12 vegetation and the chemistry of atmospheric pollutants will also affect particulate matter  
13 levels<sup>1</sup>; and

14 WHEREAS, inhaling fine particles can lead to a broad range of adverse health effects, including  
15 lung cancer, chronic obstructive pulmonary disease (COPD), and cardiovascular  
16 disease<sup>1</sup>; and

17 WHEREAS, allergic illnesses, including hay fever, affects roughly one-third of the U.S.  
18 population, and more than 34 million Americans have been diagnosed with asthma<sup>1</sup>;  
19 and

20 WHEREAS, pollen season in the United States is occurring earlier and increasing in season  
21 duration, especially for vegetation with highly allergenic pollen, such as ragweed<sup>1</sup>; and

22 WHEREAS, rising carbon dioxide concentrations and temperatures may also lead to earlier  
23 flowering, more flowers, and increased pollen levels in ragweed<sup>4</sup>; and

24 WHEREAS, increases in the frequency or severity of some extreme weather events, such as  
25 extreme precipitation, flooding, droughts, and storms, threaten the health of people  
26 during and after the event<sup>1</sup>; and

27 WHEREAS, extreme environmental events caused by climate change can affect human health  
28 by damaging roads and bridges, disrupting access to hospitals and pharmacies<sup>1</sup>; and

29 WHEREAS, extreme environmental events caused by climate change can affect human health  
30 by interrupting communication, utility, and access to health care services<sup>1</sup>; and

31 WHEREAS, extreme environmental events caused by climate change can affect human health  
32 by reducing the availability of food and drinking water<sup>1</sup>; and

33 WHEREAS, runoff and flooding resulting from increased precipitation, hurricane rainfall, and  
34 storm surge will increasingly contaminate water bodies used for recreation (such as lakes  
35 and beaches), shellfish harvesting waters, and sources of drinking water<sup>1</sup>; and

1 WHEREAS, health impacts may include gastrointestinal illness, negative effects on the body's  
2 nervous and respiratory systems, or liver and kidney damage<sup>1</sup>; and

3 WHEREAS, extreme weather events and storm surges can damage or exceed the capacity of  
4 water infrastructure (such as drinking water or wastewater treatment plants), increasing  
5 the risk that people will be exposed to contaminants<sup>1</sup>; and

6 WHEREAS, extreme environmental events caused by climate change can affect human health  
7 by contributing to carbon monoxide poisoning from improper use of portable electric  
8 generators during and after storms<sup>1</sup>; and

9 WHEREAS, changes in temperature and precipitation, such as droughts and floods, could  
10 reduce agricultural output and increasing incidences of malnutrition in the United  
11 States<sup>7</sup>; and

12 WHEREAS, higher air temperature can increase morbidity and mortality of Salmonella and  
13 other bacteria-related food poisoning because bacteria grow more rapidly in warm  
14 environments<sup>1</sup>; and

15 WHEREAS, climate change will have a variety of impacts that may increase the risk of  
16 exposure to chemical contaminants in food<sup>1</sup>; and

17 WHEREAS, higher concentrations of carbon dioxide in the air lowers the levels of protein and  
18 essential minerals in crops such as wheat, rice, and potatoes, making these foods less  
19 nutritious<sup>1</sup>; and

20 WHEREAS, extreme environmental events caused by climate change can affect human health  
21 by creating or worsening mental health impacts such as depression and post-traumatic  
22 stress disorder (PTSD)<sup>1</sup>; and

23 WHEREAS, individuals with mental illness are especially vulnerable to extreme heat; studies  
24 have found that having a pre-existing mental illness tripled the risk of death during heat  
25 waves<sup>1</sup>; and

26 WHEREAS, the perceived threat of climate change (from news sources and/or social media)  
27 can influence stress responses and mental health<sup>1</sup>; and

28 WHEREAS, some groups of people are at higher risk for mental health impacts, such as  
29 children and older adults, pregnant and postpartum women, people with pre-existing  
30 mental illness, people with low incomes, and emergency workers<sup>1</sup>; and

31 WHEREAS, the geographic range of ticks that carry Lyme disease is limited by temperature<sup>1</sup>;  
32 and

33 WHEREAS, as air temperatures rise, ticks are likely to become active earlier in the season, and  
34 their range is likely to continue to expand northward<sup>1</sup>; and

35 WHEREAS, the risks for climate-sensitive diseases can be much higher in poorer communities  
36 with fewer resources to prevent and treat illness<sup>6</sup>; and



- 1 WHEREAS, communities of color (including Indigenous communities as well as specific racial  
2 and ethnic groups), low income, immigrants, and limited English proficiency face  
3 disproportionate vulnerabilities due to a wide variety of factors, such as higher risk of  
4 exposure, socioeconomic and educational factors that affect their adaptive capacity, and  
5 a higher prevalence of medical conditions that affect their sensitivity<sup>1</sup>; and
- 6 WHEREAS, children are vulnerable to many health risks due to biological sensitivities and  
7 more opportunities for exposure (due to activities such as playing outdoors)<sup>1</sup>; and
- 8 WHEREAS, occupational groups, such as outdoor workers, paramedics, firefighters, and  
9 transportation workers, as well as workers in hot indoor work environments, will be  
10 especially vulnerable to extreme heat and exposure to vector borne diseases<sup>1</sup>; and
- 11 WHEREAS, people with chronic medical conditions are typically vulnerable to extreme heat,  
12 especially if they are taking medications that make it difficult to regulate body  
13 temperature<sup>1</sup>; and
- 14 WHEREAS, there must be a just transition for all communities and workers to ensure  
15 economic security for people and communities that have historically relied on fossil fuel  
16 industry; and
- 17 WHEREAS, there must be justice and equity for frontline communities by prioritizing  
18 investment, training, climate and community resiliency, economic and environmental  
19 benefits in these communities; now, therefore be it
- 20 RESOLVED, that the American Osteopathic Association (AOA) recognizes climate change as  
21 a public health crisis; and, be it further
- 22 RESOLVED, that the AOA publicly endorse legislation that includes provisions such as a plan  
23 to create an ecologically friendly economy and infrastructure; and, be it further
- 24 RESOLVED, that the AOA joins the U.S. Call to Action.

Explanatory Statement: Submitted by Author:

The US Call to Action is an organization that calls “on government, business, and civil society leaders, elected officials, and candidates for office to recognize climate change as a health emergency and to work across government agencies and with communities and businesses to prioritize action on this Climate, Health and Equity Policy Action Agenda.”

References

1. USGCRP (2016). Impacts of Climate Change on Human Health in the United States: A Scientific Assessment. Crimmins, A., J. Balbus, J.L. Gamble, C.B. Beard, J.E. Bell, D. Dodgen, R.J. Eisen, N.Fann, M.D. Hawkins, S.C. Herring, L. Jantarasami, D.M. Mills, S. Saha, M.C. Sarofim, J.Trtnanj, and L.Ziska, Eds. U.S. Global Change Research Program, Washington, DC. 312 pp. [dx.doi.org/10.7930/J0R49NQX](https://dx.doi.org/10.7930/J0R49NQX).
2. USGCRP (2016). Luber, G., K. Knowlton, J. Balbus, H. Frumkin, M. Hayden, J. Hess, M. McGeehin, N. Sheats, L. Backer, C. B. Beard, K. L. Ebi, E. Maibach, R. S. Ostfeld, C. Wiedinmyer, E. Zielinski-Gutiérrez, and L. Ziska, 2014: Ch. 9: Human Health. Climate Change Impacts in the United States: The Third National Climate Assessment, J. M. Melillo, Terese

- (T.C.) Richmond, and G. W. Yohe, Eds., U.S. Global Change Research Program, 220-256. doi:10.7930/J0PN93H5.
3. USGCRP (2009). Global Climate Change Impacts in the United States. Karl, T.R., J.M. Melillo, and T.C. Peterson (eds.). United States Global Change Research Program. Cambridge University Press, New York, NY, USA.
  4. CCSP (2008). Analyses of the effects of global change on human health and welfare and human systems. A Report by the U.S. Climate Change Science Program and the Subcommittee on Global Change Research. Gamble, J.L. (ed.), K.L. Ebi, F.G. Sussman, T.J. Wilbanks, (Authors). U.S. Environmental Protection Agency, Washington, DC, USA.
  5. EPA (2014). Air Quality Trends. Accessed March 1, 2016.
  6. IPCC (2014). Climate Change 2014: Synthesis Report. Contribution of Working Groups I, II and III to the Fifth Assessment Report of the Intergovernmental Panel on Climate Change [Core Writing Team, R.K. Pachauri and L.A. Meyer (eds.)]. IPCC, Geneva, Switzerland, 151 p. (PDF, 80 pp, 4.6MB).
  7. USDA (2015). Climate Change, Global Food Security, and the U.S. Food System. Brown, M.E., J.M. Antle, P. Backlund, E.R. Carr, W.E. Easterling, M.K. Walsh, C. Ammann, W. Attavanich, C.B. Barrett, M.F. Bellemare, V. Dancheck, C. Funk, K. Grace, J.S.I. Ingram, H. Jiang, H. Maletta, T. Mata, A. Murray, M. Ngugi, D. Ojima, B. O'Neill, and C. Tebaldi, 146 p

Explanatory Statement: Reference Committee

Intent of resolution needs to be clarified; second RESOLVED references legislation that is not defined; third RESOLVED calls for partnering with an unknown organization. There are at least three issues identified in the many WHEREAS statements that are best divided into three separate resolutions.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Student Osteopathic Medical Association)*

DATE: **October 14, 2020**

SUBJECT: ADVERSE CHILDHOOD EXPERIENCES SCREENING

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Professional Affairs

---

1 WHEREAS, Adverse Childhood Experiences (ACEs) are cumulative potentially traumatic  
2 events that occur in childhood (0-17 years), including experiencing or witnessing  
3 violence in the home or community, having a family member attempt or die by suicide,  
4 or growing up in a household with substance misuse, mental health problems, or  
5 instability due to parental separation or household members being in jail or prison<sup>1</sup>; and

6 WHEREAS, the ACEs can be accurately scored on a validated screening instrument in the  
7 primary care setting<sup>2</sup>; and

8 WHEREAS, the ACEs score has been recognized as a strong predictor of both medical and  
9 physical health outcomes, including but not limited to: risks of injury, sexually  
10 transmitted infections, maternal and child health problems, teen pregnancy,  
11 involvement in sex trafficking, and a wide range of chronic diseases, education and job  
12 opportunity losses, and leading causes of death<sup>1, 3-6</sup>; and

13 WHEREAS, as of January 1, 2020, per the Surgeon General of California, Dr. Nadine Burke  
14 Harris, the ACEs Aware Initiative in California has begun funding providers for ACEs  
15 Screening to improve public health and address the state's estimated \$112.5 billion per  
16 year cost in health care expenditures and disease burden as a result of ACEs-related  
17 premature death and years of productive life lost to disability<sup>2</sup>; and

18 WHEREAS, preventing ACEs could potentially reduce many health conditions with economic  
19 and social costs to families, communities, and society of hundreds of billions of dollars  
20 each year<sup>7</sup>; now, therefore be it

21 RESOLVED, that the American Osteopathic Association (AOA) **ENCOURAGES support**  
22 ~~and advocate for~~ the inclusion of Adverse Childhood Experiences (ACEs) screenings  
23 in primary care settings.

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. National Center for Injury Prevention and Control. Preventing Adverse Childhood Experiences. cdc.gov. <https://www.cdc.gov/violenceprevention/childabuseandneglect/aces/fastfact.html>. Published December 31, 2019. Accessed February 10, 2020.
2. Miller TR, Waehrer GM, Oh DL, et al. Adult health burden and costs in California during 2013 associated with prior adverse childhood experiences. *PLOS ONE*. 2020;15(1):e0228019. doi:10.1371/journal.pone.0228019

3. American Academy of Family Physicians. Adverse Childhood Experiences. cdc.gov. <https://www.aafp.org/about/policies/all/adversechildhood-experiences.html>. Published April 2, 2019. Accessed February 10, 2020.
4. Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. *Am J Prev Med.* 1998;14(4):245-258. doi:10.1016/s0749-3797(98)00017-8
5. Portwood S. Adverse childhood experiences: Current research and practice applications. <https://www.apa.org>. <https://www.apa.org/pi/families/resources/newsletter/2018/11/adverse-experiences>. Accessed February 10, 2020.
6. American Academy of Pediatrics. ACEs and Toxic Stress. AAP.org. <http://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/resilience/Pages/ACEs-and-Toxic-Stress.aspx>. Published 2020. Accessed February 10, 2020.
7. National Center for Injury Prevention and Control. Preventing Adverse Childhood Experiences: Leveraging the Best Available Evidence. 2019.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: INCLUSION OF PATIENT EDUCATION ON ORGAN DONATION AS  
A COMPONENT OF A PRIMARY CARE VISIT

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Professional Affairs

---

1 WHEREAS, there are more than 110,000 patients are on the waiting list in need of a life-saving  
2 organ transplantation in the United States<sup>1,2</sup>; and

3 WHEREAS, an average of 20 patients die each day while waiting for a transplant due to a  
4 shortage of donated organs<sup>3</sup>; and

5 WHEREAS, in 2008, children, especially those under 5 years of age, had the highest death rate  
6 on the transplant waiting list compared to any other age range<sup>4</sup>; and

7 WHEREAS, the number of pediatric deceased donors continued to decline and majority of  
8 pediatric donors less than 18 years of age are allocated to adults<sup>4</sup>; and

9 WHEREAS, liver and kidney disease kill over 120,000 individuals each year, which is more  
10 people than Alzheimer's, breast cancer, or prostate cancer<sup>3</sup>; and

11 WHEREAS, in 2019, 83.7% of patients on the waiting list were waiting for a kidney and 11.6%  
12 of patients were waiting on a liver donation<sup>5</sup>; and

13 WHEREAS, 95% of adults support organ donation but only 58% are actually registered as  
14 organ donors<sup>5</sup>; and

15 WHEREAS, every ten minutes, someone is added to the national transplant waiting list,  
16 contributing to the persistent gap between the supply and demand of organs<sup>5</sup>; and

17 WHEREAS, “currently, there are limited programs educating the population about organ  
18 donation in the United States resulting in a situation in which the public lacks basic  
19 knowledge and understanding of organ donation, i.e. the dire need, living vs. deceased,  
20 which organs can be donated during one’s lifetime, the time, effort and risk involved”<sup>3</sup>;  
21 and

22 WHEREAS, education provided by United States federal government organizations, including  
23 the national DMV website, does not sufficiently educate the public on organ donation  
24 facts, myths, and resources<sup>6</sup>; and

25 WHEREAS, American Osteopathic Association (AOA) Policy H411-A/16 states that the AOA  
26 “will develop and continue to promote physician and public education programs to  
27 advance the cause of organ and tissue donation and transplantation,” and “urges the  
28 Osteopathic Family” to not only volunteer personally as organ and tissue donors, but  
29 also to “actively encourage their patients to do the same”; and

1 WHEREAS, a Quality Improvement (QI) study, in which patients were provided an organ  
2 donation pamphlet and registration form, performed by the University of Toronto at a  
3 primary care clinic showed an overall 18.3% increase in successful organ donor  
4 registrations<sup>7</sup>; and

5 WHEREAS, a study of 300 patients showed that 40% of the participants who were previously  
6 not organ donors committed to becoming organ donors after receiving a verbal or  
7 written intervention that shared information regarding organ donations during a visit at  
8 a family practice medical center. The data from this study suggests that “the family  
9 physician-patient encounter is an excellent opportunity for educating patients and  
10 increasing the commitment to organ donation<sup>8</sup>; now, therefore be it

11 RESOLVED, that the American Osteopathic Association (AOA) adopts an official position  
12 supporting organ donation counseling during a visit with a new primary care physician  
13 at the provider’s discretion as a means of educating and encouraging patients to become  
14 organ donors in order to ameliorate the national organ shortage.

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. U.S. Department of Health and Human Services, Health Resources and Services Administration (2018). Organ Procurement and Transplantation. Retrieved from <https://optn.transplant.hrsa.gov/>
2. United Network for Organ Sharing (2018). Retrieved from <https://unos.org/data/>
3. American Transplant Foundation (2018). Retrieved from <https://www.americantransplantfoundation.org/about-transplant/facts-and-myths/>
4. McDiarmid, S.V., Cherikh, W.S., Sweet, S.C. Preventable Death: Children on the Transplant Waiting List (2008.)
5. U.S. Department of Health and Human Services, Health Resources and Services Administration (2019). Organ Donation Statistics. Retrieved from <https://www.organdonor.gov/statistics-stories/statistics.html>
6. DMV.org (2018). Retrieved from <https://www.dmv.org/organ-donation-myths.php>
7. National Center for Biotechnology Information, Inc. (2018). Increasing Organ Donor Registration in a Primary Care Clinic. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411726/>
8. Bidigare, S. A. (2000). Family Physicians Role in Recruitment of Organ Donors. Archives of Family Medicine, 9(7), 601–605. doi: 10.1001/archfami.9.7.60

Explanatory Statement: Reference Committee

The Committee believes the current policy on file (411-A/16) addresses this issue. In addition, many states already show such information on drivers’ licenses.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H411-A/16 ORGAN AND TISSUE DONATION AND TRANSPLANTATION INITIATIVES – COMMITMENT TO

**Prior HOD action on similar or same topic:** Policy reaffirmed as amended in 2016.

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: INEQUALITIES IN MEDICAID FUNDING AFFECTING U.S. TERRITORIES

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Professional Affairs

---

- 1 WHEREAS, Puerto Rico, American Samoa, the Commonwealth of the Northern Mariana  
2 Islands (CNMI), Guam, and the U.S. Virgin Islands (USVI) are U.S. territories, which  
3 poses the obligation to pay federal taxes<sup>5</sup>; and
- 4 WHEREAS, a large proportion of U.S. citizens living on U.S. territories rely on Medicaid or  
5 Children’s Health Insurance Program (CHIP) to pay for their healthcare, although the  
6 total number varies per territory<sup>7</sup>; and
- 7 WHEREAS, 79% of U.S. citizens living in American Samoa were enrolled in Medicaid,  
8 compared to 37% in Puerto Rico, in 2017<sup>7</sup>; and
- 9 WHEREAS, differences in funding between territorial and mainland Medicaid programs can be  
10 narrowed down to two key policies: statutory caps on federal funding and the federal  
11 Medicaid match rate formula<sup>1,7</sup>; and
- 12 WHEREAS, federal funding for mainland Medicaid programs are not capped, therefore every  
13 dollar spent is reimbursed by the federal government as long as they are valid under the  
14 program’s rules<sup>1,7</sup>; and
- 15 WHEREAS, federal funding for territorial Medicaid programs are statutorily capped based on  
16 Section 1108 of the Social Security Act<sup>7</sup>; and
- 17 WHEREAS, U.S. territories receive an allotted amount of funds for Medicaid every year  
18 regardless of fluctuations in enrollment or service usage<sup>7</sup>; and
- 19 WHEREAS, the federal government does not match territorial Medicaid spending beyond the  
20 annual cap, therefore shifting the economic burden to each territory’s finances<sup>1,7</sup>; and
- 21 WHEREAS, the federal Medicaid match rate (Federal Medical Assistance Percentage, or  
22 FMAP) is used for determining the amount of federal matching funds for most  
23 Medicaid expenditures<sup>3</sup>; and
- 24 WHEREAS, on the mainland, FMAPs vary depending on the state’s per capita income, and  
25 states with lower per capita incomes have an increased FMAP due to greater economic  
26 need<sup>1</sup>; and
- 27 WHEREAS, in U.S. territories, the FMAP is a fixed rate and is based on a different formula  
28 that does not consider per capita income, in which the statutory FMAP for all U.S.  
29 territories is set at 55%, with exception of recent, temporary changes<sup>1,7</sup>; and



1 WHEREAS, in U.S. territories, the statutory cap on Medicaid funding along with the fixed  
2 FMAP has led to budget deficits and the need for frequent infusions of funds to  
3 support the programs temporarily<sup>1,7</sup>; and

4 WHEREAS, territories received a considerable infusion of federal funds for Medicaid under the  
5 Patient Protection and Affordable Care Act in 2010<sup>7</sup>; and

6 WHEREAS, the Balanced Budget Act of 2018 gave Puerto Rico and the USVI further funding  
7 for Medicaid at 100% FMAP until September 30, 2019<sup>7</sup>; and

8 WHEREAS, the Additional Supplemental Appropriations for Disaster Relief Act of 2019 was  
9 enacted to provide added funds to CNMI at 100% FMAP through the end of fiscal year  
10 2019, and permitted Guam and American Samoa to use their remaining ACA funds at  
11 100% FMAP during the same period<sup>7</sup>; and

12 WHEREAS, although it is estimated that all territories will be able to adequately fund their  
13 Medicaid and CHIP programs through the end of fiscal year 2019, the added funds that  
14 are keeping them viable will expire at the end of this year<sup>7</sup>; and

15 WHEREAS, estimates show that there will be significant budget deficits in fiscal year 2020 in  
16 all five territories once the additional funds have expired<sup>7</sup>; and

17 WHEREAS, prior to these infusions, territories such as Puerto Rico had substantial  
18 shortcomings in federal funding for its Medicaid program<sup>1,7</sup>; and

19 WHEREAS, the combinatory effect of a low FMAP and the statutory cap creates an estimated  
20 effective match rate of approximately 18% in Puerto Rico, a rate usually found in states  
21 with a high PCI<sup>2</sup>; and

22 WHEREAS, for Puerto Rico, it is estimated that if the statutory cap is removed and the  
23 territorial FMAP is calculated using the mainland's formula, which reflects per capita  
24 income, the effective match rate would increase from 18% to 83%, the maximum  
25 allowed under these laws<sup>4,6</sup>; and

26 WHEREAS, unjustified differences in Medicaid federal funding between Puerto Rico and the  
27 mainland has led the island to set limits on medical services typically provided under the  
28 mainland program<sup>2</sup>; and

29 WHEREAS, prior to the recent temporary federal infusions, inadequate funding for the island's  
30 Medicaid program led Puerto Rico to take measures that reduce spending by: decreasing  
31 the eligibility for Medicaid as compared to mainland criteria, withholding investment in  
32 health information technology despite CMS incentives, reducing or suspending provider  
33 payments, and excluding benefits from Medicaid coverage, such as long term care<sup>2</sup>; and

34 WHEREAS, it is estimated that the impending Medicaid budget shortfalls of fiscal year 2020  
35 will drive all five territories to enact changes that reduce costs, such as the  
36 aforementioned measures taken by Puerto Rico in the past<sup>7</sup>; and

37 WHEREAS, the Congressional Task Force on Economic Growth in Puerto Rico warned in  
38 2016 that failure to increase funding for Puerto Rico's Medicaid program would

1 presumably compel its government to reduce enrollment of low-income individuals,  
2 therefore harming their quality of life and spurring outmigration, which can further  
3 exacerbate an already critical fiscal crisis<sup>8</sup>; and

4 WHEREAS, despite differences between territories and the mainland in the amount of federal  
5 taxes paid by individuals and businesses, all members of the Congressional Task Force  
6 on Economic Growth in Puerto Rico concluded that territories deserved more equitable  
7 treatment in Medicaid funding<sup>8</sup>; and

8 WHEREAS, the Congressional Task Force on Economic Growth in Puerto Rico  
9 recommended in 2016 that Congress act swiftly to improve financing for territorial  
10 Medicaid programs so that it reflects the size and need of their low-income citizens<sup>8</sup>;  
11 and

12 WHEREAS, the American Osteopathic Association represents a profession that advocates for  
13 access to healthcare; now, therefore be it

14 RESOLVED, that the American Osteopathic Association (AOA) supports an increase in or  
15 removal of the federal funding cap on territorial Medicaid programs, thereby  
16 ~~alleviating~~ **REDUCING** costs and preventing the cost-reducing measures that  
17 negatively impact the quality of and access to healthcare of low-income U.S. citizens  
18 **AND U.S. NATIONALS** living on the U.S. territories; and, be it further

19 RESOLVED, that the AOA supports changing the territorial Federal Medical Assistance  
20 Percentage formula so that it considers per capita income, thereby tailoring the federal  
21 matching rate to each population's financial needs.

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. Perreira, K., Lallemand, N., Napoles, A., & Zuckerman, S. (2017). Environmental Scan of Puerto Rico's Health Care Infrastructure. Retrieved September 21, 2019, from [https://www.urban.org/sites/default/files/publication/87016/2001051-environmental-scan-of-puerto-ricos-health-care-infrastructure\\_1.pdf](https://www.urban.org/sites/default/files/publication/87016/2001051-environmental-scan-of-puerto-ricos-health-care-infrastructure_1.pdf)
2. Perreira, K., Peters, R., Lallemand, N., & Zuckerman, S. (2017). Puerto Rico Health Care Infrastructure Assessment Site Visit Report. Retrieved September 21, 2019, from [https://www.urban.org/sites/default/files/publication/87011/2001050-puerto-rico-health-care-infratructure-assessment-site-visit-report\\_1.pdf](https://www.urban.org/sites/default/files/publication/87011/2001050-puerto-rico-health-care-infratructure-assessment-site-visit-report_1.pdf)
3. Federal Medical Assistance Percentages or Federal Financial Participation in State Assistance Expenditures. (2017). Retrieved September 21, 2019, from ASPE website: <https://aspe.hhs.gov/federal-medical-assistance-percentages-or-federal-financial-participation-state-assistance-expenditures>.
4. Sebelius, K. (2013). Report to the President's Task Force on Puerto Rico Status. US Department of Health and Human Services. Retrieved September 22, 2019, from [https://obamawhitehouse.archives.gov/sites/default/files/uploads/Puerto\\_Rico\\_Task\\_Force\\_Exec\\_Summary.pdf](https://obamawhitehouse.archives.gov/sites/default/files/uploads/Puerto_Rico_Task_Force_Exec_Summary.pdf)

5. Fernández Campbell, A. (2017). Puerto Rico pays taxes. The US is obligated to help it just as much as Texas and Florida. Retrieved September 23, 2019, from Vox website: <https://www.vox.com/policy-and-politics/2017/10/4/16385658/puerto-rico-taxes-hurricane>
6. Park, E. (2016). Addressing Puerto Rico’s Medicaid Funding Shortfalls Would Help Ensure Fiscal Stability and Growth. (2017). Retrieved September 23, 2019, from Center on Budget and Policy Priorities website: <https://www.cbpp.org/research/health/addressing-puerto-ricos-medicaid-funding-shortfalls-would-help-ensure-fiscal>
7. Schwartz, A. L. (2019). Statement of Anne L. Schwartz, PhD, Executive Director. Retrieved October 2, 2019, from <https://energycommerce.house.gov/sites/democrats.energycommerce.house.gov/files/documents/Schwartz.pdf>.
8. Congressional Task Force on Economic Growth in Puerto Rico. (2016). Retrieved from <https://www.finance.senate.gov/imo/media/doc/Bipartisan%20Congressional%20Task%20Force%20on%20Economic%20Growth%20in%20Puerto%20Rico%20Releases%20Final%20Report.pdf>

Explanatory Statement: Reference Committee

The addition of “Nationals” to page 3, line 17 will cover citizens of American Samoa.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H339-A/17 EQUITY IN MEDICARE & MEDICAID PAYMENTS

**Prior HOD action on similar or same topic:** Policy approved in 2017.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: IMPROVING INSULIN AFFORDABILITY

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Professional Affairs

---

1 WHEREAS, Diabetes Type 1 is one of the most common chronic diseases starting in early  
2 childhood in the United States that is fatal without lifelong insulin treatment<sup>1</sup>; and

3 WHEREAS, over 1.4 million American children and adults are living with Type I diabetes  
4 mellitus and 7.4 million Americans with diabetes use one or more formulations of  
5 insulin<sup>2</sup>; and

6 WHEREAS, the number of youth with Type 1 diabetes is projected to increase by 23% in  
7 2050<sup>3</sup>; and

8 WHEREAS, the researchers who discovered insulin, Richard Banting, J. B. Collip, and Charles  
9 Best, sold their patent rights for only \$1 each because their goal was to ensure the  
10 quality, purity, and potency of insulin sold on the market rather than to profit<sup>4</sup>; and

11 WHEREAS, the first license to manufacture insulin was granted for humanitarian purposes  
12 rather than for profit<sup>5</sup>; and

13 WHEREAS, counter to the spirit of the initial sale and licensure of insulin, the global insulin  
14 market was a \$24 billion industry in 2014 and will top \$48 billion by 2020<sup>6</sup>; and

15 WHEREAS, the cost of insulin has tripled over a mere decade from 2002-2013, despite only  
16 incremental added benefits of new insulin products on the market<sup>7,8,9</sup>; and

17 WHEREAS, 39% of insulin users reported an increase in the amount they personally pay for  
18 insulin in the past year, including 52% of insulin-dependent children<sup>10</sup>; and

19 WHEREAS, an uninsured person pays up to \$480 per vial of insulin, with varying out-of-  
20 pocket expenses for insured persons<sup>11</sup>; and

21 WHEREAS, the out-of-pocket expense for insulin has doubled per prescription<sup>11</sup>; and

22 WHEREAS, it costs uninsured patients ten times more for insulin treatment at \$7,000 annually  
23 versus \$700 annually with insurance<sup>12</sup>; and

24 WHEREAS, the diabetes related costs from the Medicare eligible population is expected to  
25 skyrocket to \$171 billion in 2034, an increase of 380% from 2009<sup>13</sup>; and

26 WHEREAS, one in four insulin dependent diabetics with associated poor glycemic control  
27 reported insulin underuse or rationing due to cost<sup>12,14,15,16</sup>; and

1           WHEREAS, those who regularly take less insulin than prescribed or miss doses report being  
2           forced to choose between affording insulin versus essentials like housing, utilities,  
3           transportation, and even other health related purchases, such as doctors visits<sup>10</sup>; and

4           WHEREAS, one-third of patients with lower incomes who report cost-related insulin underuse  
5           also report difficulty affording diabetes equipment, thus increasing the risk for  
6           hospitalization<sup>16</sup>; and

7           WHEREAS, many uninsured and underinsured patients are not only rationing insulin but also  
8           resorting to black market purchases of discounted insulin on unregulated classified  
9           advertisement websites such as Craigslist<sup>17,18</sup>; and

10          WHEREAS, diabetics who are forced to ration their insulin have developed preventable  
11          complications like diabetic ketoacidosis with some resulting in diabetic coma or  
12          death<sup>12,14,15,19</sup>; and

13          WHEREAS, diabetic ketoacidosis is a complication that could be avoided with adequate insulin  
14          treatment, but costs \$26,566 per hospitalization, resulting in a healthcare burden of \$5.1  
15          billion<sup>2</sup>; and

16          WHEREAS, an increasing number of patients are dying due to inability to afford insulin with  
17          diabetes being the 7th leading cause of death in 2017<sup>2,21</sup>; and

18          WHEREAS, deaths related to insulin rationing occurs even amongst middle class individuals  
19          with health insurance coverage<sup>22,23</sup>; and

20          WHEREAS, the expansion of Medicaid eligibility in some states addressing gaps in affordable  
21          access to diabetes medication and treatment has resulted in a significant increase in  
22          insulin prescriptions being filled<sup>22,24</sup>; and

23          WHEREAS, when primary patents expired in 2015 for Sanofi’s Lantus, the world’s most widely  
24          prescribed insulin and the world’s leading drug for Type 1 Diabetics, more than 70  
25          secondary patent applications were filed in an effort to maintain its market  
26          monopoly<sup>25,26,27</sup>; and

27          WHEREAS, market share holding pharmaceutical companies consistently file lawsuits against  
28          other companies over plans to produce and sell a generic form of insulin, claiming that  
29          patents will be violated and that rights will be infringed upon<sup>25,27</sup>; and

30          WHEREAS, Eli Lilly agreed to make an ‘authorized generic’ known as insulin Lispro available  
31          for purchase at a 50% price reduction, but a spot check found it was only stocked in  
32          17% of pharmacies across the country in favor of Eli Lilly’s ‘name brand’ drug known  
33          as Humalog, which offer a larger, more profitable rebate to insurance companies<sup>28</sup>; and

34          WHEREAS, cheaper forms of insulin being made available are older formulations or analog  
35          insulins that are now rarely prescribed because it takes too long to take effect and then  
36          stays in the bloodstream for over 8 hours postprandial, increasing the risk for  
37          hypoglycemic events<sup>29</sup>; and

1           WHEREAS, unbranded biosimilar versions of insulin are projected to be priced at 10-51% less  
2           than name brand biologic insulins, with a cost saving potential of between \$25 billion to  
3           \$150 billion over ten years<sup>30,31</sup>; and

4           WHEREAS, unbranded biosimilar drugs have been available in Europe for years,  
5           pharmaceutical companies are distorting safety concerns to delay or prohibit the  
6           introduction of biosimilars into the American market<sup>30</sup>; and

7           WHEREAS, pharmaceutical companies have resorted cutting deals with makers of biosimilars  
8           to prevent or delay the entry of lower cost biosimilars into the American market<sup>30,32</sup>; and

9           WHEREAS, forty-five states and Puerto Rico have enacted laws protecting patients' rights to  
10          try a biosimilar drug and protecting the substitution of biosimilar products by  
11          pharmacists<sup>33</sup>; and

12          WHEREAS, two Congressional bills aimed at protecting against industry collusion to keep  
13          biosimilars out of the American market and at advancing public awareness and  
14          education on biosimilars have had no actions taken since they were introduced in  
15          2019<sup>34,35</sup>; and

16          WHEREAS, the Food and Drug Administration has set standards for biosimilar drugs that  
17          protect against concerns of safety, efficacy, and quality<sup>36</sup>; and

18          WHEREAS, the Senate Finance Committee Chairman initiated an investigation into the price  
19          spikes and high cost of insulin for people with diabetes in January 2019, but the only  
20          action taken to date is seeking insulin cost data from the Centers for Medicare and  
21          Medicaid Services Administrator<sup>37,38,39</sup>; and

22          WHEREAS, the Chairman of the House Committee on Oversight and Reform confirmed in  
23          January 2019 that “there is a strong bipartisan consensus that we must do something to  
24          rein in out-of-control price increases...” by the pharmaceutical industry<sup>40</sup>; and

25          WHEREAS, two Congressional bills aimed at making insulin affordable have had no actions  
26          taken since they were introduced in January and February 2019<sup>41,42</sup>; and

27          WHEREAS, Colorado and Illinois are the first two states to enact laws that cap insulin co-  
28          pays<sup>43,44,45,46</sup>; and

29          WHEREAS, Virginia recently passed a bill capping insulin copays that is pending their  
30          governor’s signature into law, which would make it the third state in the country to pass  
31          a law capping the cost of insulin and it would be the lowest cap set by any state at \$50  
32          per month<sup>47,48</sup>; and

33          WHEREAS, the bills in Colorado, Illinois, and Virginia only apply to patients who have health  
34          insurance coverage and only those who are covered through state-regulated commercial  
35          insurance plans<sup>43,44,45,46,47,48</sup>; and

36          WHEREAS, 28 U.S. Code § 1498 grants the U.S. federal government the right to use or  
37          manufacture a patented drug at reasonable compensation to the patent owner<sup>49,50</sup>; and

1 WHEREAS, 28 U.S. Code § 1498 affords patent owners the right to petition the Court of  
2 Federal Claims for compensation, which would allow pharmaceutical companies the  
3 ability to seek a reasonable amount while prohibiting them from unilaterally setting  
4 predatory market prices on insulin<sup>50,51</sup>; and

5 WHEREAS, 28 U.S. Code § 1498 was frequently used for crucial drugs in the 1960s and 1970s,  
6 including a Department of Defense purchase of an antibiotic directly from a generic  
7 manufacturer at 28% of the price charged by the patent holder, Pfizer<sup>49</sup>; and

8 WHEREAS, the government's use of 28 U.S. Code § 1498 has waned not due to decreased  
9 need but due to the increasing strength of the pharmaceutical lobby<sup>49</sup>; and

10 WHEREAS, Medicare is prohibited from negotiating drug prices due to language inserted into  
11 legislation that was written by the pharmaceutical lobby<sup>49,52</sup>; and

12 WHEREAS, 28 U.S. Code § 1498 provides a reasonable counterweight to Medicare's inability  
13 to negotiate drug prices, allowing the government to negotiate prices directly with the  
14 manufacturer and function as a free market buyer<sup>49,52,53</sup>; and

15 WHEREAS, 28 U.S. Code § 1498 continues to be applied today in areas outside of prescription  
16 drugs, such as patented methods of hazardous waste clean up, electronic passport  
17 technology, and genetically mutated mice in scientific research<sup>49,50</sup>; and

18 WHEREAS, 28 U.S. Code § 1498 continues to be applied for prescription drugs in cases of  
19 extreme need or urgency, such as the anthrax scare in 2001<sup>49</sup>; and

20 WHEREAS, just the threat of 28 U.S. Code § 1498 from the federal government to purchase a  
21 generic version of the antibiotic ciprofloxacin during the anthrax scare in 2001  
22 prompted the patent holder, Bayer, to cut the selling price in half<sup>49,54</sup>; and

23 WHEREAS, there is growing support of exercising 28 U.S. Code § 1498 to procure Hepatitis C  
24 treatment drugs, which have been priced by the patent holder, Gilead, at \$80,000 per  
25 person for the full course of treatment, earning them \$36 billion in just two years, well  
26 above the initial cost of research and development<sup>49,50,55,56</sup>; and

27 WHEREAS, the costs of initial research and development can ultimately amount to as little as  
28 4% of profits<sup>51,53</sup>; and

29 WHEREAS, the American Osteopathic Association (AOA) enacted H339-A/19 to support  
30 increased regulation of pharmacy benefit managers as a way to make life-saving  
31 medications, including but not limited to insulin, free for all uninsured patients and fully  
32 covered for all insured patients, but has no broader policy directly aimed at insulin cost  
33 control; now, therefore be it

34 RESOLVED, that the American Osteopathic Association (AOA) support legislation capping  
35 insulin copays with every state legislature via their respective state medical societies; and,  
36 be it further

1 RESOLVED, that the AOA support legislation that protects the introduction of biosimilar  
 2 insulin products into the American market and patient access to biosimilar; and, be it  
 3 further

4 RESOLVED, that the AOA support federal enforcement of 28 U.S. Code § 1498 for recent  
 5 and medically effective short-acting and long-acting forms of insulin to address  
 6 affordability and accessibility for all diabetic patients, including the uninsured.

Explanatory Statement: Submitted by Author:

While there is bipartisan support for solutions to this issue, attempts at new and comprehensive federal legislation have stalled. There have been recent movements in the right direction from a handful of state legislatures capping the cost of insulin. This is a realistic interim solution for insured individuals and this proposal aims to support the implementation of similar bills in remaining states. The limitation is that these legislations do not benefit uninsured individuals. Therefore, to address insulin affordability more broadly, this proposal seeks legislation that protects the introduction of biosimilars that would foster the market competition in insulin costs. Finally, gaps in insulin affordability is a long-standing, drastic problem that requires a drastic solution. This proposal, rather than seeking a wholly new legislation, seeks enforcement of an existing law that the federal government can invoke at its discretion.

References:

1. Imperatore G., Mayer-Davis E.J., Orchard T.J., & Zhong V.W. (2017). Prevalence and Incidence of Type I Diabetes Among Children and Adults in the United States and Comparison with Non-U.S. Countries. In Cowie C.C., Casagrande S.S., Menke A., Cissell M.A., Eberhardt M.S., Meigs J.B., Gregg E.W., Knowler W.C., Barrett-Connor E., Becker D.J., Brancati F.L., Boyko E.J., Herman W.H., Howard B.V., Narayan K.M.V., Rewers M., Fradkin J.E. (Eds.), *Diabetes in America*. (3rd ed., pp. 2.1-2.17) Bethesda, MD: National Institutes of Health. Retrieved on February 2, 2019, from: <https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america-3rd-edition>.
2. Centers for Disease Control and Prevention. *National Diabetes Statistics Report, 2020*. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020. Retrieved on February 28, 2020, from <https://www.cdc.gov/diabetes/data/statistics/statistics-report.html>
3. Imperatore, G., Boyle, J. P., Thompson, T. J., Case, D., Dabelea, D., Hamman, R. F., . . . Standiford, D. (2012). Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050. *Diabetes Care*, 35(12), 2515-2520. doi:<https://doi.org/10.2337/dc12-0669>
4. Rosenfeld, L. (2002, December). Insulin: Discovery and Controversy. *Clinical Chemistry*, 48(12): 2270-88. Retrieved from: <http://clinchem.aaccjnl.org/content/48/12/2270.full#sec-21>.
5. Woodfield, J. (2016, February 3). *What is the price of profit? The true cost of insulin in the United States*. Retrieved on February 2, 2019, from: <https://www.diabetes.co.uk/in-depth/what-is-the-price-of-profit-the-true-cost-of-insulin-in-the-united-states/>
6. Tsai, A. (2016, March). The rising cost of insulin. *Diabetes Forecast*, Retrieved from February 27, 2020, from [www.diabetesforecast.org/2016/mar-apr/rising-costs-insulin.html](http://www.diabetesforecast.org/2016/mar-apr/rising-costs-insulin.html)
7. Freed, S. (2016, May 7). *What is the Actual Cost of Insulin for Your Patients?*. Retrieved on February 2, 2019, from: <http://www.diabetesincontrol.com/actual-cost-of-insulin-for-your-patients/>
8. Hua, X., Carvalho, N., Tew, M., Huang, E. S., Herman, W. H., & Clarke, P. (2016). Expenditures and prices of antihyperglycemic medications in the united states: 2002-2013. *Journal of the American Medical Association*, 315(13), 1400-1402. doi:<https://doi.org/10.1001/jama.2016.0126>
9. Silverman, E. (2016, April 5). Insulin prices have skyrocketed, putting drug makers on the defensive. *Stat*, Retrieved on February 2, 2019, from



<https://www.statnews.com/pharmalot/2016/04/05/insulin-prices-skyrocketed-putting-drug-makers-defensive/>

10. American Diabetes Association. (2018). *Insulin affordability survey, 2018*. Arlington, VA; 2020. Retrieved on February 28, 2020, from <http://main.diabetes.org/dorg/PDFs/2018-insulin-affordability-survey.pdf>
11. Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., . . . Yatvi, A. L. (2018). Insulin access and Affordability Working group: Conclusions and recommendations. *Diabetes Care*, 41(6), 1299-1311. doi:<https://doi.org/10.2337/dci18-0019>
12. Johnson, C., Y. (2016, October 31). Why treating diabetes keeps getting more expensive. *Washington Post*. Retrieved on February 2, 2019, from [https://www.washingtonpost.com/news/wonk/wp/2016/10/31/why-insulin-prices-have-kept-rising-for-95-years/?utm\\_term=.17cda82418ca](https://www.washingtonpost.com/news/wonk/wp/2016/10/31/why-insulin-prices-have-kept-rising-for-95-years/?utm_term=.17cda82418ca)
13. Huang, E. S., Basu, A., O'Grady, M., & Capretta, J. C. (2009). Projecting the future diabetes population size and related costs for the U.S. *Diabetes Care*, 32(12), 2225–2229. <https://doi.org/10.2337/dc09-0459>
14. Randall, L., Begovic, J., Hudson, M., Smiley, D., Peng, L., Pitre, N., & Umpierrez, G., Denise. (2011). Recurrent Diabetic Ketoacidosis in Inner-City Minority Patients Behavioral, Socioeconomic, and Psychosocial Factors. *Diabetes Care*, 34(9): 1891-6. <https://doi.org/10.2337/dc11-0701>
15. Caffrey, M. (2019). Gathering evidence on insulin rationing: Answers and future questions. *AJMC: Evidence-Based Diabetes Management*, September. Retrieved on February 27, 2020, from <https://www.ajmc.com/journals/evidence-based-diabetes-management/2019/september-2019/gathering-evidence-on-insulin-rationing-answers-and-future-questions>
16. Herkert, D., Vijayakumar, P., Luo, J., Schwartz, J. I., Rabin, T. L., DeFilippo, E., & Lipska, K. J. (2018). Cost-related insulin underuse among patients with diabetes. *JAMA Intern Med*, 179(1), 112-114. doi: <https://doi.org/10.1001/jamainternmed.2018.5008>
17. Carroll, L. (2020, February 17). Unregulated sales of insulin common on craigslist. *Reuters* Retrieved on February 27, 2020, from <https://www.reuters.com/article/us-health-medication-black-market/unregulated-sales-of-insulin-common-on-craigslist-idUSKBN20B1M0>
18. Ahamed, A., Kullmann, K. C., Frasso, R., & Goldstein, J. N. (2020). Analysis of unregulated sale of life-saving prescription drugs online in the united states. *JAMA Intern Med*, doi: <https://doi.org/10.1001/jamainternmed.2019.7514>
19. Popken, B. (2019, November 15). With rise in patients dying from rationing insulin, U.N. tries a new solution. *NBC News* Retrieved on February 27, 2020, from <https://www.nbcnews.com/business/business-news/rise-patients-dying-rationing-insulin-u-n-tries-new-solution-n1083816>
20. Desai, D., Mehta, D., Mathias, P., Menon, G., & Schubart, U. K. (2018). Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: A nationwide analysis. *Diabetes Care*, 41(8), 1631-1638. doi:<https://doi.org/10.2337/dc17-1379>
21. Higgs, M.M. (2017, April 5). *The High Price of Insulin is Literally Killing People*. Retrieved on February 2, 2019 from: [https://tonic.vice.com/en\\_us/article/ezwwze/the-high-price-of-insulin-is-literally-killing-people](https://tonic.vice.com/en_us/article/ezwwze/the-high-price-of-insulin-is-literally-killing-people)
22. Gordon, S. (August 6th, 2018) *Access to Diabetes Drugs Improved Under Affordable Care Act: Study*, Retrieved on February 2, 2019, from: <https://consumer.healthday.com/public-health-information-30/affordable-care-act-obamacare-955/access-to-diabetes-drugs-improved-under-affordable-care-act-study-736519.html>
23. Rapaport, L. (2020, March 3). Two in five U.S. diabetics struggle with medical bills. *Reuters*. Retrieved on March 8, 2020, from <https://www.reuters.com/article/us-health-diabetes-finances/two-in-five-u-s-diabetics-struggle-with-medical-bills-idUSKBN20Q2YG>

24. Myerson, R., Lu, T., Tonnu-Mihara, I., & Huang, E. S. (2018, Medicaid eligibility expansions may address gaps in access to diabetes medications. *Health Affairs*, 37  
doi:<https://doi.org/10.1377/hlthaff.2018.0154>
25. Amin, T. (2018, December 7). Patent abuse is driving up drug prices. just look at lantus. *Stat*, Retrieved February 27, 2020, from <https://www.statnews.com/2018/12/07/patent-abuse-rising-drug-prices-lantus/>
26. Collier R. (2013). Drug patents: the evergreening problem. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, 185(9), E385–E386.  
<https://doi.org/10.1503/cmaj.109-4466>
27. Stempel, J. (2014, July 8). Sanofi sues eli lilly over insulin rival to lantus. *Reuters*. Retrieved February 27, 2020, from <https://www.reuters.com/article/us-elililly-sanofi-lawsuit/sanofi-sues-eli-lilly-over-insulin-rival-to-lantus-idUSKBN0FD20720140708>
28. Rowland, C. (2019, December 27). Under fire over high prices, eli lilly promised cheaper insulin in 2019. the result has some senators steamed. *Washington Post*. Retrieved on March 1, 2020, from [https://www.washingtonpost.com/business/economy/under-fire-over-high-prices-eli-lilly-promised-cheaper-insulin-in-2019-the-result-has-some-senators-steamed/2019/12/26/6c440b44-204e-11ea-86f3-3b5019d451db\\_story.html](https://www.washingtonpost.com/business/economy/under-fire-over-high-prices-eli-lilly-promised-cheaper-insulin-in-2019-the-result-has-some-senators-steamed/2019/12/26/6c440b44-204e-11ea-86f3-3b5019d451db_story.html)
29. Farley, A. (2019, February 19). Drug prices are killing diabetics. ‘Walmart insulin’ isn’t the solution. *Washington Post*. Retrieved on March 8, 2020, from <https://www.washingtonpost.com/outlook/2019/02/19/drug-prices-are-killing-diabetics-walmart-insulin-isnt-solution/>
30. Rowland, C. (2019, January 9). ‘Marketers are having a field day’: Patients stuck in corporate fight against generic drugs. *Washington Post* Retrieved on March 8, 2020, from [https://www.washingtonpost.com/business/economy/drugmakers-alleged-scare-tactics-may-hold-back-competition/2019/01/09/612ac994-046d-11e9-9122-82e98f91ee6f\\_story.html](https://www.washingtonpost.com/business/economy/drugmakers-alleged-scare-tactics-may-hold-back-competition/2019/01/09/612ac994-046d-11e9-9122-82e98f91ee6f_story.html)
31. Mulcahy, A. W., Hlavka, J. P., & Case, S. R. (2017). Biosimilar cost savings in the united states: Initial experience and future potential. *RAND Corporation*, doi:<https://doi.org/10.7249/PE264>
32. Mathias, T. (2018, April 5). AbbVie, samsung bioepis in deal; humira biosimilar U.S. release in 2023. *Reuters*. Retrieved on March 8, 2020, from <https://www.reuters.com/article/us-abbvie-biogen/abbvie-samsung-bioepis-in-deal-humira-biosimilar-u-s-release-in-2023-idUSKCN1HC1SP>
33. Cauchi, R. (2019). *State laws and legislation related to biologic medications and substitution of biosimilars*. Washington, D.C.: National Conference of State Legislatures. Retrieved on March 8, 2020, from <https://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx>
34. Preserve access to affordable generics and biosimilars act, S.64, 116th Congress. Retrieved on March 8, 2020, from <https://www.congress.gov/bill/116th-congress/senate-bill/64>
35. Advancing education on biosimilars act of 2019, S.1681, 116th Congress. Retrieved on March 8, 2020, from <https://www.congress.gov/bill/116th-congress/senate-bill/1681>
36. *Biosimilar development, review, and approval*. (2017). U.S. Food & Drug Administration. Retrieved on March 8, 2020, from <https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval>
37. Alonso-Zaldivar R. (2019, January 29). *GOP senator pledges insulin probe as Congress holds hearings*. AP News. Retrieved on February 2, 2019, from <https://apnews.com/56f383814d124b53a59a8dc044bcbfa1>
38. Drug pricing in america: A prescription for change, part I: Committee on Finance, United States Senate, 116th Congress (2019). Retrieved on March 8, 2020, from <https://www.finance.senate.gov/hearings/drug-pricing-in-america-a-prescription-for-change-part-i>

39. Committee on Finance. (2019). Grassley, wyden seek insulin cost data from CMS. Retrieved on March 3, 2020, from <https://www.finance.senate.gov/chairmans-news/grassley-wyden-seek-insulin-cost-data-from-cms>
40. Pear R. (2019, January 29). *On Both Ends of Capitol, Both Parties Warn Big Pharma on Drug Prices*. The New York Times. Retrieved on February 2, 2019, from <https://www.nytimes.com/2019/01/29/us/politics/drug-prices-congress.html>
41. Insulin Access for All Act, H.R.366, 116th Congress (2019). Retrieved on February 2, 2019, from <https://www.congress.gov/bill/116th-congress/house-bill/366>
42. Affordable Insulin Act, H.R.1478, 116th Congress (2019), Retrieved on February 28, 2020, from <https://www.congress.gov/bill/116th-congress/house-bill/1478/>
43. Zdanowicz, C. (2019, May 23). Colorado is the first state to cap skyrocketing insulin co-pays. *CNN*. Retrieved on February 28, 2020, from <https://www.cnn.com/2019/05/23/health/colorado-insulin-price-cap-trnd/index.html>
44. Reduced insulin prices, HB19-1216, 2019 Regular Session Colorado General Assembly. (2019). Retrieved on February 28, 2020, from <https://leg.colorado.gov/bills/hb19-1216>
45. Munks, J. (2020, January 24). Saying 'diabetes doesn't discriminate,' gov. J.B. pritzker signs measure limiting out-of-pocket cost of insulin to \$100 for 30 day supply. *Chicago Tribune* Retrieved on February 27, 2020, from <https://www.chicagotribune.com/politics/ct-insulin-cap-bill-signing-20200124-i4ryr72utra37j4mipmbqr2aiu-story.html>
46. Pricing-prescription insulin, SB0667, 101st Session Illinois General Assembly. (2010). Retrieved on February 28, 2020, from <http://www.ilga.gov/legislation/BillStatus.asp?GA=101&DocTypeID=SB&DocNum=667&GAIID=15&SessionID=108&LegID=116604#actions>
47. Seipel, B. (2020, March 6). Virginia lawmakers pass lowest insulin price cap in nation at \$50 a month. *The Hill*. Retrieved on March 7, 2020, from [https://thehill.com/policy/healthcare/486419-virginia-lawmakers-pass-lowest-insulin-price-cap-in-nation-at-50-a-month?fbclid=IwAR0XGI3fkNNGSPxZmS4FZvX2SKYALoSSYoe9G18d6Hc\\_rRTtRnyc-wCs6iE](https://thehill.com/policy/healthcare/486419-virginia-lawmakers-pass-lowest-insulin-price-cap-in-nation-at-50-a-month?fbclid=IwAR0XGI3fkNNGSPxZmS4FZvX2SKYALoSSYoe9G18d6Hc_rRTtRnyc-wCs6iE)
48. Health insurance; cost-sharing payments for prescription insulin drugs, HB66, 2020 Virginia General Assembly. (2020). Retrieved on March 8, 2020, from <https://lis.virginia.gov/cgi-bin/legp604.exe?201+sum+HB66>
49. Dodge, J. (2017). *The government can legally commandeer drug patents*. The People's Policy Project. Retrieved on March 8, 2020, from <https://www.peoplespolicyproject.org/2017/10/02/the-government-can-legally-commandeer-drug-patents/>
50. 28 U.S. code § 1498. patent and copyright cases (1948). Retrieved on March 8, 2020, from <https://www.govinfo.gov/app/details/USCODE-2011-title28/USCODE-2011-title28-front/context>
51. Brennan, H., Kapczynski, A., Monahan, C. H., & Rizvi, Z. (2017). A prescription for excessive drug pricing: Leveraging government patent use for health. *Yale Journal of Law & Technology*, 18(1). Retrieved on February 28, 2020, from <https://digitalcommons.law.yale.edu/yjolt/vol18/iss1/7/>
52. Lee, T. T., Gluck, A. R., & Curfman, G. D. (2016). The politics of medicare and drug-price negotiation (updated). *Health Affairs*. Retrieved on March 8, 2020, from <https://www.healthaffairs.org/doi/10.1377/hblog20160919.056632/full/>
53. Kapczynski, A., & Kesselheim, A. S. (2016). 'Government patent use': A legal approach to reducing drug spending. *Health Affairs*, 35(5), 791-797. doi:<https://doi.org/10.1377/hlthaff.2015.1120>
54. Bradsher, K., & Andrews, E. L. (2001, October 24). A nation challenged: Cipro; U.S. says bayer will cut cost of its anthrax drug. *New York Times*, Section B, pp.7. Retrieved on March 8, 2020, from <https://www.nytimes.com/2001/10/24/business/a-nation-challenged-cipro-us-says-bayer-will-cut-cost-of-its-anthrax-drug.html>

55. Tribble, S. J. (2017, May 4). Louisiana proposes tapping A federal law to slash hepatitis C drug prices. *Kaiser Health News* Retrieved on March 8, 2020, from <https://khn.org/news/louisiana-proposes-tapping-a-federal-law-to-slash-hepatitis-c-drug-prices/>
56. 56. Gee, R. E. (2017). *Hepatitis C in louisiana is increasing and an important health equity issue*. Baton Rouge, LA: Louisiana Department of Health. Retrieved on March 8, 2020, from [https://khn.org/wp-content/uploads/sites/2/2017/04/gee-letter-4\\_12\\_17.pdf](https://khn.org/wp-content/uploads/sites/2/2017/04/gee-letter-4_12_17.pdf)

Explanatory Statement: Reference Committee

With the numerous WHEREAS statements, the intent of resolution needs to be clarified. There are multiple issues covered that should be separated into separate resolutions.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Student Osteopathic Medical Association)*

DATE: **October 14, 2020** \_\_\_\_\_

SUBJECT: MEDICATION FOR OPIOID USE DISORDER INSURANCE  
COVERAGE

SUBMITTED BY: American Osteopathic Academy of Addiction Medicine

REFERRED TO: Committee on Professional Affairs

---

1 WHEREAS, the American Osteopathic Association has previously resolved to “remove any  
2 arbitrary and restrictive limits for buprenorphine insurance coverage” (H336-A/15) for  
3 the treatment of Opioid Use Disorder (OUD); and

4 WHEREAS, only 29.9% of patients with OUD received evidence-based Medication for Opioid  
5 Use Disorder (MOUD) treatment in 2017; and

6 WHEREAS, prior authorization is a burdensome process that impedes upon the physician-  
7 patient relationship, often in an arbitrary and non-evidence-based manner; and

8 WHEREAS, failure to expeditiously begin MOUD treatment, or an interruption in therapy, can  
9 cause devastating consequences for patients, families, and communities, including  
10 preventable deaths; now, therefore be it

11 RESOLVED, that the American Osteopathic Association (AOA) will explicitly advise the  
12 Center for Medicare and Medicaid Services (CMS) and commercial insurers to remove  
13 prior authorization restrictions for Medication for Opioid Use Disorder (MOUD); and,  
14 be it further

15 RESOLVED, that the AOA strongly encourage the American Osteopathic Academy of  
16 Addiction Medicine (AOAAM) to maintain the above position.

Explanatory Statement: Submitted by Author:

In 2017 overdose deaths due to opioids once again constituted the highest single cause of accidental deaths in the United States. Various buprenorphine preparations, including long-acting injectable buprenorphine, have been shown to be very effective as reducing deaths and decreasing illicit opioid use, but burden prior authorization requirements often render physicians and other providers unable to optimize treatment. Given the various tolerance and efficacy patients experience with regard to various buprenorphine preparations, every effort should be made to limit or eliminate prior authorization, as even a slight delay in treatment or interruption of therapy can be deadly.

Explanatory Statement: Reference Committee

The Committee believes the current policy on file (336-A/15) addresses this issue.

H336-A/15 BUPRENORPHINE MAINTENANCE TREATMENT INSURANCE COVERAGE

The American Osteopathic Association (AOA) recommends that state Medicaid administrators remove any arbitrary and restrictive limits for buprenorphine coverage and that state Medicaid administrators and third party payers recognize that chronic disease management includes a combination of psychotherapeutic and pharmacological interventions that will yield the best outcomes for patients with opioid use disorder. 2015

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: RECRUITMENT AND RETENTION OF NATIVE AMERICANS IN  
MEDICINE

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Professional Affairs

---

- 1 WHEREAS, there are approximately 5.2 million American Indian/Alaska Native (AI-AN)  
2 people in the United States, including those of more than one race; 1.7% of the  
3 population<sup>1</sup>; and
- 4 WHEREAS, there are currently 95 (0.3%) students of AI-AN ethnicity enrolled in osteopathic  
5 medical schools and 3,400 (0.4%) AI-AN physicians practicing in the United States<sup>2</sup>;  
6 and
- 7 WHEREAS, the AI-AN population has an average life expectancy that is 5.5 years less than  
8 that of the United States population, and has higher mortality rates in many categories,  
9 including: heart disease, malignant neoplasm, chronic liver disease and cirrhosis,  
10 diabetes mellitus, unintentional injuries, assault/homicide, intentional self-harm/suicide,  
11 and chronic lower respiratory diseases<sup>3</sup>; and
- 12 WHEREAS, research indicates that physician-patient racial and ethnic concordance leads to  
13 patients perceiving a higher quality of care, increased use of care, and higher satisfactory  
14 rating of care<sup>4</sup>; and
- 15 WHEREAS, AI-AN physicians are more likely to practice in Native communities<sup>5</sup>; and
- 16 WHEREAS, there have been instances of medical schools succeeding in enrolling higher  
17 average numbers of AI-AN students by integrating social and cultural aspects into their  
18 institutions and engaging the tribal nations and communities by setting up educational  
19 pathway programs in these areas<sup>6</sup>; and
- 20 WHEREAS, the Association of Native American Medical Students (ANAMS) is a student  
21 organization representing Native American graduate health professional students that  
22 supports and provides a resource network with the goal of increasing the number of  
23 Native American students in medicine and the successful completion of their graduate  
24 health professions curricula<sup>7</sup>; and
- 25 WHEREAS, the Student Osteopathic Medical Association (SOMA) has made it a priority to  
26 recruit underrepresented minorities in medicine through the National Outreach for  
27 Diversity (NOD) programming and through advocating for the improvement of  
28 accreditation standards on diversity at Osteopathic medical schools outlined in Policy S-  
29 19-23<sup>8</sup>; and
- 30 WHEREAS, existing American Osteopathic Association policy H433-A/15 (Minority Health  
31 Disparities) states for action to be taken for the development of strategies to actively  
32 recruit underrepresented minority physicians into the profession in both primary care



1 and subspecialties, but does not mention retaining minority physicians<sup>9</sup>; now, therefore  
2 be it

3 RESOLVED, that the American Osteopathic Association (AOA) work with various  
4 stakeholders (including the Student Osteopathic Medical Association and the  
5 Association of Native American Medical Students) to establish best practices to increase  
6 the number of Native Americans recruited and retained in medicine and the allied  
7 professions.

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. The American Indian and Alaska Native Population: 2010 Census Briefs. (2012). United States Census Bureau, 2010. Retrieved from <https://www.census.gov/history/pdf/c2010br-10-112019.pdf>
2. Study of Declining Native American Medical Student Enrollment. (2018). AMA Council on Medical Education Report.
3. Indian Health Disparities from 2009-2011. (2019). Indian Health Service. Retrieved from [https://www.ihs.gov/sites/newsroom/themes/responsive2017/display\\_objects/documents/factsheets/Disparities.pdf](https://www.ihs.gov/sites/newsroom/themes/responsive2017/display_objects/documents/factsheets/Disparities.pdf)
4. Saha, S., Komaromy, M., Koepsell, T. and Bindman, A. (1999). Patient-Physician Racial Concordance and the Perceived Quality and Use of Health Care. Archives of Internal Medicine , [online] 159(9), p.997. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10326942>
5. Analyzing Physician Workforce Racial and Ethnic Composition Associations: Physician Specialties. (2014). Association of American Medical Colleges. Retrieved from <https://www.aamc.org/system/files/d/1/444068-aibphysicianworkforce.pdf>
6. Reshaping the Journey. (2018). Association of American Medical Colleges. Retrieved from [https://store.aamc.org/downloadable/download/sample/sample\\_id/243/](https://store.aamc.org/downloadable/download/sample/sample_id/243/)
7. Association of Native American Medical Students. (2020). Retrieved from <http://www.anamstudents.org>
8. SOMA Resolution S-19-23 <http://policysearch.wpengine.com/wp-content/uploads/S-19-23.pdf>
9. MINORITY HEALTH DISPARITIES. (2015). American Osteopathic Association, H433-A/15. Retrieved from <http://policysearch.wpengine.com/wp-content/uploads/H433-A2015-MINORITY-HEALTH-DISPARITIES.pdf>

Explanatory Statement: Reference Committee

The Committee believes the American Osteopathic Association should be supportive and inclusive of all minorities who pursue a career in the osteopathic medicine, and not just one. Support and inclusion of all minorities is currently covered under existing AOA policy, as was noted in the resolution.



Background Information: Provided by AOA Staff

**Current AOA Policy:**

H429-A/14 MINORITIES, UNDERREPRESENTED (URM) -- INCREASING NUMBERS OF APPLICANTS, GRADUATES AND FACULTY AT COLLEGES OF OSTEOPATHIC MEDICINE

H409-A/16 MINORITY HEALTH AND OSTEOPATHIC MEDICAL EDUCATION

**Prior HOD action on similar or same topic:** H429-A/14 policy approved in 2014 (Referred to BOE and BSAPH in 2019). H409-A/16 policy reaffirmed in 2016.

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: SUSTAINABILITY AT AOA EVENTS

SUBMITTED BY: Maine Osteopathic Association

REFERRED TO: Committee on Professional Affairs

---

1 WHEREAS, there is agreement within the scientific community that the Earth is undergoing  
2 adverse global climate change and that anthropogenic contributions are significant; and

3 WHEREAS, large in person events can generate significant waste and be harmful to the  
4 environment; and

5 WHEREAS, the American Osteopathic Association (AOA) has traditionally held at minimum  
6 three events of over two hundred people per year; now, therefore be it

7 RESOLVED, that the American Osteopathic Association (AOA) will make efforts to make  
8 events “green” and sustainable such as: choosing eco-friendly venues (IACC Green Star  
9 certified, i.e.), using compostable or reusable cups and glasses, fabric napkins, going  
10 paperless, limiting food waste, reducing transportation footprints, choosing virtual  
11 meeting options as appropriate, etc.; and, be it further

12 RESOLVED, that the AOA will report to the House of Delegates annually on these  
13 improvements, starting in 2021.

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

Based on Finance Committee’s estimate, the Committee believes the costs to implement is prohibitive and could result in a negative fiscal impact. In times of a pandemic, there is potential that use of reusable items could contribute to spread.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$250,000 in additional expenses annually.

The staff estimates that providing sustainable options regarding cups, plates, utensils, etc. for meals and breaks at AOA sponsored events would cost an addition \$250,000 annually. Presently, due to COVID-19 venues are not offering or providing a sustainable option; additionally, virtual meetings are the current option for the foreseeable future, therefore under these circumstances a direct fiscal impact cannot be accurately determined at this time.

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H357-A/19 NUTRITION AND LEADING BY EXAMPLE

SUBMITTED BY: Osteopathic Physicians and Surgeons of Oregon

REFERRED TO: Committee on Professional Affairs

---

- 1 WHEREAS, at the 2018 American Osteopathic Association (AOA) House of Delegates,  
2 resolution H-365 was approved resolving that the AOA consider meal nutritional  
3 content when planning events; and
- 4 WHEREAS, the preponderance of evidence shows negative health outcomes associated with  
5 the consumption of sugar sweetened beverages and processed meats and;
- 6 WHEREAS, the World Health Organization, International Agency for Research on Cancer has  
7 classified processed meat as carcinogenic to humans (Group 1); and
- 8 WHEREAS, nudges, defined as a subtle environment cues designed to make healthy food  
9 choices the easy choice have been shown to increase consumption of healthy foods; and
- 10 WHEREAS, the AOA has the opportunity to lead by example - recognizing the impact that  
11 nutrition has on human health when providing meals; and
- 12 RESOLVED, that sugar sweetened beverages and processed meats be excluded from all  
13 American Osteopathic Association (AOA) sponsored events where a meal is served;  
14 and, be it further
- 15 RESOLVED, that the AOA encourage osteopathic medical schools, residency programs, and  
16 hospitals to offer plant-based meals and eliminate sugar sweetened beverages and  
17 processed meats when meals are served.

Explanatory Statement: Submitted by Finance Committee.

The staff determined an additional annual cost for breakfast, lunch and breaks of \$135,000 in Food & Beverage expenses. This would only be incurred if offsets were not taken from other components of the Food & Beverage order for events. However, as meeting staff will strictly remain within their overall individual event budgets, the appropriate reductions would be made in other areas to offset the increased expenses associated with the “healthier” menu options thus no direct fiscal impact. The Committee recognizes that there could be an indirect fiscal impact that cannot be predicted.

Explanatory Statement: Reference Committee

Based on Finance Committee’s estimate, the Committee believes the costs to implement is prohibitive and could result in a negative fiscal impact.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H324-A/14 USE OF THE TERM “PHYSICIAN” “DOCTOR” AND  
“PROVIDER”

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Professional Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
2 policy be REAFFIRMED AS AMENDED.

3 **H324-A/14 USE OF THE TERM “PHYSICIAN” “DOCTOR” AND “PROVIDER”**

4 The American Osteopathic Association (AOA) adopts as policy: (1) that AOA members are  
5 encouraged to use the terms “physician” or “doctor” to describe themselves, leaving other  
6 terms such as “practitioner,” “clinician,” or “provider” to be used by non-physician clinicians or  
7 to categorize health care professionals as a whole; (2) supports the appropriate use of  
8 credentials and professional degrees in advertisements; (3) SUPPORTS providing a mechanism  
9 for physicians to report advertisements related to medical care that are false or deceptive; (4)  
10 opposes non-physician clinicians’ use of the title “physician,” AS WELL AS USE OF THE  
11 TITLE or “doctor” WITHOUT SPECIFYING THE TYPE OF DOCTORATE RECEIVED,  
12 because such communication is likely to deceive CONFUSE the public by implying that the  
13 non-physician clinician is engaged in the unlimited practice of medicine; (5) opposes legislation  
14 that would expand the use of the term “physician” to persons other than US-trained DOs, and  
15 MDs; AND (6) supports a policy that physicians and non-physician clinicians SHOULD  
16 identify themselves to their patients noting USING their degree in both a verbal description  
17 INTRODUCTION as well as BY a OTHER IDENTIFICATION CLEARLY VISIBLE  
18 DURING PATIENT ENCOUNTERS visual identification by use of a nametag; (7) will not  
19 support legislation, which would allow non-physician clinicians to be called “physician;” (8)  
20 supports a policy reserving the title “physician” for US-trained DOs, and MDs who have  
21 established the integrity of their education, training, examination and regulations for the  
22 unlimited practice of medicine; and (9) opposes the misuse of the title “doctor” by non-  
23 physician clinicians, in all communications and clinical settings because such use deceives the  
24 public by implying the non-physician clinician’s education, training or credentialing is equivalent  
25 to a DO or MD. 2009; reaffirmed as amended 2014

Explanatory Statement: Submitted by Author

Per the directive of the 2019 AOA House of Delegates, the BSGA convened a workgroup to discuss updates to this policy, specifically regarding use of the term “doctor” by non-DOs/MDs. The amended policy takes into account the fact that many types of healthcare professionals now undergo additional years of education and training in pursuit of a doctorate, and as of 2015, the doctorate is now the qualifying degree for physical therapists. Beginning in 2027, a doctorate will be required of occupational therapists as well. The revised policy balances patient safety by ensuring that patients are aware of who is providing their care, while appropriately recognizing doctoral degrees earned by non-physicians. In addition, the term “provider” is still commonly used among healthcare and governmental organizations to refer to healthcare professionals (including physicians) as a whole, and the revised policy reflects that fact.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: CDC GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN  
— UNITED STATES, 2016

SUBMITTED BY: Iowa Osteopathic Medical Association

REFERRED TO: Committee on Professional Affairs

---

1 WHEREAS, WHEREAS, in 2016 the United States Centers for Disease Control and  
2 Prevention (CDC) released its *“Guideline for Prescribing Opioids for Chronic Pain — United*  
3 *States, 2016”*<sup>1</sup> (Guidelines); and

4 WHEREAS, following its release, many legislatures and regulatory bodies adopted the  
5 Guidelines as standards of practice, enacted rules, and have taken action against  
6 prescribers who failed to rigidly follow the guidelines; and

7 WHEREAS these actions led the CDC to issue a statement warning against the misapplication  
8 of the Guideline<sup>2</sup>; and

9 WHEREAS in an article published in the New England Journal of Medicine, Deborah Dowell,  
10 MD, MPH, Chief Medical Officer, National Center for Injury Prevention and Control  
11 further stated, *“Unfortunately, some policies and practices purportedly derived from the guideline*  
12 *have in fact been inconsistent with, and often go beyond, its recommendations. A consensus panel has*  
13 *highlighted these inconsistencies, which include inflexible application of recommended dosage and*  
14 *duration thresholds and policies that encourage hard limits and abrupt tapering of drug dosages,*  
15 *resulting in sudden opioid discontinuation or dismissal of patients from a physician’s practice.”*<sup>3</sup>; and

16 WHEREAS the misapplication of the Guidelines has a high potential for patient harm and may  
17 impose needless suffering on patients and bring unwarranted sanctions against  
18 physicians; and

19 WHEREAS through its participation in the American Medical Association's Opioid Task  
20 Force, the American Osteopathic Association (AOA) has developed and published  
21 recommendations<sup>4</sup> to assist physicians in reversing the opioid epidemic in the US;  
22 now, therefore be it

23 RESOLVED, the American Osteopathic Association (AOA) opposes the misuse and inflexible  
24 application of the United States Centers for Disease Control and Prevention (CDC)  
25 ~~released its~~ *“Guideline for Prescribing Opioids for Chronic Pain — United States, 2016,*  
26 *(Guidelines) by law makers and regulators; and be it further,*

27 RESOLVED the AOA opposes the codification of the Guidelines into law or regulation and  
28 their use as a measure of the appropriateness of physicians prescribing; and be it further

29 RESOLVED the AOA recommends physicians read and consider the use of the 2019 AMA  
30 Opioid Task Force 2019 Guidelines<sup>4</sup> **4** in patients being treated for non-malignant  
31 chronic pain conditions.

Explanatory Statement: Submitted by Author

2019 AMA Opioid Task Force 2019 Guidelines attached

References

1. Deborah Dowell, MD, CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016, MMWR 65(1);1-49  
[https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6501e1er.htm](https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6501e1er.htm) accessed June 12, 2020
2. CDC Advises Against Misapplication of the Guideline for Prescribing Opioids for Chronic Pain, <https://www.cdc.gov/media/releases/2019/s0424-advises-misapplication-guideline-prescribing-opioids.html> Accessed June 12, 2020
3. Deborah Dowell, M.D., M.P.H., No Shortcuts to Safer Opioid Prescribing, 2019, N Engl J Med 380:2285-2287, <https://www.nejm.org/doi/full/10.1056/NEJMp1904190>
4. 2019 Recommendations of the AMA Opioid Task Force, 2019, <https://www.end-opioid-epidemic.org/recommendations-for-physicians/>, accessed June 12, 2020

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**





**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES**

**OCTOBER 2020 MEETING  
PUBLIC AFFAIRS - RESOLUTION ROSTER  
WITH ACTION**

**HOUSE OF DELEGATES' REFERENCE COMMITTEE DESCRIPTION:**

- Committee on Public Affairs (400 series)  
This reference committee reviews and considers matters relating to public and industrial health, research and physical fitness.

Res. No.	Resolution Title	Submitted By	Action
H400	Interference in the Physician-Patient Relationship by Personal Injury Attorneys and Insurance Carrier Agents (H400-15)	BSAPH / BSA	ADOPTED
H401	Osteopathic Name and Identity (H401-A/15)	BOE	ADOPTED <i>(for sunset)</i>
H402	Public Education Regarding the Importance and Safety of Vaccines for Infants, Children, and Adults (H402-A/15)	BSAPH	ADOPTED
H403	Support for the Advisory Committee on Immunization Practices (ACIP) Recommendations (H403-A/15)	BSAPH	ADOPTED
H404	Vaccination Rates – Daycare Notification to Parents (H404-A/15)	BSGA	ADOPTED
H405	Protection of Safe Water Supply (H405-A/15)	BFHP / BSAPH	ADOPTED
H406	Antibiotic Stewardship (H407-A/15)	BSAPH	ADOPTED
H407	Vaccines for Children Program (H408-A/15)	BSAPH	ADOPTED
H408	Seat Belt Laws – Primary Enforcement (H409-A/15)	BSGA	ADOPTED
H409	Intrauterine Fetal Demise Awareness (H410-A/15)	BSAPH	ADOPTED
H410	Antifreeze Poisoning (H411-A/15)	BSAPH	NOT ADOPTED
H411	Aircraft Emergency Medical Supplies (H412-A/15)	BFHP	ADOPTED
H412	Animals in Medical Research (H413-A/15)	BSAPH	ADOPTED
H413	Cancer (H415-A/15)	BSAPH	ADOPTED
H414	Cardiopulmonary Resuscitation, Training (H416-A/15)	BSAPH	ADOPTED
H415	Children’s Safety Seats (H418-A/15)	BSAPH	ADOPTED
H416	Death – Right to Die (H419-A/15)	BSGA	ADOPTED
H417	Environmental Responsibility--Waste Materials (H420-A/15)	BSAPH	ADOPTED
H418	Firearms and Non-Powdered Guns - Education for Users (H421-A/15)	BFHP	ADOPTED
H419	Genetic Manipulation of Food Products – Consumers Right to Know (H422-A/15)	BSAPH	ADOPTED



**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES**

**OCTOBER 2020 MEETING  
PUBLIC AFFAIRS - RESOLUTION ROSTER  
WITH ACTION**

<b>Res. No.</b>	<b>Resolution Title</b>	<b>Submitted By</b>	<b>Action</b>
H420	Condom Usage – Health Education (H423-A/15)	BSAPH	ADOPTED
H421	Support of Literacy Programs (H424-A/15)	BSAPH	ADOPTED
H422	Tanning Devices (H425-A/15)	BSGA	ADOPTED
H423	Tobacco Settlement Funds (H426-A/15)	BSGA	ADOPTED
H424	Healthy Family, Support of (H428-A/15)	BSAPH	ADOPTED
H425	Immunization of 9 to 26 Year Old Male and Females with Human Papilloma Virus Vaccine (H429-A/15)	BSAPH	ADOPTED as AMENDED
H426	Drugs, Curbing Counterfeit (H430-A/15)	BFHP	ADOPTED
H427	Sleep Disorders – Promoting the Understanding and Prevention of (H432-A/15)	BSAPH	ADOPTED
H428	Minority Health Disparities (H433-A/15)	BSAPH	ADOPTED as AMENDED
H429	Infant Walker (Mobile) – Ban on the Manufacture, Sale and Use of (H434-A/15)	BSAPH	ADOPTED
H430	Develop In-Vitro Fertilization Standards of Care (H435-A/15)	BSAPH	ADOPTED as AMENDED
H431	Complementary and Alternative Medicine by Non-Physicians (H436-A/15)	BSGA	REFERRED
H432	Continued Support OF Combating Bio-Terrorism Activities (H437-A/15)	BFHP	ADOPTED as AMENDED
H433	Childhood Obesity – Worsening Epidemic in the American Society (H438-A/15)	BSAPH	ADOPTED
H434	Immunizations – Mainstay of Preventive Medical Practice (H439-A/15)	BSAPH	ADOPTED
H435	Texting While Driving (H440-A/15)	BSAPH	ADOPTED
H436	Silver Alert System (H442-A/15)	BFHP	ADOPTED
H437	National Institutes of Health Grants (H443-A/15)	BFHP	ADOPTED as AMENDED
H438	Screening for Breast Cancer (H444-A/15)	BSAPH	ADOPTED
H439	Gender Identity Non-Discrimination (H445-A/15)	BSAPH	ADOPTED
H440	Traumatic Brain Injury Awareness (H446-A/15)	BSAPH	ADOPTED as AMENDED
H441	Support for Family Caregivers (H448-A/15)	BSAPH	ADOPTED
H442	Firearm Violence (H450-A/15)	BFHP	ADOPTED as AMENDED
H443	Addressing Police Use of Disproportionate Force...	SOMA	REFERRED



**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES  
OCTOBER 2020 MEETING  
PUBLIC AFFAIRS - RESOLUTION ROSTER  
WITH ACTION**

<b>Res. No.</b>	<b>Resolution Title</b>	<b>Submitted By</b>	<b>Action</b>
H444	Adopting and Promoting Non-Stigmatizing Language for Substance Use Disorders	SOMA	ADOPTED
H445	AOA Response to Novel Public Health Threats	MOA	ADOPTED
H446	Background Checks and Firearms Safety Training as a Condition of Firearms Purchase	BFHP	ADOPTED
H447	Fentanyl Testing Strips	AOAAM	ADOPTED as AMENDED
H448	Firearms Policy	BFHP	REFERRED
H449	Homeless Support	OPSC	ADOPTED as AMENDED
H450	Medical Amnesty for Underage Consumption of Alcohol	AOAAM	REFERRED
H451	Opposition to Abstinence-Only Sex Education	SOMA	WITHDRAWN
H452	REFERRED RESOLUTION: Breastfeeding While on Medication Assisted Treatment (MAT)	BSAPH	ADOPTED
H453	REFERRED SUNSET RESOLUTION: H-411 - A/2019: H413-A/14 Epidemic Terrorist Attack Victims, Government Responsibility of Health Care	BFHP	ADOPTED as AMENDED
H454	REFERRED SUNSET RESOLUTION: H429 A/14 Minorities, Underrepresented (URM) – Increasing Numbers of Applicants...	BSAPH	ADOPTED as AMENDED
H455	REFERRED RESOLUTION: Regulation of E-Cigarettes and Nicotine Vaping	BSAPH	ADOPTED as AMENDED
H456	Recognizing Health Care as a Human Right	MOA	NOT ADOPTED
H457	Support a Culture of Patient Safety and Speaking Up from Medical Students and Preceptors in Healthcare Settings	SOMA	WITHDRAWN
H458	WITHDRAWN	IOMA	WITHDRAWN

SUBJECT: H400-A/15 INTERFERENCE IN THE PHYSICIAN-PATIENT  
RELATIONSHIP BY PERSONAL INJURY ATTORNEYS AND  
INSURANCE CARRIER AGENTS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health / Bureau of Socioeconomic  
Affairs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health and Bureau of  
2 Socioeconomic Affairs recommends that the following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H400-A/15 INTERFERENCE IN THE PHYSICIAN-PATIENT RELATIONSHIP**  
5 **BY PERSONAL INJURY ATTORNEYS AND INSURANCE CARRIER**  
6 **AGENTS**

7 The American Osteopathic Association opposes any interference in the physician-patient  
8 relationship by persons with financial and business interests regarding a personal injury incident.  
9 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

---

DATE: **October 14, 2020**

---

SUBJECT: H401-A/15 OSTEOPATHIC NAME AND IDENTITY

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau of Osteopathic Education recommends that the following policy  
2 be SUNSET.

3 **H401-A/15 OSTEOPATHIC NAME AND IDENTITY**

4 The American Osteopathic Association will advise the Accreditation Council for Graduate  
5 Medical Education that MDs who complete osteopathic-recognized residencies should describe  
6 themselves as “MDs who have been trained in Osteopathic Manipulative Medicine” and not as  
7 Osteopathic Physicians or DOs. 2015.

Explanatory Statement: Submitted by Author

The BOE recommends this policy be sunset because the AOA no longer separately accredits graduate medical education programs.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED** *(for sunset)*

DATE: **October 14, 2020**

SUBJECT: H402-A/15 PUBLIC EDUCATION REGARDING THE IMPORTANCE  
AND SAFETY OF VACCINES FOR INFANTS, CHILDREN, AND  
ADULTS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H402-A/15 PUBLIC EDUCATION REGARDING THE IMPORTANCE AND**  
5 **SAFETY OF VACCINES FOR INFANTS, CHILDREN, AND ADULTS**

6 The American Osteopathic Association supports the widespread use and high compliance rate  
7 of the Health and Human Services National Vaccine Implementation Plan for infants, children,  
8 and adults through education of the public using media and marketing tools available to its  
9 organization. 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H403-A/15 SUPPORT FOR THE ADVISORY COMMITTEE ON  
IMMUNIZATION PRACTICES (ACIP) RECOMMENDATIONS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H403-A/15 SUPPORT FOR THE ADVISORY COMMITTEE ON**  
5 **IMMUNIZATION PRACTICES (ACIP) RECOMMENDATIONS**

6 The AOA encourages osteopathic physicians consider the vaccination history as an integral part  
7 of their patient's health record and should counsel their patients on appropriate vaccinations for  
8 their age and health conditions. Osteopathic physicians should take all reasonable steps to  
9 ensure their patients of all ages are fully immunized against vaccine preventable illnesses and  
10 make vaccine recommendations to their patients according to the recommendations of the  
11 Advisory Committee on Immunization Practices (ACIP) and published in the Morbidity and  
12 Mortality Weekly Report (MMWR) and should not advocate alternative schedules. 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H404-A/15 VACCINATION RATES – DAYCARE NOTIFICATION TO PARENTS

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H404-A/15 VACCINATION RATES – DAYCARE NOTIFICATION TO**  
5 **PARENTS**

6 The American Osteopathic Association (AOA) supports legislation at the state level that  
7 requires daycare facilities to notify parents (in compliance with Health Insurance Portability and  
8 Accountability Act (HIPAA) regulations and state regulations where applicable) that their  
9 facility has in its care unvaccinated children who may pose a health risk to high risk populations.  
10 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**



SUBJECT: H405-A/15 PROTECTION OF SAFE WATER SUPPLY

SUBMITTED BY: Bureau on Federal Health Programs / Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs and the Bureau on Scientific Affairs  
2 recommends that the following policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H405-A/15 PROTECTION OF SAFE WATER SUPPLY**

5 The American Osteopathic Association (AOA) ~~will~~ encourageS the oil industry and the  
6 Environmental Protection Agency (EPA) to seek out new technologies for safer disposal of  
7 waste well water and the protection of our water supply. 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

---

DATE: **October 14, 2020**

---

SUBJECT: H407-A/15 ANTIBIOTIC STEWARDSHIP

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H407-A/15 ANTIBIOTIC STEWARDSHIP**

5 The American Osteopathic Association (AOA), supports the five core actions outlined in the  
6 National Strategy for Combating Antibiotic-Resistant Bacteria and calls upon osteopathic  
7 physicians to adopt the principles of responsible antibiotic use, or antibiotic stewardship, which  
8 is a commitment to ~~always~~ use antibiotics only when they are **MEDICALLY** necessary to ~~treat,~~  
9 ~~and in some cases prevent, disease; to choose the right antibiotics; and to administer~~  
10 ~~appropriately.~~ **2015**

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H408-A/15 VACCINES FOR CHILDREN PROGRAM

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H408-A/15 VACCINES FOR CHILDREN PROGRAM**

5 The American Osteopathic Association supports the expansion of the Vaccines for Children  
6 (VFC) Program to include all Advisory Committee on Immunizations Practices (ACIP) age  
7 appropriate vaccines for all underinsured children, in keeping with the original goals of the  
8 program. 2005; revised 2010; reaffirmed 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H409-A/15 SEAT BELT LAWS – PRIMARY ENFORCEMENT

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H409-A/15 SEAT BELT LAWS – PRIMARY ENFORCEMENT**  
5 The American Osteopathic Association ~~endorses~~ **SUPPORTS** the ~~passage of~~ primary  
6 enforcement seat belt laws in every state. 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H410-A/15 INTRAUTERINE FETAL DEMISE AWARENESS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H410-A/15 INTRAUTERINE FETAL DEMISE AWARENESS**

5 The American Osteopathic Association supports increasing public awareness of the risk for  
6 intrauterine fetal demise and encourages the director of the National Institutes of Health to  
7 allocate more resources to intrauterine fetal demise research. 2010; reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H411-A/15 ANTIFREEZE POISONING

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H411-A/15 ANTIFREEZE POISONING**

5 The American Osteopathic Association supports the addition of a bittering agent to antifreeze  
6 to lessen the likelihood of accidental ingestion. 2010; revised 2015.

Explanatory Statement: Submitted by Author  
None provided.

Explanatory Statement: Reference Committee

The addition of a bittering agent to antifreeze is now the law in all 50 states so this policy is no longer needed.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H412-A/15 AIRCRAFT EMERGENCY MEDICAL SUPPLIES

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H412-A/15 AIRCRAFT EMERGENCY MEDICAL SUPPLIES**

5 The American Osteopathic Association supports the concept that airlines, under the control of  
6 the Federal Aviation Administration, maintain a policy for adequately equipping commercial  
7 aircraft of greater than 19 seats with at least minimal diagnostic and emergency medical supplies  
8 and supports legislation and regulation that any physician providing emergency service while on  
9 board aircraft be immune from any liability or legal action. 1984; revised 1989, 1995; reaffirmed  
10 2000, revised 2005, reaffirmed 2010; reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H413-A/15 ANIMALS IN MEDICAL RESEARCH

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H413-A/15 ANIMALS IN MEDICAL RESEARCH**

5 The American Osteopathic Association (AOA) supports the use of animals for valid medical  
6 research projects and the humane handling and treatment of such animals, and their ready  
7 availability from legitimate sources. The AOA supports eventual elimination of the use of  
8 animals in medical research as better techniques become available. 1990; reaffirmed 1995;  
9 revised 2000, revised 2005; reaffirmed 2010; reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**



SUBJECT: H415-A/15 CANCER

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H415-A/15 CANCER**

5 The American Osteopathic Association recognizes, endorses, and approves the continuing  
6 efforts of the National Cancer Institute to develop means to significantly reduce the incidence  
7 of cancer and the suffering and death resulting from cancer. THE AOA ~~and~~ will disseminate to  
8 the medical community and the public ~~it serves~~, information gained from osteopathic and other  
9 research activities on the applications of the latest advances in cancer prevention, detection,  
10 early diagnosis and treatment. 1974; reaffirmed 1980, 1985; revised 1990, 1995, reaffirmed 2000,  
11 revised 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H416-A/15 CARDIOPULMONARY RESUSCITATION, TRAINING

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H416-A/15 CARDIOPULMONARY RESUSCITATION, AND AUTOMATED**  
5 **EXTERNAL DEFIBRILLATOR TRAINING**

6 The American Osteopathic Association strongly supports instruction in cardiopulmonary  
7 resuscitation (CPR) AND AUTOMATED EXTERNAL DEFIBRILLATOR (AED)  
8 TRAINING to the general public; and encourages member physicians to qualify as instructors  
9 in basic life support so as to enable them to teach cardiopulmonary resuscitation AND AED  
10 courses on a voluntary basis. 1980; revised 1985, 1990, 1995, 2000, reaffirmed 2005, 2010; 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H418-A/15 CHILDREN'S SAFETY SEATS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRM as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H418-A/15 CHILDREN'S SAFETY SEATS**

5 The American Osteopathic Association supports the ADIPTION AND enforcement of child  
6 safety seat statutes in accordance with the National Highway Traffic Safety Administration  
7 Guidelines. 1985; revised 1990; reaffirmed 1995; revised 2000, 2005; revised 2010; reaffirmed  
8 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H419-A/15 DEATH - RIGHT TO DIE

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H419-A/15 ~~DEATH - RIGHT TO DIE~~ END OF LIFE**

5 The AOA believes that the decision to withhold or withdraw treatment from a patient whose  
6 prognosis is terminal, or when death is imminent, shall be based upon the wishes of the patient  
7 or THEIR ~~his/her~~ family or legal representative if the patient lacks capacity to act on THEIR  
8 ~~his/her~~ own behalf as mandated by applicable law. 1979; revised 1984, 1989, 1995, 2000, 2005;  
9 revised 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H420-A/15 ENVIRONMENTAL RESPONSIBILITY--WASTE MATERIALS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H420-A/15 ENVIRONMENTAL RESPONSIBILITY--WASTE MATERIALS**

5 The American Osteopathic Association supports ~~the recycling of all recyclables.~~ 1995; revised  
6 2000, revised 2005; revised 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H421-A/15 FIREARMS AND NON-POWDERED GUNS -  
EDUCATION FOR USERS

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H421-A/15 FIREARMS AND NON-POWDERED GUNS - EDUCATION FOR**  
5 **USERS**

6 The American Osteopathic Association supports education involving firearm and non-  
7 powdered guns safety and the inherent risk, benefits and responsibility of ownership. 1990;  
8 reaffirmed 1995, 2000, 2005; revised 2010; revised 2015 [Editor's Note: Non-Powdered Guns  
9 are defined as: BB, air and pellet guns, expelling a projectile (usually made of metal or hard  
10 plastic) through the force **OF COMPRESSED AIR OR GAS, ELECTRICITY, of air**  
11 **pressure, CO2 pressure,** or spring action. Non-powder guns are distinguished from firearms,  
12 which use gunpowder to generate energy to launch a projectile.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H422-A/15 GENETIC MANIPULATION OF FOOD PRODUCTS –  
CONSUMERS RIGHT TO KNOW

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H422-A/15 GENETIC MANIPULATION OF FOOD PRODUCTS –**  
5 **CONSUMERS RIGHT TO KNOW**

6 The American Osteopathic Association supports efforts that require clear identification of any  
7 genetically manipulated food products so that consumers may be properly informed as they  
8 make food choices. 2000, revised 2005, reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H423-A/15 CONDOM USAGE – HEALTH EDUCATION

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H423-A/15 CONDOM USAGE – HEALTH EDUCATION**

5 The American Osteopathic Association supports full disclosure of the risks and benefits of  
6 condom usage and the data on condom failure rates and causes of failure, whenever condom  
7 usage is taught. 1995; revised 2000, 2005, reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**



SUBJECT: H424-A/15 SUPPORT OF LITERACY PROGRAMS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H424-A/15 SUPPORT OF LITERACY PROGRAMS**

5 The American Osteopathic Association supports programs that promote literacy in the United  
6 States. 1990; revised 1995; reaffirmed 2000, revised 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H425-A/15 TANNING DEVICES

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRM as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H425-A/15 TANNING DEVICES**

5 The American Osteopathic Association SUPPORTS EDUCATION AND LEGISLATION  
6 TO REDUCE THE use of tanning devices EXCEPT WHERE MEDICALLY INDICATED.  
7 1990; revised 1995, 2000, reaffirmed 2005; revised 2010; reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H426-A/15 TOBACCO SETTLEMENT FUNDS

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRM as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H426-A/15 TOBACCO SETTLEMENT FUNDS**

5 The American Osteopathic Association supports the use of the tobacco settlement fund  
6 EXCLUSIVELY for health care services, education and research. 2000, revised 2005;  
7 reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H428-A/15 HEALTHY FAMILY, SUPPORT OF

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H428-A/15 HEALTHY FAMILY, SUPPORT OF**

5 The American Osteopathic Association recommends that their members support healthy  
6 families by encouraging families to do the following: (1) try to eat at least one meal per day  
7 together, using healthful nutritional guidelines; (2) a set time be spent together as a family to  
8 help with school work and include reading to and with children; (3) ENCOURAGING  
9 MEDIA-FREE TIME ~~limiting non-educational use of television, computer, texting /~~  
10 ~~telephones and video game to no more than 2 hours per day;~~ (4) limiting exposure to violence;  
11 and (5) engaging in a healthy lifestyle that includes exercise. 2005; revised 2010; reaffirmed  
12 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H429-A/15 IMMUNIZATION OF 9 TO 26 YEAR OLD MALE AND FEMALES WITH HUMAN PAPILOMA VIRUS VACCINE

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H429-A/15 IMMUNIZATION OF 9 TO 26 YEAR OLD MALE AND FEMALES**  
5 **WITH HUMAN PAPILOMA VIRUS VACCINE**

6 The American Osteopathic Association recommends SUPPORTS EDUCATION AND  
7 IMMUNIZATION for Human Papilloma Virus (HPV) immunization for both females and  
8 males, 9—26 45 years of age. 2010; reaffirmed 2015

9 Explanatory Statement

10 Overview:

11 Human Papillomavirus is a human-specific class of sexually transmitted viruses with over 200  
12 types associated with multiple diseases in humans. These include benign conditions such as  
13 genital and nongenital warts and malignant conditions such as cervical, anal, oropharyngeal,  
14 vaginal, and vulvar cancer(4).There are approximately 33,700 cases of cancer caused by HPV  
15 diagnosed annually(1). Furthermore, the incidence of cervical cancer worldwide is predicted to  
16 increase by 50% with the current rate of vaccination (3). Risk factors for developing these  
17 malignant conditions include exposure to and infection with associated strains of the HPV  
18 Virus (4,5). A recombinant vaccine has been developed including 9 strains associated with  
19 malignancy, including types 16 and 18 which are responsible for 70-80% of all cases of Cervical  
20 Cancer and 90% of Anal Cancer(6). Based on recent data from the CDC and clinical trials  
21 (7,8,9), the FDA has recommended that the recombinant vaccine be administered in both  
22 women and men until the age of 45(1,2).

23 Background:

24 The HPV recombinant vaccines that have been Bivalent, or targeting 2 strains, have been  
25 available since 2006. These initial vaccines targeted 2 strains most commonly associated with  
26 Cervical Cancer: strains 16 and 18. In 2017, the Gardasil 9 vaccine was released targeting 9  
27 strains of the virus: 6, 11, 16, 18, 31, 33, 45, 52, and 58 (6). Although 2 of these strains (strains 6  
28 and 11) are more likely to be associated with the development of non-cancerous genital and  
29 nongenital warts, the link between presence of warts and development of cancerous lesions is  
30 currently being studied (5).

1 The vaccine was recommended to be administered to women and men ages 9-25(2) as evidence  
2 demonstrated that the vaccine is most effective in those who have not previously been exposed  
3 to the HPV virus (1,8,9).

4 Since 1999, there has been a decrease in the incidence of HPV related cervical carcinoma by  
5 1.6%, however there has been an increase in HPV related Cancer of the Mouth and Throat,  
6 known as Oropharyngeal Squamous Cell Carcinoma by 2.7% in men and 0.8% in women (7). A  
7 study conducted in 2016 revealed that there was a decrease in infection rates and development  
8 of Cervical Intraepithelial Neoplasia (a precancerous lesions which can develop into Cervical  
9 Carcinoma) in women over 25 who had received the HPV recombinant vaccine and had no  
10 previous exposure to HPV over a 7 year period (8,9). In 2018, the FDA revised the Prescribing  
11 Information for Gardasil to allow the vaccine to be administered to both women and men until  
12 the age of 45 if there was no previous history of HPV infection (2).

13 Recommendations:

14 Clinical trials (8,9) have proven that the vaccine is just as effective in both Males and Females  
15 over the age of 25 who do not have a history of HPV, the policy should be updated in  
16 conjunction with the Prescriber Information and the FDA recommendations - any male  
17 without a history of HPV associated warts (genital and nongenital) between the ages of 25-45  
18 and any female between the ages of 25-45 with no history of HPV related warts (genital and  
19 nongenital) or negative HPV test with Pap Smear be eligible for 9-valent HPV recombinant  
20 vaccine if not previously administered.

21 In conjunction with current guidelines, regular pap smears should include HPV testing for  
22 women above the age of 18, extending the age limit in guidelines beyond the age of 26 (1,6,7).

23 Sources:

- 24 1. ACIP Evidence to Recommendations for HPV Vaccine  
25 <https://www.cdc.gov/vaccines/acip/recs/grade/HPV-adults-etr.html>
- 26 2. Gardasil 9 Prescribing Information  
27 [https://www.merck.com/product/usa/pi\\_circulars/g/gardasil\\_9/gardasil\\_9\\_pi.pdf](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf)
- 28 3. WHO Call to Action to Eradicate Cervical Cancer  
29 [https://www.who.int/reproductivehealth/DG\\_Call-to-Action.pdf?ua=1](https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf?ua=1)
- 30 4. UpToDate HPV [https://www.uptodate.com/contents/human-papillomavirus-](https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations?search=hpv&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)  
31 [infections-epidemiology-and-disease-](https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations?search=hpv&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)  
32 [associations?search=hpv&source=search\\_result&selectedTitle=1~150&usage\\_type=default&di-](https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations?search=hpv&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)  
33 [splay\\_rank=1](https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations?search=hpv&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)
- 34 5. Virology of HPV Infections and Link to Cancer  
35 [https://www.uptodate.com/contents/virology-of-human-papillomavirus-infections-and-the-](https://www.uptodate.com/contents/virology-of-human-papillomavirus-infections-and-the-link-to-)  
36 [link-to-](https://www.uptodate.com/contents/virology-of-human-papillomavirus-infections-and-the-link-to-)

- 1 cancer?search=hpv&source=search\_result&selectedTitle=3~150&usage\_type=default&display  
2 \_rank=3
- 3 6. HPV Vaccination
- 4 [https://www.uptodate.com/contents/human-papillomavirus-  
6 splay\\_rank=2](https://www.uptodate.com/contents/human-papillomavirus-vaccination?search=hpv&source=search_result&selectedTitle=2~150&usage_type=default&di<br/>5 splay_rank=2)
- 7 7. Trends in HPV Related Cancers 1999-2015
- 8 [https://www.cdc.gov/mmwr/volumes/67/wr/mm6733a2.htm?s\\_cid=mm6733a2\\_w%20%5B  
9 cdc.gov%5D](https://www.cdc.gov/mmwr/volumes/67/wr/mm6733a2.htm?s_cid=mm6733a2_w%20%5B<br/>9 cdc.gov%5D)
- 10 8. Efficacy, Safety, and Immunogenicity of HPV 16/18 ASOV-adjuvanted vaccine in  
11 women over 25 years
- 12 <https://www.ncbi.nlm.nih.gov/pubmed?term=27373900>
- 13 9. FUTURE Trial for HPV Vaccination
- 14 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636904/#S5title>
- 15 10. AOA 2019 Policy Compendium
- 16 <https://osteopathic.org/wp-content/uploads/2019-Policy-Compendium.pdf>

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H430-A/15 DRUGS, CURBING COUNTERFEIT

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H430-A/15 DRUGS, CURBING COUNTERFEIT**

5 The American Osteopathic Association supports the Food and Drug Administration’s (FDA)  
6 efforts to educate osteopathic physicians on how to identify counterfeit drugs. 2005; revised  
7 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**



SUBJECT: H432-A/15 SLEEP DISORDERS – PROMOTING THE UNDERSTANDING AND PREVENTION OF

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H432-A/15 SLEEP DISORDERS – PROMOTING THE UNDERSTANDING**  
5 **AND PREVENTION OF**

6 The American Osteopathic Association supports programs that promote education and  
7 understanding of sleep and its impact on health and encourages osteopathic physicians to  
8 educate their patients about sleep disorders and the importance of sleep and its impact on  
9 health. 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H433-A/15 MINORITY HEALTH DISPARITIES

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H433-A/15 MINORITY HEALTH DISPARITIES**

5 The American Osteopathic Association adopts the following Position Statement on Minority  
6 Health Disparities (2005; reaffirmed 2010; 2015):

7 **POSITION STATEMENT ON MINORITY HEALTH DISPARITIES**

8 The minority healthcare crisis in America stems from a multitude of factors. In particular,  
9 healthcare disparities most greatly affect underrepresented minorities, which include African-  
10 Americans, Hispanic-Americans, Asian-Americans, Native Americans and Pacific Islanders. In  
11 order to effectively create positive change, certain questions must be addressed. These include,  
12 but are not limited to: Which minorities are most affected by disease-specific illness? Why do  
13 these disparities exist? What can be done to eliminate them? Will a concerted effort to increase  
14 awareness and education about health-care disparities result in improved delivery of quality  
15 healthcare?

16 There is a need for the osteopathic profession and all of organized medicine to develop  
17 strategies which address health care disparities among minorities and prepare culturally  
18 competent physicians. Guidance should be offered to educate practicing physicians and trainees  
19 to better resolve known disparities and serve diverse populations. Efforts must be made to  
20 assure cultural competency and to identify and overcome language and other barriers to  
21 delivering health care to minorities.

22 Healthcare disparities include differences in health coverage, health access and quality of care.  
23 Health disparities result in morbidity and mortality experienced by one population group in  
24 relation to another.

25 Cultural competency is a set of academic and personal skills that allow one to understand and  
26 appreciate cultural differences among groups. The better a healthcare professional understands  
27 a patient's behavior, values and other personal factors, the more likely that patient will receive  
28 effective, high quality care.

29 Racial and ethnic healthcare disparities caused by problems with access to, and utilization of,  
30 quality care may be alleviated through improvements in the cultural competency skills of  
31 physicians. Healthcare disparities may also be alleviated through effective recruitment of  
32 underrepresented minorities into health professions schools.

33 The Centers for Disease Control, in conjunction with the U.S. Department of Health and  
34 Human Services, created an Office of Minority Health in 1985. Through this collaboration, the  
35 Racial and Ethnic Approaches to Community Health Act (REACH) was designed to identify

1 and eliminate disparities in a number of major areas. Disparities in access to care as well as  
2 quality of care in these areas result in poorer outcomes for racial and ethnic minorities.

3 The identified areas of disparity include: 1) infant mortality; 2) breast and cervical cancer  
4 screening and malignancy; 3) cardiovascular and cerebrovascular disease; 4) diabetes; 5)  
5 **INFECTIOUS DISEASES (I.E., COVID-19, INFLUENZA, HIV/AIDS);** ~~HIV/AIDS;~~  
6 and 6) child and adult immunizations. In addition, serious disparities exist in the provision of  
7 care for mental health problems, substance abuse and suicide prevention.

8 The American Osteopathic Association calls for the following actions to be taken to address  
9 minority health disparities and to improve cultural competency of its physician members:

- 10 1. ~~The creation of a forum~~ **THE EDUCATION OF PHYSICIANS REGARDING**  
11 ~~ABOUT to increase physician knowledge on~~ racial and ethnic healthcare needs,  
12 including disparities in the areas listed above;
- 13 2. ~~The elimination of provider stereotypical beliefs~~ **BIASES AMONG HEALTH CARE**  
14 ~~PROFESSIONALS~~ **THE PROMOTION OF EDUCATION REGARDING**  
15 **IMPLICIT OR EXPLICIT BIASES AMONG HEALTHCARE**  
16 **PROFESSIONALS** that may play a role in clinical decision-making;
- 17 3. The evaluation and analysis of medical information which would permit the targeting of  
18 populations who are at greatest risk;
- 19 4. The identification of new methods to involve physician members in the communities in  
20 which they serve;
- 21 5. The identification and integration of available resources to better serve minority  
22 communities, including houses of worship, schools and local government;
- 23 6. The inclusion of cultural competency training throughout the continuum of osteopathic  
24 education;
- 25 7. The development of strategies to actively recruit underrepresented minority physicians  
26 into the profession in both primary care and subspecialties;
- 27 8. The development of approaches to encourage all physicians to provide care to  
28 underserved minority populations;
- 29 9. The adoption of strategies to assist physicians to effectively communicate with their  
30 patients, addressing translation and other barriers to patient understanding.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H434-A/15 INFANT WALKER (MOBILE) – BAN ON THE  
MANUFACTURE, SALE AND USE OF

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H434-A/15 INFANT WALKER (MOBILE) – BAN ON THE MANUFACTURE,**  
5 **SALE AND USE OF**

6 The American Osteopathic Association supports the ban on the manufacture, sale and use of  
7 mobile infant walkers; and urges osteopathic physicians to educate parents and other caregivers  
8 on the risks associated with the use of these devices. 2003; revised 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

Infant Walker–Related Injuries in the United States Ariel Sims, Thitphalak Chounthirath, Jingzhen  
Yang, Nichole L. Hodges and Gary A. Smith Pediatrics October 2018, 142 (4) e20174332; DOI:  
<https://doi.org/10.1542/peds.2017-4332>

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

---

DATE: **October 14, 2020**

---

SUBJECT: H435-A/15 DEVELOP IN-VITRO FERTILIZATION STANDARDS OF CARE

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H435-A/15 DEVELOP IN-VITRO FERTILIZATION STANDARDS OF CARE**  
5 The American Osteopathic Association supports the appropriate and evidenced based use of  
6 in-vitro fertilization in a manner that promotes the health and safety of both the mother and  
7 embryo; and supports the ethical guidelines for the practice of in-vitro fertilization ~~set by the~~  
8 ~~American Society of Reproductive medicine~~ that include, but are not limited to, the appropriate  
9 number of embryos implanted per patient. 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H436-A/15 COMPLEMENTARY AND ALTERNATIVE MEDICINE  
BY NON-PHYSICIANS

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRM as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H436-A/15 COMPLEMENTARY AND ALTERNATIVE MEDICINE BY –**  
5 **CULTURAL SENSITIVITY TO AND AWARENESS OF**

6 The American Osteopathic Association (1) encourages its members to become knowledgeable  
7 about complementary and alternative medicine; (2) encourages its members to discuss the use  
8 of complementary and alternative medicine with their patients in a respectful and culturally  
9 sensitive manner; ~~AND~~ (3) encourages the continued performance of well-designed, evidence-  
10 based research on the efficacy and safety of complementary and alternative medicine. ; ~~and (4)~~  
11 ~~opposes all attempts to permit non-physicians to gain practice rights or expand their scope of~~  
12 ~~practice to include complementary and alternative medicine practices.~~ **AND (4) OPPOSES**  
13 **ALL ATTEMPTS TO PERMIT NON-DO/MD PHYSICIANS TO GAIN**  
14 **ADDITIONAL PRACTICE RIGHTS OR EXPAND THEIR SCOPE OF PRACTICE**  
15 **TO INCLUDE COMPLEMENTARY AND ALTERNATIVE MEDICINE**  
16 **PRACTICES.** 2010; reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

This statement was added back into H431 because AOA should strongly oppose any expansion of scope of practice from non-physicians.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Bureau of Osteopathic Research and Public Health)*

DATE: **October 14, 2020**

SUBJECT: H437-A/15 CONTINUED SUPPORT OF COMBATING BIO-TERRORISM ACTIVITIES

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H437-A/15 CONTINUED SUPPORT OF COMBATING BIO-TERRORISM**  
5 **ACTIVITIES**

6 The American Osteopathic Association ~~recommends the continued support~~ of any and all  
7 constitutionally legal efforts to prevent and respond to future acts of bio-terrorism in the  
8 United States. 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H438-A/15 CHILDHOOD OBESITY – WORSENING EPIDEMIC IN  
THE AMERICAN SOCIETY

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H438-A/15 CHILDHOOD OBESITY – WORSENING EPIDEMIC IN THE**  
5 **AMERICAN SOCIETY**

6 The American Osteopathic Association ENCOURAGES ~~will makes efforts to educate~~ schools  
7 and vending machine suppliers TO INCLUDE ~~of the need of~~ healthy choice snacks IN  
8 VENDING MACHINES; and supports the limited use of vending machines in schools to  
9 avoid unnecessary caloric intake. 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**



SUBJECT: H439-A/15 IMMUNIZATIONS – MAINSTAY OF PREVENTIVE  
MEDICAL PRACTICE

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H439-A/15 IMMUNIZATIONS – MAINSTAY OF PREVENTIVE MEDICAL**  
5 **PRACTICE**

6 The American Osteopathic Association will create stronger ties with pro-immunization groups  
7 within and outside the osteopathic profession; and whenever possible, will assist these pro-  
8 immunization groups with appropriate evidence-based information regarding the safety of  
9 immunizations and significant positive effects of the proper use of immunizations relative to  
10 the overall public safety. 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H440-A/15 TEXTING WHILE DRIVING

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H440-A/15 TEXTING WHILE DRIVING**

5 The American Osteopathic Association supports efforts to educate all drivers concerning the  
6 dangers of texting and driving and supports efforts to ban the use of texting while driving.  
7 2010; reaffirmed 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H442-A/15 SILVER ALERT SYSTEM

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H442-A/15 SILVER ALERT SYSTEM**

5 The American Osteopathic Association supports the formation of a “Silver Alert” System on a  
6 national level to notify communities of missing persons with mental disabilities, particularly  
7 seniors with cognitive or developmental impairments. 2010; reaffirmed 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H443-A/15 NATIONAL INSTITUTES OF HEALTH GRANTS

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommends that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H443-A/15 NATIONAL INSTITUTES OF HEALTH (NIH) - GRANTS**

5 The American Osteopathic Association encourages osteopathic physicians, osteopathic medical  
6 schools, and their affiliated institutions to pursue NIH funding for biomedical research; and  
7 requests that the NIH include osteopathic medical schools in the overall United States medical  
8 school funding reports and also to include a category specific to Osteopathic  
9 MANIPULATIVE TREATMENT (OMT) IN THE ESTIMATES OF FUNDING FOR  
10 VARIOUS RESEARCH, CONDITION, AND DISEASE CATEGORIES (RCDC) among  
11 ~~the Research Condition and Disease Categories~~ reported each year to Congress and the  
12 American public. 2010; reaffirmed 2015

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H444-A/15 SCREENING FOR BREAST CANCER

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H444-A/15 SCREENING FOR BREAST CANCER**

5 The American Osteopathic Association recognizes and promotes the importance of the  
6 integrity of the patient-physician relationship and recommends that breast cancer clinical  
7 preventive screenings and coverage be individualized to the extent possible for every patient.  
8 2010; reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H445-A/15 GENDER IDENTITY NON-DISCRIMINATION

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H445-A/15 GENDER IDENTITY NON-DISCRIMINATION**

5 The American Osteopathic Association supports the provision of adequate and medically  
6 necessary treatment for transgender and gender-variant people and opposes discrimination on  
7 the basis of gender identity. 2010; reaffirmed 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: H446-A/15 TRAUMATIC BRAIN INJURY AWARENESS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H446-A/15 TRAUMATIC BRAIN INJURY AWARENESS**

5 The American Osteopathic Association (**AOA**) believes that osteopathic physicians should be  
6 aware of and utilize “best practices” when caring for victims of civil or military conflicts, or  
7 natural or man-made disasters, including civilians, returning veterans and their families,  
8 particularly those with traumatic brain injury (TBI); and the AOA will work in conjunction with  
9 state, specialty and regional societies to provide educational programs to advance this goal.  
10 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H448-A/15 SUPPORT FOR FAMILY CAREGIVERS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H448-A/15 SUPPORT FOR FAMILY CAREGIVERS**

5 The American Osteopathic Association, recognizing a growing number of family caregivers  
6 have unaddressed needs related to personal health and wellbeing, supports caregivers by  
7 participating in the developing public debate regarding health care policy to include family  
8 caregivers and encourages its members to gain education in caregiver illnesses, resources in their  
9 area and treat and/ refer when appropriate. 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**



SUBJECT: H450-A/15 FIREARM VIOLENCE

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 RESOLVED, that the Bureau on Federal Health Programs recommends that the following  
2 policy be ~~SUNSET~~ **REAFFIRMED**.

3 (Old language is crossed out and new language is in CAPS)

4 **H450-A/15 FIREARM VIOLENCE**

5 The American Osteopathic Association (AOA) (1) supports the federal government's January  
6 2013 clarification, "that no federal law in any way prohibits doctors or other health care  
7 providers from reporting their patients' threats of violence to the authorities, and issuing  
8 guidance making clear that the Affordable Care Act does not prevent doctors from talking to  
9 patients about gun safety;" (2) supports funding for the Centers for Disease Control and  
10 Prevention (CDC), the National Institutes of Health (NIH) and other research entities to  
11 conduct research on firearm violence and to provide recommendations on reducing firearm  
12 violence; (3) supports promotion of policies that will increase access to mental health services  
13 and for the appropriate coverage of mental health services by public and private health care  
14 programs; and (4) encourages enhanced education of gun safety and safe handling of firearms;  
15 and (5) approves the attached Policy Statement on Firearm Violence. 2013; revised 2015

16 **AOA Policy Statement – Firearm Violence**

17 The American Osteopathic Association (AOA) is dedicated to preventing violence in our communities,  
18 especially the increased prevalence of firearm violence. As physicians, we see first-hand the devastating  
19 consequences of violence to victims and their families. The AOA recognizes that laws, regulations, and  
20 policies have the potential to decrease the occurrence of violence, especially firearm violence, in our  
21 communities. The AOA supports:

22 **Preserving the Ability of Physicians to Educate and Counsel their Patients on Firearm Violence**

23 Preserving the rights of physicians and other health care professionals to counsel patients on  
24 prevention, including the prevention of injury or death as a result of firearms is critical. Physicians play  
25 an important role in preventing firearm injuries through health screenings, patient counseling, and  
26 referral to mental health services. The AOA supports the Administration's January 2013 clarification,  
27 "that no federal law in any way prohibits doctors or other health care providers from reporting their  
28 patients' threats of violence to the authorities, and issuing guidance making clear that the Affordable  
29 Care Act does not prevent doctors from talking to patients about gun safety." We must ensure that no  
30 federal or state law hinders, restricts, or criminalizes the patient-physician relationship.

31 **Advancing Research to Reduce Firearm Violence**

32 Advancing research to reduce firearm violence is a public health issue that deserves the allocation of  
33 appropriate resources. The AOA supports funding for the Centers for Disease Control (CDC) and  
34 Prevention, the National Institutes of Health (NIH), and other research entities to conduct research on  
35 firearm violence and to provide recommendations on reducing firearm violence.

36 **Improving Access to Mental Health Services and Resources**

1 Improving access to mental health services and resources is essential to reducing firearm violence. The  
2 AOA supports promotion of policies that will increase access to mental health services and for the  
3 appropriate coverage of mental health services by public and private health care programs. Access to  
4 mental health services and resources for young adults should be a priority. The early identification of  
5 diagnosable mental health issues and subsequent treatment is vital to reducing firearm violence.

Explanatory Statement: Submitted by Author

As per H437-A/19 FIREARM VIOLENCE The American Osteopathic Association (AOA) will develop a comprehensive policy which consolidates all current firearm violence policies into a single unified policy and present it for consideration by the 2020 AOA House of Delegates. 2019

Explanatory Statement: Reference Committee

H448/2020 FIREARMS POLICY requires that all firearms policies “should be maintained and taken up for review and reconsideration by the House of Delegates on an individual basis.” Therefore, H442 should be reaffirmed.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H437-A/19 FIREARM VIOLENCE

**Prior HOD action on similar or same topic:** Policy approved in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: ADDRESSING POLICE USE OF DISPROPORTIONATE FORCE  
AGAINST AFRICAN AMERICANS AND OTHER MARGINALIZED  
POPULATIONS AS AN EMERGING NATIONAL PUBLIC HEALTH  
ISSUE

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, according to the study published April 2019 by The Proceedings of the National  
2 Academies of Sciences, in the U.S., police violence is a leading cause of death for  
3 minority populations such as African American, American Indian and Alaskan Natives;  
4 with African American males having the highest incidence rate, facing a 1 in 1,000-  
5 lifetime risk of being killed during a police encounter, which is 2.5 times higher than  
6 their white male counterparts<sup>3</sup>; and

7 WHEREAS, deficiencies in internal policies and training<sup>4</sup>, coupled with lack of adherence to  
8 force continuum, requiring officers to prevent excessive force and de-escalate  
9 encounters, has created a window to limit the accountability of police force, resulting in  
10 increased mortality within already marginalized people of color <sup>3,5</sup>; and

11 WHEREAS, the American Public Health Association (AHPA) passed a policy in 2018  
12 acknowledging the current law enforcement system mediates the physical and  
13 psychological violence directed against marginalized populations that results in the  
14 disproportionate death, injuries and trauma of these marginalized populations, with  
15 these law-enforcement related deaths amounting to 54,754 years of life lost<sup>2</sup>; and

16 WHEREAS, the AOA approved policy H439-A/16 which states the AOA's support of "the  
17 protection of [LGBTQ] individuals from discriminating practices and harassment<sup>1</sup>; and  
18 reaffirmation of the equal rights and protections for all patient populations; and

19 WHEREAS, an AOA policy that specifically acknowledges gun-violence against marginalized  
20 populations would be concordant with the previously approved resolution H630-A/18  
21 resolving that the AOA joins like-minded organizations in the call for congressional  
22 legislation that labels gun violence as a national public health issue<sup>1</sup>; now, therefore be it

23 RESOLVED, that the American Osteopathic Association (AOA) acknowledges the  
24 disproportionate use of force by law enforcement against African Americans and other  
25 marginalized groups and its physical and mental health effects on communities.

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. AOA Policy Search. (n.d.). Retrieved from <https://osteopathic.org/about/leadership/policy-search/>.

2. AHPA, (2019, January 29). Addressing Law Enforcement Violence as a Public Health Issue. (n.d.). Retrieved from <https://www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2019/01/29/law-enforcement-violence>
3. Edwards, F., Lee, H., & Esposito, M. (2019, August 20). Risk of being killed by police use of force in the United States by age, race–ethnicity, and sex. Retrieved from <https://www.pnas.org/content/116/34/16793>.
4. Jackman, T. (2015, October 15). De-escalation training to reduce police shootings facing mixed reviews at launch. Available at: [https://www.washingtonpost.com/local/public-safety/de-escalation-training-to-reduce-police-shootings-facing-mixed-reviews-at-launch/2016/10/14/d6d96c74-9159-11e6-9c85-ac42097b8cc0\\_story.html](https://www.washingtonpost.com/local/public-safety/de-escalation-training-to-reduce-police-shootings-facing-mixed-reviews-at-launch/2016/10/14/d6d96c74-9159-11e6-9c85-ac42097b8cc0_story.html)
5. Obasogie, O. K., & Newman, Z. (2017, December 18). Police Violence, Use of Force Policies, and Public Health. Retrieved from <https://journals.sagepub.com/doi/full/10.1177/0098858817723665>

Explanatory Statement: Reference Committee

Refer back to SOMA to rewrite the Resolve statement to include the health implications of this policy.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Student Osteopathic Medical Association)*

DATE: **October 14, 2020**

SUBJECT: ADOPTING AND PROMOTING NON-STIGMATIZING LANGUAGE  
FOR SUBSTANCE USE DISORDERS

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, in a cross-cultural study on 18 of the most stigmatized conditions across 14  
2 countries, the World Health Organization determined substance use disorder to be the  
3 most stigmatized condition in the world<sup>1</sup>; and

4 WHEREAS, there are 20.8 million people in the United States struggling with a substance use  
5 disorder, yet only 10% receive help<sup>2</sup> despite the high prevalence of 14,500 treatment  
6 facilities<sup>3</sup> and 100,000 recovery support meetings across the nation<sup>4</sup>; and

7 WHEREAS, stigma is a commonly cited reason for not seeking treatment and recovery<sup>5</sup>; and

8 WHEREAS, research shows that stigmatizing language causes clinicians to have more  
9 pejorative attitudes and even to recommend punishment instead of treatments for this  
10 medical condition<sup>6</sup>; and

11 WHEREAS, the International Society of Addiction Journal Editors recommends against the  
12 use of terminology that can stigmatize people with substance abuse disorders<sup>7</sup>; and

13 WHEREAS, the Office of National Drug Control Policy issued a memorandum to the Heads  
14 of Executive Departments and Agencies about the importance of changing federal  
15 terminology related to substance use disorders<sup>8</sup>; and

16 WHEREAS, the American Osteopathic Association (AOA) has not yet issued a resolution to  
17 adopt and education members on the importance of non-stigmatizing language related  
18 to substance use disorders; and

19 WHEREAS, the AOA has shown a commitment to addressing substance use disorders through  
20 outreach, education modules<sup>9</sup>, and policy efforts<sup>10</sup>;

21 WHEREAS, the AOA’s 2019 policy compendium contained the word “abuse” in the context  
22 of substance use disorders 36 times throughout the written policies, not including  
23 language in citations or organizational names such as the National Institute of Drug  
24 Abuse – situations in which this word would have been reasonable<sup>10</sup>; now, therefore be  
25 it

26 RESOLVED, that the American Osteopathic Association (AOA) commit to the use of  
27 clinically- accurate, non-stigmatizing, person-first language (“substance use disorder,”  
28 “recovery,” “substance misuse,” “positive or negative urine screen,” and “person with a  
29 substance use disorder”) and discourage the use of stigmatizing terminology (“substance  
30 abuse,” “substance abuser,” “addict,” “alcoholic,” and “clean/dirty”) in future

1 publications, resolutions, and educational materials both in print and online; and, be it  
2 further

3 RESOLVED, that the AOA encourages its members and organizational partners to incorporate  
4 clinically-accurate, non-stigmatizing, person first language into their clinical practice.

Explanatory Statement: Submitted by Author

The following bibliography are the citations referenced in WHEREAS statements above.

References

1. Room, R., Rehm, J., Trotter, R.T., Paglia, A., & Üstün, T.B. (2001). Cross-cultural views on stigma valuation parity and societal attitudes towards disability. Üstün, T.B. (Ed.). Seattle, WA: Hofgrebe & Huber.
2. United States Department of Health and Human Services. (2016). Office of the Surgeon General, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington, DC.
3. National Institute on Drug Abuse. (2018). Principles of Drug Abuse Treatment: A Research Based Guide (Third Edition). Washington, DC.
4. Kelly, J.F. (2016, September). Addiction, Stigma, Treatment, Recovery. Talk presented at Massachusetts General Hospital Recovery Month; September 2016; Boston, Massachusetts.
5. Substance Abuse and Mental Health Services Administration. (2018). Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
6. Kelly, J.F., Westerhoff, C.M. (2010). Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. International Journal of Drug Policy, 21(3), 202-207.
7. International Society of Addiction Journal Editors website. (2015). Statements and Guidelines: Addiction Terminology. Retrieved October 5, 2019 from <http://www.isaje.net/addiction-terminology.html>.
8. Botticelli, M.P. Executive Office of the President of the United States. Memorandum to Heads of Executive Departments and Agencies: Changing Federal Terminology Regarding Substance Use and Substance Use Disorders. Washington, DC.
9. American Osteopathic Association website. (n.d.). Preventing Drug and Substance Use Disorders. Retrieved on October 5, 2019 from <https://osteopathic.org/practicing-medicine/providing-care/preventing-drug-use-disorders>
10. American Osteopathic Association website. (2019, September). American Osteopathic Association Policy Compendium 2019. Retrieved October 5, 2019 from <https://osteopathic.org/wp-content/uploads/2019-Policy-Compendium.pdf>.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: AOA RESPONSE TO NOVEL PUBLIC HEALTH THREATS

SUBMITTED BY: Maine Osteopathic Association

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, the United States Center for Disease Control and Prevention has attributed more  
2 than two million cases and one hundred and twenty thousand deaths in the U.S. as of  
3 June 2020 due to the COVID-19 pandemic, with more than nine million cases and  
4 nearly five hundred thousand deaths globally attributed to COVID-19 according to the  
5 World Health Organization; and

6 WHEREAS, more than twenty-eight thousand people were infected during the 2014-2016  
7 Ebola epidemic, with over eleven thousand deaths; and

8 WHEREAS, healthcare workers may be at a higher risk than the general population for  
9 infection to novel public health threats<sup>1</sup>; and

10 WHEREAS, medical providers around the world have experienced shortages of the equipment  
11 needed to properly test for, protect themselves and treat recent infectious disease; now,  
12 therefore be it

13 RESOLVED, that the American Osteopathic Association (AOA) will continue to serve as a  
14 trusted source of information and education for physicians, health professionals and the  
15 public relative to urgent, emergent and novel public health threats; and, be it further

16 RESOLVED, that the AOA will advocate for and support those responding to urgent,  
17 emergent and novel public health threats, including all healthcare workers and  
18 volunteers; and, be it further

19 RESOLVED that the AOA will advocate for proactive planning, improved public health  
20 infrastructure, disease threat surveillance and evidence-based responses to novel public  
21 health threats affecting the U.S. population.

Explanatory Statement: Submitted by Author

The following bibliography is the citation referenced in WHEREAS statements above.

<sup>1</sup>Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review. Ann Intern Med 2020;May 5:[Epub ahead of print]

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None



FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: BACKGROUND CHECKS AND FIREARMS SAFETY TRAINING AS A  
CONDITION OF FIREARMS PURCHASE

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, firearm-related deaths in the United States have increased to a twenty year high<sup>1</sup>;  
2 and

3 WHEREAS, nearly 40,000 people died in 2017 as a result of firearm-related violence, suicides,  
4 and accidents in the United States, the highest rate among industrialized countries<sup>2,3</sup>; and

5 WHEREAS, intentional suicide by discharge of firearms in the United States increased in 2017,  
6 totaling 23,854, compared to 22,938 in 2016<sup>4</sup>; and

7 WHEREAS, firearms are the third-leading cause of death due to injury after poisoning and  
8 motor vehicle accidents<sup>5,6</sup>; and

9 WHEREAS, 109 firearm deaths occur each day due to firearm-related homicides, suicides, and  
10 unintentional deaths<sup>7</sup>; and

11 WHEREAS, firearm-related violence in the United States had a total societal cost of \$229  
12 billion in 2015<sup>8</sup>; and

13 WHEREAS, in 2017, of the 25 million individuals who submitted to a background check to  
14 purchase or transfer possession of a firearm, 103,985 were by prohibited purchasers and  
15 were blocked from making a purchase<sup>9</sup>; an estimated 6.6 million firearms are sold  
16 annually with no background checks<sup>10</sup>; now, therefore, be it

17 RESOLVED, that the American Osteopathic Association (AOA) recognizes public health data  
18 demonstrating the impact of firearms on mortality and wellness in the United States and  
19 will support federal legislation requiring comprehensive background checks for all  
20 firearm purchases, including sales by gun dealers, sales at gun shows, and online sales  
21 for purchase, which does not extend to firearms transfers between family members or  
22 firearms attained through inheritance; and, be it further

23 RESOLVED, that the AOA will support efforts to require firearms safety training, including  
24 military or law enforcement training, as a condition to purchase any class of firearms;  
25 and be it further

26 RESOLVED, that H421-A/15 is superseded by this resolution.

Explanatory Statement: Submitted by Author

The intent of this policy is to supplement the following existing policies:

H630-A/18 Comprehensive Gun Violence Reform

H318-A/16 Firearms--Commission Of A Crime While Using A Firearm

H340-A/16 Physician Gag Rules--Opposition To

H450-A/15 Firearm Violence

H424-A/19 Firearm Safety

References

<sup>1</sup> Center for Disease Control and Prevention. WONDER Database. Underlying Cause of Death, 1999 – 2017.

<sup>2</sup> Id.

<sup>3</sup> Grinshteyn E, Hemenway D. Violent Death Rates: The US Compared with Other High-Income OECD Countries, 2010. *Am J Med.* 2016;129:266-73.

<sup>4</sup> National Vital Statistics Reports Volume 68, Number 9 June 24, 2019 Deaths: Final Data for 2017 Available at: [https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68\\_09-508.pdf](https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf)

<sup>5</sup> Centers for Disease Control and Prevention. Injury Prevention & Control: Data & Statistics (WISQARS). Atlanta, GA: Centers for Disease Control and Prevention; 2014.

<sup>6</sup> Centers for Disease Control and Prevention. Deaths: Final Data for 2016. Atlanta, GA: Centers for Disease Control and Prevention; 2018.

<sup>7</sup> Center for Disease Control and Prevention. WONDER Database. Underlying Cause of Death, 1999 – 2017.

<sup>8</sup> Follman M, Lurie J, Lee J, West J. The True Cost of Gun Violence in America. 15 April 2015.

<sup>9</sup> Federal Bureau of Investigation. National Instant Criminal Background Check System (NICS) Operations. 2017. Accessed at <https://www.fbi.gov/file-repository/2017-nics-operations-report.pdf/view>

<sup>10</sup> Cook PJ, Ludwig J. Guns in America: National Survey on Private Ownership and Use of Firearms. Washington, DC: U.S. Department of Justice, National Institute of Justice Research in Brief; May 1997.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H425-A/19 FIREARM SAFETY

**Prior HOD action on similar or same topic:** Policy reaffirmed as amended n 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: FENTANYL TESTING STRIPS

SUBMITTED BY: American Osteopathic Academy of Addiction Medicine

REFERRED TO: Committee on Public Affairs

---

- 1 WHEREAS, the American Osteopathic Association (AOA) has in place a broad policy  
2 supporting harm reduction for people who use drugs (PWUD) and/or patients with  
3 Substance Use Disorder (SUD); and
- 4 WHEREAS, the AOA makes no specific mention in their harm reduction policy of the benefits  
5 of fentanyl testing strips; and
- 6 WHEREAS, fentanyl testing strips have been demonstrated to be an inexpensive and effective  
7 method of harm reduction; and
- 8 WHEREAS, fentanyl testing strips are illegal to possess, often under "drug paraphernalia"  
9 statues in various states; now, therefore be it
- 10 RESOLVED, that the American Osteopathic Association (AOA) will **explicitly** support the  
11 universal legalization of fentanyl testing strips, both for Public Health initiatives, as well  
12 as personal use; and, be it further
- 13 RESOLVED, that the AOA strongly encourage the American Osteopathic Academy of  
14 Addiction Medicine (AOAAM) to maintain the above position.

Explanatory Statement: Submitted by Author

In 2016 overdose deaths involving illicitly manufactured fentanyl surpassed heroin and prescription opioid deaths in the US; the number grows. Fentanyl test strips may be an effective overdose prevention tool when included with other evidence-based treatments to prevent opioid overdoses.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: FIREARMS POLICY

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, the AOA House of Delegates adopted H437-A/19, Firearm Violence, which  
2 requires the American Osteopathic Association (AOA) to develop a comprehensive  
3 policy that consolidates all current firearm violence policies into a single unified policy  
4 and present it for consideration by the 2020 AOA House of Delegates; and

5 WHEREAS, consolidated, unified policies can have the unintended consequence of disrupting  
6 continuity of AOA policy; and

7 WHEREAS, background and history on a given topic can be lost through the consolidation and  
8 elimination of multiple policies into a single policy, making additions or changes to  
9 future policy more difficult; and

10 WHEREAS, having a broad array of policies on a given topic allows the AOA to accurately  
11 respond to federal and state legislative and regulatory concerns with nuanced and  
12 specific policy to reference; and

13 WHEREAS, the AOA risks having no policy relating to firearm violence should a portion of a  
14 single, consolidated policy on firearms be found to be no longer germane in future  
15 years; now, therefore, be it

16 RESOLVED, that the American Osteopathic Association (AOA) will develop a comprehensive  
17 white paper, which will include all current AOA policies relating to firearm violence,  
18 into a single, unified document which will be presented for review and consideration by  
19 the Bureau on Federal Health Policy (BFHP). This unifying white paper will be  
20 presented in lieu of a developing a single firearm violence policy resolution; and

21 RESOLVED, that H437-A/19 is superseded by this resolution; and

22 RESOLVED, that the AOA House of Delegates adopt the attached white paper which includes  
23 all current AOA policies relating to firearm violence.

24

1 **AOA Policy White Paper – Firearm Policy**

2 **Introduction**

3 The American Osteopathic Association (AOA) is dedicated to reducing the impact of violence on  
4 health and wellness in our communities, including injury and death that result from firearm violence. As  
5 physicians, we see firsthand the consequences of violence to victims and their families. The AOA  
6 recognizes that laws, regulations, and policies have the potential to decrease the occurrence of violence,  
7 especially firearm violence, in our communities.

8 Much of the AOA policy is predicated on an understanding of the role of firearms on public health in  
9 the United States. According to the Centers for Disease Control and Prevention (CDC), firearm-related  
10 deaths in the U.S. have increased to a twenty year high<sup>i</sup>. Additionally, nearly 40,000 people died in 2017  
11 as a result of firearm-related violence, suicides, and accidents in the U.S., the highest rate among  
12 industrialized countries<sup>iiii</sup>. Firearms are also the third-leading cause of death due to injury after  
13 poisoning and motor vehicle accidents<sup>ivv</sup>. CDC data also shows that 109 firearm deaths occur each day  
14 due to firearm-related homicides, suicides, and unintentional deaths<sup>vi</sup>. Beyond the impact on the health  
15 and well-being of Americans, there is an economic impact with gun violence in the U.S. costing \$229  
16 billion in 2015<sup>vii</sup>.

17 **Background**

18 **H437-A/19 FIREARM VIOLENCE** was adopted at the 2019 AOA House of Delegates meeting,  
19 which states that the “*American Osteopathic Association (AOA) will develop a comprehensive policy which*  
20 *consolidates all current firearm violence policies into a single unified policy and present it for consideration by the 2020*  
21 *AOA House of Delegates.*” This resolution was then referred to the Bureau on Federal Health Policy  
22 (BFHP) for development. After consideration of the request, the BFHP came to the conclusion that  
23 developing a single unifying policy sets a potentially problematic precedent in which background and  
24 history of a topic can be lost, and makes additions or changes to future policy more difficult.

25 Beyond setting a precedent, if part of the policy in future years is no longer germane, the full resolution  
26 could be in jeopardy, potentially effecting any and all related policies, which in this case could impact  
27 more than a half-dozen separate policies relating to firearms. Having a broad array of policies on a  
28 given topic allows AOA staff to accurately respond to federal and regulatory concerns with nuanced  
29 policy to reference.

30 With these concerns in mind, the BFHP thought it best that the AOA develop a comprehensive white  
31 paper, in lieu of a single firearm violence policy resolution, which includes all current AOA policies  
32 relating to firearm violence.

33 This white paper is intended to provide a complete and cohesive representation of current AOA policy  
34 relating to firearm violence and safety as of the 2019 AOA House of Delegates. This document is  
35 broken down by *Education, Research, and Miscellaneous*.

36 **Policies Preserving the Ability of Physicians to Educate and Counsel their Patients on Firearm**  
37 **Violence**

38 Preserving the rights of physicians and other health care professionals to counsel patients on  
39 prevention, including the prevention of injury or death, as a result of firearms is critical. Physicians play

1 an important role in preventing firearm injuries through health screenings, patient counseling, and  
2 referral to mental health services.

3 **Current Resolutions on Firearm Education:**

4 • **H425-A/19 FIREARM SAFETY**

5 The American Osteopathic Association (AOA) recommends that when appropriate,  
6 physicians ask patients and/or caregivers about the presence of firearms in the home  
7 and counsel patients who own firearms about the potential dangers inherent in gun  
8 ownership, especially if vulnerable individuals, children and adolescents are present. The  
9 AOA recommends strategies such as secure storage and the use of safety locks to  
10 eliminate the inappropriate access to firearms by vulnerable individuals, children and  
11 adolescents and recommends all physicians to educate families in the safe use and  
12 storage of firearms. 1994; revised 1999, 2004; reaffirmed 2009; 2014; reaffirmed as  
13 amended 2019

14 • **H421-A/15 FIREARMS AND NON-POWDERED GUNS – EDUCATION FOR**  
15 **USERS**

16 The American Osteopathic Association supports education involving firearm and non-  
17 powdered guns safety and the inherent risk, benefits and responsibility of ownership.  
18 1990; reaffirmed 1995, 2000, 2005; revised 2010; revised 2015 *[Editor's Note: Non-*  
19 *Powdered Guns are defined as: BB, air and pellet guns, expelling a projectile*  
20 *(usually made of metal or hard plastic) through the force of air pressure, CO2*  
21 *pressure, or spring action. Non-powder guns are distinguished from firearms,*  
22 *which use gunpowder to generate energy to launch a projectile.]*

23 • **H340-A/16 PHYSICIAN GAG RULES – OPPOSITION TO**

24 The American Osteopathic Association (AOA) is opposed to governmental actions and  
25 policies that limit the rights of physicians and other health care practitioners to inquire  
26 of their patients whether they possess guns and how they are secured in the home or to  
27 counsel their patients about the potential dangers of guns in the home and safe practices  
28 to attempt to avoid those potential dangers. The AOA opposes any further legislation  
29 or initiatives advocating physician gag rules that limit physicians' right to free speech or  
30 other rights. 2016

31 • **H428-A/19 PHYSICIAN-PATIENT RELATIONSHIP AS RELATED TO**  
32 **PROPOSED GUN CONTROL LAWS, PROTECTION OF THE**

33 While the American Osteopathic Association supports measures that save the  
34 community at large from gun violence, the AOA opposes public policy that mandates  
35 reporting of information regarding patients and gun ownership or use of guns except in  
36 those cases where there is duty to protect, as established by the Tarasoff ruling, for fear  
37 of degrading the valuable trust established in the physician-patient relationship. 2013;  
38 reaffirmed 2019

39 **Policies on Advancing Research to Reduce Firearm Violence**

40 Advancing research to reduce firearm violence is a public health issue that deserves the allocation of  
41 appropriate resources. The AOA supports funding for the Centers for Disease Control (CDC) and  
42 Prevention, the National Institutes of Health (NIH), and other research entities, to conduct research on  
43 firearm violence and to provide recommendations on reducing firearm violence.

1 **Current Resolutions on Firearm Research:**

2 • **H450-A/15 FIREARM VIOLENCE**

3 The American Osteopathic Association (AOA) (1) supports the federal government’s  
4 January 2013 clarification, “that no federal law in any way prohibits doctors or other health  
5 care providers from reporting their patients’ threats of violence to the authorities, and  
6 issuing guidance making clear that the Affordable Care Act does not prevent doctors from  
7 talking to patients about gun safety;” (2) supports funding for the Centers for Disease  
8 Control and Prevention (CDC), the National Institutes of Health (NIH) and other research  
9 entities to conduct research on firearm violence and to provide recommendations on  
10 reducing firearm violence; (3) supports promotion of policies that will increase access to  
11 mental health services and for the appropriate coverage of mental health services by public  
12 and private health care programs; and (4) encourages enhanced education of gun safety and  
13 safe handling of firearms; and (5) approves the attached Policy Statement on Firearm  
14 Violence. 2013; revised 2015

15 • **H630-A/18 COMPREHENSIVE GUN VIOLENCE REFORM**

16 The American Osteopathic Association joins like-minded organizations in the call for  
17 Congressional legislation that:

- 18 1. Labels gun violence as a national public health issue.
- 19 2. Funds appropriate research on gun violence as part of future federal budgets.
- 20 3. Establishes constitutionally appropriate restrictions on the manufacturing and sale,  
21 for civilian use, of large-capacity magazines and firearms with features designed to  
22 increase their rapid and extended killing capacity. 2018

23 **Current Miscellaneous Resolutions:**

24 • **Safety- H318-A/16 FIREARMS – COMMISSION OF A CRIME WHILE USING A**  
25 **FIREARM**

26 The American Osteopathic Association supports the position that persons accused of a  
27 crime involving a firearm be prosecuted to the full extent of the law. 1994; revised 1996,  
28 2001; reaffirmed 2006; reaffirmed as amended 2011; reaffirmed 2016

29 **Conclusion**

30 As noted above, the AOA House of Delegates adopted a policy that calls for the identification of all  
31 current firearm violence policies in a single document. This paper reflects that policy and highlights  
32 wide range of issues addressed in AOA firearm policies, with seven individual policies identified for  
33 inclusion in this paper. At least two resolutions (H425-A/19 and H421-A/15) support education and  
34 recommend safety precautions for gun owners. One (H340-A/16) opposes any governmental action  
35 that would limit the right of physicians to discuss gun owners and safe storage with their patients.  
36 Another (H428-A/19) opposes any mandated reporting of patient gun ownership. Two policies (H450-  
37 A/15 and H630-A/18) support federal funding for research on firearm violence. H630-A/18 also labels  
38 gun violence as a national public health issue and supports federal legislation that would establish  
39 constitutionally appropriate restrictions on the manufacturing and sale of certain classes of firearms.

40 There is a separate and distinct focus in most of these policies, with focus ranging from education, to  
41 protecting the rights of physicians, to support for research, and support for certain restrictions on sales.



- 1 As such, these policies, as well as any future firearm-related policies, should be maintained and taken up
- 2 for review and reconsideration by the House of Delegates on an individual basis.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H437-A/19 FIREARM VIOLENCE

**Prior HOD action on similar or same topic:** Policy approved in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** (*to Bureau on Federal Health Programs*)

DATE: **October 14, 2020**

---

<sup>i</sup> Center for Disease Control and Prevention. WONDER Database. Underlying Cause of Death, 1999 – 2017.

<sup>ii</sup> Id.

<sup>iii</sup> Grinshteyn E, Hemenway D. Violent Death Rates: The US Compared with Other High-Income OECD Countries, 2010. *Am J Med.* 2016;129:266-73.

<sup>iv</sup> Centers for Disease Control and Prevention. Injury Prevention & Control: Data & Statistics (WISQARS). Atlanta, GA: Centers for Disease Control and Prevention; 2014.

<sup>v</sup> Centers for Disease Control and Prevention. Deaths: Final Data for 2016. Atlanta, GA: Centers for Disease Control and Prevention; 2018.

<sup>vi</sup> Center for Disease Control and Prevention. WONDER Database. Underlying Cause of Death, 1999 – 2017.

<sup>vii</sup> Follman M, Lurie J, Lee J, West J. The True Cost of Gun Violence in America. 15 April 2015.

SUBJECT: HOMELESS SUPPORT

SUBMITTED BY: Osteopathic Physicians & Surgeons of California

REFERRED TO: Committee on Public Affairs

---

1 ~~WHEREAS, the state of California has a disproportionate share of homeless in the country;~~  
2 ~~and~~

3 WHEREAS, many people in the homeless community have experienced social, racial, and  
4 economic inequalities that contribute to medical, mental, and alcohol/drug addiction  
5 illnesses, which are often left untreated due to lack of access to health care resources;  
6 and

7 WHEREAS, as osteopathic physicians, we are trained in approaching population health and  
8 public health holistically, including addressing access to proper nutrition, hydration,  
9 thermal protection, shelter, and hygiene; and

10 ~~WHEREAS, the public health and population health issues of the entire homeless population~~  
11 ~~are providing a public health and population hazard to the community at large; and~~

12 ~~WHEREAS, the lack of affordable and available housing for the homeless during and after~~  
13 ~~implementation of comprehensive treatment programs has contributed to the~~  
14 ~~unprecedented rise in the nation's homelessness; and~~

15 WHEREAS, there are ~~current~~ ONGOING debates regarding cost effective housing programs  
16 which MAY include dormitory, group, and individual housing; and

17 WHEREAS, the lack of a comprehensive state ~~and~~ OR national strategy to address the  
18 homeless issues as a comprehensive population health and public health problemS and  
19 ~~medical problem~~ has resulted in significant numbers of those affected to have essentially  
20 LITTLE OR no medical care and little community support to treat their medical and  
21 psychiatric issues; and

22 WHEREAS, the American Osteopathic Association has previously stated their support of  
23 efforts aimed at addressing the root causes of homelessness in House resolution H-428  
24 – A/2018; now, therefore be it

25 RESOLVED, that the American Osteopathic Association (AOA) reaffirm support for ~~all~~ state  
26 and federal efforts, including efforts by private organizations, as well as those  
27 enumerated in the 2018 House of Delegates resolution number H-428 – A/2018, and  
28 that those efforts include addressing social determinants ~~of~~ AFFECTING health,  
29 substance abuse programs, mental health resources, clinical care programs and  
30 provision of stable housing for all homeless individuals that are seeking temporary or  
31 permanent shelter; ~~and, be it further~~

1           ~~RESOLVED~~, that the AOA, with the guidance of the Department of Educational  
2           ~~Affairs and any other relevant department(s)~~, develop recommendations for  
3           ~~curriculum and submit them to the Commission on Osteopathic College~~  
4           ~~Accreditation (COCA), American Association of Colleges of Osteopathic~~  
5           ~~Medicine (AACOM), National Board of Osteopathic Medical~~  
6           ~~Examiners(NBOME), Accreditation Council for Graduate Medical Education~~  
7           ~~(ACGME), and other educational entities at all levels of osteopathic medical~~  
8           ~~education, including undergraduate, postgraduate, and osteopathic continuing~~  
9           ~~medical education, in order to address healthcare issues related to clinical and~~  
10           ~~social aspects of homelessness and report to the AOA House of Delegates at its~~  
11           ~~July 2021 meeting.~~

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: MEDICAL AMNESTY FOR UNDERAGE CONSUMPTION OF ALCOHOL

SUBMITTED BY: American Osteopathic Academy of Addiction Medicine

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, state laws prohibit the consumption of alcohol below the age of twenty-one (21)  
2 years; and

3 WHEREAS, people aged 12 to 20 years drink 11% of all alcohol consumed in the United  
4 States; and

5 WHEREAS, underage drinkers and associated social contacts are often reticent to seek medical  
6 help for themselves or their ill peers for fear of legal reprisal, resulting in tragic and  
7 unnecessary deaths; now, therefore be it

8 RESOLVED, that legal immunity for the underage consumption of alcohol for those who  
9 consume alcohol underage and seek medical attention, as well as any “Good  
10 Samaritans” who aid in their seeking of medical attention, should be the *de jure* standard  
11 in each state, enacted into law by state legislatures; and, be it further

12 RESOLVED, that this legal immunity applies specifically and exclusively to the consumption of  
13 alcohol before the legal age, but *not* for any infractions or crimes committed while under  
14 the influence of alcohol or as a result of the consumption of alcohol (e.g. driving under  
15 the influence, physical altercations, etc.); and, be it further

16 RESOLVED, that the American Osteopathic Association (AOA) supports full legal immunity  
17 for these individuals, and urge state and national lawmakers to enact “Good Samaritan”  
18 laws to increase access to life-saving medical care for underage consumers of alcohol.

Explanatory Statement: Submitted by Author

Instances of excessive drinking involving the death of minors could be avoided if minors can seek medical assistance without fear of criminal charges, including manslaughter.

Explanatory Statement: Reference Committee

Refer back to the American Osteopathic Academy of Addiction Medicine for clarification.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** (*to American Osteopathic Academy of Addiction Medicine*)

DATE: **October 14, 2020**

SUBJECT: BREASTFEEDING WHILE ON MEDICATION ASSISTED TREATMENT (MAT) (Response to RES. NO. H-415 - A/2019, Referencing H-417-A/14 BREASTFEEDING WHILE ON METHADONE MAINTENANCE)

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, sunset resolution H-415 - A/2019, titled “BREASTFEEDING WHILE ON  
2 METHADONE MAINTENANCE”, was referred to the Bureau on Scientific Affairs  
3 and Public Health (BSAPH) to evaluate breastfeeding and other forms of medication  
4 assisted treatment (MAT) for opioid addiction, not just methadone; now therefore be it,  
5 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
6 attached white paper, titled, “BREASTFEEDING WHILE ON MEDICATION  
7 ASSISTED TREATMENT (MAT)”, and the recommendations within be adopted as  
8 policy.

9 **Breastfeeding While on Medication Assisted Therapy**

10 **Introduction**

11 Opioid use among pregnant women is a growing public health concern. In 2014, the Centers for Disease  
12 Control and Prevention (CDC) recorded a 333% national increase in opioid use disorder (OUD) among  
13 pregnant women, with 6.5 cases of opioid abuse per 1,000 hospital deliveries, compared to 1.5 cases in  
14 1999.<sup>1</sup> Opioid use during pregnancy is not uncommon; as many as 1 in 5 pregnant women enrolled in  
15 Medicaid filled an opioid prescription during their pregnancy.<sup>2</sup> Prenatal opioid exposure has been directly  
16 linked to adverse health outcomes for mothers and babies across the nation. These adverse health outcomes  
17 include increased maternal mortality and morbidity, poor fetal development, preterm births, still births, birth  
18 defects, and increased incidence of Neonatal Abstinence Syndrome (NAS).<sup>3</sup>

19 Studies have found that breastfeeding among women being treated for OUD offers many benefits that can  
20 mitigate the impacts of OUD for the mother and infant. Benefits include, but are not limited to, reduced  
21 hospital stays and decreased need for morphine treatment in infants born with NAS.<sup>4</sup>

22 **Opioid Use Disorder Treatment**

23 Medication Assisted Treatment, or MAT, is defined as the use of medications in combination with  
24 counseling and behavioral therapies to treat OUD and aid patients in sustaining their recovery.<sup>5</sup> MAT may  
25 be utilized with pregnant women to treat opioid use disorder and avoid the severe consequences associated  
26 with untreated opioid use disorder or stopping opioid usage too quickly. The U.S. Food and Drug  
27 Administration has approved three medications, buprenorphine, methadone, and naltrexone for OUD  
28 treatment.<sup>5</sup>

29 Naltrexone is the newest therapy approved by the U.S. Food and Drug Administration to treat opioid use  
30 disorder in pregnant women. Since it is also the least studied therapy, there is a research gap regarding the  
31 safety and effectiveness of naltrexone during pregnancy.<sup>6</sup> As a result, MAT for pregnant women commonly  
32 entails the use of methadone or buprenorphine with naloxone, in conjunction with coordinated care among  
33 behavioral therapists, OB-GYNs, and addiction specialists.<sup>7</sup> Both methadone and buprenorphine treatment

1 are endorsed by the American College of Obstetricians and Gynecologists and the American Society of  
2 Addiction Medicine as best practices for addressing opioid use during pregnancy.<sup>4</sup>

3 Methadone, a long-acting opioid agonist that decreases the desire to take opioids, was established as the  
4 standard of care in 1998 for treating OUD in pregnant women. The Substance Abuse and Mental Health  
5 Service Administration (SAMHSA) identified methadone as a safe drug to take while pregnant or preparing  
6 for pregnancy, along with counseling and participation in social support programs.<sup>8</sup>

7 Recently, The American Society of Addiction Medicine (ASAM) recognized Buprenorphine combined with  
8 Naloxone as the standard of care for the treatment of women who are pregnant or breastfeeding with  
9 OUD. The American Osteopathic Academy of Addiction Medicine (AOAAM) supports ASAM consensus  
10 that the combination of Buprenorphine and Naloxone is regularly used, safe, and effective.<sup>9</sup> Buprenorphine  
11 is the first medication to treat opioid use disorder that was authorized to be administered in physician  
12 offices, resulting in improved access to treatment.<sup>10</sup> Studies indicate that buprenorphine reduces fluctuations  
13 in fetal levels of opioids, minimizes repeated prenatal withdrawal, decreases overdoses, and limits drug  
14 interactions.<sup>10</sup>

15 Neonatal withdrawal, also called neonatal abstinence syndrome (NAS), is an anticipated and treatable  
16 condition caused by perinatal exposure to opioids, including methadone and the combination of  
17 buprenorphine with naloxone.<sup>11</sup> Although NAS may still occur in infants whose mothers receive MAT, the  
18 symptoms are milder than they would be without treatment.<sup>4</sup>

19 Postpartum, both infants and women on maintenance therapies can experience greater benefits through  
20 breast feeding. Although trace amounts of both methadone and buprenorphine have been found to seep  
21 into breast milk, research has shown that the benefits of breastfeeding outweigh the negligible risk  
22 associated with the medication that enters breast milk.<sup>8,10</sup>

### 23 **Breastfeeding**

24 Because of the associated benefits, exclusive breastfeeding, without other supplementation, is recommended  
25 for healthy women by both the American Academy of Pediatrics and the World Health Organization for the  
26 first 6 months of life.<sup>12,13</sup> Breastfeeding contributes to attachment between a woman and her infant,  
27 encourages skin-to-skin contact.<sup>11</sup> The antibodies and hormones found in breast milk defend the infant's  
28 immune system against illness and lower the risk of asthma, leukemia, childhood obesity, lower respiratory  
29 infections, eczema, diarrhea, vomiting, and Sudden Infant Death Syndrome.<sup>14</sup> Breastfeeding also improves  
30 the health of mothers post-delivery, simultaneously, lowering potential risk for diabetes, breast cancer, and  
31 ovarian cancer. Breast milk is also easier for infants to digest and cost efficient for parents.<sup>14</sup>

32 The American Academy of Pediatrics (AAP) recommendation applies to women who take methadone or  
33 buprenorphine as well, without regard for dosage.<sup>15</sup> Breastfeeding among women who are opioid dependent  
34 is also encouraged by both, the American College of Obstetricians and Gynecologists (ACOG) and the  
35 American College of Osteopathic Obstetricians and Gynecologists (ACOOG), as long as the women are  
36 taking methadone or buprenorphine consistently, abstaining from illicit drugs, and have no underlying  
37 complexities or conditions, such as human immunodeficiency virus (HIV) and or Hepatitis C with  
38 open/bleeding and cracked nipples.<sup>11</sup> Additionally, The ACOOG supports the ACOG committee review  
39 that women in the post-partum period who return to using street drugs and are not on stable OUD therapy  
40 should refrain from breastfeeding.<sup>16</sup> After 6 months, the AAP recommends continuation of breastfeeding,  
41 alongside introduction of complementary foods during the first year of life.<sup>12</sup>

42 In spite of these endorsements, less than 25% of mothers exclusively breastfeed for 6 months in the United  
43 States.<sup>12</sup> Formula supplementation of breast milk is commonly utilized. Supplementation is reportedly  
44 associated with many side effects that can lead to adverse infant and maternal outcomes. Formula  
45 supplements can negatively impact the “maternal milk supply, the duration of exclusive breastfeeding, and

1 the infant’s gut microbiome; alteration of the neonatal gut environment can be responsible for mucosal  
2 inflammation and disease, autoimmunity disorders, and allergic conditions in both childhood and  
3 adulthood”.<sup>17</sup>

4 The Centers for Disease Control and Prevention established the breastfeeding report card, which provides  
5 national data on breastfeeding rates, breastfeeding support indicators, and breastfeeding practices.<sup>12</sup> The  
6 breastfeeding report card indicates that, in 2015, 83.2% of infants were breastfed starting at birth, 57.6%  
7 were still breastfed at some level at 6 months, and 35.9% at 12 months.<sup>12</sup> This data suggests that “the early  
8 postpartum period is a critical time for establishing breastfeeding, but mothers may not be getting the  
9 support they need from health care providers, family members, and employers to meet their breastfeeding  
10 goals”.<sup>12</sup>

11 Uptake of breastfeeding is likely even lower among women with OUD. National Institute on Drug Abuse  
12 (NIDA) states that the rate of breastfeeding is normally “low” among mothers with OUD. Increased formal  
13 breastfeeding education, direct support for mothers, health care providers training on breastfeeding  
14 techniques, and peer support are all effective interventions that promote the start and sustainability of  
15 breastfeeding among mothers.<sup>18</sup>

### 16 **Conclusion**

17 Increasing rates of maternal opioid use during pregnancy and NAS are public health concerns. The  
18 utilization of MAT with methadone or buprenorphine has been approved as a safe mechanism for  
19 combatting opioid use during pregnancy and while breastfeeding.

20 Breastfeeding improves maternal and infant morbidity and mortality and decreases the impact of adverse  
21 health conditions. Breastfeeding infants who were exposed to opioids prenatally have the added advantage  
22 of lessening the impact of other conditions, such as NAS. Encouraging breastfeeding among mothers with  
23 exposure to opioids, who are undergoing MAT, is a significant step toward addressing OUD and NAS and  
24 improving maternal and child health. It shall be noted that the ACOOG and AOAAM supports the content  
25 of this paper and the policy recommendations outlined to encourage exclusive breastfeeding among  
26 mothers with a history of OUD.

### 27 **American Osteopathic Association Policy**

28 Given the research surrounding the positive impact of breastfeeding, the American Osteopathic Association  
29 adopts the following policy statements as its official position on breastfeeding among mothers with  
30 exposure to opioid use disorder in the United States:

- 31 1. The American Osteopathic Association (AOA) acknowledges that exclusive breastfeeding  
32 significantly improves maternal and infant health outcomes.
- 33 2. The American Osteopathic Association supports methadone and buprenorphine/naloxone assisted  
34 treatment as standards of care for addressing opioid use disorder during pregnancy and in the  
35 postpartum period.
- 36 3. The American Osteopathic Association (AOA) encourages exclusive breastfeeding among mothers  
37 with a history of Opioid Use Disorder (OUD), who are under physician care, actively engaged in a  
38 recovery program, on appropriate opioid agonists (methadone or buprenorphine), abstaining from  
39 illicit drugs, and who have no other contraindications, such as human immunodeficiency virus  
40 (HIV) infection and or Hepatitis C with open/bleeding and cracked nipples.
- 41 4. The American Osteopathic Association (AOA) recommends the use of counseling, coordination of  
42 care, and social support for mothers during pregnancy and breastfeeding in the postpartum period.

### 43 **References:**

44 <sup>1</sup> Haight SC, KO JY, Tong VT, Bohm MK, Callaghan WM. *Opioid Use Disorder Documented at Delivery*  
45 *Hospitalization – United States, 199-2014*. MMWR Morb Mortal Wkly Rep 2018; 67:845-849

- 1   <sup>2</sup> Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. *Increase in Prescription Opioid Use During*  
2   *Pregnancy Among Medicaid-Enrolled Women*. *Obstetric Gynecology* 2014; 123-997-1002.
- 3   <sup>3</sup> Jilani SM, Frey MT, Pepin D, et al. *Evaluation of State – Mandated Reporting of Neonatal Abstinence Syndrome*  
4   *– Six States, 2013 – 2017*. *MMWR Morb Mortal Wkly Rep* 2019; 68; 6-10
- 5   <sup>4</sup> National Institute on Drug Abuse. *Treating Opioid Use Disorder During Pregnancy*. (2017); Retrieved From  
6   [https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/treating-](https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/treating-opioid-use-disorder-during-pregnancy#ref)  
7   [opioid-use-disorder-during-pregnancy#ref](https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/treating-opioid-use-disorder-during-pregnancy#ref)
- 8   <sup>5</sup> U.S. Food and Drug Administration. *Information about Medication Assisted Treatment – MAT*. (2020);  
9   Retrieved from [https://www.fda.gov/drugs/information-drug-class/information-about-medication-](https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat)  
10   [assisted-treatment-mat](https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat)
- 11   <sup>6</sup> National Institute on Drug Abuse. *Could Naltrexone Be Used to Treat Pregnant Women with Opioid*  
12   *Addiction*. (2018); Retrieved From [https://www.drugabuse.gov/about-nida/noras-blog/2018/02/could-](https://www.drugabuse.gov/about-nida/noras-blog/2018/02/could-naltrexone-be-used-to-treat-pregnant-women-opioid-addiction)  
13   [naltrexone-be-used-to-treat-pregnant-women-opioid-addiction](https://www.drugabuse.gov/about-nida/noras-blog/2018/02/could-naltrexone-be-used-to-treat-pregnant-women-opioid-addiction)
- 14   <sup>7</sup> Centers for Disease Control and Prevention. *Basics About Opioid Use During Pregnancy*. 2019; Retrieved  
15   From <https://www.cdc.gov/pregnancy/opioids/basics.html>
- 16   <sup>8</sup> Substance Abuse and Mental Health Services Administration. *Methadone*. (2020); Retrieved From  
17   <https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone>
- 18   <sup>9</sup> The American Society of Addiction Medicine. *The ASAM National Practice Guideline for the Treatment of*  
19   *Opioid Use Disorder 2020 Focused Update*. 2020. Page 51 Received From  
20   [https://www.asam.org/docs/default-source/quality-science/npg-jam-](https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2)  
21   [supplement.pdf?sfvrsn=a00a52c2\\_2](https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2)
- 22   <sup>10</sup> Substance Abuse and Mental Health Services Administration. *Buprenorphine*. (2019); Retrieved From  
23   <https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine>
- 24   <sup>11</sup> The American College of Obstetricians and Gynecologists. *Opioid Use and Opioid Use Disorder in*  
25   *Pregnancy*. (2017). Retrieved From [https://www.acog.org/clinical/clinical-guidance/committee-](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy)  
26   [opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy)
- 27   <sup>12</sup> Centers for Disease Control and Prevention. *Breastfeeding Report Card*. (2018). Retrieved From  
28   <https://www.cdc.gov/breastfeeding/data/reportcard.htm>
- 29   <sup>13</sup> The World Health Organization. *Exclusive Breastfeeding for Optimal Growth, Development, and Health of*  
30   *Infants*. (2020); Retrieved From <https://www.who.int/elena/titles/exclusive-breastfeeding/en/>
- 31   <sup>14</sup> U.S. Department of Health & Human Services. Office on Women’s Health. *Making the Decision to*  
32   *Breastfeed*. (2020). Retrieved From [https://www.womenshealth.gov/breastfeeding/making-decision-](https://www.womenshealth.gov/breastfeeding/making-decision-breastfeed)  
33   [breastfeed](https://www.womenshealth.gov/breastfeeding/making-decision-breastfeed)
- 34   <sup>15</sup> The American College of Obstetricians and Gynecologists. *Opioid Use and Opioid Use Disorder in*  
35   *Pregnancy*. (2017). Retrieved From [https://www.acog.org/clinical/clinical-guidance/committee-](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy)  
36   [opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy)
- 37   <sup>16</sup> Committee on Obstetric Practice. Committee Opinion No. 711: *Opioid Use and Opioid Use Disorder in*  
38   *Pregnancy*. *Obstetric Gynecol*. 2017;130(2): e81-e94. doi:10.1097/AOG.0000000000002235



1 <sup>17</sup> Walker, Formula Supplementation of Breastfed Infants: Helpful or Hazardous? *ICAN: Infant, Child,*  
2 *& Adolescent Nutrition*, (2015) 7(4), 198–207. <https://doi.org/10.1177/1941406415591208>

3 <sup>18</sup> Agency for Health Care Research and Quality. Rockville, MD. *Section 2.0 Recommendations for Adults.*  
4 (2014) Retrieved From <https://www.ahrq.gov/prevention/guidelines/guide/section2.html>

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:**

H428-A/17 BREASTFEEDING – PROMOTION, PROTECTION AND SUPPORT OF  
H425-A/18 BREASTFEEDING EXCLUSIVITY

**Prior HOD action on similar or same topic:** H428-A/17 policy revised in 2017; H425-A/18 policy reaffirmed as amended 2018

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: REFERRED SUNSET RES. NO. H-411 - A/2019: H413-A/14 EPIDEMIC  
TERRORIST ATTACK VICTIMS, GOVERNMENT  
RESPONSIBILITY OF HEALTH CARE

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, the AOA House of Delegates referred sunset resolution H-411-A/2019 titled  
2 H413-A/14 EPIDEMIC TERRORIST ATTACK VICTIMS, GOVERNMENT  
3 RESPONSIBILITY OF HEALTH CARE to the Bureau on Federal Health Programs  
4 for “clarity on who should be included, who will benefit, definition of terrorist act, and  
5 if this is a national or international policy; now, therefore be it

6 RESOLVED, that the Bureau on Federal Health Programs recommend that the following  
7 policy be REAFFIRMED as AMENDED:

8 **H413-A/14 ~~EPIDEMIC~~ DOMESTIC OR FOREIGN TERRORIST ATTACK**  
9 **VICTIMS, GOVERNMENT RESPONSIBILITY OF HEALTH CARE**

10 The American Osteopathic Association SUPPORTS **ALL HEALTHCARE PERSONNEL**  
11 **AND FIRST RESPONDERS AND** ~~believes that victims of an epidemic~~ DOMESTIC OR  
12 FOREIGN terrorist attacks (e.g., anthrax) ~~are victims of a new age conflict against America and~~  
13 ~~as victims of an attack against America; they~~ IN THE UNITED STATES BEING ~~should be~~  
14 eligible for healthcare TREATMENT STEMMING FROM THE ACT to be covered by the  
15 United States Government. 2004; reaffirmed as amended 2009; reaffirmed 2014

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: H429 A/14 MINORITIES, UNDERREPRESENTED (URM) –  
INCREASING NUMBERS OF APPLICANTS, GRADUATES, AND  
FACULTY AT COLLEGES OF OSTEOPATHIC MEDICINE

SUBMITTED BY: Bureau of Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS sunset resolution. H-421 – A/2019 titled “MINORITIES,  
2 UNDERREPRESENTED (URM) – INCREASING NUMBERS OF APPLICANTS,  
3 GRADUATES, AND FACULTY AT COLLEGES OF OSTEOPATHIC  
4 MEDICINE”, was referred to the Bureau of Scientific Affairs and Public Health for an  
5 analysis of the statistics to determine if the target deadline should be extended; now,  
6 therefore be it

7 RESOLVED, that the Bureau of Scientific Affairs and Public Health recommends that  
8 the following policy be REAFFIRMED AS AMENDED:

9 **H429 A/14 MINORITIES, UNDERREPRESENTED (URM) – INCREASING**  
10 **NUMBERS OF APPLICANTS, GRADUATES, AND FACULTY AT**  
11 **COLLEGES OF OSTEOPATHIC MEDICINE**

12 The American Osteopathic Association encourages an increase in the total number of URM<sup>1</sup>  
13 graduates from colleges of osteopathic medicine by the year ~~2020~~ **2025** and encourages an  
14 increase in the total number of URM faculty by the year ~~2025~~ ~~2020~~. 2014

Explanatory Statement: Submitted by Author

**INTRODUCTION**

It is widely accepted that increasing racial and ethnic diversity among health professionals is associated with improved health outcomes for racial and ethnic minority patients, greater patient satisfaction, and better educational experiences for medical students.

Despite this widespread recognition, in 2017, the Health Resources and Services Administration (HRSA) Bureau of Health Workforce reported that “all minority groups, except Asians, are underrepresented in Health Diagnosis and Treating occupations.”<sup>2</sup> Osteopathic physicians and faculty are included in these occupations.

**PROGRESS**

The American Osteopathic College of Osteopathic Medical Application Service (AOCOMAS) publication, titled, “AACOMAS Applicants to Osteopathic Medical Schools by Race and Ethnicity”, tabulated the number and percentage of Underrepresented Minorities (URM). The report states that in academic year 2013-14, 11.7% and 2019-20, 17.0% identified as URM. Thus, there was an absolute increase of 5.3% in the applications submitted from URM over 6 years.<sup>3</sup>

While there was an improvement in the application rate of URM to osteopathic colleges, the same was not observed in the graduation rate. The American Association of Colleges of Osteopathic Medicine

(AACOM) publication, “Graduates of US Osteopathic Medical School by Race/Ethnicity”, reported that for the academic year 2011-12, 8.4% of graduates identified as Hispanic/Latino; American Indian and Alaskan Native, non-Hispanic; Black/African American, non-Hispanic; Pacific Islander, non-Hispanic. In 2017-18, the most recent data, 8.2% of graduates identified as the same ethnic and racial groups. In other words, over a 6-year period, the proportion of medical school graduates, who identified as belonging to an URM group, had an absolute decline of 0.2%.<sup>4</sup>

Additionally, according to the most recent AACOM reports titled, “2012-13 Osteopathic Medical College Faculty by Race/Ethnicity”<sup>5</sup> and “2016-17 Osteopathic Medical College Faculty by Race/Ethnicity”<sup>6</sup>, there were 1,164 of a total 37,197 (3.1%) faculty in academic year 2012-13, and 1,710 of a total 46,848.39 (3.6%) faculty in academic year 2016-17 who identified as Hispanic, American Indian/Alaskan Native, non-Hispanic; Black/African American, non-Hispanic; and Pacific Islander, non-Hispanic. Thus, the absolute change in faculty employed at an osteopathic college was 0.5% over the 4-year period.

## **CONCLUSION/RECOMMENDATIONS**

There has been modest progress in increasing the proportion of applicants and faculty at osteopathic medical schools who identify as URM, current statistics are far from that of the general population. There has been little improvement in the graduation rate among URM. Given that the proportion of racial and ethnic minorities in the United States exceeded 18% at the most recent Census and is progressively climbing, it is recommended that the AOA and the AACOM continue to prioritize the development of an osteopathic workforce that more closely represents the people served by the profession.

## **REFERENCES**

1. i.e., Hispanic/Latino ethnicity, Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander
2. (2017). Sex, Race, and Ethnic Diversity of U.S. Health Occupations (2011-2015). U.S. Department of Health and Human Services Health Resources and Services Administration, Bureau of Health Workforce National Center for Health Workforce Analysis. Retrieved 3 27, 2020, from <https://bhw.hrsa.gov/sites/default/files/bhw/nchwa/diversityushealthoccupations.pdf>
3. American Association of Colleges of Osteopathic Medicine. (2018). Applicants by Race and Ethnicity 1976-2019. Washington, DC: American Association of Colleges of Osteopathic Medicine. Retrieved 3 31, 2020, from <https://www.aacom.org/reports-programs-initiatives/aacom-reports/applicants>
4. American Association of Colleges of Osteopathic Medicine. (2015). Graduates by Race and Ethnicity 1985-2018. Washington, DC: American Association of Colleges of Osteopathic Medicine. Retrieved 3 31, 2020, from <https://www.aacom.org/reports-programs-initiatives/aacom-reports/graduates-and-gme>
5. American Association of Colleges of Osteopathic Medicine. (2014). 2012-13 Osteopathic Medical College Faculty by Race-Ethnicity. Washington, DC: American Association of Colleges of Osteopathic Medicine. Retrieved 3 31, 2020, from [https://www.aacom.org/docs/default-source/archive-data-and-trends/2012-13-com-facbyre.pdf?sfvrsn=ee416197\\_14](https://www.aacom.org/docs/default-source/archive-data-and-trends/2012-13-com-facbyre.pdf?sfvrsn=ee416197_14)
6. American Association of Colleges of Osteopathic Medicine. (2018). 2016-17 Osteopathic Medical College Faculty by Race/Ethnicity. Washington, DC: American Association of Colleges of Osteopathic Medicine. Retrieved 3 27, 2020, from [https://www.aacom.org/docs/default-source/data-and-trends/2016-17-osteopathic-medical-college-faculty-by-race-ethnicity.pdf?sfvrsn=1b12597\\_6](https://www.aacom.org/docs/default-source/data-and-trends/2016-17-osteopathic-medical-college-faculty-by-race-ethnicity.pdf?sfvrsn=1b12597_6)

Background Information: Provided by AOA Staff

**Current AOA Policy:**

H433-A/15 MINORITY HEALTH DISPARITIES

H323-A/19 MINORITIES IN THE OSTEOPATHIC PROFESSION – COLLECTING DATA

**Prior HOD action on similar or same topic:** 433-A/15 policy reaffirmed in 2015; H323-A/19 policy reaffirmed as amended in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: REGULATION OF E-CIGARETTES AND NICOTINE VAPING  
(Response to RES. NO. H - 424 - A/2019 referencing H - 435 - A/2014)

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, RES. NO. H-424 - A/2019 was referred to the Bureaus of Scientific Affairs and  
2 Public Health to update the white paper; now, therefore be it

3 RESOLVED, that the following policy paper and the recommendations provided within be  
4 adopted as the amended policy of the AOA.

5 **REGULATION OF E-CIGARETTES AND NICOTINE VAPING**

6 **BACKGROUND**

7 The adverse health effects associated with tobacco use are well documented public health concerns.  
8 Smoking can damage every human organ, and it can lead to death from heart disease, cancers or  
9 strokes. According to the World Health Organization (WHO), 1 in 10 deaths each year, or nearly 8  
10 million deaths around the world, are caused by tobacco use.<sup>1,2</sup> More than 7 million of those deaths are  
11 the result of direct tobacco use, while around 1.2 million are the result of non-smokers being exposed  
12 to second-hand smoke.<sup>2</sup> In the United States, this translates to 480,000 deaths per year from cigarette  
13 smoking and second-hand smoke exposure.<sup>3</sup>

14 In response to the negative health effects of tobacco products and cigarettes in particular, a natural  
15 market for smoking cessation and reduction products has emerged over the past 4 decades.<sup>4</sup> The use of  
16 electronic nicotine delivery systems (ENDS), such as electronic cigarettes (e-cigarettes), has reached a  
17 rapidly expanding consumer base.<sup>5</sup> E-cigarettes are often used or promoted to reduce consumption of  
18 tobacco products.<sup>6</sup> Alternative strategies for reaching smoking cessation goals include switching to low  
19 or light cigarettes or using nicotine-infused chewing gum, lozenges, lollipops, dermal patches or  
20 hypnosis.<sup>7</sup>

21 In the US, e-cigarettes are the most frequently utilized tobacco product among youth, who are also  
22 more likely than adults to use them. In 2019, over 5 million US middle and high school students had  
23 used e-cigarettes in the past 30 days.<sup>8</sup> In 2018, 3.2% of US adults were current e-cigarette users.<sup>9</sup>

24 The name e-cigarette is an umbrella term that includes any battery-powered device that vaporizes liquid  
25 nicotine for delivery via inhalation. These devices are most commonly referred to as electronic  
26 cigarettes, e-cigarettes, e-cigs, vaping, vape pens, vape pipes, hookah pens, e-hookahs, but could  
27 potentially be referred to by other terms. Since its 2007 introduction in the United States, the e-  
28 cigarette market has grown to include more than 460 brands.<sup>10</sup> E-cigarettes are a 2.5 billion dollar  
29 business in the United States.<sup>11</sup> The attraction to e-cigarettes crosses many segments of the population,  
30 appealing to tobacco cigarette smokers trying to quit as well as non-smokers who want to try nicotine  
31 without the harmful additives.<sup>12</sup> Though some states and municipalities have started to ban e-cigarettes,  
32 tobacco cigarette smokers can use e-cigarettes as a source of nicotine in some venues where  
33 conventional cigarettes are banned.

1 Costs associated with smoking-related illnesses continue to escalate. In 2014, smoking-related illness  
2 costs in the United States were more than \$300 billion each year, including approximately \$170 billion  
3 for direct medical care for adults, and more than \$156 billion in lost productivity. Nearly \$5.6 billion of  
4 the lost productivity cost was due to secondhand smoke exposure.<sup>13</sup>

5 Overall, e-cigarettes may be less harmful for heavy or moderate smokers because they may reduce  
6 exposure to carcinogens and other toxic chemicals that cause serious disease and death.<sup>14</sup> However, the  
7 effect of long term consumption of nicotine and associated aerosols remains unclear. Studies have  
8 shown that e-cigarette vapors may be harmful, particularly in places with limited ventilation and for  
9 people with compromised health. Furthermore, e-juice liquids have been found to increase accidental  
10 poisonings in children. The full scale of health and safety hazards of vaping for users and secondhand  
11 users is undetermined.<sup>15</sup>

## 12 ANALYSIS

13 Regulation of e-cigarettes by the Food and Drug Administration (FDA) only began in earnest in 2016.  
14 The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) provided the FDA  
15 authority to regulate the manufacture, marketing and distribution of tobacco products.<sup>16</sup> However, e-  
16 cigarettes were not initially included in the FDA’s regulation of tobacco products. Unlike tobacco  
17 cigarettes, e-cigarettes have enjoyed the ability to advertise on television and radio.<sup>17</sup> This allows e-  
18 cigarette companies to market their product in a more liberal fashion in response to market demands,  
19 including the use of celebrity endorsements.<sup>18</sup> However, some manufacturers have voluntarily begun to  
20 limit their advertising in an attempt to avoid federally imposed restrictions on advertising.

### 21 The Composition of E-Cigarettes

22 The e-cigarette is a smokeless, battery-powered device that vaporizes liquid nicotine for delivery via  
23 inhalation.<sup>19</sup> Using an e-cigarette may also be referred to as “vaping”, or as “juuling”, the branded form  
24 of flavored e-cigarettes popular among younger consumers. The e-cigarette contains nicotine derived  
25 from tobacco plant and several secondary chemical ingredients.<sup>20</sup> It is primarily composed of a nicotine  
26 cartridge, atomizer, and a battery.<sup>21</sup> The atomizer, which converts the nicotine liquid into a fine mist,  
27 consists of a metal wick and heating element.<sup>22</sup> When screwed onto the cartridge, the nicotine liquid  
28 from the cartridge, which could also include flavoring, comes into contact with the atomizer unit and is  
29 carried to the metal coil heating element.<sup>23</sup> A single cartridge can hold the nicotine equivalent of an  
30 entire pack of traditional cigarettes.<sup>24</sup> E-cigarettes can also be used to deliver marijuana and other  
31 drugs.<sup>25</sup>

32 While the typical e-cigarette is sold in the shape of a cigarette, many products are sold in the shape of  
33 discreet objects such as pipes, pens, lipsticks, and other everyday items.<sup>26</sup> Often, they can be legally used  
34 where traditional tobacco products are banned.

### 35 Federal Efforts to Regulate

36 In 2016, the FDA finalized a rule extending regulatory authority to cover all tobacco products,  
37 including electronic nicotine delivery systems (ENDS) that meet the definition of a tobacco product.<sup>27</sup>  
38 The FDA now regulates the manufacture, import, packaging, labeling, advertising, promotion, sale, and  
39 distribution of ENDS. Prior to this rule, the FDA could regulate e-cigarettes only if the manufacturer  
40 made a therapeutic claim, such as the product was being marketed as a cessation device.<sup>28</sup>

41 The rule established restrictions on youth access to newly regulated tobacco products by: (1) banning  
42 their sale to individuals younger than 18 years of age (federal legislation raised this to 21 years in 2019)

1 and requiring age verification via photo ID; and (2) prohibiting the sale of tobacco products in vending  
2 machines (unless in an adult-only facility).<sup>29</sup>

3 The Federal Food, Drug, and Cosmetic Act was signed into law on December 20, 2019, and raised the  
4 federal minimum age of sale for tobacco products from 18 to 21 years.<sup>30</sup> Retailers are now prohibited  
5 from selling tobacco products to anyone under the age of 21.

6 Further, in January 2020, the FDA banned all mint- and fruit-flavored e-cigarettes, but exempted  
7 menthol- and tobacco-flavored products, in an effort to target products widely used by minors while  
8 preserving an “off-ramp” for adults who are trying to quit smoking.<sup>31</sup>

9 Tobacco is a major threat to public health, and one of the goals of the FDA is to protect Americans  
10 from tobacco-related diseases and death. This rule allows the FDA to protect youth by restricting their  
11 access to tobacco products, helps consumers better understand the risks of using these products,  
12 prohibits false and misleading product claims, and prevents new tobacco products from being marketed  
13 unless a manufacturer demonstrates that the product meets relevant public health standards.

#### 14 State Efforts to Regulate

15 Various states and municipalities have also enacted laws restricting the sale of e-cigarettes.<sup>32</sup> Twenty-  
16 seven states, along with the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, and 1,107  
17 municipalities have passed laws that ban smoking in all non-hospitality workplaces, restaurants, and  
18 bars; of these, 22 states and 929 municipalities also restrict e-cigarette use in 100% smoke-free venues.<sup>33</sup>

19 In November 2019, **Massachusetts** became the first state to restrict the sale of *all* flavored tobacco  
20 products, including e-cigarettes and menthol cigarettes.<sup>34</sup> **New Jersey** prohibited the use of e-cigarettes  
21 in all enclosed indoor places of public access as well as in working places, and in January 2020, the state  
22 enacted legislation banning the sale of *all* flavored e-cigarettes.<sup>35,36</sup> In March 2020, **Rhode Island** also  
23 announced a permanent ban on the sale of flavored e-cigarettes.<sup>37</sup> Six other states (Michigan, Montana,  
24 New York, Oregon, Utah and Washington) temporarily banned the sale of flavored e-cigarettes in 2019,  
25 but of those, only Montana’s and Washington’s bans are currently in effect while the others are facing  
26 various legal challenges.<sup>38</sup>

27 As of 2019, twenty-three (23) states and the District of Columbia have enacted statutes which require  
28 licenses for retail sales of e-cigarettes.<sup>39</sup>

#### 29 Arguments for E-Cigarettes

30 Proponents of e-cigarettes consider e-cigarettes to be less harmful than traditional tobacco products  
31 and believe they increase adult smoking cessation.<sup>40</sup> While it has been established that e-cigarettes  
32 contain fewer carcinogenic elements than traditional tobacco cigarettes, the long-term health effects of  
33 e-cigarette use are unknown.<sup>41</sup> According to the American Lung Association there are approximately  
34 600 ingredients in cigarettes.<sup>42</sup> When burned, they create more than 7,000 chemicals.<sup>43</sup> At least 69 of  
35 these chemicals are known to cause cancer, and many are poisonous.<sup>44</sup> While e-cigarettes may have  
36 fewer component chemicals, a study found that the usage of e-cigarettes contributes to indoor air  
37 contamination.<sup>45</sup> A 2016 report from the WHO determined that second-hand aerosols from e-cigarettes  
38 are a new source of pollution for hazardous particulate matter (PM). The levels of nickel, chromium,  
39 and other metals found in second-hand aerosols are higher than ambient air and higher than second-  
40 hand tobacco smoke.<sup>46</sup>



1 The greatest appeal of e-cigarettes for smoking cessation is that they deliver nicotine to alleviate  
2 nicotine withdrawal symptoms. E-cigarettes evoke the psychological response to cigarette smoking  
3 because of its shape and the familiar behavior aspect of smoking.<sup>47</sup> A 2011 survey of 104 e-cigarette  
4 users revealed that 66% started using them with the intention to quit smoking and almost all felt that  
5 the e-cigarette had helped them to succeed in quitting smoking.<sup>48</sup> Another survey of 3,037 e-cigarette  
6 users revealed that 77% of respondents used e-cigarettes to quit smoking or to avoid relapse.<sup>49</sup> None  
7 said they used them to reduce consumption of tobacco with no intent to quit smoking.<sup>50</sup> However, the  
8 overall effectiveness of e-cigarettes is still in question. In a randomized study, participants given e-  
9 cigarettes, nicotine patches and placebo e-cigarettes that lacked nicotine were able to quit smoking at  
10 roughly the same rates, with insufficient statistical power to conclude superiority of nicotine e-  
11 cigarettes.<sup>51</sup>

## 12 Consequences of E-Cigarettes

13 Advocates of e-cigarettes contend that e-cigarettes are less risky than traditional tobacco products and  
14 can serve as a mode of harm reduction by reducing smoking or serving as a smoking cessation  
15 strategy.<sup>52</sup> While there is limited evidence that suggests that adult smokers could benefit from e-cigarette  
16 use instead of combustible tobacco products, smokers would need to fully switch to e-cigarettes and  
17 stop smoking cigarettes and other tobacco products completely to achieve any meaningful health  
18 benefits from e-cigarettes. Experts who serve on the US Preventive Services Task Force have resolved  
19 that there is insufficient evidence to recommend e-cigarettes for smoking cessation in adults, including  
20 pregnant women. Thus, e-cigarettes are not currently approved by the FDA as an aid to quit smoking.<sup>53</sup>

21 Another major concern is that e-cigarettes appeal to youth by being flavorful, trendy and a convenient  
22 accessory.<sup>54</sup> The flavorings being used, such as candy and other sweet flavorings are particularly  
23 attractive to younger populations. For this reason, these flavorings are banned in traditional cigarettes.<sup>55</sup>  
24 Despite a downturn prior to 2017, e-cigarette use among youth has drastically increased. From 2017 to  
25 2018, the percent of middle school students who used e-cigarettes increased 48%, resulting in 570,000  
26 middle school students, or 4.9%, who were current e-cigarette users. Among high school students  
27 during the same period, current e-cigarette use, defined as use at least one day in the past 30 days,  
28 increased by 78%, from 11.7% to 20.8%, the equivalent of 3.05 million high school students using e-  
29 cigarettes in 2018. Current e-cigarette users in high school who reported use on 20 days or more in the  
30 past 30-day period increased from 20% to 27.7%. During the same timeframe, use of flavored e-  
31 cigarettes increased among high school students who currently used e-cigarettes as well. Use of any  
32 flavored e-cigarette went up among current users from 60.9% to 67.8%, and menthol use increased  
33 from 42.3% to 51.2% among all current e-cigarette users, including consumers of multiple products,  
34 and from 21.4% to 38.1% among those using only e-cigarettes. From 2018 to 2019, the number of  
35 middle school and high school students who reportedly used e-cigarettes in the past 30 days increased  
36 from a total of 3.6 million to 5.4 million youth.<sup>56</sup>

37 In addition to exposure to the carcinogenic and toxic effects of tobacco, smokers become addicted to  
38 the nicotine.<sup>57</sup> Nicotine addiction is characterized as a form of drug dependence recognized in the  
39 Diagnostic and Statistical Manual of Mental Disorders (DSM-V).<sup>58</sup> E-cigarette cartridges can contain up  
40 to 20 times the nicotine of a single cigarette, and the process of vaping lacks the normal cues associated  
41 with cigarette completion, such as the butt of the cigarette ending a dose.<sup>59</sup>

42 Conditioning has a secondary role in nicotine addiction. Smokers associate particular cues with the high  
43 of smoking, often causing relapse when those seeking to quit smoking are confronted with those cues.<sup>60</sup>  
44 E-cigarettes allow quitting smokers to respond to those cues. This poses a risk of overconsumption.  
45 The lack of finality to an e-cigarette is determined only by the battery or nicotine cartridge.

1 Distinguishable from tobacco cigarettes, smokers who have turned to the e-cigarette no longer have the  
2 butt of the cigarette as a cue to stop smoking.<sup>61</sup>

3 E-cigarettes can cause other inadvertent injuries as well. The CDC, the US Food and Drug  
4 Administration (FDA), state and local health departments, and other clinical and public health  
5 organizations have investigated a national outbreak of e-cigarette, or vaping, product use-associated  
6 lung injury (EVALI).<sup>62</sup> EVALI is an inflammatory response in the lungs triggered by inhaled  
7 substances. EVALI has been found to vary due to the substantial variety of products and ingredients  
8 used. It may present as pneumonia or an inflammatory condition known as fibrinous pneumonitis.<sup>63</sup> As  
9 of February 2020, 2,807 hospitalized EVALI cases or deaths were reported to CDC from all 50 states,  
10 the District of Columbia, Puerto Rico and U.S. Virgin Islands. Sixty-eight (68) deaths were confirmed  
11 in 29 states and the District of Columbia. Vitamin E acetate, an additive in some THC-containing e-  
12 cigarette products, was found to be strongly associated with the EVALI outbreak.<sup>64</sup>

13 Additionally, e-cigarettes are manufactured from metal and ion components that introduce concerns  
14 about faulty products and malfunctions.<sup>65</sup> Defective e-cigarette batteries have caused fires and  
15 explosions, some of which have resulted in serious injuries. Lithium-ion batteries have reportedly  
16 overheated, caught fire or exploded, an event known as thermal runaway. From 2015 to 2017, an  
17 estimated 2,035 e-cigarette explosions and burn injuries presented to hospital emergency departments.  
18 Although the explosions are relatively rare, they can cause severe injuries.<sup>66</sup>

## 19 CONCLUSION

20 The AOA supports FDA and state regulation of the ingredients in all electronic cigarette cartridges,  
21 requiring ingredient labels and warnings, and eliminating the use of flavors that are banned in  
22 traditional cigarettes.

23 The AOA supports FDA and state regulation prohibiting sales and advertisements of electronic  
24 cigarettes to persons under the age of 21. Advertisements for electronic cigarettes should be subject to  
25 the same rules and regulations that are enforced on traditional cigarettes.

26 The AOA further encourages federal, state and local government action to ban the use of electronic  
27 cigarette devices in all spaces where traditional cigarettes are currently barred from use.

28 The AOA promotes tobacco and nicotine cessation treatment, and the use of any such treatment that  
29 has been proven safe and effective by the FDA.

30 The AOA supports research by the FDA and other organizations into the health and safety impact of  
31 e-cigarettes and liquid nicotine.

32 The AOA encourages physicians to ~~consider the health risks when recommending e-cigarettes to~~  
33 ~~patients, to~~ educate patients about the risks of e-cigarette use, and to counsel patients to submit  
34 voluntary reports to the US Department of Health and Human Services Safety Reporting Portal  
35 ([www.safetyreporting.hhs.gov](http://www.safetyreporting.hhs.gov)) if they sustain adverse reactions to e-cigarettes.

## 36 REFERENCES

- 37 1. WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva: World  
38 Health Organization; 2017. License: CC BY-NC-SA 3.0 IGO.
- 39 2. Tobacco free initiative: tobacco facts, WHO available at [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/tobacco)  
40 [sheets/detail/tobacco](https://www.who.int/news-room/fact-sheets/detail/tobacco)
- 41 3. Available at [https://www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/fast\\_facts/index.htm#diseases](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm#diseases)

- 1 4. Jordan Paradise, No Sisyphean Task: How the FDA Can Regulate Electronic Cigarettes, 13 Yale J. Health Pol’y L. &
- 2 Ethics 326, 329 (2013).
- 3 5. *Id.* at 330.
- 4 6. Jordan Paradise at 329.
- 5 7. *Id.*
- 6 8. Available at [https://www.cdc.gov/tobacco/basic\\_information/e-cigarettes/about-e-cigarettes.html#who-is-using-e-](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html#who-is-using-e-cigarettes)
- 7 [cigarettes](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html#who-is-using-e-cigarettes)
- 8 9. Available at [https://www.cdc.gov/tobacco/data\\_statistics/sgf/2020-smoking-cessation/fact-sheets/adult-smoking-](https://www.cdc.gov/tobacco/data_statistics/sgf/2020-smoking-cessation/fact-sheets/adult-smoking-cessation-e-cigarettes-use/index.html)
- 9 [cessation-e-cigarettes-use/index.html](https://www.cdc.gov/tobacco/data_statistics/sgf/2020-smoking-cessation/fact-sheets/adult-smoking-cessation-e-cigarettes-use/index.html)
- 10 10. NIDA. (2020, January 8). Vaping Devices (Electronic Cigarettes). Retrieved from
- 11 <https://www.drugabuse.gov/publications/drugfacts/vaping-devices-electronic-cigarettes> on 2020, May 21
- 12 11. Dan Radel, Healthy or Harmful? Smoking out the truth about e-cigarettes, available at
- 13 [http://special.app.com/article/20131027/NJLIFE04/310270144/Healthy-or-harmful-Smoking-out-the-truth-about-](http://special.app.com/article/20131027/NJLIFE04/310270144/Healthy-or-harmful-Smoking-out-the-truth-about-e-cigarettes)
- 14 [e-cigarettes](http://special.app.com/article/20131027/NJLIFE04/310270144/Healthy-or-harmful-Smoking-out-the-truth-about-e-cigarettes)
- 15 12. *Id.* at 331.
- 16 13. Available at
- 17 [https://www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/economics/econ\\_facts/index.htm#economic-costs;](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/economics/econ_facts/index.htm#economic-costs;)
- 18 Accessed May 22, 2020.
- 19 14. Jordan Paradise at 333.
- 20 15. Marcham CL, Springston JP. Electronic cigarettes in the indoor environment. Rev Environ Health.
- 21 2019;34(2):105-124. doi:10.1515/reveh-2019-0012, available at <https://pubmed.ncbi.nlm.nih.gov/31112510/>
- 22 16. Available at <http://publichealthlawcenter.org/sites/default/files/resources/telc-fs-ftc&tobacco-2012.pdf>
- 23 17. 15 U.S.C. § 1335.
- 24 18. Stuart Elliotts, E-Cigarette Makers’ Ads Echo Tobacco’s Heyday, New York Times, August 29, 2013, available at
- 25 <http://www.nytimes.com/2013/08/30/business/media/e-cigarette-makers-ads-echo-tobaccos-heyday.html>
- 26 19. Jordan Paradise at 353.
- 27 20. *Id.* at 353.
- 28 21. Tobacco fact sheet: Electronic Cigarettes (E-Cigarettes), Legacy for Longer Healthier Lives, available at
- 29 <http://www.legacyforhealth.org>.
- 30 22. Jordan Paradise at 354.
- 31 23. *Id.*
- 32 24. Available at <http://www.smokingeverywhere.com/cartridge.php>.
- 33 25. Available at [https://www.cdc.gov/tobacco/basic\\_information/e-cigarettes/about-e-cigarettes.html#what-are-e-](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html#what-are-e-cigarettes)
- 34 [cigarettes](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html#what-are-e-cigarettes)
- 35 26. Jordan Paradise at 354.
- 36 27. U.S. Food and Drug Administration, *Vaporizers, E-Cigarettes, and other Electronic Nicotine Delivery Systems*
- 37 *(ENDS)*, Last updated: Sep. 12, 2019, [https://www.fda.gov/tobacco-products/products-ingredients-](https://www.fda.gov/tobacco-products/products-ingredients-components/vaporizers-e-cigarettes-and-other-electronic-nicotine-delivery-systems-ends)
- 38 [components/vaporizers-e-cigarettes-and-other-electronic-nicotine-delivery-systems-ends](https://www.fda.gov/tobacco-products/products-ingredients-components/vaporizers-e-cigarettes-and-other-electronic-nicotine-delivery-systems-ends)
- 39 28. Sophie Novack, E-Cigarette Ads spark Lawmakers’ Concern for Youth, The National Journal (Sept. 29, 2013).
- 40 29. U.S. Food and Drug Administration, Tobacco 21. [https://www.fda.gov/tobacco-products/retail-sales-tobacco-](https://www.fda.gov/tobacco-products/retail-sales-tobacco-products/tobacco-21)
- 41 [products/tobacco-21](https://www.fda.gov/tobacco-products/retail-sales-tobacco-products/tobacco-21)
- 42 30. P.L. 116-94.
- 43 31. Alltucker, Ken. FDA Bans Mint- and Fruit-Flavored Vaping Products but Exempts Menthol and Tobacco. USA
- 44 Today (Jan. 2, 2020). [https://www.usatoday.com/story/news/health/2020/01/02/vaping-ban-fda-strikes-mint-and-](https://www.usatoday.com/story/news/health/2020/01/02/vaping-ban-fda-strikes-mint-and-fruit-flavored-products/2796299001/)
- 45 [fruit-flavored-products/2796299001/](https://www.usatoday.com/story/news/health/2020/01/02/vaping-ban-fda-strikes-mint-and-fruit-flavored-products/2796299001/).
- 46 32. Jordan Paradise at 374.
- 47 33. American Nonsmokers’ Rights Foundation., Overview List – Number of Smokefree and Other Tobacco-Related
- 48 Laws. <https://no-smoke.org/wp-content/uploads/pdf/mediaordlist.pdf>.
- 49 34. Bach, Laura. States & Localities that Have Restricted the Sale of Flavored Tobacco Products. Campaign for Tobacco-
- 50 Free Kids (Mar. 18, 2020). <https://www.tobaccofreekids.org/assets/factsheets/0398.pdf>.
- 51 35. N.J. Stat. Ann. SEC 26:3D-58.
- 52 36. Bach, Laura *supra*.
- 53 37. *Id.*
- 54 38. *Id.*
- 55 39. Public Health Law Center, *Retail Licensure on E-Cigarettes*, June 15, 2019,
- 56 [https://www.publichealthlawcenter.org/sites/default/files/States-with-Laws-Requiring-Licenses-for-Retail-Sales-of-](https://www.publichealthlawcenter.org/sites/default/files/States-with-Laws-Requiring-Licenses-for-Retail-Sales-of-ECigarettes-June152019.pdf)
- 57 [ECigarettes-June152019.pdf](https://www.publichealthlawcenter.org/sites/default/files/States-with-Laws-Requiring-Licenses-for-Retail-Sales-of-ECigarettes-June152019.pdf)

- 1 40. Daniel J. Denoon, E-cigarettes under fire, No-Smoke Electronic Cigarettes draw Criticism from FDA, quoting Craig  
2 Youngblood, president of InLife, e-cigarette company *available at* [www.webmd.com/smoking-](http://www.webmd.com/smoking-cessation/features/ecigarettes-under-fire)  
3 [cessation/features/ecigarettes-under-fire](http://www.webmd.com/smoking-cessation/features/ecigarettes-under-fire).
- 4 41. Dan Radel, *supra* quoting Robert Lahita, Chair of Medicine at New Beth Israel Medical Center.
- 5 42. *Available at* <https://www.lung.org/quit-smoking/smoking-facts/whats-in-a-cigarette>; updated March 13, 2020.
- 6 43. *Id.*
- 7 44. *Id.*
- 8 45. Schober et al, Use of Electronic Cigarettes (E-Cigarettes) Impairs Indoor Air Quality and Increases FeNO Levels of  
9 E-Cigarette Consumers, International Journal of Hygiene Environment and Health.
- 10 46. Nick Wilson et. al., Should E-Cigarette Use be Included in Indoor Smoking Bans?, Bulletin of the World Health  
11 Organization, 95:540-541 (2017). *Available at* <http://www.who.int/bulletin/volumes/95/7/16-186536/en/>
- 12 47. Michael B. Siegal et. al., Electronic Cigarettes as a Smoking-Cessation Tool: Results from an online Study, 40 Am. J.  
13 Preventive Med. 472, 474 (2011).
- 14 48. Jonathan Foulds et. al., Electronic Cigarettes (E-Cigs): Views of aficionados and Clinical/public health perspectives,  
15 65 Int'l J. Clinical prac. 1037 (2011)
- 16 49. *Id.*
- 17 50. *Id.*
- 18 51. Christopher Bullen, Electronic Cigarettes For Smoking Cessation: A Randomised Controlled Trial, The Lancet,  
19 November 16, 2013, *available at* [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961842-](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961842-5/abstract)  
20 [5/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961842-5/abstract)
- 21 52. Jordan Paradise at 329.
- 22 53. *Available at* [https://www.cdc.gov/tobacco/data\\_statistics/sgr/2020-smoking-cessation/fact-sheets/adult-smoking-](https://www.cdc.gov/tobacco/data_statistics/sgr/2020-smoking-cessation/fact-sheets/adult-smoking-cessation-e-cigarettes-use/index.html)  
23 [cessation-e-cigarettes-use/index.html](https://www.cdc.gov/tobacco/data_statistics/sgr/2020-smoking-cessation/fact-sheets/adult-smoking-cessation-e-cigarettes-use/index.html)
- 24 54. *Jordan Paradise at 329.*
- 25 55. Bridget M. Kuehn, *supra*.
- 26 56. *Available at* [https://www.cdc.gov/tobacco/basic\\_information/e-cigarettes/about-e-cigarettes.html#what-are-e-](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html#what-are-e-cigarettes)  
27 [cigarettes](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html#what-are-e-cigarettes)
- 28 57. Neal L. Benowitz, Nicotine Addiction, 362 New. Eng. J. Med. 2295 (2010).
- 29 58. American Psychological Association, Diagnostic and Statistical Manual of Mental Disorders: DSM-V, 5th ed.; 2013.  
30 571-4.
- 31 59. Jordan Paradise at 335.
- 32 60. Neal L. Benowitz, *supra*.
- 33 61. Jordan Paradise at 359.
- 34 62. *Available at* [https://www.cdc.gov/tobacco/basic\\_information/e-cigarettes/severe-lung-disease.html#overview](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#overview)
- 35 63. EVALI: New information on vaping-induced lung injury; *Available at* [https://www.health.harvard.edu/blog/evali-](https://www.health.harvard.edu/blog/evali-new-information-on-vaping-induced-lung-injury-2020040319359)  
36 [new-information-on-vaping-induced-lung-injury-2020040319359](https://www.health.harvard.edu/blog/evali-new-information-on-vaping-induced-lung-injury-2020040319359)
- 37 64. *Available at* [https://www.cdc.gov/tobacco/basic\\_information/e-cigarettes/severe-lung-disease.html#overview](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#overview)
- 38 65. *Id.* at 335.
- 39 66. Rossheim ME, Livingston MD, Soule EK, et al Electronic cigarette explosion and burn injuries, US Emergency  
40 Departments 2015–2017 Tobacco Control 2019;28:472-474.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 14, 2020**

SUBJECT: RECOGNIZING HEALTH CARE AS A HUMAN RIGHT

SUBMITTED BY: Michigan Osteopathic Association

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, there are many components that contribute to good health, including the ability to  
2 respond to sickness, disease and injury; and

3 WHEREAS, achieving the goal of living a healthy life is impossible without the ability to access  
4 health care; and

5 WHEREAS, health care should be available to everyone; and

6 WHEREAS, the lack of available health care is a barrier to opportunity, success and quality of  
7 life; and

8 WHEREAS, Osteopathic physicians and their patients' should not be divided between those  
9 who can afford to be healthy and those who cannot; and

10 WHEREAS, Osteopathic physicians and their patients' should not be divided between those  
11 who have hopes and dreams and those whose sickness, disease or injury robs them of  
12 their hopes and dreams; and,

13 WHEREAS, the World Health Organization recognizes “the highest attainable standard of  
14 health as a fundamental right of every human being,” and “the right to health includes  
15 access to timely, acceptable, and affordable health care of appropriate quality<sup>i</sup>,” and

16 WHEREAS, the United States ranks 33th out of 34 countries in the Organization for  
17 Economic Co-operation and Development (OECD) in percentage of insured  
18 population (with 88.5%), with nearly every other country at > 98%<sup>ii</sup>, and

19 WHEREAS, 25-30 million Americans are still uninsured after implementation of the  
20 Affordable Care Act (ACA), and the non-partisan Congressional Budget Office  
21 estimates that this number would increase to 48 million, and continue to increase  
22 annually, with an ACA repeal<sup>iii</sup>; now, therefore be it

23 RESOLVED, that the American Osteopathic Association (AOA) recognizes that health care is  
24 a human right for every person<sup>1</sup>, not a privilege as an official policy statement to inform  
25 and guide ongoing work of the AOA as a tenet of our osteopathic profession.

26 References:

27 <sup>i</sup> World Health Organization Media Center. “Health and Human Rights.” Fact Sheet N 232,  
28 Dec 2015. Accessed Feb 2017. <http://www.who.int/mediacentre/factsheets/fs323/en/>

29 <sup>ii</sup> OECD (2015), Health at a Glance 2015: OECD Indicators, OECD Publishing, Paris.  
30 [http://dx.doi.org/10.1787/health\\_glance-2015-en](http://dx.doi.org/10.1787/health_glance-2015-en)

1           <sup>iii</sup> Congressional Budget Office. “How Repealing Portions of the Affordable Care Act Would  
2           Affect Health Insurance Coverage and Premiums.” Jan 2017.

3           <https://www.cbo.gov/publication/52371>

4           <sup>iv</sup> Bauchner, H. “Health Care in the United States: A Right or a Privilege.” JAMA. 2017;  
5           317(1):29. <http://jamanetwork.com/journals/jama/fullarticle/2595503>

6           <sup>1</sup> Journal of the American Medical Association (JAMA), the editor-in-chief of JAMA voiced a  
7           hope that all physicians and professional societies will “speak with a single voice and say that  
8           health care is a basic right for every person, and not a privilege to be available and affordable  
9           only for a majority<sup>iv</sup>.”

Explanatory Statement: Submitted by Author

Resolution H431 – A/2019 was referred back to the Michigan Osteopathic Association, with a request  
“for clarity and direction”. It has been revised and re-submitted for consideration by the AOA HOD.

Explanatory Statement: Reference Committee

The resolution was referred back to Michigan at the 2019 HOD meeting for “clarity and direction.”  
However, the Committee believes that the resolution does not adequately define “healthcare as a  
human right” versus “health as a human right” and does not address the legal implications of defining  
healthcare as a human right.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **November 7, 2020**

SUBJECT: RECOGNITION OF HEALTH CARE AS A HUMAN RIGHT

SUBMITTED BY: Michigan Osteopathic Association

REFERRED TO: Committee on Public Affairs

---

1 WHEREAS, the World Health Organization recognizes “the highest attainable standard of  
2 health as a fundamental right of every human being,” and states “the right to health  
3 includes access to timely, acceptable, and affordable health care of appropriate quality”<sup>1</sup>;  
4 and

5 WHEREAS, the United States ranks 33rd out of 34 countries in the Organization for  
6 Economic Co-operation and Development (OECD) in percentage of insured  
7 population (with 88.5%), with nearly every other country at > 98%<sup>2</sup>; and

8 WHEREAS, 25-30 million Americans are still uninsured after implementation of the  
9 Affordable Care Act (ACA), and the non-partisan Congressional Budget Office  
10 estimates that this number would increase to 48 million, and continue to increase  
11 annually, with an ACA repeal<sup>3</sup>; now, therefore, be it

12 RESOLVED, that the American Osteopathic Association recognizes that health care is a  
13 human right for every person<sup>4</sup>, not a privilege.

14 References:

- 15 1. World Health Organization Media Center. “Health and Human Rights.” Fact Sheet N°232, Dec  
16 2015. Accessed Feb 2017. <http://www.who.int/mediacentre/factsheets/fs323/en/>  
17 2. OECD (2015), Health at a Glance 2015: OECD Indicators, OECD Publishing, Paris.  
18 [http://dx.doi.org/10.1787/health\\_glance-2015-en](http://dx.doi.org/10.1787/health_glance-2015-en)  
19 3. Congressional Budget Office. “How Repealing Portions of the Affordable Care Act Would Affect  
20 Health Insurance Coverage and Premiums.” Jan 2017. <https://www.cbo.gov/publication/52371>  
21 4. Bauchner, H. “Health Care in the United States: A Right or a Privilege.” JAMA. 2017; 317(1):29.  
22 <http://jamanetwork.com/journals/jama/fullarticle/2595503> - Journal of the American Medical  
23 Association (JAMA), the editor-in-chief of JAMA voiced a hope that all physicians and professional  
24 societies will “speak with a single voice and say that health care is a basic right for every person, and  
25 not a privilege to be available and affordable only for a majority.”

Reference Committee Explanatory Statement:

The committee believes that the resolution, as written, lacks clarity and direction.

ACTION TAKEN **REFERRED** *(to the Michigan Osteopathic Medical Association)*

DATE **July 27, 2019**

---





**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES  
OCTOBER 2020 MEETING  
CONSTITUTION & BYLAWS - RESOLUTION ROSTER  
WITH ACTION**

**HOUSE OF DELEGATES' REFERENCE COMMITTEE DESCRIPTION:**

- Committee on Constitution and Bylaws (500 series)  
This reference committee reviews and considers the wording of all proposed amendments to the AOA's Constitution, Bylaws and the Code of Ethics.

<b>Res. No.</b>	<b>Resolution Title</b>	<b>Submitted By</b>	<b>Action</b>
H500	Amendment to the American Osteopathic Association Bylaws – Implement Changes to Governance Structure	BOT	ADOPTED
H501	Amendments to the American Osteopathic Association Bylaws – Update to Bureau of Membership	BOT	ADOPTED
H502	Amendments to the American Osteopathic Association Bylaws – Procedure for Notice of Proposed Changes to Bylaws	BOT	ADOPTED



SUBJECT: AMENDMENTS TO THE AMERICAN OSTEOPATHIC ASSOCIATION  
BYLAWS – IMPLEMENT CHANGES TO GOVERNANCE  
STRUCTURE

SUBMITTED BY: AOA Board of Trustees

REFERRED TO: Committee on Constitution & Bylaws

---

1 WHEREAS, the AOA Board of Trustees, on recommendation of the Committee on AOA  
2 Governance & Organizational Structure, has approved a resolution that calls for  
3 changes to the names by which some of the AOA’s Departments are known to better  
4 identify their function within the AOA’s governance structure; and

5 WHEREAS, it is necessary to amend the AOA’s Constitution and Bylaws to reflect these  
6 changes to the Department names; now, therefore, be it

7 RESOLVED, that the AOA House of Delegates approve the following amendments to the  
8 American Osteopathic Association Bylaws:

9 Old material crossed out (~~crossed out~~) | New material in CAPS

10 **AOA Bylaws**

11 **Article IX - Departments, Bureaus, and Committees**

12 The Board of Trustees and House of Delegates, consistent with the powers given to it by these  
13 Bylaws, shall establish and determine the duties of departments, bureaus, councils,  
14 commissions, committees, and task forces necessary to further the policies of the Association.  
15 The Association’s departments shall include the Departments of Affiliated RELATIONS  
16 ~~Affairs~~, FINANCE ~~Business Affairs~~, EDUCATION ~~Educational Affairs~~, Governmental  
17 Affairs, MEMBERSHIP ~~Professional Affairs~~, and Research, ~~Quality &~~ AND Public Health.  
18 The activities of all departments, bureaus and committees shall, so far as possible, be executed  
19 in close cooperation with the Chief Executive Officer. Upon the expiration of the terms of  
20 office of chairs and members of the departments, bureaus, or committees, all records of the  
21 same shall be delivered by the chairs to the Chief Executive Officer. All employed staff of  
22 departments, bureaus, and committees in the offices shall be under the jurisdiction of the Chief  
23 Executive Officer.

Explanatory Statement: Submitted by Author

The AOA Board of Trustees approved changes to the organizational structure at its midyear meeting in February 2020, including renaming the six Departments as follows:

1. Affiliate Affairs to become Affiliate Relations
2. Business Affairs to become Finance
3. Educational Affairs to become Education
4. Governmental Affairs – no change
5. Professional Affairs to become Membership
6. Research Quality & Public Health to become Research and Public Health

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: AMENDMENTS TO THE AMERICAN OSTEOPATHIC ASSOCIATION  
BYLAWS – UPDATE TO BUREAU OF MEMBERSHIP

SUBMITTED BY: AOA Board of Trustees

REFERRED TO: Committee on Constitution & Bylaws

---

1 WHEREAS, the AOA’s Committee on AOA Governance & Organizational Structure has  
2 reviewed the AOA’s Constitution and Bylaws; and

3 WHEREAS, the AOA’s Bylaws refer to the “Committee on Membership” which is now called  
4 the “Bureau of Membership”; now, therefore, be it

5 RESOLVED, that the AOA House of Delegates approve the following amendments to the  
6 American Osteopathic Association Bylaws:

7 Old material crossed out (~~crossed-out~~) | New material in CAPS

8 **AOA Bylaws**

9 **Article II (Membership), Section 2-Membership Requirements**

10 a. Applicants for Regular Membership . . . Such information and application shall be carefully  
11 reviewed by the BUREAU OF ~~Committee on~~ Membership, which shall make an appropriate  
12 recommendation for reinstatement to the Board of Trustees. An applicant whose license to  
13 practice is revoked or suspended, or who is currently serving a sentence for conviction of a  
14 felony offense, shall not be considered eligible for membership in this Association.

15 b. Honorary Life Member . . . Honorary life membership may also be conferred by the Board  
16 of Trustees on a regular member who has been in good standing for 25 consecutive years  
17 immediately preceding, and who has rendered outstanding service to the profession at either the  
18 state or national level, or who is recommended for such a membership by official action of his  
19 divisional society and the BUREAU OF ~~Committee on~~ Membership. Such honorary life  
20 members shall have the privileges and duties of regular members including the payment of  
21 assessments levied by the Association, but shall not be required to pay dues.

22 c. Life Member . . . The BUREAU OF ~~Committee on~~ Membership may waive this requirement  
23 on individual consideration. Such members shall have the privileges and duties of regular  
24 members, but shall not be required to pay dues or assessments beginning the year AOA  
25 Constitution & Bylaws 6 in which the age of 70 is attained.

Explanatory Statement: Submitted by Author

This amendment, if approved, will change references in the AOA’s Bylaws from “Committee on Membership” to “Bureau of Membership.”

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**

SUBJECT: AMENDMENTS TO THE AMERICAN OSTEOPATHIC ASSOCIATION  
BYLAWS – PROCEDURE FOR NOTICE OF PROPOSED CHANGES  
TO BYLAWS

SUBMITTED BY: Committee on AOA Governance & Organizational Structure

REFERRED TO: Committee on Constitution & Bylaws

---

1 WHEREAS, the current procedure for amending the AOA’s Bylaws calls for providing notice  
2 to members through publication in the JAOA and notice to affiliated organizations  
3 represented in the House of Delegates by U.S. mail; and

4 WHEREAS, the JAOA is transitioning to on-line publication and notice by electronic mail is  
5 more efficient and cost-effective than notice by U.S. mail; now, therefore, be it

6 RESOLVED, that the AOA House of Delegates approve the following amendments to the  
7 American Osteopathic Association Bylaws:

8 Old material crossed out (~~crossed out~~) | New material in CAPS

9 **AOA Bylaws**

10 **Article XI - Amendments Section 1—Bylaws**

11 These Bylaws may be amended at any annual or special meeting of the House of Delegates by a  
12 two-thirds vote of the total number of delegates accredited for voting, provided that the  
13 amendment shall have been filed with the Chief Executive Officer at least two months before  
14 the meeting at which the amendment is to be voted upon. Upon receiving a copy of the  
15 amendment, it shall be the duty of the Chief Executive Officer to cause it to be distributed by  
16 US MAIL OR ELECTRONIC ~~first class mail, postage paid~~, to each divisional and specialty  
17 society entitled to send voting representatives to the House of Delegates, posted on the AOA’s  
18 website, and published in THE ON-LINE EDITION OF The Journal of the American  
19 Osteopathic Association at least one month before the meeting. The Board of Trustees may  
20 revise the proposed amendment if necessary to secure conformity to this Constitution and  
21 Bylaws and shall then refer it to the House for final action not later than the day prior to the  
22 end of the meeting.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 14, 2020**



**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES  
OCTOBER 2020 MEETING  
AD HOC - RESOLUTION ROSTER  
WITH ACTION**

**HOUSE OF DELEGATES' REFERENCE COMMITTEE DESCRIPTION:**

- Ad Hoc Committee (600 series)  
This reference committee reviews and considers materials relating to physician practice issues, affiliate dynamics, insurance and communications activities.

Res. No.	Resolution Title	Submitted By	Action
H600	Dissemination of Publications in Osteopathic Research (H600-A/15)	BOCER	ADOPTED
H601	Reduction of Osteopathic Training Positions in Post-Graduate Medical Education (H601-A/15)	BOE	ADOPTED <i>(for sunset)</i>
H602	Reimbursement for Physician Time Spent Obtaining Pre-Certification and Pre-Authorization (H602-A/15)	BSA	ADOPTED <i>(for sunset)</i>
H603	Pay for Performance (H604-A/15)	BSA	ADOPTED as AMENDED
H604	Proper Badge Identification of Employees in a Hospital Setting (H606-A/15)	BSAPH	ADOPTED
H605	Interoperability of Health Information Technology (H607-A/15)	BSA	ADOPTED
H606	Gifts to Physicians from Industry (H612-A/15)	Ethics	ADOPTED
H607	Physician Competency Retesting (H614-A/15)	BOS	ADOPTED as AMENDED
H608	Health Plan Coverage of Tobacco Cessation Treatment (H615-A/15)	BSA	ADOPTED
H609	Encouraging Patient Participation in Their Health Care (H616-A/15)	BSAPH	ADOPTED
H610	Frivolous Liability Lawsuits (H617-A/15)	BFHP	ADOPTED <i>(for sunset)</i>
H611	Provider Tax (H618-A/15)	BSGA	ADOPTED
H612	Medicaid Payment (H619-A/15)	BSGA	ADOPTED as AMENDED
H613	Lay Midwives (H620-A/15)	BSGA	ADOPTED
H614	Medical Malpractice Judgments Requiring Reimbursement of Medicare Payments (H621-A/15)	BSA	REFERRED
H615	Electronic Health Records – Physician Assistance Programs for Transition to (H622-A/15)	BSA	ADOPTED as AMENDED
H616	Prescription Medications -- Overrides for (H624-A/15)	BSGA	NOT ADOPTED



**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES  
OCTOBER 2020 MEETING  
AD HOC - RESOLUTION ROSTER  
WITH ACTION**

<b>Res. No.</b>	<b>Resolution Title</b>	<b>Submitted By</b>	<b>Action</b>
H617	Pediatric Psychiatric Care Health Records (H625-A/15)	BSA / BSAPH	ADOPTED
H618	Attention Deficit Disorder / Attention Deficit Hyperactivity Disorder (H626-A/15)	BSA	ADOPTED
H619	Medicare Recovery Audit Contractors (H628-A/15)	BSA	REFERRED
H620	Medicare Law and Rules (H629-A/15)	BFHP	REFERRED
H621	Veterans Administration Credentialing of Non-Physician Providers Health Records (H630-A/15)	BFHP	ADOPTED
H622	Tax Credits for Health Profession Shortage Areas (H631-A/15)	BFHP	ADOPTED
H623	Osteopathic Manipulative Treatment (OMT) in a Pre-Paid Environment –Payment Policies for (H632-A/15)	BSA	ADOPTED
H624	Prescription of Drugs for Off Label Uses (H633-A/15)	BFHP	ADOPTED
H625	Newborn and Infant Hearing Screens (H635-A/15)	BSAPH	ADOPTED
H626	Medicare Preventive Medical Screening (H636-A/15)	BFHP	ADOPTED
H627	Confidentiality of Patient Records (H637-A/15)	Ethics	ADOPTED
H628	Diabetics Confined to Correctional Institutions (H638-A/15)	BSAPH	ADOPTED
H629	Discrimination by Insurers (H639-A/15)	BSA	ADOPTED
H630	Executions in Capital Crimes Criminal Cases (H640-A/15)	Ethics	ADOPTED
H631	Managed Care – All Products Clauses (H642-A/15)	BSGA	ADOPTED
H632	Medical Procedure Patents (H643-A/15)	BFHP	ADOPTED
H633	Medicare Contractor Denial Letters (H644-A/15)	BSA	ADOPTED as AMENDED
H634	Osteopathic Medical Student, Resident, and Physician Mental Health (H646-A/15)	BEL	ADOPTED
H635	American Osteopathic Association (AOA) Osteopathic Manipulative Treatment (OMT) Coverage Determination Guidance (H647-A/15)	BSA	ADOPTED
H636	Access to Care – Network Adequacy and Coverage	BSGA	ADOPTED as AMENDED
H637	Addressing Fears and Barriers to Telemedicine Implementation and Alignment	MOA	ADOPTED as AMENDED
H638	Addressing Social Determinants of Health Through Data Collection and Improved Access to Social Services	SOMA	REFERRED



**SPECIAL SESSION OF THE  
AOA HOUSE OF DELEGATES  
OCTOBER 2020 MEETING  
AD HOC - RESOLUTION ROSTER  
WITH ACTION**

<b>Res. No.</b>	<b>Resolution Title</b>	<b>Submitted By</b>	<b>Action</b>
H639	Elimination of Prior Authorization and Step Therapy	MOA	NOT ADOPTED
H640	H623-A/18 Non-Physician Clinicians	BSGA	ADOPTED as AMENDED
H641	Marketing AOA Board Certification	AOCOPM	NOT ADOPTED
H642	Prior Authorization	BSA	ADOPTED
H643	Professional Liability Insurance Reform	BSGA	ADOPTED
H644	Re-Establishment of the Bureau of Osteopathic Specialty Societies (BOSS)	AOCOPM	NOT ADOPTED
H645	REFERRED RESOLUTION: H636-A/2019 Obesity Treatment Reimbursement in Primary Care	BSA	ADOPTED as AMENDED
H646	REFERRED RESOLUTION: H-615: Postpartum Depression	BSAPH	ADOPTED
H647	REFERRED SUNSET RESOLUTION: H-619 - A/2019: H624-A/14 Managed Care Plans – Service, Access and Costs in	BSA	ADOPTED
H648	Researching Patient Safety and Provider Qualifications	SOMA	ADOPTED as AMENDED
H649	Support the Bolstering of Veteran Health Administration Resources Through Provider Pay Reform	SOMA	ADOPTED
H650	Telemedicine; Reimbursement for	NYSOMS	ADOPTED as AMENDED



SUBJECT: H600-A/15 DISSEMINATION OF PUBLICATIONS IN  
OSTEOPATHIC RESEARCH

SUBMITTED BY: Bureau of Osteopathic Clinical Education and Research

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Osteopathic Clinical Education and Research recommends  
2 that the following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H600-A/15 DISSEMINATION OF PUBLICATIONS IN OSTEOPATHIC**  
5 **RESEARCH**

6 The American Osteopathic Association will widely disseminate publications, research, and  
7 evidence based medicine regarding Osteopathic Medicine and Osteopathic Manipulative  
8 Treatment (OMT) and its anatomical and physiological basis to the greater public via  
9 prominent, designated public information sites, social networking, public information releases,  
10 websites, and other media. 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H601-A/15 REDUCTION OF OSTEOPATHIC TRAINING  
POSITIONS IN POST-GRADUATE MEDICAL EDUCATION

SUBMITTED BY: Bureau of Osteopathic Education

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Osteopathic Education recommends that the following policy  
2 be SUNSET.

3 (Old language is crossed out and new language is in CAPS)

4 **H601-A/15 REDUCTION OF OSTEOPATHIC TRAINING POSITIONS IN**  
5 **POST-GRADUATE MEDICAL EDUCATION**

6 The American Osteopathic Association will work to create parity in reimbursement from the  
7 Centers for Medicare and Medicaid Services (CMS) for all osteopathic training to be equivalent  
8 to allopathic programs. 2015.

Explanatory Statement: Submitted by Author

The AOA no longer separately accredits graduate medical education programs.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED** *(for sunset)*

DATE: **October 13, 2020**

SUBJECT: H602-A/15 REIMBURSEMENT FOR PHYSICIAN TIME SPENT  
OBTAINING PRE-CERTIFICATION AND PRE-AUTHORIZATION

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be SUNSET.

3 (Old language is crossed out and new language is in CAPS)

4 **H602-A/15 REIMBURSEMENT FOR PHYSICIAN TIME SPENT OBTAINING**  
5 **PRE-CERTIFICATION AND PRE-AUTHORIZATION**

6 The American Osteopathic Association will include in its work plan investigation and  
7 recommendations for a framework for diagnostic and procedure coding, along with associated  
8 payment policies, for physician time spent obtaining required Medicare pre-certifications or pre-  
9 authorizations for those designated services or prescriptions and provide a template for use by  
10 state affiliates for third party payers within the jurisdiction of their state. 2015

Explanatory Statement: Submitted by Author:

The Bureau of Socioeconomic Affairs has submitted a resolution for consideration by the 2020 HOD which will merge this policy with several other existing policies to create one comprehensive policy addressing Prior Authorization.

Background Information: Provided by AOA Staff

**Current AOA Policy:**

H343-A/13 CURRENT PROCEDURAL TERMINOLOGY (CPT) CODE FOR PRIOR AUTHORIZATION

H640-A/16 PRIOR AUTHORIZATION

H632-A/17 PRIOR AUTHORIZATION

H635-A/19 PRIOR AUTHORIZATION – PATIENT AUTHORIZATION

**Prior HOD action on similar or same topic:** H343-A/13 policy reaffirmed in 2013 (referred to BSA in 2018); H640-A/16 policy approved in 2016; H632-A/17 policy approved in 2017, H635-A/19 policy approved in 2019

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED** *(for sunset)*

DATE: **October 13, 2020**

SUBJECT: H604-A/15 PAY FOR PERFORMANCE

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H604-A/15 PAY FOR PERFORMANCE**

5 In an effort to support the establishment of REASONABLE PAYMENT ~~appropriate pay-for-~~  
6 ~~performance methodology~~ that will reflect the quality of care provided by physicians and improve  
7 patient health outcomes, the AOA adopts the following principles on quality reporting and pay-for-  
8 performance (2006; reaffirmed 2011; revised 2015).

- 9 1. THE AOA SUPPORTS THE ESTABLISHMENT OF QUALITY REPORTING  
10 AND/OR PAY-FOR-PERFORMANCE SYSTEMS WHOSE PRIMARY GOALS ARE  
11 TO IMPROVE THE HEALTH CARE AND HEALTH OUTCOMES OF PATIENTS.  
12 THE AOA BELIEVES THAT SUCH PROGRAMS SHOULD NOT BE BUDGET  
13 NEUTRAL. APPROPRIATE ADDITIONAL RESOURCES SHOULD SUPPORT  
14 IMPLEMENTATION AND REWARD PHYSICIANS WHO PARTICIPATE IN THE  
15 PROGRAMS AND DEMONSTRATE IMPROVEMENTS. THE AOA  
16 RECOMMENDS THAT ADDITIONAL FUNDING BE USED TO ESTABLISH  
17 BONUS PAYMENTS.
- 18 2. THE AOA BELIEVES THAT TO THE EXTENT POSSIBLE, PARTICIPATION IN  
19 QUALITY REPORTING AND PAY-FOR-PERFORMANCE PROGRAMS SHOULD  
20 BE VOLUNTARY AND PHASED-IN OVER AN APPROPRIATE TIME PERIOD.  
21 THE AOA ACKNOWLEDGES THAT FAILURE TO PARTICIPATE MAY  
22 DECREASE ELIGIBILITY FOR BONUS OR INCENTIVE-BASED PAYMENTS BUT  
23 FEELS STRONGLY THAT PHYSICIANS MUST BE AFFORDED THE OPTION OF  
24 NOT PARTICIPATING.
- 25 3. THE AOA RECOMMENDS THAT PHYSICIANS HAVE A CENTRAL ROLE IN  
26 THE ESTABLISHMENT AND DEVELOPMENT OF QUALITY STANDARDS. A  
27 SINGLE SET OF STANDARDS APPLICABLE TO ALL PHYSICIANS IS NOT  
28 ADVISABLE. INSTEAD, STANDARDS SHOULD BE DEVELOPED ON A  
29 SPECIALTY-BY-SPECIALTY BASIS, APPLYING THE APPROPRIATE RISK  
30 ADJUSTMENTS AND TAKING INTO ACCOUNT PATIENT COMPLIANCE.  
31 ADDITIONALLY, QUALITY STANDARDS SHOULD NOT BE ESTABLISHED OR  
32 UNNECESSARILY INFLUENCED BY PUBLIC AGENCIES OR PRIVATE SPECIAL  
33 INTEREST GROUPS WHO COULD GAIN BY THE ADOPTION OF CERTAIN  
34 STANDARDS. HOWEVER, THE AOA DOES SUPPORT THE ABILITY OF  
35 APPROPRIATE OUTSIDE GROUPS WITH ACKNOWLEDGED EXPERTISE TO  
36 ENDORSE DEVELOPED STANDARDS THAT MAY BE USED.

- 1 4. THE AOA DOES NOT SUPPORT THE EXCLUSIVE USE OF CLAIMS-BASED  
2 DATA IN QUALITY EVALUATION. INSTEAD, THE AOA SUPPORTS THE  
3 DIRECT AGGREGATION OF CLINICAL DATA BY PHYSICIANS. PHYSICIANS  
4 OR THEIR DESIGNATED ENTITY WOULD REPORT THIS DATA TO THE  
5 CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) AND/OR OTHER  
6 PAYERS.
- 7 5. THE FEDERAL GOVERNMENT MUST ADOPT STANDARDS PRIOR TO THE  
8 IMPLEMENTATION OF ANY NEW HEALTH INFORMATION SYSTEM. SUCH  
9 STANDARDS MUST ENSURE INTEROPERABILITY BETWEEN PUBLIC AND  
10 PRIVATE SYSTEMS AND PROTECT AGAINST EXCLUSION OF CERTAIN  
11 SYSTEMS. INTEROPERABILITY MUST APPLY TO ALL PROVIDERS IN THE  
12 HEALTH CARE DELIVERY SYSTEM, INCLUDING PHYSICIANS, HOSPITALS,  
13 NURSING HOMES, PHARMACIES, PUBLIC HEALTH SYSTEMS, AND ANY  
14 OTHER ENTITIES PROVIDING HEALTH CARE OR HEALTH CARE RELATED  
15 SERVICES. THESE STANDARDS SHOULD BE ESTABLISHED AND IN PLACE  
16 PRIOR TO ANY COMPLIANCE REQUIREMENTS.
- 17 6. THE AOA ENCOURAGES THE FEDERAL GOVERNMENT TO REFORM  
18 EXISTING STARK LAWS IN ORDER TO ALLOW PHYSICIANS TO  
19 COLLABORATE WITH HOSPITALS AND OTHER PHYSICIANS IN THE PURSUIT  
20 OF ELECTRONIC HEALTH RECORDS (EHR) SYSTEMS WITHOUT FEAR OF  
21 PROSECUTION. THIS WILL PROMOTE WIDESPREAD ADOPTION OF EHR,  
22 EASE THE FINANCIAL BURDEN ON PHYSICIANS, AND ENHANCE THE  
23 EXCHANGE OF INFORMATION BETWEEN PHYSICIANS AND HOSPITALS  
24 LOCATED IN THE SAME COMMUNITY OR GEOGRAPHIC REGION.
- 25 7. THE AOA SUPPORTS THE ESTABLISHMENT OF PROGRAMS TO ASSIST ALL  
26 PHYSICIANS IN PURCHASING HEALTH INFORMATION TECHNOLOGY (HIT).  
27 THESE PROGRAMS MAY INCLUDE GRANTS, TAX-BASED INCENTIVES, AND  
28 BONUS PAYMENTS THROUGH THE MEDICARE PHYSICIAN PAYMENT  
29 FORMULA AS A WAY TO PROMOTE ADOPTION OF HIT IN PHYSICIAN  
30 PRACTICES. WHILE SMALL GROUPS AND SOLO PRACTICE PHYSICIANS  
31 SHOULD BE ASSISTED, PROGRAMS SHOULD NOT EXPRESSLY EXCLUDE  
32 LARGE GROUPS FROM PARTICIPATION.
- 33 8. THE AOA SUPPORTS THE ESTABLISHMENT OF PROGRAMS THAT ALLOW  
34 PHYSICIANS TO BE COMPENSATED FOR PROVIDING CHRONIC CARE  
35 MANAGEMENT SERVICES. FURTHERMORE, THE AOA DOES NOT SUPPORT  
36 THE ABILITY OF OUTSIDE VENDORS INDEPENDENT OF PHYSICIANS TO  
37 PROVIDE SUCH SERVICES.
- 38 9. THE AOA BELIEVES THAT PHYSICIANS WHO PARTICIPATE IN PAY FOR  
39 PERFORMANCE PROGRAMS HAVE THE RIGHT TO REVIEW, COMMENT, AND  
40 APPEAL ANY PERFORMANCE DATA.
- 41 10. THE AOA BELIEVES THAT PAY FOR PERFORMANCE PROGRAMS SHOULD  
42 INCLUDE MONITORING AND EVALUATION BY BOTH PAYORS AND  
43 PHYSICIAN ORGANIZATIONS TO IDENTIFY ELEMENTS THAT POSITIVELY  
44 AFFECT OUTCOMES.

- 1           11. THE AOA BELIEVES THAT PATIENT SATISFACTION MEASURES SHOULD BE  
2           LIMITED TO EASILY DEFINABLE MEASURES.

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

The Committee inserted the Principles from the original policy H604-A/15 so they could be viewed during review by the House.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**

SUBJECT: H606-A/15 PROPER BADGE IDENTIFICATION OF EMPLOYEES IN  
A HOSPITAL SETTING

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Ad HOC Committee

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H606-A/15 PROPER BADGE IDENTIFICATION OF EMPLOYEES IN A**  
5 **HOSPITAL SETTING**

6 The American Osteopathic Association encourages all healthcare providers and hospital  
7 employees to wear hospital-issued identification badges with clear delineation of their  
8 professional role and that they verbally introduce and identify themselves and their role in the  
9 patient's treatment process, with the overall goal of improving patient safety and patient  
10 communication. 2015

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

---

DATE: **October 13, 2020**

---

SUBJECT: H607-A/15 INTEROPERABILITY OF HEALTH INFORMATION TECHNOLOGY

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H607-A/15 INTEROPERABILITY OF HEALTH INFORMATION**  
5 **TECHNOLOGY**

6 The American Osteopathic Association (AOA) supports A NEW RISK-BASED  
7 OVERSIGHT FRAMEWORK FOR CLINICAL SOFTWARE, DEVELOPED THROUGH  
8 A MULTI-STAKEHOLDER CONSENSUS-BASED PROCESS. THE FRAMEWORK  
9 SHOULD TAKE INTO ACCOUNT RISK RELATIVE TO INTENDED USE,  
10 COST/BENEFIT OF PROPOSED OVERSIGHT, AND THE PRINCIPLE OF SHARED  
11 RESPONSIBILITY. PATIENT SAFETY AND APPROPRIATE IMPROVEMENTS IN  
12 QUALITY, EFFECTIVENESS, AND EFFICIENCY OF CARE DELIVERY SHOULD BE  
13 PARAMOUNT. THIS FRAMEWORK SHOULD NOT CONFLICT WITH OR  
14 DUPLICATE THE MEDICAL DEVICE REGULATION FRAMEWORK. THE AOA  
15 DOES NOT SUPPORT DATA BE TREATED AS A MEDICAL DEVICE, REGARDLESS  
16 OF THE CATEGORY OF HEALTH IT ASSOCIATED WITH THE DATA. THE AOA  
17 SUPPORTS A NATIONAL NETWORK FOR REPORTING PATIENT SAFETY  
18 EVENTS AND OTHER INFORMATION VITAL TO PUBLIC HEALTH, WHERE  
19 DATA CAN BE ACCESSED, ANALYZED, AND COMMUNICATED IN A TIMELY  
20 MANNER. THE REGULATORY FRAMEWORK SHOULD PROMOTE ~~An open~~  
21 interoperability ~~platform for health care delivery~~, in order for clinical information systems to  
22 capture and share quality, outcome, cost, AND PATIENT HEALTHCARE data. TO  
23 SUPPORT COORDINATED HEALTH CARE AND DATA ANALYTICS TO PROMOTE  
24 TRANSITION TO A VALUE-BASED HEALTHCARE SYSTEM. THE AOA SUPPORTS  
25 A COMMON DATA STRUCTURE THAT WILL ENABLE INTEROPERABILITY,  
26 SETTING A CLEAR COURSE OF ACTION, FEDERAL SUPPORT FOR AN  
27 EXCHANGE INFRASTRUCTURE, AND STANDARDS WHICH WILL MAKE IT  
28 EASIER TO SHARE INFORMATION SO PHYSICIANS AND PATIENTS CAN MAKE  
29 INFORMED DECISIONS.

30 The AOA will encourage public and private sector stakeholders to develop clinically driven,  
31 standardized products that are interoperable by design, do not require costly and time-  
32 consuming customization, and for which any upgrades or future needs can be integrated  
33 seamlessly without burdensome costs or system modifications. The AOA also supports  
34 standardization of prior authorization attachments to alleviate burden and reduce delays to care.

35 The AOA opposes vendors blocking health care professionals' ability to access, view, share, or  
36 transfer data.



1 The AOA supports policies and technologies that facilitate person-centered health care, ~~not~~  
2 ~~technology-centered healthcare and policies that include adequate positive incentives for the~~  
3 ~~adoption of health information technology.~~

4 The AOA will remain vigilant about mitigating the level of administrative burden posed by  
5 existing and new government policies. 2015

Explanatory Statement: Submitted by Author

This policy merges with H603-A/19 titled REGULATION OF HEALTH INFORMATION TECHNOLOGY SOFTWARE and includes content provided by the Michigan Osteopathic Association. Upon approval of this resolution policy H603-19 will be sunset.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H603-A/19 titled REGULATION OF HEALTH INFORMATION TECHNOLOGY SOFTWARE

**Prior HOD action on similar or same topic:** Policy reaffirmed as amended in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED** \_\_\_\_\_

DATE: **October 13, 2020** \_\_\_\_\_

SUBJECT: H612-A/15 GIFTS TO PHYSICIANS FROM INDUSTRY

SUBMITTED BY: Ethics Subcommittee

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Ethics Subcommittee recommends that the following policy be  
2 REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H612-A/15 GIFTS TO PHYSICIANS FROM INDUSTRY**

5 The American Osteopathic Association has adopted the following “Guide to Section 17 of the  
6 AOA Code of Ethics” as follows, and will distribute this information to students of osteopathic  
7 medicine and osteopathic physicians (1991, revised 1994, 1999, 2003; 2008; reaffirmed as  
8 amended 2015).

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H614-A/15 PHYSICIAN COMPETENCY RETESTING

SUBMITTED BY: Bureau of Osteopathic Specialists

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Osteopathic Specialists recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H614-A/15 PHYSICIAN COMPETENCY RETESTING**

5 The American Osteopathic Association: (1) supports the mission of physician competency, the  
6 quality movement and patient safety through self-regulation mechanisms rather than through  
7 government mandated retesting for purposes of obtaining relicensure or for receiving payment  
8 under a health benefits program. (2) continue its voluntary efforts to address and promote  
9 physician competency through the teaching of core competencies at the predoctoral and  
10 postdoctoral levels, physician assessment through osteopathic continuous certification ~~and its~~  
11 ~~AOA Clinical Assessment Program (CAP)~~. 1988; reaffirmed 1993; revised 1998, 2003;  
12 revised 2008; revised 2010; reaffirmed as amended 2015

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**

SUBJECT: H615-A/15 HEALTH PLAN COVERAGE OF TOBACCO CESSATION  
TREATMENT

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H615-A/15 HEALTH PLAN COVERAGE OF TOBACCO CESSATION TREATMENT**  
5 The American Osteopathic Association encourages all health plans to follow tobacco cessation  
6 recommendations of the Centers for Disease Control and Prevention (CDC) and encourages all  
7 health care plans to accept CPT, ~~ICD-9~~ and ICD-10 codes for tobacco use as legitimate codes  
8 for payment for services provided for these codes. 2010; reaffirmed as amended 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H616-A/15 ENCOURAGING PATIENT PARTICIPATION IN THEIR HEALTH CARE

SUBMITTED BY: Bureau of Scientific Affairs and Public Health

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H616-A/15 ENCOURAGING PATIENT PARTICIPATION IN THEIR HEALTH**  
5 **CARE**

6 The American Osteopathic Association recommends that all insurance companies consider the  
7 establishment of a system for rewarding those patients who are trying to stay health as a means  
8 of decreasing the amount of money spent on health care. 2010; reaffirmed 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H617-A/15 FRIVOLOUS LIABILITY LAWSUITS

SUBMITTED BY: Bureau of Federal Health Programs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Federal Health Programs recommends that the following  
2 policy be SUNSET.

3 (Old language is crossed out and new language is in CAPS)

4 **H617-A/15 - FRIVOLOUS LIABILITY LAWSUITS**

5 The American Osteopathic Association (AOA) supports, as a component of comprehensive  
6 tort reform, the ability of physicians who are victims of frivolous lawsuits to recover all out of  
7 pocket expenses and lost income. 2010; reaffirmed as amended 2015

Explanatory Statement: Submitted by Author

A resolution is being submitted that combines this policy with H333-A/18. It will read as follows:

**H333-A/18 PROFESSIONAL LIABILITY INSURANCE REFORM**

The American Osteopathic Association continues support of professional liability insurance reform that includes the following ~~eight~~ principles: (1) limitations on non-economic damages – including provisions that afford states the opportunity to maintain or establish laws governing limitations on non-economic damages; (2) prohibiting “loss of chance”, (3) periodic payment of future expenses or losses; (4) offsets for collateral sources; (5) joint and several liability reform; (6) limitations on attorney contingency fees; (7) establishment of uniform statutes of limitations; ~~and~~ (8) establishment of alternative professional liability insurance reforms which may include but are not limited to – health courts, non-binding arbitration and I’m sorry clauses; **AND (9) REIMBURSEMENT OF ALL OUT-OF-POCKET EXPENSES AND LOST INCOME FOR PHYSICIANS WHO ARE VICTIMS OF FRIVOLOUS LAWSUITS.** 1985, revised 1990, 1993, 1998, 2003, revised 2008; reaffirmed 2013, reaffirmed as amended 2018

Background Information: Provided by AOA Staff

**Current AOA Policy:** H333-A/18 PROFESSIONAL LIABILITY INSURANCE REFORM

**Prior HOD action on similar or same topic:** Policy reaffirmed as amended in 2018.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED** *(for sunset)*

DATE: **October 13, 2020**

SUBJECT: H618-A/15 PROVIDER TAX

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H618-A/15 PROVIDER TAX**

5 The American Osteopathic Association opposes any effort by a state or the federal government  
6 to impose a provider tax of any type. 2010; reaffirmed 2015

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H619-A/15 MEDICAID PAYMENT

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRM as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H619-A/15 MEDICAID PAYMENT**

5 The American Osteopathic Association supports ~~legislation to ESTABLISH MEDICAID-~~  
6 ~~MEDICARE PAYMENT PARITY~~ **THE EFFORTS IN EACH STATE TO UPHOLD**  
7 **THEIR OBLIGATION TO PAY PHYSICIANS AND HOSPITALS AT A FAIR AND**  
8 **EQUITABLE RATE FOR PROVIDING QUALITY CARE TO THE STATE'S**  
9 **MEDICAID RECIPIENTS.** 2010; reaffirmed as amended 2015

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

The resolution submitted to the Committee did not contain the original language. Once obtained the Committee felt the original language better conveyed the intent of the resolution. Editorial comment reimburse was changed to pay to align with AOA policy on not using the word reimburse.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**



SUBJECT: H620-A/15 LAY MIDWIVES

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H620-A/15 – LAY MIDWIVES**

5 The American Osteopathic Association opposes the licensing of lay midwives and will continue  
6 providing support to affiliate societies in opposing state’s efforts to license lay midwives. 2010;  
7 reaffirmed 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H621-A/15 MEDICAL MALPRACTICE JUDGMENTS REQUIRING REIMBURSEMENT OF MEDICARE PAYMENTS

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H621-A/15 MEDICAL MALPRACTICE JUDGMENTS REQUIRING**  
5 **REIMBURSEMENT OF MEDICARE PAYMENTS**

6 The American Osteopathic Association will seek an immediate reversal of the policy of the  
7 Centers of Medicare and Medicaid (CMS) requiring a payback of medical care rendered by a  
8 provider who has agreed to a malpractice settlement or received a judgment in a malpractice  
9 court. 2010; 2015

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

The Committee would like a report back on what steps have been taken since adoption of this resolution and the outcome to determine this policy's relevance.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Council on Economic and Regulatory Affairs)*

DATE: **October 13, 2020**

SUBJECT: H622-A/15 ELECTRONIC HEALTH RECORDS – PHYSICIAN ASSISTANCE PROGRAMS FOR TRANSITION TO

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 H622-A/15 **HEALTH INFORMATION TECHNOLOGY PHYSICIAN**  
5 **ASSISTANCE PROGRAMS FOR TRANSITION TO ELECTRONIC**  
6 **HEALTH RECORDS SUPPORT FOR ADOPTING INNOVATIVE**  
7 **HEALTH INFORMATION TECHNOLOGY**

8 The American Osteopathic Association will continue to work with state osteopathic  
9 associations to assist SUPPORT solo practice physicians and small-group practices in the  
10 adoption of health information technology (HIT). THE AOA SUPPORTS INCENTIVES OR  
11 ENHANCED PAYMENTS FOR ADOPTION OF INNOVATIVE HIT THAT  
12 IMPROVES CARE DELIVERY, COORDINATION, AND VALUE. 2005; revised 2010;  
13 reaffirmed as amended 2015

Explanatory Statement: Submitted by Author:

This policy was combined with H616-A/19 titled FEDERAL HEALTH INFORMATION TECHNOLOGY INCENTIVES – AOA SUPPORT for broader HIT interoperability. Approval of this resolution would sunset H616-A/19.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H616-A/19 titled FEDERAL HEALTH INFORMATION TECHNOLOGY INCENTIVES – AOA SUPPORT

**Prior HOD action on similar or same topic:** Policy reaffirmed in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**

SUBJECT: H624-A/15 PRESCRIPTION MEDICATIONS -- OVERRIDES FOR

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be SUNSET.

3 (Old language is crossed out and new language is in CAPS)

4 **H624-A/15 PRESCRIPTION MEDICATIONS -- OVERRIDES FOR**

5 The American Osteopathic Association support legislative efforts to: (1) decrease the hold time  
6 for physicians and staff for requesting approval from insurance pharmacy plans, (2) require  
7 insurance pharmacy plans to allow patients to continue receiving the medications for which  
8 they are prescribed and are in good control; and (3) make it easier for a physician to request an  
9 approval. 2005; reaffirmed 2010; 2015

Explanatory Statement: Submitted by Author:

Submitted a new resolution for consideration by 2020 HOD titled PRIOR AUTHORIZATION which includes content that covers this topic.

Explanatory Statement: Reference Committee

The Committee believes this policy needs to remain active since the policy the Bureau of Socioeconomic Affairs/Council on Economic and Regulatory Affairs submitted for consideration for 2020 HOD (H642), which incorporated this policy, was not approved by the Committee.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H625-A/15 PEDIATRIC PSYCHIATRIC CARE HEALTH RECORDS

SUBMITTED BY: Bureau of Socioeconomic Affairs / Bureau on Scientific Affairs and Public Health

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs and Bureau on Scientific Affairs and  
2 Public recommends that the following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H625-A/15 PEDIATRIC PSYCHIATRIC CARE ~~HEALTH RECORDS~~**

5 The American Osteopathic Association supports the development of educational programs to  
6 assist primary care physicians to identify and initiate appropriate support of pediatric psychiatric  
7 care and encourages insurance providers to adequately reimburse counseling and psychiatric  
8 care deemed necessary by the patient's primary care physician. 2005; reaffirmed 2010; 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H626-A/15 ATTENTION DEFICIT DISORDER / ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADD / ADHD)

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H626-A/15 ATTENTION DEFICIT DISORDER / ATTENTION DEFICIT**  
5 **HYPERACTIVITY DISORDER (ADD / ADHD)**

6 The American Osteopathic Association urges insurance carriers to provide coverage for  
7 attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD) patients by  
8 primary care physicians. 2005; reaffirmed 2010; 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H628-A/15 MEDICARE RECOVERY AUDIT CONTRACTORS

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H628-A/15 MEDICARE RECOVERY AUDIT CONTRACTORS**

5 The American Osteopathic Association will communicate to the Centers for Medicare &  
6 Medicaid Services (CMS) its concern about the Medicare Recovery Audit Contractors (RAC)  
7 payment methodology. 2005; revised 2010; reaffirmed 2015

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

The Committee would like a report back on what steps have been taken regarding this policy and the outcome.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Council on Economic and Regulatory Affairs)*

DATE: **October 13, 2020**

SUBJECT: H629-A/15 MEDICARE LAW AND RULES

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau on Federal Health Program recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H629-A/15 MEDICARE LAW AND RULES**

5 The American Osteopathic Association recommends that Medicare regulations that restrict a  
6 patient's freedom, as well as assess punitive damages to physicians, be challenged and that  
7 administrative burdens placed on both the patient and physician be reduced. 1995; revised 2000,  
8 2005; reaffirmed 2010; reaffirmed as amended 2015

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

The Committee would like a report back with examples and steps that have been taken to address.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Bureau on Federal Health Programs)*

DATE: **October 13, 2020**



SUBJECT: H630-A/15 VETERANS ADMINISTRATION CREDENTIALING OF  
NON-PHYSICIAN PROVIDERS HEALTH RECORDS

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau on Federal Health Programs recommends that the following  
2 policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H630-A/15 VETERANS ADMINISTRATION CREDENTIALING OF NON-**  
5 **PHYSICIAN PROVIDERS HEALTH RECORDS**

6 The American Osteopathic Association (**AOA**) supports the establishment of well-defined  
7 credentialing and privileging criteria within the Veterans Administration (VA) that prohibits  
8 non-physician providers with expanded scope of practice rights in a minority of states from  
9 demanding such privileges in the VA system and supports the establishment of a consistent  
10 requirement for the privileging of non-physician providers in the VA system. 2005; reaffirmed  
11 2010; 2015

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

---

DATE: **October 13, 2020**

---

SUBJECT: H631-A/15 TAX CREDITS FOR HEALTH PROFESSION SHORTAGE AREAS

SUBMITTED BY: Bureau on Federal Health Programs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau on Federal Health Programs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H631-A/15 TAX CREDITS FOR HEALTH PROFESSION SHORTAGE AREAS**  
5 The American Osteopathic Association (AOA) supports the establishment of tax credits for  
6 physicians who practice full time in federally designated health professions shortage areas  
7 (HPSAs) or Medicare defined physician scarcity areas and federally and/or state designated  
8 underserved areas and urges that these tax credits be available, on a sliding scale, to physicians  
9 who provide services on a part-time basis in these communities. 2005; reaffirmed 2010; 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H632-A/15 OSTEOPATHIC MANIPULATIVE TREATMENT (OMT)  
IN A PRE-PAID ENVIRONMENT –PAYMENT POLICIES FOR

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H632-A/15 OSTEOPATHIC MANIPULATIVE TREATMENT (OMT) IN A PRE-**  
5 **PAID ENVIRONMENT –PAYMENT POLICIES FOR**

6 The American Osteopathic Association will work to ensure that: (1) osteopathic manipulative  
7 treatment in any prepaid compensation model be recognized as a separate procedure; (2)  
8 osteopathic manipulative treatment as a procedure applied by fully-licensed physicians and  
9 surgeons be considered unique; and (3) osteopathic manipulative treatment in any prepaid  
10 compensation model be compensated as a special separate procedure, either by payment of  
11 additional capitation or on a fee-for-service basis without the need for prior authorization. 1995;  
12 revised 2000, 2005, 2010; reaffirmed as amended 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H633-A/15 PRESCRIPTION OF DRUGS FOR OFF LABEL USES

SUBMITTED BY: Bureau of Federal Health Programs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Federal Health Programs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H633-A/15 PRESCRIPTION OF DRUGS FOR OFF LABEL USES**

5 The American Osteopathic Association believes it is appropriate for physicians to prescribe  
6 approved drugs for uses not included in their official labeling when they can be supported as  
7 accepted medical practice. 1995; reaffirmed 2000, 2005, 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H635-A/15 NEWBORN AND INFANT HEARING SCREENS

SUBMITTED BY: Bureau of Scientific Affairs and Public Health

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H635-A/15 NEWBORN AND INFANT HEARING SCREENS**

5 The American Osteopathic Association supports adequate funding for universal hearing  
6 screening and intervention for newborns and infants. 1995; revised 2000, 2005; reaffirmed 2010;  
7 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H636-A/15 MEDICARE PREVENTIVE MEDICAL SCREENING

SUBMITTED BY: Bureau of Federal and Health Programs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Federal and Health Programs recommends that the following  
2 policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H636-A/15 MEDICARE PREVENTIVE MEDICAL SCREENING**

5 The American Osteopathic Association supports coverage of Medicare recipients for routine  
6 preventive medical services. 1995; reaffirmed 2000, revised 2005; reaffirmed 2010; 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H637-A/15 CONFIDENTIALITY OF PATIENT RECORDS

SUBMITTED BY: Ethics Subcommittee

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Ethics Subcommittee recommends that the following policy be  
2 REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H637-A/15 CONFIDENTIALITY OF PATIENT RECORDS**

5 The American Osteopathic Association opposes invasion of privacy of the patient record by  
6 any unauthorized person or agency; and endorses reasonable programs which seek to protect  
7 patient/physician relationships and guarantee confidentiality of patient records. 1980; revised  
8 1985, 1990, 1995; 2000, 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H638-A/15 DIABETICS CONFINED TO CORRECTIONAL INSTITUTIONS

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau on Scientific Affairs and Public Health recommends that the  
2 following policy be REAFFIRMED as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 H638-A/15 ~~DIABETICS PERSONS WITH DIABETES CONFINED TO~~  
5 ~~CORRECTIONAL INSTITUTIONS~~

6 The American Osteopathic Association supports the availability of American Diabetes  
7 Association (ADA) diabetic meals, beverages, and other diabetic interventions that follow ADA  
8 guidelines for all ~~diabetic inmates~~ IMPRISONED PERSONS WITH DIABETES, who are  
9 under the care of a licensed physician, and confined in correctional institutions. 2000, revised  
10 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: ADOPTED

DATE: October 13, 2020



SUBJECT: H639-A/15 DISCRIMINATION BY INSURERS

SUBMITTED BY: Bureau on Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau on Socioeconomic Affairs and Council on AOA Policy  
2 recommends that the following policy be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H639-A/15 DISCRIMINATION BY INSURERS**

5 The American Osteopathic Association will actively pursue all reasonable avenues in support of  
6 its members who are discriminated against by insurance companies and excluded from  
7 participating in insurance programs; and in those instances where there is no due process to  
8 discuss and mediate the exclusions, the AOA will petition organizations to present their  
9 credentialing criteria and deselection criteria, and will use those resources at its disposal to help  
10 obtain a fair and equitable solution to the problem and to include due process in all cases. 1995;  
11 revised 2000, 2005; revised 2010; reaffirmed 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H640-A/15 EXECUTIONS IN CAPITAL CRIMES CRIMINAL CASES

SUBMITTED BY: Ethics Subcommittee

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Ethics Subcommittee recommends that the following policy be  
2 REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H640-A/15 EXECUTIONS IN CAPITAL CRIMES CRIMINAL CASES**

5 The American Osteopathic Association deems it an unethical act for any osteopathic physician  
6 to deliver or be required to deliver a lethal injection for the purpose of execution in capital  
7 crimes. 1995; revised 2000, reaffirmed 2005; 2010; [Editor's note: In 2015 this policy was  
8 referred to the Ethics Subcommittee].

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H642-A/15 MANAGED CARE – ALL PRODUCTS CLAUSES

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of State Government Affairs recommends that the following  
2 policy be REAFFIRM as AMENDED.

3 (Old language is crossed out and new language is in CAPS)

4 **H642-A/15 MANAGED CARE – ALL PRODUCTS CLAUSES**

5 The American Osteopathic Association and state osteopathic societies oppose the use of “all  
6 products/all products developed in the future” clauses in physician managed care contracts;  
7 actively opposes the use of any other clauses that may limit the ability of the physician to  
8 choose the plans in which he or she participates; ~~will educate its members on the potential risks~~  
9 ~~of “all products/all products developed in the future” clauses and the importance of identifying~~  
10 ~~such clauses in contracts prior to their signing;~~ and supports both state and federal legislation as  
11 well as regulatory agency regulations and rulings to prohibit the use of “all products/all  
12 products developed in the future” clauses in physician managed care contracts. 2000, revised  
13 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H643-A/15 MEDICAL PROCEDURE PATENTS

SUBMITTED BY: Bureau of Federal Health Program

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Federal Health Program recommends that the following  
2 policy be REAFFIRM.

3 (Old language is crossed out and new language is in CAPS)

4 **H643-A/15 MEDICAL PROCEDURE PATENTS**

5 The American Osteopathic Association (AOA) supports measures that restrict medical  
6 procedure patents. 1995; reaffirmed 2000, revised 2005; reaffirmed 2010; 2015.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H644-A/15 MEDICARE CONTRACTOR DENIAL LETTERS

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H644-A/15 MEDICARE CONTRACTOR DENIAL OF SERVICE LETTERS**

5 The American Osteopathic Association calls upon the Centers for Medicare and Medicaid  
6 Services (CMS) to continue to involve osteopathic physicians in the development of screening  
7 parameters **FOR DENIAL OF SERVICES FOR including** osteopathic structural diagnoses  
8 and **OSTEOPATHIC** manipulative treatments. 1990; revised 1995, 2000, 2005; revised 2010;  
9 reaffirmed 2015

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**

SUBJECT: H646-A/15 OSTEOPATHIC MEDICAL STUDENT, RESIDENT, AND  
PHYSICIAN MENTAL HEALTH

SUBMITTED BY: Bureau of Emerging Leaders

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Emerging Leaders recommends that the following policy be  
2 REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H646-A/15 OSTEOPATHIC MEDICAL STUDENT, RESIDENT, AND**  
5 **PHYSICIAN MENTAL HEALTH**

6 The American Osteopathic Association (AOA) will promote mental health awareness and  
7 provide osteopathic medical students, residents, and physicians with educational information on  
8 recognizing mental health issues among themselves and their colleagues. The AOA will work  
9 with the American Association of Colleges of Osteopathic Medicine, AOA State Divisional  
10 Societies, and Advocates for the American Osteopathic Association to reduce the stigma  
11 associated with mental illness to eliminate barriers to treatment while advocating for increasing  
12 the resources for care. 2015

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff  
**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: H647-A/15 AMERICAN OSTEOPATHIC ASSOCIATION (AOA)  
OSTEOPATHIC MANIPULATIVE TREATMENT (OMT)  
COVERAGE DETERMINATION GUIDANCE

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
2 be REAFFIRMED.

3 (Old language is crossed out and new language is in CAPS)

4 **H647-A/15 AMERICAN OSTEOPATHIC ASSOCIATION (AOA) OSTEOPATHIC**  
5 **MANIPULATIVE TREATMENT (OMT) COVERAGE**  
6 **DETERMINATION GUIDANCE**

7 The American Osteopathic Association (AOA) approves the attached policy as the standard  
8 guidelines for OMT coverage and encourages all public and private payers to refer to the  
9 AOA's policy when developing new policy or revising existing guidance for OMT coverage.  
10 2015

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: ACCESS TO CARE – NETWORK ADEQUACY AND COVERAGE

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, access to health care relies upon both the availability of providers and the patients'  
2 ability to cover the costs of health care services; and

3 WHEREAS, comprehensive, high-quality health care often involves services from multiple  
4 providers across different specialties, often working in collaboration; and

5 WHEREAS, government regulators and insurance companies have a responsibility to ensure  
6 that plan networks have adequate numbers of providers available in-person to provide  
7 all necessary services in the beneficiary's area; now, therefore be it

8 RESOLVED, American Osteopathic Association (AOA) will advocate to ensure plan coverage  
9 by public and private payors for all medically necessary services in-person, within a  
10 reasonable distance/wait time for all plan beneficiaries; and be it further

11 RESOLVED, the AOA support state insurance commissioners **AND/OR OTHER**  
12 **APPROPRIATE REGULATORY AGENCIES** as the primary enforcers of network  
13 adequacy requirements.

Explanatory Statement: Submitted by Author:

**H317-A/15 PATIENT ACCESS IN RURAL AREAS** has been reviewed by the Bureau of State Government Affairs and it was determined that the content could be merged into **H635-A/16 ACCESS TO CARE – NETWORK ADEQUACY AND COVERAGE** to create a more comprehensive, streamlined policy. We suggest that both **H317-A/15** and **H635-A/16** be deleted and replaced with this resolution. Relevant revised language from those resolutions has been included in this resolution:

**H317-A/15 PATIENT ACCESS IN RURAL AREAS**

~~The American Osteopathic Association supports policy on the state and federal levels that would require all managed care health plans to have reasonably placed network physicians and hospital access; if the distance is unreasonable, the plans should pay for out of network services at no additional cost to the patient.~~

**H635-A/16 ACCESS TO CARE – NETWORK ADEQUACY AND COVERAGE**

The American Osteopathic Association (AOA) will advocate for public and private payors **TO** ensure ~~ing~~ plan coverage BY PUBLIC AND PRIVATE PAYORS for all medically necessary services **IN-PERSON, WITHIN A REASONABLE DISTANCE/WAIT TIME FOR ALL PLAN** regardless of availability within the service area of its beneficiaries, and supporting state regulators **INSURANCE COMMISSIONERS** as the primary enforcer**S** of network adequacy requirements.



Background Information: Provided by AOA Staff

**Current AOA Policy:**

H309-A/16 PATIENT ACCESS IN RURAL AREAS

H635-A/16 ACCESS TO CARE – NETWORK ADEQUACY AND COVERAGE

**Prior HOD action on similar or same topic:** H309-A/16 policy reaffirmed in 2016; H635-A/16 policy approved in 2016.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**

SUBJECT: ADDRESSING FEARS AND BARRIERS TO TELEMEDICINE  
IMPLEMENTATION AND ALIGNMENT

SUBMITTED BY: Michigan Osteopathic Association

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, telemedicine is becoming a growing entity and option for healthcare services; and  
2 WHEREAS, the potential convenience and lower costs of telemedicine may be highly attractive  
3 to patients; and  
4 WHEREAS, many physicians have expressed concern that telemedicine could adversely affect  
5 the patient/physician relationship, quality of care, and/or patient safety; and  
6 WHEREAS, appropriate oversight and regulations for telemedicine services are lacking; and  
7 WHEREAS, inferior technology and network coverage can affect consistent services; and  
8 WHEREAS, empowering a physician’s ability to engage and implement telemedicine could  
9 increase revenue, practice marketing options, and enhance relationships with physician’s  
10 existing patients; now, therefore, be it  
11 RESOLVED, that the American Osteopathic Association (AOA) engage partner organizations  
12 to support understanding, training and implementation of telemedicine in physician  
13 offices; and, be it further  
14 RESOLVED, that the AOA **BELIEVES THAT EVERY EFFORT SHOULD BE MADE**  
15 **TO ALLOW TELEMEDICINE SERVICES TO BE PROVIDED BY THE**  
16 **PATIENT’S REGULAR ATTENDING PHYSICIAN RATHER THAN BY**  
17 **PROVIERS NOT AFFILIATED WITH OR TO WHOME THE PATIENT**  
18 **HAS NOT BEEN REFERRED BY THE PATIENT’S PRIMARY CARE**  
19 **PHYSICIAN ~~engage in evaluating processes that help our physicians implement~~**  
20 **telemedicine in practices.**

Explanatory Statement: Submitted by Author  
None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H601-A/17 TELEMEDICINE – AOA POLICY ON

**Prior HOD action on similar or same topic:** Policy approved as amended in 2017.

FISCAL IMPACT: \$0

*Finance Committee Explanatory Statement* – The general provisions included in this resolution may be incorporated into the AOA’s existing processes without additional fiscal impact. Activities undertaken through the educational, legislative and legal realms currently address evolving telemedicine issues as

warranted. Additional efforts would require shifting of resources, but without an expectation of additional expenditures at this time.

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**

SUBJECT: ADDRESSING SOCIAL DETERMINANTS OF HEALTH THROUGH  
DATA COLLECTION AND IMPROVED ACCESS TO SOCIAL  
SERVICES

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, equity in health and overall wellbeing is not simply determined by individual  
2 choices but based on life chances and the resources provided in the environment one is  
3 born into <sup>1,2</sup>; and

4 WHEREAS, consistent structural differences in social opportunities amongst the indigent  
5 compared to the affluent is as important to life expectancy and health outcomes as  
6 affordable access to medical treatment<sup>1,2</sup>; and

7 WHEREAS, the glaring inequality in freedom to live a thriving, healthy life can be balanced  
8 through concerted effort to reverse structural drivers including policies, economics, and  
9 living conditions to ensure a sustainable standard of health across all socioeconomic and  
10 cultural backgrounds<sup>1,2</sup>; and

11 WHEREAS, there is widespread support for screening tools to measure social determinants of  
12 health (SDoH) such as food insecurity, domestic violence, and housing quality that  
13 currently exist in clinical practice<sup>3,4</sup>; and

14 WHEREAS, implementation of comprehensive screening with adequate linked cooperation to  
15 local community resources was a noted barrier to practical use<sup>3</sup>; and

16 WHEREAS, the success of promising universal assessment tools, such as the Center for  
17 Medicare and Medicaid Services' Accountable Health Communities (AHC) Model,  
18 could be limited by inadequate funding, lack of hospital cooperation, and omission of  
19 essential social and behavioral measures <sup>4,5</sup>; and

20 WHEREAS, American Osteopathic Association (AOA) aims to promote public health and  
21 accentuate the distinctive philosophy of Osteopathic Medicine to treat the whole-person  
22 as affirmed by AOA Policy H406-A/17 and H300-A/18; and

23 WHEREAS, private sector organizations are working with national medical organizations  
24 through the Integrated Health Model Initiative (IHMI) to address the issue of SDoH  
25 systematically through the process of creating relevant ICD-10 codes related to “critical  
26 factors of patient well-being, such as employment, education, food, housing, access to  
27 transportation, and many other factors” which will trigger social services referrals<sup>7</sup>; and

28 WHEREAS, ICD-10-CM is an international classification of diseases that plays a fundamental  
29 role in health care delivery and payment policy, and it has recently been adapted in the  
30 United States to include clinical modification (CM) which expands implications to  
31 precise measuring, disease tracking, health care utilization, and quality of patient care

1 including codes “Z00-Z99” for factors influencing health status and contact with health  
2 services<sup>6</sup>; and

3 WHEREAS, projects exist that aim to improve screening, diagnosis, treatment, and planning by  
4 using technology to streamline data collection by defining a coded library of terms  
5 related to SDoH and use interoperability of electronic health systems to address  
6 individual patient needs more effectively<sup>8</sup>; now, therefore be it

7 RESOLVED, that the American Osteopathic Association (AOA) will adopt an official position  
8 that supports the use of ICD-10-CM codes regarding social determinants of health that  
9 mitigate challenges of physician referrals to social or government resources; and, be it  
10 further

11 RESOLVED, that the AOA support legislation that improves interoperability of electronic  
12 health records to reduce overall health care costs by improving communication between  
13 members of a care team, including social services; and, be it further

14 RESOLVED, that the AOA support a validated screening tool to identify patients influenced  
15 by social determinants of health.

Explanatory Statement: Submitted by Author:

Please note the use of “structural drivers” in line 7 refers to gender norms and values, economic participation, social exclusion, wealth distribution, education, civil rights, governance, public spending priorities, and macroeconomic conditions<sup>1</sup>. Further, note that the phrase “validated screening tool” referenced in line 51 indicates issuing a position of support for the creation of a standardized measurement of social determinants of health in individual patients that can be used across the nation, in any setting, and that has been authenticated to accurately assess patients at risk without any bias or skew towards certain demographics. This tool is indicated to be used at patient intake to identify individuals, such that the proper ICD-10 codes can be documented at the time of the encounter. Please be advised that the use of the term “support(s)” in the resolved statements is meant to indicate that SOMA and the AOA will use their judgement to promote the utilization of existing ICD-10 codes whether it be issuing a statement of support, lobbying for federal legislation relating to these codes, etc.

References

1. Commission on Social Determinants of Health (CSDH), Closing the gap in a generation: health equity through action on the social determinants of health. Final report of the Commission on Social Determinants of Health. 2008, World Health Organization: Geneva.
2. U.S. Department of Health and Human Services. Healthy People 2020: Social Determinants. Retrieved October 1, 2019, from: <https://www.healthypeople.gov/2020/leading-health-indicators/2020-lhi-topics/Social-Determinants>
3. Davidson KW, McGinn T. Screening for Social Determinants of Health: The Known and Unknown. JAMA. Published online August 29, 2019. doi:10.1001/jama.2019.1091
4. Thomas-Henkel, Caitlin. Screening for Social Determinants of Health in Populations with Complex Needs: Implementation Considerations. Center for Health Care Strategies, Inc. October 2017, from <https://www.chcs.org/media/SDOH-Complex-Care-Screening-Brief-102617.pdf>
5. Centers for Medicare and Medicaid Services. Accountable Health Communities Model. Retrieved March 1, 2020, from: <https://innovation.cms.gov/initiatives/ahcm>

6. Centers for Disease Control and Prevention: National Center for Health Statistics. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Retrieved March 1, 2020, from <https://www.cdc.gov/nchs/icd/icd10cm.htm#FY%202020%20release%20of%20ICD-10-CM>
7. American Medical Association. (2019, April 2). UNH and the AMA collaborate to address access to better health [Press release]. Retrieved from <https://www.ama-assn.org/press-center/press-releases/unh-and-ama-collaborate-address-access-better-health>
8. Health Level Seven® International (HL7®). (2019, August 20). New HL7® FHIR® Accelerator Project Aims to Improve Interoperability of Social Determinants of Health Data [Press release]. Retrieved from [http://www.hl7.org/documentcenter/public\\_temp\\_E229E04C-1C23-BA17-0C76A643D1AFCAB7/pressreleases/HL7\\_PRESS\\_20190820.pdf](http://www.hl7.org/documentcenter/public_temp_E229E04C-1C23-BA17-0C76A643D1AFCAB7/pressreleases/HL7_PRESS_20190820.pdf)

Explanatory Statement: Reference Committee

The Committee feels this needs to be restructured due to lack of clarity and overlap with existing policy.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **REFERRED** *(to Student Osteopathic Medical Association)*

DATE: **October 13, 2020**

SUBJECT: ELIMINATION OF PRIOR AUTHORIZATION AND STEP THERAPY

SUBMITTED BY: Michigan Osteopathic Association

REFERRED TO: Ad Hoc Committee

---

- 1 WHEREAS, US healthcare spending is significantly greater for administrative costs than other  
2 countries; and
- 3 WHEREAS, substantial costs to medical practices are required in order to process Prior  
4 Authorizations (PAs); and
- 5 WHEREAS, administrative burdens to healthcare providers concerning PAs have substantially  
6 increased thus leading to higher cost and delays to patient care and the related adverse  
7 outcomes resulting from delays or denials of patient care; and
- 8 WHEREAS, legislative attempts to address PA issues have focused on transparency, rather than  
9 addressing the barriers to timely patient care; and
- 10 WHEREAS, PA burdens in medical practice have increased significantly; and
- 11 WHEREAS, PA's and step therapy have been shown to lead to unnecessary hospitalizations  
12 and overall health care, cost as well as increased patient morbidity and mortality; now,  
13 therefore be it
- 14 RESOLVED, that the American Osteopathic Association advocate for elimination of prior  
15 authorizations as a third payor pre-requisite for the provision of quality health care in  
16 order to avoid harm and/or death due to delays in care.

Explanatory Statement: Submitted by Author

None provided.

Explanatory Statement: Reference Committee

Complete elimination of prior authorization and step therapy could result in improper utilization. The committee feels that H642, reviewed by this committee, can be used to help place guardrails on these practices.

Background Information: Provided by AOA Staff

**Current AOA Policy:**

H343-A/13 CURRENT PROCEDURAL TERMINOLOGY (CPT) CODE FOR PRIOR AUTHORIZATION  
H602-A/15 REIMBURSEMENT FOR PHYSICIAN TIME SPENT OBTAINING PRE-CERTIFICATION AND PRE-AUTHORIZATION  
H640-A/16 PRIOR AUTHORIZATION  
H632-A/17 PRIOR AUTHORIZATION  
H635-A/19 PRIOR AUTHORIZATION – PATIENT AUTHORIZATION

**Prior HOD action on similar or same topic:** H343-A/13 policy reaffirmed in 2013 (referred to BSA in 2018); H602-A/15 policy approved in 2015; H640-A/16 policy approved in 2016; H632-A/17 policy approved in 2017, H635-A/19 policy approved in 2019

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 13, 2020**



SUBJECT: H623-A/18 NON-PHYSICIAN CLINICIANS

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, the Bureau of State Government Affairs (BSGA) convened a workgroup to review  
2 the American Osteopathic Association’s (AOA) Non-Physician Clinicians policy in light  
3 of the ongoing attempts by non-physician clinicians to independently practice medicine,  
4 despite wide variances in their education, training, and competency demonstration  
5 requirements (all of which fall short of the nationally standardized requirements for  
6 physicians); and,

7 WHEREAS, current AOA policy H623-A/18 NON-PHYSICIAN CLINICIANS; supports  
8 either (undefined) “collaboration” or “supervision” by physicians, to ensure meaningful  
9 physician involvement and oversight in states that do not currently allow non-physician  
10 clinicians to practice independently; and

11 WHEREAS, it is the belief of the BSGA that the AOA should retain its current opposition to  
12 independent practice for non-physicians, **TO VOICE OPPOSITION TO THE**  
13 **ESTABLISHMENT OF EDUCATIONAL PROGRAMS TITLED**  
14 **“RESIDENCIES AND FELLOWSHIPS” FOR ADVANCED PRACTICE**  
15 **NURSES, PHYSICIAN ASSISTANTS, PHYSICAL THERAPISTS AND**  
16 **OTHERS, AND** add support for regulating these professionals by state medical  
17 licensing boards in states that currently allow non-physician clinicians to practice  
18 independently by law, to ensure that they are being held to the same standards of care as  
19 physicians; now, therefore be it

20 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
21 policy be REAFFIRMED AS AMENDED.

22 H623-A/18 NON-PHYSICIAN CLINICIANS The American Osteopathic Association has adopted  
23 the attached policy paper as its position on non-physician clinicians including appropriate onsite  
24 supervision. 2000, revised 2005; revised 2010; reaffirmed 2015; revised 2018

25 Policy Statement - 2018 NON-PHYSICIAN CLINICIANS

26 OVER THE COURSE OF THE PAST CENTURY, SCIENTIFIC AND TECHNOLOGICAL  
27 ADVANCEMENTS HAVE LED TO IMPROVEMENTS IN THE TREATMENT OF  
28 DISEASE AND STANDARDS OF PATIENT CARE. AS A RESULT, THE STANDARDIZED  
29 MEDICAL EDUCATION, SUPERVISED POSTGRADUATE (“RESIDENCY”) TRAINING  
30 AND EXAMINATION SERIES THAT ~~THE DO/MD~~ PHYSICIANS IN THE UNITED  
31 STATES ARE REQUIRED TO COMPLETE IN ORDER TO OBTAIN AN UNLIMITED  
32 MEDICAL LICENSE HAS INCREASED AS WELL. AT THE SAME TIME, HOWEVER,  
33 SOME STATES ARE CREATING LEGISLATIVE PATHWAYS TO INDEPENDENT  
34 MEDICAL PRACTICE FOR OTHER TYPES OF CLINICIANS, DESPITE THE ABSENCE

1 OF NATIONALLY STANDARDIZED EDUCATION, TRAINING AND TESTING  
2 PATHWAYS FOR THESE CLINICIAN GROUPS, OR EVIDENCE REGARDING PATIENT  
3 SAFETY OUTCOMES.

4 The current DO/MD medical model, IN WHICH MEDICAL STUDENTS AND RESIDENT  
5 PHYSICIANS ARE REQUIRED TO DEMONSTRATE THEIR ABILITY TO SAFELY  
6 PROVIDE CARE TO PATIENTS UNDER THE SUPERVISION OF FULLY LICENSED  
7 PHYSICIANS, LEADING TO GREATER AUTONOMY OVER TIME, has proven its ability to  
8 provide ~~professionals~~ PHYSICIANS with THE complete KNOWLEDGE AND SKILL BASE  
9 ~~medical education and training and testing~~ needed to ensure patient safety AND OPTIMIZE  
10 OUTCOMES. IN ADDITION, MOST STATES IMPOSE ADDITIONAL CONTINUING  
11 MEDICAL EDUCATION (CME) REQUIREMENTS, AND MANY PHYSICIANS ELECT TO  
12 UNDERGO RIGOROUS CERTIFYING BOARD EXAMINATIONS TO DEMONSTRATE  
13 EXCELLENCE IN A PARTICULAR SPECIALTY, WHICH HELPS TO ENSURE THAT  
14 PHYSICIANS REMAIN TRAINED TO PROVIDE THE CURRENT HIGHEST STANDARD  
15 OF PATIENT CARE OVER THE COURSE OF THEIR CAREERS.

16 Thus, it is appropriate that the practice of medicine and the quality of medical care ~~are~~ REMAIN the  
17 responsibility of ~~properly licensed~~ physicians, WHO ARE THE ONLY CLINICIAN GROUP  
18 PROPERLY TRAINED, LICENSED AND REGULATED ACCORDING TO UNIFORM  
19 LAWS GOVERNING MEDICAL LICENSURE IN THE UNITED STATES. The American  
20 Osteopathic Association (AOA) ~~further~~ VALUES THE UNIQUE TRAINING AND  
21 CONTRIBUTIONS OF ALL MEMBERS OF THE PATIENT CARE TEAM, AND supports the  
22 concept of uniform licensure pathways for ~~non-physician~~ ALL clinician GROUPS, based upon scope  
23 of practice. THE AOA ~~is~~ FURTHER SUPPORTS APPROPRIATE PHYSICIAN  
24 INVOLVEMENT IN PATIENT CARE PROVIDED BY NON-PHYSICIAN CLINICIANS,  
25 AND opposes any legislation or regulations which would authorize the independent practice of  
26 medicine by an individual who has not completed the state’s requirements for physician licensure.

27 As non-physician clinicians continue to seek wider roles, public policy dictates THAT patient safety  
28 and proper patient care should be foremost in mind when the issues encompassing expanded  
29 practice rights for non-physician clinicians – autonomy, scopes of practice, prescriptive rights,  
30 liability and reimbursement, among others – are addressed.

31 A. **Patient Safety.** The AOA supports the “team” approach to medical care, with the physician as  
32 the leader of that team. The AOA further supports the position that patients should be made clearly  
33 aware at all times whether they are being treated by a non-physician clinician or a physician. The  
34 AOA recognizes the growth of non-physician clinicians and supports their rights to practice with  
35 appropriate physician involvement within the scope of ~~the~~ relevant state statutes.

36 B. **Independent Practice.** It is the AOA’s position that roles within the “team” framework must be  
37 clearly defined, through established STATE-LEVEL SUPERVISORY protocols and signed  
38 agreements, so physician involvement in patient care is sought when a patient’s case dictates AND  
39 PATIENTS CAN REST ASSURED THAT PHYSICIAN INVOLVEMENT IN THEIR CARE  
40 WILL REMAIN THE SAME REGARDLESS OF PRACTICE SETTING WITHIN THE

1 STATE. ~~The AOA feels nonphysician clinician professions that have traditionally been under the~~  
2 ~~supervision of physicians must retain physician involvement in patient care. Those non-physician~~  
3 ~~clinician professions that have traditionally remained independent of physicians must involve~~  
4 ~~physicians in patient care when warranted.~~ FURTHER, aAll non-physician clinicians must refer a  
5 patient to a physician when the patient’s condition is beyond the non-physician clinician’s scope of  
6 education, training or expertise.

7 C. Liability. The AOA endorses the view that physician liability for non-physician clinician actions  
8 should be reflective of the quality AND DEGREE of supervision being provided and should not  
9 exonerate the non-physician clinician from liability. It is the AOA’s position that non-physician  
10 clinicians ~~acting~~ PROVIDING CARE IN INDEPENDENT PRACTICE STATES ~~autonomously~~  
11 ~~of physicians~~ should be REGULATED AND DISCIPLINED BY THE ENTITIES  
12 RESPONSIBLE FOR REGULATING AND DISCIPLINING PHYSICIANS (I.E. STATE  
13 MEDICAL BOARDS), TO ENSURE THAT ALL CLINICIANS WHO ARE  
14 INDEPENDENTLY PRACTICING MEDICINE ARE held to the SAME STANDARD OF  
15 CARE AND THE equivalent degree of liability ~~as that of a physician. Within this independent~~  
16 ~~practice framework,~~ TO THAT END, the AOA ~~further~~ ALSO believes that non-physician clinicians  
17 should be required to obtain EQUIVALENT malpractice insurance ~~in those states that currently~~  
18 ~~require~~ TO physicians IN STATES THAT CURRENTLY REQUIRE PHYSICIANS to possess  
19 malpractice insurance.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H623-A/18 NON-PHYSICIAN CLINICIANS

**Prior HOD action on similar or same topic:** Policy approved as amended in 2018.

Fiscal Impact: \$0

ACTION TAKEN **ADOPTED as AMENDED**

DATE **October 13, 2020**

SUBJECT: H623-A/18 NON-PHYSICIAN CLINICIANS

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, the Bureau of State Government Affairs (BSGA) convened a workgroup to review  
2 the American Osteopathic Association’s (AOA) Non-Physician Clinicians policy in light  
3 of the ongoing attempts by non-physician clinicians to independently practice medicine,  
4 despite wide variances in their education, training, and competency demonstration  
5 requirements (all of which fall short of the nationally standardized requirements for  
6 physicians); and,

7 WHEREAS, current AOA policy H623-A/18 NON-PHYSICIAN CLINICIANS; supports  
8 either (undefined) “collaboration” or “supervision” by physicians, to ensure meaningful  
9 physician involvement and oversight in states that do not currently allow non-physician  
10 clinicians to practice independently; and

11 WHEREAS, it is the belief of the BSGA that the AOA should retain its current opposition to  
12 independent practice for non-physicians, **TO VOICE OPPOSITION TO THE**  
13 **ESTABLISHMENT OF EDUCATIONAL PROGRAMS TITLED**  
14 **“RESIDENCIES AND FELLOWSHIPS” FOR ADVANCED PRACTICE**  
15 **NURSES, PHYSICIAN ASSISTANTS, PHYSICAL THERAPISTS AND**  
16 **OTHERS, AND** add support for regulating these professionals by state medical  
17 licensing boards in states that currently allow non-physician clinicians to practice  
18 independently by law, to ensure that they are being held to the same standards of care as  
19 physicians; now, therefore be it

20 RESOLVED, that the Bureau of State Government Affairs recommend that the following  
21 policy be REAFFIRMED AS AMENDED.

22 H623-A/18 NON-PHYSICIAN CLINICIANS The American Osteopathic Association has adopted  
23 the attached policy paper as its position on non-physician clinicians including appropriate onsite  
24 supervision. 2000, revised 2005; revised 2010; reaffirmed 2015; revised 2018

25 Policy Statement - 2018 NON-PHYSICIAN CLINICIANS

26 OVER THE COURSE OF THE PAST CENTURY, SCIENTIFIC AND TECHNOLOGICAL  
27 ADVANCEMENTS HAVE LED TO IMPROVEMENTS IN THE TREATMENT OF  
28 DISEASE AND STANDARDS OF PATIENT CARE. AS A RESULT, THE STANDARDIZED  
29 MEDICAL EDUCATION, SUPERVISED POSTGRADUATE (“RESIDENCY”) TRAINING  
30 AND EXAMINATION SERIES THAT ~~The DO/MD~~ PHYSICIANS IN THE UNITED  
31 STATES ARE REQUIRED TO COMPLETE IN ORDER TO OBTAIN AN UNLIMITED  
32 MEDICAL LICENSE HAS INCREASED AS WELL. AT THE SAME TIME, HOWEVER,  
33 SOME STATES ARE CREATING LEGISLATIVE PATHWAYS TO INDEPENDENT  
34 MEDICAL PRACTICE FOR OTHER TYPES OF CLINICIANS, DESPITE THE ABSENCE

1 OF NATIONALLY STANDARDIZED EDUCATION, TRAINING AND TESTING  
2 PATHWAYS FOR THESE CLINICIAN GROUPS, OR EVIDENCE REGARDING PATIENT  
3 SAFETY OUTCOMES.

4 The current DO/MD medical model, IN WHICH MEDICAL STUDENTS AND RESIDENT  
5 PHYSICIANS ARE REQUIRED TO DEMONSTRATE THEIR ABILITY TO SAFELY  
6 PROVIDE CARE TO PATIENTS UNDER THE SUPERVISION OF FULLY LICENSED  
7 PHYSICIANS, LEADING TO GREATER AUTONOMY OVER TIME, has proven its ability to  
8 provide ~~professionals~~ PHYSICIANS with THE complete KNOWLEDGE AND SKILL BASE  
9 ~~medical education and training and testing~~ needed to ensure patient safety AND OPTIMIZE  
10 OUTCOMES. IN ADDITION, MOST STATES IMPOSE ADDITIONAL CONTINUING  
11 MEDICAL EDUCATION (CME) REQUIREMENTS, AND MANY PHYSICIANS ELECT TO  
12 UNDERGO RIGOROUS CERTIFYING BOARD EXAMINATIONS TO DEMONSTRATE  
13 EXCELLENCE IN A PARTICULAR SPECIALTY, WHICH HELPS TO ENSURE THAT  
14 PHYSICIANS REMAIN TRAINED TO PROVIDE THE CURRENT HIGHEST STANDARD  
15 OF PATIENT CARE OVER THE COURSE OF THEIR CAREERS.

16 Thus, it is appropriate that the practice of medicine and the quality of medical care ~~are~~ REMAIN the  
17 responsibility of ~~properly licensed~~ physicians, WHO ARE THE ONLY CLINICIAN GROUP  
18 PROPERLY TRAINED, LICENSED AND REGULATED ACCORDING TO UNIFORM  
19 LAWS GOVERNING MEDICAL LICENSURE IN THE UNITED STATES. The American  
20 Osteopathic Association (AOA) ~~further~~ VALUES THE UNIQUE TRAINING AND  
21 CONTRIBUTIONS OF ALL MEMBERS OF THE PATIENT CARE TEAM, AND supports the  
22 concept of uniform licensure pathways for ~~non-physician~~ ALL clinician GROUPS, based upon scope  
23 of practice. THE AOA ~~is~~ FURTHER SUPPORTS APPROPRIATE PHYSICIAN  
24 INVOLVEMENT IN PATIENT CARE PROVIDED BY NON-PHYSICIAN CLINICIANS,  
25 AND opposes any legislation or regulations which would authorize the independent practice of  
26 medicine by an individual who has not completed the state’s requirements for physician licensure.

27 As non-physician clinicians continue to seek wider roles, public policy dictates THAT patient safety  
28 and proper patient care should be foremost in mind when the issues encompassing expanded  
29 practice rights for non-physician clinicians – autonomy, scopes of practice, prescriptive rights,  
30 liability and reimbursement, among others – are addressed.

31 A. **Patient Safety.** The AOA supports the “team” approach to medical care, with the physician as  
32 the leader of that team. The AOA further supports the position that patients should be made clearly  
33 aware at all times whether they are being treated by a non-physician clinician or a physician. The  
34 AOA recognizes the growth of non-physician clinicians and supports their rights to practice with  
35 appropriate physician involvement within the scope of ~~the~~ relevant state statutes.

36 B. **Independent Practice.** It is the AOA’s position that roles within the “team” framework must be  
37 clearly defined, through established STATE-LEVEL SUPERVISORY protocols and signed  
38 agreements, so physician involvement in patient care is sought when a patient’s case dictates AND  
39 PATIENTS CAN REST ASSURED THAT PHYSICIAN INVOLVEMENT IN THEIR CARE  
40 WILL REMAIN THE SAME REGARDLESS OF PRACTICE SETTING WITHIN THE

1 STATE. ~~The AOA feels nonphysician clinician professions that have traditionally been under the~~  
2 ~~supervision of physicians must retain physician involvement in patient care. Those non-physician~~  
3 ~~clinician professions that have traditionally remained independent of physicians must involve~~  
4 ~~physicians in patient care when warranted.~~ FURTHER, aAll non-physician clinicians must refer a  
5 patient to a physician when the patient’s condition is beyond the non-physician clinician’s scope of  
6 education, training or expertise.

7 C. Liability. The AOA endorses the view that physician liability for non-physician clinician actions  
8 should be reflective of the quality AND DEGREE of supervision being provided and should not  
9 exonerate the non-physician clinician from liability. It is the AOA’s position that non-physician  
10 clinicians ~~acting~~ PROVIDING CARE IN INDEPENDENT PRACTICE STATES ~~autonomously~~  
11 ~~of physicians~~ should be REGULATED AND DISCIPLINED BY THE ENTITIES  
12 RESPONSIBLE FOR REGULATING AND DISCIPLINING PHYSICIANS (I.E. STATE  
13 MEDICAL BOARDS), TO ENSURE THAT ALL CLINICIANS WHO ARE  
14 INDEPENDENTLY PRACTICING MEDICINE ARE held to the SAME STANDARD OF  
15 CARE AND THE equivalent degree of liability ~~as that of a physician. Within this independent~~  
16 ~~practice framework,~~ TO THAT END, the AOA ~~further~~ ALSO believes that non-physician clinicians  
17 should be required to obtain EQUIVALENT malpractice insurance ~~in those states that currently~~  
18 ~~require~~ TO physicians IN STATES THAT CURRENTLY REQUIRE PHYSICIANS to possess  
19 malpractice insurance.

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** H623-A/18 NON-PHYSICIAN CLINICIANS

**Prior HOD action on similar or same topic:** Policy approved as amended in 2018.

Fiscal Impact: \$0

ACTION TAKEN **ADOPTED as AMENDED**

DATE **October 13, 2020**

SUBJECT:                    MARKETING AOA BOARD CERTIFICATION

SUBMITTED BY:    American Osteopathic College of Occupational and Preventive Medicine

REFERRED TO:     Ad Hoc Committee

---

- 1            WHEREAS, the American Osteopathic Association (AOA) has deemed authority from the  
2                    U.S. Department of Education to certify physicians; and
- 3            WHEREAS, AOA board certified physicians have historically been supportive and involved  
4                    members of the AOA and its divisional societies; and
- 5            WHEREAS, the AOA, and its state associations’ and specialty colleges’, collectively known as  
6                    divisional societies, health and viability will be strengthened by having many early career  
7                    physicians sit for AOA examinations; and
- 8            WHEREAS, graduates of Accreditation Council of Graduate Medical Education (ACGME)  
9                    programs must be informed of and provided reasons for pursuing AOA board  
10                  certification; and
- 11           WHEREAS, the eighteen (18) AOA certifying boards depend upon item-writers who are  
12                  overwhelmingly practicing physicians; and
- 13           WHEREAS, the AOA internally uses the tag line “*Practicing Physicians Certifying Practicing*  
14                    *Physicians*”; now, therefore be it
- 15           RESOLVED, that the American Osteopathic Association (AOA) implement a branding  
16                    campaign for its specialty certifying boards to include incorporating the tag line  
17                    “*Practicing Physicians Certifying Practicing Physicians*” on all AOA certifying boards webpages  
18                    and letterhead; and, be it further
- 19           RESOLVED, that the AOA develop and broadly distribute a one-page info sheet targeting  
20                    Graduate Medical Education (GME) sponsoring institutions, program directors,  
21                    postdoctoral trainees, and board-eligible physicians; and, be it further
- 22           RESOLVED that the info sheet shall incorporate the tag line “*Practicing Physicians Certifying*  
23                    *Practicing Physicians*” and discuss AOA certification in terms of relevance of exam to  
24                    practice, affordability, value, convenience and ease of maintenance.

Explanatory Statement: Submitted by Author:

Potential candidates must be provided with reasons for pursuing AOA Board Certification: distinctiveness, value, relevance of exam to practice, affordability, convenience and ease of maintenance.

With ease of electronic communication and website branding, this resolution can be implemented with low costs and may help to expand our customer base and thus drive revenues to the certifying boards, specialty colleges, and the AOA.

The following Divisional Societies have endorsed this resolution:

- American Academy of Osteopathy
- American College of Osteopathic Family Physicians
- American College of Osteopathic Internists
- American College of Osteopathic Obstetricians & Gynecologists
- American College of Osteopathic Pediatricians
- American Osteopathic Academy of Addiction Medicine
- American Osteopathic Academy of Orthopedics
- American Osteopathic Academy of Sports Medicine
- American Osteopathic College of Dermatology
- American Osteopathic College of Occupational and Preventive Medicine
- American Osteopathic Colleges of Ophthalmology and Otolaryngology – Head and Neck Surgery
- American Osteopathic College of Pathologists

Explanatory Statement: Reference Committee

This policy conflicts with marketing campaigns and efforts recently started by the AOA.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: Up to \$59,500 in additional expense.

The additional expenses incurred if the AOA pursued this resolution would consist of the cost of disposing current letterhead and business cards and the estimated costs of reprinting letterhead and business cards of \$10,500, and estimated costs for rebranding between \$16,500 and \$49,000 at \$165 per hour. Rebranding could be from 100 to 300 hours including 30-40 hours for content and design work by AOA staff. The range of additional expenses would be between \$27,000 and \$59,500.

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 13, 2020**



SUBJECT: PRIOR AUTHORIZATION

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, prior authorization (PA) results in care delays and adverse events, with a recent  
2 American Medical Association survey finding that 91% of physicians report care delays  
3 associated with PA and 28% report that PA has led to serious adverse events for their  
4 patients<sup>1</sup>; and

5 WHEREAS, prior authorization increases administrative burden for physicians with 86% of  
6 physicians citing high level of burden associated with PA requirements; and

7 WHEREAS, the American Osteopathic Association has numerous policies relating to PA and  
8 the 2019 House of Delegates directed the Bureau of Socioeconomic Affairs to unify  
9 policies into a comprehensive policy statement; now, therefore be it

10 RESOLVED, that the American Osteopathic Association (AOA) adopts the following policy  
11 and principles statement on prior authorization; and be it further

12 RESOLVED, the AOA will merge policies H343-A/13, H602-A/15; H632-A/17, H635-A/19,  
13 H637-A/19, and H640-A/16.

14 **Prior Authorization**

15 Prior authorization requirements have been found to result in care delays that place patients at  
16 risk and to increase provider burden<sup>2</sup>. In order to ensure that prior authorization is  
17 implemented in an appropriate manner that minimizes burden and risk, the AOA believes that  
18 implementation of PA by payers and pharmacy benefit managers should abide by the following  
19 principles.

- 20 • Prior authorizations should be clinically relevant, evidence-based, transparent, and as  
21 minimally intrusive on the physician, medical staff, and patient as possible.
- 22 • Prior authorization programs that negatively impact access to care, delay treatment, result in  
23 abandonment, increase cost of care and administrative costs, do not align with recognized  
24 clinical practice guidelines, or have a negative impact on quality of care or outcomes should  
25 be discontinued.
- 26 • Payors should appropriately compensate providers for complying with utilization review.
- 27 • Prior authorization request forms should be standardized and electronic whenever feasible to  
28 promote procedural uniformity and reduce administrative burden.
- 29 • Allow continuation of medications already being administered or prescribed when a patient  
30 changes health plans and not allow changes without discussion and approval of the  
31 ordering physician.

---

<sup>1</sup> American Medical Association. “2018 AMA Prior Authorization (PA) Physician Survey”.

<sup>2</sup> American Medical Association. “2018 AMA Prior Authorization (PA) Physician Survey”.

- 1 • Providers should be notified of changes to prior authorization requirements at least 45 days  
2 prior to change.
- 3 • Payers and Plans should be required to report a list of services and prescription medications  
4 subject to prior authorization and corresponding denial, delay, and approval rates.
- 5 • Prior authorization requirements should be minimized as much as possible and eliminate the  
6 application of prior authorization to services and prescription medications that are routinely  
7 approved
- 8 • There should be an easily accessible and responsive direct communication tool to resolve  
9 conflicts between health plans and ordering physicians

10 As part of its efforts to advocate for these principles and ensure their incorporation into policy,  
11 the AOA will advocate for legislation and regulatory changes that would require payers and  
12 pharmacy benefit managers to:

- 13 • Disclose in sales, promotional materials and advertising that their products utilize a prior  
14 authorization process which may result in a delay in or denial of diagnosis and or treatment  
15 which may be detrimental to the patient's health or well-being;
- 16 • Consider a physician's attestation of clinical diagnosis or order sufficient documentation of  
17 medical necessity for durable medical equipment;
- 18 • Include in contracts with healthcare providers hold harmless clauses that indemnify  
19 healthcare providers against financial loss due to injury to a patient as a result of the payor's  
20 failure or refusal to grant a prior authorization request in a timely manner;
- 21 • Provide appropriate notice to patients and physicians when formulary and benefit changes  
22 are made;
- 23 • Include a correct phone number and web address on the patient identification card for  
24 initiating the prior authorization process; Make all forms used in the prior authorization  
25 process readily available to healthcare providers, including EMR templates;
- 26 • Publish and make available to the public all requirements for prior authorization and follow  
27 those published policies;
- 28 • Provide sufficient knowledgeable staff to ensure that healthcare providers are able to contact  
29 medical claims payers and pharmacy benefit managers without average hold times exceeding  
30 10 minutes;
- 31 • Compensate medical practices and healthcare providers for the cost of time spent on  
32 inappropriately denied PA requests; and
- 33 • To identify and hold accountable the payor's medical director/claim adjudicator for the  
34 results of their decisions.

Explanatory Statement: Submitted by Author

Upon approval of this resolution the policies noted in the last resolved statement will be sunset.

Background Information: Provided by AOA Staff

**Current AOA Policy:**

H343-A/13 CURRENT PROCEDURAL TERMINOLOGY (CPT) CODE FOR PRIOR  
AUTHORIZATION

H602-A/15 REIMBURSEMENT FOR PHYSICIAN TIME SPENT OBTAINING PRE-  
CERTIFICATION AND PRE-AUTHORIZATION

H640-A/16 PRIOR AUTHORIZATION

H632-A/17 PRIOR AUTHORIZATION

H635-A/19 PRIOR AUTHORIZATION – PATIENT AUTHORIZATION

**Prior HOD action on similar or same topic:** H343-A/13 policy reaffirmed in 2013 (referred to BSA in 2018); H602-A/15 policy approved in 2015; H640-A/16 policy approved in 2016; H632-A/17 policy approved in 2017, H635-A/19 policy approved in 2019

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: PROFESSIONAL LIABILITY INSURANCE REFORM

SUBMITTED BY: Bureau of State Government Affairs

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, the current state of the legal system imposes great costs on the U.S. health care  
2 system and society in general by forcing physicians to maintain costly amounts of  
3 professional liability insurance; and

4 WHEREAS, these costs may ultimately be borne by patients through increased prices or  
5 through the loss of solo/small group practices in rural and underserved areas, where  
6 physicians may be unable to afford the cost of this insurance; and

7 WHEREAS, this legal system incentivizes physicians to practice defensive medicine to protect  
8 themselves from litigation, and discourages some physicians from pursuing riskier  
9 specialties such as obstetrics, even though specialists in these areas are needed; now,  
10 therefore be it

11 RESOLVED, that the American Osteopathic Association continues support of professional  
12 liability insurance reform that includes the following principles:

- 13 1) limitations on non-economic damages - including provisions that afford states the  
14 opportunity to maintain or establish laws governing limitations on non-economic  
15 damages;
- 16 2) prohibiting “loss of chance” liability;
- 17 3) periodic payment of future expenses or losses;
- 18 4) offsets for collateral sources;
- 19 5) joint and several liability reform;
- 20 6) limitations on attorney contingency fees;
- 21 7) establishment of uniform statutes of limitations;
- 22 8) establishment of alternative professional liability insurance reforms which may  
23 include but are not limited to – health courts, non-binding arbitration and “I’m  
24 sorry” clauses; and
- 25 9) reimbursement of all out-of-pocket expenses and lost income for physicians who  
26 are victims of frivolous lawsuits.

27 and, be it further

28 RESOLVED, that upon approval, AOA policies H617-A/15 FRIVOLOUS LIABILITY  
29 LAWSUITS and H333-A/18 PROFESSIONAL LIABILITY INSURANCE REFORM  
30 be sunset.

Explanatory Statement: Submitted by Author

**H617-A/15 FRIVOLOUS LIABILITY LAWSUITS** has been reviewed by the Bureau of State Government Affairs and it was determined that the content should be merged into **H333-A/18 PROFESSIONAL LIABILITY INSURANCE REFORM** to create a more comprehensive, streamlined

policy. We suggest that both **H617-A/15** and **H333-A/18** be deleted and replaced with this resolution. Relevant revised language from those resolutions has been included in this resolution:

**H617-A/15 FRIVOLOUS LIABILITY LAWSUITS**

~~The American Osteopathic Association (AOA) supports, as a component of comprehensive tort reform, the ability of physicians who are victims of frivolous lawsuits to recover all out of pocket expenses and lost income.~~

**H333-A/18 PROFESSIONAL LIABILITY INSURANCE REFORM**

The American Osteopathic Association continues support of professional liability insurance reform that includes the following ~~eight~~ principles: (1) limitations on non-economic damages – including provisions that afford states the opportunity to maintain or establish laws governing limitations on non-economic damages; (2) prohibiting “loss of chance”, (3) periodic payment of future expenses or losses; (4) offsets for collateral sources; (5) joint and several liability reform; (6) limitations on attorney contingency fees; (7) establishment of uniform statutes of limitations; ~~and~~ (8) establishment of alternative professional liability insurance reforms which may include but are not limited to – health courts, non-binding arbitration and I’m sorry clauses; **AND (9) REIMBURSEMENT OF ALL OUT-OF-POCKET EXPENSES AND LOST INCOME FOR PHYSICIANS WHO ARE VICTIMS OF FRIVOLOUS LAWSUITS.**

Background Information: Provided by AOA Staff

**Current AOA Policy:**

H617-A/15 FRIVOLOUS LIABILITY LAWSUITS

H333-A/18 PROFESSIONAL LIABILITY INSURANCE REFORM

**Prior HOD action on similar or same topic:** H617-A/15 policy approved in 2015; H333-A/18 policy approved in 2018.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: RE-ESTABLISHMENT OF THE BUREAU OF OSTEOPATHIC  
SPECIALTY SOCIETIES (BOSS)

SUBMITTED BY: American Osteopathic College of Occupational and Preventive Medicine

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, the American Osteopathic Association’s (AOA) Bureau of Osteopathic Specialty  
2 Societies (BOSS), existed to allow for elected representatives from each of the specialty  
3 colleges to assemble to discuss AOA policy proposals and their impact on the Specialty  
4 Colleges; and

5 WHEREAS, other AOA Bureaus, Councils and Committees were able to refer matters to the  
6 BOSS for comment and refinement; and

7 WHEREAS, the BOSS was discontinued without provision of an alternative structure to ensure  
8 that specialty college elected leaders continued to have a vehicle for collaborative  
9 discernment on matters affecting their members; and

10 WHEREAS, the AOA Council on Osteopathic Continuing Medical Education (COCME),  
11 recently asked the Bureau of Osteopathic Specialists (BOS), the Bureau representing the  
12 AOA’s Specialty Certifying Boards, to weigh in on proposed changes to CME  
13 requirements, including the tracking of specialty credits; however, the specialty colleges  
14 had no venue or opportunity to provide input; and

15 WHEREAS, sweeping changes to CME requirements and the tracking of specialty credits  
16 impact CME attendance at specialty college events and have significant fiscal impact on  
17 divisional societies, organized elements within the AOA structure should exist to solicit  
18 debate and support among key constituent groups, including the specialty college  
19 elected leaders; and

20 WHEREAS, since the disbandment of BOSS, the profession has gained additional expertise,  
21 experience and competence meeting in a virtual environment, the BOSS can now be re-  
22 implemented with very little fiscal impact to the AOA; now, therefore be it

23 RESOLVED, that the Bureau of Osteopathic Specialty Societies (BOSS) be re-established,  
24 whose membership is comprised of one elected representative from each specialty  
25 society; and, be it further

26 RESOLVED, that the American Osteopathic Association (AOA) host at least two meetings per  
27 year: one prior to the AOA Mid-Year Board of Trustees meeting and the other prior to  
28 the Annual Business Meeting; as well as other times as requested by the BOSS; and, be  
29 it further

30 RESOLVED that the AOA can organize these meetings in a virtual or hybrid environment, in  
31 conjunction with the AOA Mid-Year Board of Trustees meeting and the Annual  
32 Business Meeting, to minimize the fiscal impact to the AOA and the specialty colleges.

Explanatory Statement: Submitted by Author

The Bureau of Osteopathic Specialty Societies (BOSS) enable elected leaders of the specialty colleges to come together to discuss a myriad of issues:

- Proposed AOA Board and House resolutions
- Joint responses to public comment periods from other AOA Bureaus, Councils and Committees
- Joint responses to public comment periods from the ACGME, COCA, and various federal government agencies (HRSA, MEDPAC, CMS, etc.)
- Advocacy for needed revisions to ACGME Common Program requirements
- Collaboration on common issues, such as student chapters, supporting of transitions from medical school to postdoctoral training
- Tracking of and service to postdoctoral trainees
- Joint CME programming and planning

The following divisional societies have endorsed this resolution:

- American Academy of Osteopathy
- American College of Osteopathic Family Physicians
- American College of Osteopathic Emergency Physicians
- American College of Osteopathic Obstetricians & Gynecologists
- American College of Osteopathic Pediatricians
- American College of Osteopathic Surgeons
- American Osteopathic Academy of Addiction Medicine
- American Osteopathic Academy of Sports Medicine
- American Osteopathic Association of Prolotherapy Regenerative Medicine
- American Osteopathic College of Anesthesiologists
- American Osteopathic College of Dermatology
- American Osteopathic College of Occupational and Preventive Medicine
- American Osteopathic Colleges of Ophthalmology and Otolaryngology – Head and Neck Surgery
- American Osteopathic College of Pathologists

Explanatory Statement: Reference Committee

AOA has just completed a systematic review and restructuring of its bureaus, councils, and committees. The AOA has also updated affiliate agreements with their input. This policy would be counterproductive to the AOA's recent efforts that it has undertaken in collaboration with affiliates.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **NOT ADOPTED**

DATE: **October 13, 2020**

SUBJECT: REFERRED RESOLUTION: H636-A/2019 OBESITY TREATMENT  
REIMBURSEMENT IN PRIMARY CARE

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, the AOA House of Delegates (HOD) referred resolution H-636-A/2019 titled  
2 OBESITY TREATMENT REIMBURSEMENT IN PRIMARY CARE submitted by  
3 the Michigan Osteopathic Association; and

4 WHEREAS, the HOD requested the Bureau of Socioeconomic Affairs “review the feasibility  
5 of obtaining payment for the treatment of obesity as a primary diagnosis and whether  
6 new CPT and diagnosis codes need to be created for payment purposes”; now,  
7 therefore be it

8 RESOLVED, that resolution H-636-A/2019 titled OBESITY TREATMENT  
9 REIMBURSEMENT IN PRIMARY CARE, be ADOPTED as amended

10 RES. NO. H-636 - A/2019

11 SUBJECT: OBESITY TREATMENT REIMBURSEMENT IN PRIMARY CARE

12 WHEREAS, the prevalence of obesity was 39.8% and affected about 93.3 million of US adults  
13 in 2015~2016<sup>1</sup>; and

14 WHEREAS, Obesity-related conditions include heart disease, stroke, type 2 diabetes and  
15 certain types of cancer that are some of the leading causes of preventable, premature  
16 death; and

17 WHEREAS, ensuring physician reimbursement for obesity treatment should be a priority to  
18 reduce morbidity and mortality of the population; and

19 WHEREAS, it is well within the scope of practice of ALL primary care physicians to treat this  
20 condition ~~and obesity is not currently a payable diagnosis for primary care~~; now,  
21 therefore, be it

22 RESOLVED, that the American Osteopathic Association (AOA) ~~publicly affirms and~~  
23 ~~advocates that all diagnosis codes for obesity and morbid obesity be a billable and~~  
24 ~~reimbursable diagnostic code for any and all practicing primary care physicians~~ IS  
25 COMMITTED TO EXPANDING PAYMENT FOR SERVICES RELATED TO  
26 OBESITY DIAGNOSIS AND TREATMENT, INCLUDING NON-PRIMARY  
27 CARE PHYSICIANS AND NON-PHYSICIANS WHO PROVIDE COUNSELING  
28 IN CONSULTATION WITH A PHYSICIAN; and, be it further



1 RESOLVED, that the AOA WILL work with ~~insurers~~, payors, legislators, and other  
2 stakeholders to ensure access to treatment for obesity to address this public health  
3 epidemic.

4 References

- 5 1. Centers for Disease Control Overweight and Obesity,  
6 <https://www.cdc.gov/obesity/data/adult.html>; Accessed March 15, 2019.

Explanatory Statement: Submitted by Author:

None provided.

Explanatory Statement: Reference Committee

The Committee felt that the statement “obesity is not currently a payable diagnosis for primary care” may not always be the case and may vary from payor to payor. The change suggested would prevent the resolution from becoming obsolete and still convey the original intent.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**

SUBJECT: POST PARTUM DEPRESSION (Response to RES. NO. H-612 - A/18  
referencing H-615-A/13)

SUBMITTED BY: Bureau on Scientific Affairs and Public Health

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, on July 21, 2018, the House of Delegates (HOD) Ad Hoc Reference Committee  
2 referred H615-A/13 POSTPARTUM DEPRESSION to the Bureau on Scientific  
3 Affairs and Public Health (BSAPH) to produce a report on outcomes; and

4 WHEREAS, at the 2019 HOD the BSAPH requested and received additional time to collect  
5 the requested data from AOA’s internal sources as well external key stakeholders (e.g.,  
6 COMS, osteopathic state, and specialty associates); and

7 WHEREAS, the BSAPH developed and administered a survey to its external stakeholders to  
8 collect the requested information and provide a final report to the HOD in 2020; now,  
9 therefore be it,

10 RESOLVED, that the Bureau of Scientific Affairs and Public Health recommends that the  
11 following policy be REAFFIRMED.

12 **H615-A/13 POSTPARTUM DEPRESSION**

13 The American Osteopathic Association encourages its members to participate in continuing  
14 medical education programs on postpartum depression (PPD); urges colleges of osteopathic  
15 medicine (COMs) and osteopathic state and specialty associations to offer CME on PPD as part  
16 of their educational offerings; and endorses the use of screening tools and encourage the  
17 measurement of outcomes in their use. 2003; 2008; reaffirmed as amended 2013.

Explanatory Statement: Submitted by Author

**Introduction**

Postpartum depression is a type of depression that occurs after women give birth. Symptoms of postpartum depression are more severe and enduring than those of “baby blues,” which describes the worry, sadness, and tiredness many women combat after having a baby. Postpartum depressive symptoms (PDS) are common, and they can impact the mother, infant and family. PDS have been linked to adverse maternal and infant outcomes, including low breastfeeding initiation and duration and poor maternal and infant bonding. (Ko JY, 2017)

Fathers may also experience depression during the first year of their child’s life. According to the Centers for Disease Control and Prevention (CDC), about 1 out of 5 fathers will suffer one or more incidences of depression before their child reaches 12 years of age. Younger fathers, those with a history of depression, and those experiencing financial challenges were most susceptible. (Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, 2020)

Based on the Pregnancy Risk Assessment Monitoring System (PRAMS) data, the CDC estimates that 1 in 8 women nationally experience PDS. (America's Health Rankings, 2019). Estimates of the number of

women affected by postpartum depression vary by age and race/ethnicity. Additionally, postpartum depression estimates differ by state, and can be as high as 1 in 5 women (Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, 2020).

Postpartum depression may be prevented and/ or mitigated by ensuring women have supportive and psychological care following childbirth. This includes home visits, peer support and interpersonal therapy. (Donna E. Stewart, 2016) Additionally, Postpartum Depression (PPD) is treatable with social support, counseling, and/ or medication. Though most people recover with treatment of PPD, many are not screened or diagnosed (America's Health Rankings, 2019).

Studies indicate that 66 percent of past-year depression among pregnant women in the US were undiagnosed, and only half of pregnant women with depressive symptoms received treatment. Studies also uncovered several barriers to treatment among women with PPD, particularly among Latinx and African American women. Given the significant burden of PPD, and the fact that PPD is preventable and highly treatable, the US public health strategy, Healthy People 2020, includes an objective to reduce the number of women who experience postpartum depressive symptoms subsequent to a live birth. (America's Health Rankings, 2019)

### **Osteopathic CME Education on PPD**

In 2020, the BSAPH distributed a survey to 150 osteopathic CME providers at colleges of osteopathic medicine (COMs) and osteopathic state and specialty associations to ascertain whether or not the affiliate groups offered continuing medical education programs on PPD, endorsed the use of screening tools, or encouraged outcomes measurement from 2014 through 2019.

Sixty-nine (46%) organizations responded to the survey. Nine respondents (13%) reported a total of 26 educational CME activities on PPD delivered to their constituents from 2014 through 2019. The majority of the activities were live events, and as many as 1200 learners participated. Three (4%) of the organizations also promoted screening tools and encouraged outcomes measurement.

### **Conclusions/ Recommendations**

There has been some education in the osteopathic community on PPD. However, depression for many women across the country is still a very significant issue that is underdiagnosed and untreated.

Therefore, it is recommended that the AOA continue to encourage the osteopathic community to provide and participate in continuing medical education on PPD and the best practices for screening, diagnosis, monitoring and treatment.

### **References**

America's Health Rankings. (2019). *Health of Women and Children Report*. Retrieved April 28, 2020, from [https://www.americashealthrankings.org/explore/health-of-women-and-children/measure/postpartum\\_depression/state/ALL](https://www.americashealthrankings.org/explore/health-of-women-and-children/measure/postpartum_depression/state/ALL)

Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion. (2020, May 4). *Depression Among Women*. Retrieved from Centers for Disease Control and Prevention, Reproductive Health: <https://www.cdc.gov/reproductivehealth/depression/index.htm>

Donna E. Stewart, C. M. (2016). Postpartum Depression. *N Engl J Med*, 2177-2186.

Ko JY, R. K. (2017). *Trends in Postpartum Depressive Symptoms — 27 States, 2004, 2008, and 2012*. *MMWR Morb Mortal Wkly Rep* 2017. doi:DOI: <http://dx.doi.org/10.15585/mmwr.mm6606a1External>.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: Up to approximately \$130,000 in additional expense.

The amount of additional expense will depend upon the type of activity and number of CME hours involved. For example, a conservative estimate based upon a one CME hour journal article would be \$13,000, whereas, a high-end estimate based upon a 10 credit CME in-person workshop could be \$130,000.

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: REFERRED SUNSET RES. NO. H-619 - A/2019: H624-A/14 MANAGED CARE PLANS – SERVICE, ACCESS AND COSTS IN

SUBMITTED BY: Bureau of Socioeconomic Affairs

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, the AOA House of Delegates referred sunset resolution H-619-A/2019 titled  
2 H624-A/14 MANAGED CARE PLANS – SERVICE, ACCESS AND COSTS IN to  
3 the Bureau of Socioeconomic Affairs for “clarification on intent of the resolution,  
4 definition of “open access models”, and relevance of the resolution”; now, therefore be  
5 it

6 RESOLVED, that the Bureau of Socioeconomic Affairs recommends that the following policy  
7 be REAFFIRMED as AMENDED:

8 **H624-A/14 MANAGED CARE PLANS – SERVICE, ACCESS AND COSTS IN**

9 The American Osteopathic Association (AOA) supports efforts to ~~combine tiered formulary~~  
10 ~~and open access models with expanded~~ THE use of variable co-pays that reflect the total  
11 THAT SUPPORT PROGRAM costs. ~~of these programs and~~ THE AOA ALSO supports  
12 efforts to design benefits that align consumer needs, ~~and~~ accountability and individual physician  
13 incentives. 1999; revised 2004; reaffirmed as amended 2009; reaffirmed as amended 2014

Explanatory Statement: Submitted by Author:

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:** None

**Prior HOD action on similar or same topic:** None

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: RESEARCHING PATIENT SAFETY AND PROVIDER QUALIFICATIONS

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, mid-level practitioners, defined as, but not limited to, health-care providers such  
2 as nurse practitioners, nurse midwives, nurse anesthetists, clinical nurse specialists and  
3 physician assistants <sup>1</sup> have increasingly sought expanded scope of practice with success;  
4 and

5 WHEREAS, nurse practitioners (NPs) now have full scope of practice in 24 states with  
6 intention to continue expansion of scope efforts <sup>2</sup>; and

7 WHEREAS, NPs have introduced a new degree, DNP, or Doctor of Nursing Practice, that has  
8 increased confusion for patients in clinical settings, where said DNPs refer to  
9 themselves as doctors, and at times do not adequately inform patients that they are not  
10 physicians; and

11 WHEREAS, The Code of Federal Regulations defines the term physician to include doctors of  
12 medicine (MD), surgeons, podiatrists, dentists, clinical psychologists, optometrists,  
13 chiropractors, and osteopathic practitioners within the scope of their practice as defined  
14 by State law<sup>7</sup>; and

15 WHEREAS, The Social Security Administration defines physician to mean means doctor of  
16 medicine, doctor of osteopathy (including osteopathic practitioner), doctor of dental  
17 surgery or dental medicine, doctor of podiatric medicine, or doctor of optometry, or a  
18 chiropractor, legally authorized to practice by a State in which he/she performs this  
19 functions [within given parameters]<sup>8</sup>; and

20 WHEREAS, Florida, New York, Arizona, Delaware have proposed laws limiting the use of  
21 doctor to persons with a Medical Doctor (MDs) or Doctor of Osteopathic Medicine  
22 (DOs) degree; Six states have passed laws making it a felony for nurse practitioners to  
23 refer to themselves as doctor; Nine states require nurse practitioners to follow their  
24 introduction with a clarifying statement <sup>9,10,11</sup>; and

25 WHEREAS, American Osteopathic Association (AOA) House of Delegates resolution number  
26 H324-A/14 states that the AOA opposes the misuse of the title “doctor” by non-  
27 physician clinicians, in all communications and clinical settings because such use  
28 deceived the public by implying that the non-physician clinician’s education, training, or  
29 credentialing is equivalent to a DO or MD<sup>13</sup>; and

30 WHEREAS, attempts at promoting mid-level practitioners to independent practice is done  
31 without proper reverence to their important purpose in healthcare, as mid-level support  
32 for physicians; and

1 WHEREAS, such attempts are often aided by a gross oversimplification of the crucial role  
2 belonging to the primary care specialties to which NPs are often assumed to enter; and

3 WHEREAS, one major justification for the expanded numbers of these practitioners and their  
4 scopes of practice is the physician shortage, which is projected that by 2025, demand for  
5 physicians will exceed supply by a range of 46,000 to 90,000<sup>3</sup>; and

6 WHEREAS, we acknowledge that the physician shortage is a real and serious problem on the  
7 horizon, but we also cannot afford to sacrifice patient safety or care in the name of  
8 momentary expediency; and

9 WHEREAS, American physicians, Medical Doctors (MDs) or Doctor of Osteopathic Medicine  
10 (DOs), undergo one to two and a half additional years of schooling, three additional  
11 years of residency training, and fifteen to eighteen thousand more training hours than  
12 “Doctors of Nursing Practice”<sup>4</sup>; and

13 WHEREAS, physicians are trained to direct and lead care, while midlevel providers such as  
14 nurse practitioners are not, the DNP degree is administrative in nature and not an  
15 advanced clinical degree; and

16 WHEREAS, there is inadequate evidence to support a transition to midlevel independence; and

17 WHEREAS, we must applaud and support nurse practitioners stance that their educational  
18 model is “patient centered” and “holistic”, we must interject that they are not unique in  
19 this view point and reject the accusation that the “medical model” is “disease focused”;  
20 and

21 WHEREAS, continually expanding midlevel provider scope of practice creates an opportunity  
22 for a two tiered healthcare system to develop, where rural and underserved populations  
23 have limited access to physician providers while those in larger cities have greater access  
24 to physician providers, further exacerbating existing disparities in healthcare; and

25 WHEREAS, the AOA has previously called for a review and validation of nonphysician  
26 credentials and standards of care and supported a position that patients should be made  
27 clearly aware at all times if they are being treated by a non-physician provider or  
28 clinician (H634-A/15)<sup>6</sup>; now, therefore be it

29 RESOLVED, that the American Osteopathic Association (AOA) ~~supports~~ **ENCOURAGES**  
30 independent research on the qualification and outcomes of nurse practitioners and  
31 other midlevel providers that practice independently; **AND, BE IT FURTHER**

32 **RESOLVED, THAT THE AOA RESEARCH & PUBLIC HEALTH STAFF**  
33 **PERFORM AN META ANALYSIS OF CURRENT, VALID AND**  
34 **PUBLISHED RESEARCH ON CLINICAL OUTCOMES, RESOURCE**  
35 **UTILIZATION AND MALPRACTICE EXPERIENCE FOR**  
36 **INDEPENDENTLY PRACTICING NPS AND PAS AND PROVIDE THIS**  
37 **INFORMATION TO OSTEOPATHIC PHYSICIANS.**

Explanatory Statement: Submitted by Author

Commonly it is asserted that midlevel providers provide access to rural communities. Firstly, the data shows that midlevel providers such NPs and PAs do not practice in rural areas in a statistically meaningful different pattern as compared to physicians. Second, it is unjust to reinforce a two-tiered health care system by creating policy that promotes rural community care that is highly dependent on midlevel providers. Instead the policy focus should be to attract and retain physicians in rural areas. To solve a physician shortage, we must focus on physician policy.

References

1. Catherine S. Bishop, Dnp, Np, Aocnp®. (2012). Advanced Practitioners Are Not Mid-Level Providers. *Journal of the Advanced Practitioner in Oncology*, 3(5).  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093350/>
2. Carlson, K. (2017, March 2). NP Practice Authority Grows - March 2017 Update. Retrieved February 22, 2020, from <https://nurse.org/articles/nurse-practitioner-scope-of-practice-expands-mar17/>
3. AAMC. (2015, March 1). Physician Supply and Demand Through 2025: Key Findings. Retrieved February 22, 2020, from <https://www.aamc.org/download/426260/data/physiciansupplyanddemandthrough2025keyfindings.pdf>
4. Primary Care Coalition. (n.d.). Compare the Education Gaps Between Primary Care Physicians and Nurse Practitioners. Retrieved from <https://www.tafp.org/Media/Default/Downloads/advocacy/scope-education.pdf>
5. H634-A/15, AOA HOD Cong. (2015) (enacted)
6. 20 CFR 702.404 - Physician defined. (n.d.). Retrieved February 25, 2020, from <https://www.law.cornell.edu/cfr/text/20/702.404>
7. SSA - POMS: HI 00401.295 - Physician Defined. (2015, April 06). Retrieved February 25, 2020, from <https://secure.ssa.gov/poms.nsf/lnx/0600401295>
8. DECAPUA, D. (2016, April 28). Are Nurse Practitioner Doctors Real Doctors? Retrieved February 24, 2020, from <https://www.bartonassociates.com/blog/are-nurse-practitioner-doctors-real-doctors/>
9. Harris, G. (2011, October 01). When the Nurse Wants to Be Called 'Doctor'. Retrieved February 24, 2020, from <http://www.nytimes.com/2011/10/02/health/policy/02docs.html>
10. State medical boards trying to limit who can be called "Doctor". (n.d.). Retrieved February 24, 2020, from <https://www.clinicaladvisor.com/the-waiting-room/state-medical-boards-trying-to-limit-who-can-be-called-doctor/article/284167/>
11. D-35.992, AMA BOT Cong. (2016) (enacted)
12. H324-A/14, AOA HOD Cong. (2014) (enacted)

Background Information: Provided by AOA Staff

**Current AOA Policy:** H613-A/16 PHYSICIAN SUPPLY IN RURAL, UNDERSERVED UNITED STATES – RECOMMENDATIONS FOR IMPROVING

**Prior HOD action on similar or same topic:** Policy reaffirmed in 2016.

FISCAL IMPACT: \$102,500 in additional expenses over a two (2) year period.

The additional expense would be incurred if AOA sponsors the research. Additional expenses would include: Initiate/Manage Grant Award \$1,500; Grant Reviewers \$1,000; grant award of \$100,000.



ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**

SUBJECT: SUPPORT THE BOLSTERING OF VETERAN HEALTH  
ADMINISTRATION RESOURCES THROUGH PROVIDER PAY  
REFORM

SUBMITTED BY: Student Osteopathic Medical Association

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, veterans represented 7% (approximately 22.6 million people) of the United States  
2 population in 2016<sup>1</sup>; and

3 WHEREAS, the Veterans Administration (VA) pays private contractors up to \$295-300 for  
4 each authorization of private care per veteran<sup>2</sup>; and

5 WHEREAS, existing health services provided directly by the United States Department of  
6 Veterans Affairs remain hindered by chronic staffing shortages including 138 of 140  
7 facilities reporting shortages of physicians, especially primary care and psychiatry  
8 specialties, and 108 of 140 facilities reporting shortages of nursing occupations<sup>3</sup>; and

9 WHEREAS, existing health services provided directly by the United States Department of  
10 Veterans Affairs remain hindered by uncompetitive pay because of outdated Office of  
11 Personnel Management (OPM) classifications preventing the ability to offer more  
12 competitive salaries or advancement opportunities<sup>4</sup>; and

13 WHEREAS, existing health services provided directly by the United States Department of  
14 Veterans Affairs remain hindered by personnel management issues including a lack of  
15 data on contract physicians and physician trainees resulting in insufficient workforce  
16 planning<sup>5</sup>; and

17 WHEREAS, VA physicians are more knowledgeable about the care for combat injuries, post-  
18 traumatic stress disorder, and other health injuries the veteran population faces<sup>6</sup>; and

19 WHEREAS, American Osteopathic Association (AOA) Resolution H-614-A/18 reaffirms the  
20 support of adequate healthcare funding and use of community physicians “when  
21 Veterans’ Health Administration facilities cannot provide adequate or timely access”<sup>7</sup>;  
22 now, therefore be it

23 RESOLVED, that the American Osteopathic Association support both staffing management  
24 and competitive pay reform at the Veterans’ Health Administration (VHA) to ensure  
25 that a full, stable workforces, as budgeted by the Department of Veterans Affairs, is  
26 available to meet the health needs of the United States veteran population.

Explanatory Statement: Submitted by Author

Per Resolution H617-A/13, SOMA and the AOA already supports adequate federal funding for health care for veterans at all VHA facilities, as well as federal funding for services from community health providers when VHA facilities are unable to provide adequate or timely access. SOMA and the AOA should advocate for improvements to existing VHA health care services by overhauling staffing data and management; thus, better allowing the VHA to strengthen its current services and provider pool by offering more competitive pay. These issues have been ongoing for years. Not enough has been done to ensure the VHA, which provides care to millions of Americans, keeps a level of modernity adequate enough to meet estimated needs. Addressing these issues would help reduce the need to rely on private health services, which have not met expectations for timeliness.

The intention of this resolution is to provide broad language for SOMA and the AOA to tackle these positions in a manner they find appropriate, without limiting methodology.

References

1. Bialik, K. (2017, November 10). 5 facts about U.S. veterans. Retrieved from <https://www.pewresearch.org/fact-tank/2017/11/10/the-changing-face-of-americas-veteran-population/>
2. VA Office of Inspector General. (2017, January 17). Audit of the Timeliness and Accuracy of Choice Payments Processed Through the Fee Basis Claims System. <https://www.va.gov/oig/pubs/VAOIG-15-03036-47.pdf>
3. Veteran Health Administration. (2018, June 21). Steps Taken to Improve Physician Staffing, Recruitment, and Retention, but Challenges Remain. Retrieved from <https://www.gao.gov/assets/700/692661.pdf>
4. Daigh, J. D. (2018, June 14). OIG Determination of Veterans Health Administration's Occupational Staffing Shortages: FY 2018. Retrieved from <https://www.va.gov/oig/pubs/VAOIG-18-01693-196.pdf>
5. Draper, D. A. (2018, June 21). Steps Taken Lab to Improve Physician Staffing, Recruitment, and Retention, but Challenges Remain. Retrieved from <https://docs.house.gov/meetings/VR/VR03/20180621/108430/HHRG-115-VR03-Wstate-DraperD-20180621.pdf>
6. Tanielian, T., Farmer, C.M., Burns, R.M., Duffy, E.L., Setodji, C.M. (2018). Ready or not? Assessing the Capacity of New York State Health Care Providers to Meet the Needs of Veterans. [https://www.rand.org/pubs/research\\_reports/RR2298.html](https://www.rand.org/pubs/research_reports/RR2298.html)
7. American Osteopathic Association 98th Annual House of Delegates Meeting. (2018). <https://osteopathic.org/wp-content/uploads/2018-HOD-Resolutions-with-action.pdf>

Background Information: Provided by AOA Staff

**Current AOA Policy:** H414-A/18 ENVIRONMENTAL HEALTH

**Prior HOD action on similar or same topic:** Policy reaffirmed in 2018.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED**

DATE: **October 13, 2020**

SUBJECT: TELEMEDICINE; REIMBURSEMENT FOR

SUBMITTED BY: New York State Osteopathic Medical Society

REFERRED TO: Ad Hoc Committee

---

1 WHEREAS, the world continues to face a global health crisis through the pandemic spread of  
2 the corona virus COVID-SARS-19; and

3 WHEREAS, the health and safety of the peoples throughout the United States is uncertain; and

4 WHEREAS, in 2018 the Directorate for Global Health Security and Biodefense was shut down  
5 thereby limiting the national ability to respond to an emerging infectious disease crisis;  
6 and

7 WHEREAS, school districts throughout the United States have cancelled classes and look to  
8 digital platforms for instruction and have revisited and redefined the need for face-to-  
9 face time in the classroom, including hybrid versions of in-person and virtual  
10 encounters; and

11 WHEREAS, the number of confirmed cases and deaths in the United States continues to rise;  
12 and

13 WHEREAS, the disease continues to pose a heightened risk to those with  
14 immunocompromised and other vulnerable populations including the elderly, those  
15 with chronic lung disease, heart disease, cancer, and/or diabetes; and,

16 WHEREAS, a number of states witnessed their governor declaring public health states of  
17 emergency; and

18 WHEREAS, there has been inconsistent responses in such states as to quarantining measures,  
19 prevention techniques including masking and social distancing, and

20 WHEREAS, currently there are a number of United States' residents under mandatory  
21 quarantine and a far greater number confined to voluntary home isolation; and

22 WHEREAS, emergency responders have adopted policies that are designed to limit potential  
23 spread of the virus and some departments have been directed not to respond to calls  
24 from individuals that are experiencing coughs with high fevers and to also cease efforts  
25 of life-support or avoid transportation to hospitals for more definitive care if stricken  
26 citizens are above a certain age and/or if there was an extended effort; and

27 WHEREAS, individuals are instructed NOT to go to their physicians' offices if experiencing  
28 cough with fever unless they are in a high risk situation or experiencing shortness of  
29 breath when they are told to present to the emergency department of a hospital; and

1           WHEREAS, individuals ill with other medical conditions may likewise avoid needed in-person  
2           medical evaluation and treatment for fear of infection exposure; and

3           WHEREAS, on March 4, 2020, Congress voted to approve an emergency COVID-SARS-19  
4           spending bill of 8.3 billion dollars to address this growing health crisis; and

5           WHEREAS, the medical community and community health centers serve as vital role in the  
6           maintenance of health and prevention of disease; and

7           WHEREAS, after 9/11/2001, the country watched as St. Vincent Hospital and Medical Center  
8           of New York City took on the role of receiving hospital for 9/11 workers and sustained  
9           incredible financial losses from which the hospital did not recover and was forced to  
10          close, and identified the particular risk to those who selflessly put themselves and their  
11          institution in harm's way for the good of the peoples in their community; and

12          WHEREAS, the physicians and other medical providers in the private sector must be enabled  
13          to respond to the growing need for medical services including mandatory quarantine  
14          and voluntary isolation; and

15          WHEREAS, technology is available to patients and physicians alike to allow for personalized  
16          advice and management through various means including telephonic and video  
17          communications (telemedicine); and

18          WHEREAS, there is acceptance of the utilization telemedicine for geographic areas where  
19          access to physicians and other health care providers is not readily accessible; and

20          WHEREAS, there are means available for these situations and circumstances for these  
21          physicians and others to be paid for their services using such telemedicine technology  
22          that was enacted on a temporary emergency basis; and

23          WHEREAS, the COVID-19 pandemic has created situations where persons are instructed to  
24          limit personal access to their physicians in an effort to curtail the spread of the  
25          contagion; and

26          WHEREAS, it is essential to provide up-to-the-minute information and medical care as safely  
27          and efficiently as possible, and

28          WHEREAS, the guidelines that determine that combined audio-visual interaction is necessary  
29          for one level of payment versus strictly telephonic interaction at another fails to  
30          recognize that those who are of a certain age or economic status may not have the  
31          means to utilize other than verbal-auditory interaction; and

32          WHEREAS, Medicare's coverage of telemedicine is slated to end in the near future if no  
33          extension is enacted and especially when the coronavirus no longer poses a public  
34          health emergency, and

35          WHEREAS, private insurers, which followed the federal government's lead, could revert to  
36          paying doctors for virtual visits at a fraction of the cost for traditional visits, if anything  
37          at all; now, therefore be it

1 RESOLVED, that the American Osteopathic Association work with the American Medical  
2 Association to advocate for legislation or an Executive Order to mandate that all health  
3 insurance plans, including those issued by CMS (Medicaid and Medicare Services) and  
4 entities covered under ERISA Law continue to reimburse for such services at a level  
5 that is commensurate with a **level 4** face-to-face visit; ~~and be it further~~

6 ~~RESOLVED that community health centers, physicians and other clinical practitioners~~  
7 ~~be directed to submit claims for services to individuals who have no health~~  
8 ~~insurance to their respective State Offices of Emergency Management so as to~~  
9 ~~utilize emergency funds approved by Congress so as to be able to provide~~  
10 ~~medical care to the widest population of at-risk individuals as possible.~~

Explanatory Statement: Submitted by Author

None provided.

Background Information: Provided by AOA Staff

**Current AOA Policy:**

H613-A/16 PHYSICIAN SUPPLY IN RURAL, UNDERSERVED UNITED STATES –  
RECOMMENDATIONS FOR IMPROVING

H601-A/17 TELEMEDICINE – AOA POLICY ON

H343-A/18 PHYSICIAN PAYMENT FOR ELECTRONIC ADVICE, COUNSELING AND  
TREATMENT PLANS

H630-A/19 COMMUNICATION TECHNOLOGY-BASED AND REMOTE EVALUATION  
SERVICES

**Prior HOD action on similar or same topic:** H613-A/16 policy reaffirmed as amended in 2016;  
H601-A/17 policy reaffirmed as amended in 2017; H348-A/18 policy reaffirmed in 2018; H630-A/19  
policy approved in 2019.

FISCAL IMPACT: \$0

ACTION TAKEN: **ADOPTED as AMENDED**

DATE: **October 13, 2020**



1 PROCLAIMED, that the American Osteopathic Association will continue ongoing efforts  
2 using social media and other means to educate the public and dispel inaccuracies of U.S.  
3 trained DOs; and, be it further

4 PROCLAIMED, that the American Osteopathic Association encourages its members, affiliated  
5 organizations, our patients and our Allopathic colleagues to use social media and other  
6 means to accurately represent the profession of Osteopathic Medicine to the public;  
7 and, be it further

8 PROCLAIMED, that the American Osteopathic Association will continue to provide online  
9 resources and support to its members and advocates to develop a grassroots social  
10 media campaign to further the understanding of the profession of Osteopathic  
11 Medicine by the public; **AND, BE IT FURTHER**

12 **PROCLAIMED, THAT THE AMERICAN OSTEOPATHIC ASSOCIATION ON**  
13 **BEHALF OF THE OSTEOPATHIC PROFESSION EXPRESSES**  
14 **APPRECIATION AND GRATITUDE TO THE JOURNALISTS,**  
15 **ORGANIZATIONS, AND OTHER PERSONS THAT SUPPORT AN**  
16 **ACCURATE PORTRAYAL OF OSTEOPATHIC MEDICINE AND**  
17 **OSTEOPATHIC PHYSICIANS IN THE MEDIA.**

Explanatory Statement: Submitted by Author  
None provided.

FISCAL IMPACT:

ACTION TAKEN ADOPTED

DATE November 7, 2020